U.S. patent application number 17/351693 was filed with the patent office on 2021-12-16 for phi-4 polypeptides and methods for their use.
This patent application is currently assigned to PIONEER HI-BRED INTERNATIONAL, INC.. The applicant listed for this patent is PIONEER HI-BRED INTERNATIONAL, INC.. Invention is credited to RUTH CONG, JINGTONG HOU, ZHENGLIN HOU, PHILLIP A PATTEN, TAKASHI YAMAMOTO.
Application Number | 20210388377 17/351693 |
Document ID | / |
Family ID | 1000005784697 |
Filed Date | 2021-12-16 |
United States Patent
Application |
20210388377 |
Kind Code |
A1 |
CONG; RUTH ; et al. |
December 16, 2021 |
PHI-4 POLYPEPTIDES AND METHODS FOR THEIR USE
Abstract
Compositions and methods for controlling pests are provided. The
methods involve transforming organisms with a nucleic acid sequence
encoding an insecticidal protein. In particular, the nucleic acid
sequences are useful for preparing plants and microorganisms that
possess insecticidal activity. Thus, transformed bacteria, plants,
plant cells, plant tissues and seeds are provided. Compositions are
insecticidal nucleic acids and proteins of bacterial species. The
sequences find use in the construction of expression vectors for
subsequent transformation into organisms of interest, as probes for
the isolation of other homologous (or partially homologous) genes.
The insecticidal proteins find use in controlling, inhibiting
growth or killing lepidopteran, coleopteran, dipteran, fungal,
hemipteran, and nematode pest populations and for producing
compositions with insecticidal activity.
Inventors: |
CONG; RUTH; (PALO ALTO,
CA) ; HOU; JINGTONG; (SAN PABLO, CA) ; HOU;
ZHENGLIN; (ANKENY, IA) ; PATTEN; PHILLIP A;
(PORTOLA VALLEY, CA) ; YAMAMOTO; TAKASHI; (DUBLIN,
CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
PIONEER HI-BRED INTERNATIONAL, INC. |
Johnston |
IA |
US |
|
|
Assignee: |
PIONEER HI-BRED INTERNATIONAL,
INC.
JOHNSTON
IA
|
Family ID: |
1000005784697 |
Appl. No.: |
17/351693 |
Filed: |
June 18, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16406216 |
May 8, 2019 |
11091771 |
|
|
17351693 |
|
|
|
|
15919927 |
Mar 13, 2018 |
10337026 |
|
|
16406216 |
|
|
|
|
15178330 |
Jun 9, 2016 |
9951348 |
|
|
15919927 |
|
|
|
|
13839702 |
Mar 15, 2013 |
9394345 |
|
|
15178330 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
Y02A 40/146 20180101;
C07K 2319/02 20130101; C12N 15/8286 20130101; A01N 43/50 20130101;
C07K 14/21 20130101; C07K 14/195 20130101; C07K 14/24 20130101;
C07K 14/245 20130101; A01N 37/46 20130101; C07K 14/32 20130101 |
International
Class: |
C12N 15/82 20060101
C12N015/82; C07K 14/195 20060101 C07K014/195; A01N 37/46 20060101
A01N037/46; A01N 43/50 20060101 A01N043/50; C07K 14/21 20060101
C07K014/21; C07K 14/24 20060101 C07K014/24; C07K 14/245 20060101
C07K014/245; C07K 14/32 20060101 C07K014/32 |
Claims
1. A PHI-4 polypeptide having improved insecticidal activity
compared to AXMI-205 (SEQ ID NO: 35).
2. The PHI-4 polypeptide of claim 1, wherein the PHI-4 polypeptide
comprises an amino acid sequence of the formula, TABLE-US-00017
(SEQ ID NO: 3) 5 10 15 Met Xaa Ser Ala Ala Asn Ala Gly Xaa Leu Gly
Asn Leu Xaa Gly 20 25 30 Xaa Thr Ser Xaa Gly Met Xaa Tyr Xaa Val
Asn Gly Leu Tyr Ala 35 40 45 Ser Pro Glu Ser Leu Xaa Gly Gln Pro
Leu Phe Xaa Xaa Gly Gly 50 55 60 Xaa Leu Asp Ser Xaa Xaa Ile Glu
Gly Xaa Xaa Xaa Xaa Phe Pro 65 70 75 Xaa Ser Met His Val His Thr
Tyr Phe His Ser Asp Xaa Xaa Gln 80 85 90 Xaa Val Ser Xaa Xaa Ile
Xaa Xaa Xaa Arg Xaa Xaa Xaa Ser Xaa 95 100 105 His Val Gly Xaa Ser
Gly Xaa Xaa Xaa Leu Phe Ser Xaa Ser Xaa 110 115 120 Ser Val Asp Xaa
Thr Thr Xaa Xaa Gln Gln Leu Xaa Glu Ile Thr 125 130 135 Xaa Ser Ser
Thr Arg Glu Xaa His Val Leu Trp Tyr Ile Ser Leu 140 145 150 Pro Gly
Ala Ala Thr Leu Xaa Ser Met Leu Xaa Xaa Xaa Xaa Xaa 155 160 165 Xaa
Asp Xaa Xaa Xaa Pro Asn Met Xaa Ala Met Xaa Leu Phe Xaa 170 175 180
Xaa Xaa Gly Pro Xaa Xaa Xaa Xaa Xaa Ala Ala Val Gly Gly Arg 185 190
195 Leu Xaa Xaa Xaa Xaa Ala Ser Lys Xaa Leu Xaa Met Xaa Ser Ser 200
205 210 Xaa Ser Leu Ser Thr Thr Xaa Xaa Xaa Ser Xaa Xaa Ala Xaa Xaa
215 220 225 Gly Glu Ile Xaa Ile Xaa His Gly Ser Xaa Met Glu Lys Gln
Val 230 235 240 Asn Ser Phe Xaa Xaa Xaa Ser Thr Ile Arg Xaa Thr Ala
Thr Gly 245 250 255 Gly Lys Pro Gly Xaa Thr Xaa Arg Ile Leu His Gly
Pro Asp Ser 260 265 270 Xaa Xaa Ala Phe Ser Xaa Trp Ala Xaa Ser Leu
Leu Xaa Tyr Ala 275 280 285 Thr Leu Met Asp Phe Xaa Thr Xaa Ser Leu
Xaa Xaa Ile Xaa Ala 290 295 300 Leu Xaa Asp Xaa Pro Xaa Xaa Xaa Xaa
Glu Xaa Xaa Xaa Ala Xaa 305 310 315 Pro Xaa Xaa Met Xaa Xaa Ser Gln
Xaa Ser Ile Pro Xaa Val Asp 320 325 330 Xaa Val Leu Leu Met Asp Ala
Arg Pro Pro Met Val Xaa Ala Gly 335 340 345 Xaa Asp Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Asp Xaa Xaa Xaa Xaa Xaa 350 355 360 Xaa Ser Thr Ser Xaa
Xaa Tyr Lys Xaa Xaa Gly Gln Phe Xaa Gln 365 370 375 Arg Xaa His Xaa
Ser Val Ala Asp Gly His Xaa Pro Ile Xaa Xaa 380 385 390 Asp Leu Phe
Asp Xaa Gly Xaa Xaa Xaa Xaa Pro Val Gly Xaa Gln 395 400 405 Xaa Val
Trp Asp Xaa Xaa Xaa Xaa Gly Lys Xaa Xaa Xaa Tyr Xaa 410 415 420 Cys
Trp Arg Xaa Xaa Xaa Xaa Gln Gly Tyr Xaa Xaa Xaa Gly Asp 425 430 435
Val Xaa Met Leu Ala Xaa Ser Gly Tyr Asn Pro Pro Asn Leu Pro 440 445
450 Xaa Xaa Xaa Cys Xaa His Xaa Ser Leu Xaa Ala Xaa Xaa Xaa Thr 455
460 465 Leu Xaa Xaa Xaa Xaa Trp Xaa Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa
470 475 480 Xaa Val Ser Leu Trp Xaa Pro Gly Ala Ala Gly Ala Val Ala
Ser 485 490 495 Ser Cys Phe Ala Gly Val Pro Asn Tyr Asn Asn Pro Pro
Asn Ser 500 505 510 Gly Xaa Ile Xaa Xaa Leu Xaa Gly Ser Ile Ala Cys
Val Xaa Thr 515 520 525 Ser Ala Ile Ala Ser Met Xaa Xaa Met Xaa Ser
Met Leu Ser Xaa 530 535 His Xaa Gly Met Glu Ala Met Met Ser Lys
Leu,
wherein Xaa at position 2 is Ala or Arg; Xaa at position 9 is Gln,
Lys or Glu; Xaa at position 14 is Pro or Ala; Xaa at position 16 is
Val or Asp; Xaa at position 19 is Met or Leu; Xaa at position 22 is
Gly or Ser; Xaa at position 24 is Asp, Asn or Gln; Xaa at position
36 is Leu or Met; Xaa at position 42 is Asp, Asn or Gln; Xaa at
position 43 is Phe or Glu; Xaa at position 46 is Glu, Asp, Asn or
Gly; Xaa at position 50 is Ile or Val; Xaa at position 51 is Glu or
Gln; Xaa at position 55 is Arg or Lys; Xaa at position 56 is Ser or
Thr; Xaa at position 57 is Tyr or Phe; Xaa at position 58 is Thr or
Ser; Xaa at position 61 is Arg, Lys or Glu; Xaa at position 73 is
Phe or Tyr; Xaa at position 74 is Lys, Glu, Gly, Arg, Met, Leu, His
or Asp; Xaa at position 76 is Asp or Gln; Xaa at position 79 is Lys
or Glu; Xaa at position 80 is Glu or Ser; Xaa at position 82 is
Glu, Ile, Leu, Tyr or Gln; Xaa at position 83 is Glu or Gln; Xaa at
position 84 is Tyr or Phe; Xaa at position 86 is Glu or Gln; Xaa at
position 87 is Lys or Gln; Xaa at position 88 is Met, Ile or Leu;
Xaa at position 90 is Gln or Glu; Xaa at position 94 is Val or Ile;
Xaa at position 97 is Arg, Asn, Asp, Glu, Gln, Gly or Ser; Xaa at
position 98 is Tyr or Phe; Xaa at position 99 is Lys, Leu, Tyr,
Ile, Met, Phe, Cys, Val or Asn; Xaa at position 103 is Ala or Gly;
Xaa at position 105 is Leu or Ile; Xaa at position 109 is Phe, Lys,
Gly, Met, Ser, Asp, Asn, Glu, Cys, Ala or Arg; Xaa at position 112
is Thr or Ser; Xaa at position 113 is Asp, Glu or Met; Xaa at
position 117 is Thr or Ser; Xaa at position 121 is Tyr or Phe; Xaa
at position 127 is Ala or Thr; Xaa at position 142 is Arg or Glu;
Xaa at position 146 is Arg or Gln; Xaa at position 147 is Arg, Glu
or Gln; Xaa at position 148 is Asp, Phe, Pro, Val, Glu, His, Trp,
Ala, Arg, Leu, Ser, Gln or Gly; Xaa at position 149 is Phe or Val;
Xaa at position 150 is Arg, Gln or Glu; Xaa at position 151 is Asp,
Ser, Ala, Asn, Trp, Val, Gln, Cys, Met, Leu, Arg or Glu; Xaa at
position 153 is Leu or Ile; Xaa at position 154 is Asn or Asp; Xaa
at position 155 is Asn or Lys; Xaa at position 159 is Pro or Asp;
Xaa at position 162 is Glu, Asp or Gln; Xaa at position 165 is Lys,
Glu, Gln, Pro, Thr, Ala, Leu, Gly, Asp, Val, His, Ile, Met, Trp,
Phe, Tyr or Arg; Xaa at position 166 is Arg or Gln; Xaa at position
167 is Tyr, Trp or Cys; Xaa at position 170 is Tyr or His; Xaa at
position 171 is Tyr or Phe; Xaa at position 172 is Ile, Leu or Val;
Xaa at position 173 is Ser or Ala; Xaa at position 174 is Glu or
Gln; Xaa at position 182 is Asp or Gln; Xaa at position 183 is Tyr
or Val; Xaa at position 184 is Ser or Thr; Xaa at position 185 is
Ala or Ser; Xaa at position 189 is Thr, Lys or Ile; Xaa at position
191 is Lys or Gln; Xaa at position 193 is Asp or Asn; Xaa at
position 196 is Gln, Lys, Asn, Asp, Glu, Ala, Ile or Arg; Xaa at
position 202 is Ala or Val; Xaa at position 203 is Glu, Thr or His;
Xaa at position 204 is Met or Ala; Xaa at position 206 is Tyr or
Phe; Xaa at position 207 is Lys or Gln; Xaa at position 209 is Leu
or Pro; Xaa at position 210 is Val or Ile; Xaa at position 214 is
Lys, Ser or Gln; Xaa at position 216 is Glu, Gln, Phe, Val, Tyr or
Arg; Xaa at position 220 is Glu, His, Asp, Thr, Tyr, Val, Ser, Gln,
Arg, Trp, Met, Ala, Phe, Ile, Leu, Cys or Asn; Xaa at position 229
is Arg or Glu; Xaa at position 230 is Ser or Glu; Xaa at position
231 is Asn or Ser; Xaa at position 236 is Leu or Pro; Xaa at
position 245 is Met or Leu; Xaa at position 247 is Asp or Tyr; Xaa
at position 256 is Gln, Lys or Glu; Xaa at position 257 is Gln,
Ile, Glu, Cys, Ser, His, Trp or Met; Xaa at position 261 is Gln,
Glu or Lys; Xaa at position 264 is Glu or Gln; Xaa at position 268
is Asp or Asn; Xaa at position 276 is Ser or Ala; Xaa at position
278 is Glu, Asn or Gln; Xaa at position 281 is Gln, Lys or Glu; Xaa
at position 282 is Pro or Gly; Xaa at position 284 is Trp or Arg;
Xaa at position 287 is Ala or Cys; Xaa at position 289 is Lys, Leu,
Val, Pro, Glu, Gln, Tyr, Thr, Asp, Phe, Ser, Met, Arg, Trp, Ile,
His, Asn, Cys, Gly or Ala; Xaa at position 291 is Glu or Gln; Xaa
at position 292 is Arg or Gln; Xaa at position 293 is Arg, Glu or
Gln; Xaa at position 294 is Val or Ala; Xaa at position 296 is Leu
or Ile; Xaa at position 297 is Glu or Gln; Xaa at position 298 is
Asp or Gln; Xaa at position 300 is Phe or Tyr; Xaa at position 302
is Glu or Gln; Xaa at position 303 is Phe or Tyr; Xaa at position
305 is Lys or Gln; Xaa at position 306 is Gln or Lys; Xaa at
position 309 is Gln, Lys or Glu; Xaa at position 313 is Lys, Gln or
Arg; Xaa at position 316 is Lys or Gln; Xaa at position 328 is Lys,
Glu or Gln; Xaa at position 331 is Glu, Asn or Gln; Xaa at position
333 is Ser, Arg, Gly, Lys, Val, Asn, Ala, His, Gln, Thr, Asp, Ile,
Leu, Cys or Glu; Xaa at position 334 is Gly, Arg, Lys, Ile or Trp;
Xaa at position 335 is Ser or Ala; Xaa at position 336 is Gly or
Ala; Xaa at position 337 is Ala, Val or Gly; Xaa at position 338 is
Ser, His, Val, Lys, Ala, Gly, Thr, Ile, Glu, Met, Arg, Pro, Asp,
Asn or Leu; Xaa at position 339 is Glu, Asn, Gln, Ile, Pro, Met,
Ser, Ala, Cys, Phe, Val, Leu, Asp, Trp, His or Arg; Xaa at position
341 is Leu or Val; Xaa at position 342 is Ala, Ser or Val; Xaa at
position 343 is Val or Ile; Xaa at position 344 is Phe or Trp; Xaa
at position 345 is Asn or His; Xaa at position 346 is Pro or Ala;
Xaa at position 350 is Asn or Ser; Xaa at position 351 is Gly or
Val; Xaa at position 354 is Met or Leu; Xaa at position 355 is Val,
Ile or Leu; Xaa at position 359 is Gly or Ala; Xaa at position 362
is Asn or Ser; Xaa at position 364 is Ala or Ser; Xaa at position
371 is Ala, Gly or Thr; Xaa at position 374 is Phe or Ile; Xaa at
position 375 is Lys or Arg; Xaa at position 380 is Leu or Gly; Xaa
at position 382 is Val, Asp or Leu; Xaa at position 383 is Leu, Ile
or Val; Xaa at position 384 is Lys, Ala or Gly; Xaa at position 385
is Ala or Gly; Xaa at position 389 is Trp or Tyr; Xaa at position
391 is Arg, Leu, Glu, Gln or Asp; Xaa at position 395 is Asp or
Cys; Xaa at position 396 is Ala, Leu, Lys, Asn, Gly, Ile, Met, Arg,
Tyr, Gln or His; Xaa at position 397 is Gly, Arg or Ala; Xaa at
position 398 is Ser, Gln or Cys; Xaa at position 401 is Ser, His,
Pro, Gly, Lys, Val, Arg, Ile, Asn, Phe, Thr, Ala, Asp, Met, Gln or
Glu; Xaa at position 402 is Lys, Phe, His, Arg, Trp, Gly, Asn, Leu,
Tyr, Thr, Val, Met, Pro or Ala; Xaa at position 403 is Asp, Tyr,
Trp, Phe or Glu; Xaa at position 405 is Ala or Ser; Xaa at position
409 is Ala or Pro; Xaa at position 410 is Ile or Val; Xaa at
position 411 is Pro or Ala; Xaa at position 412 is Pro or Ala; Xaa
at position 416 is Arg, Glu or Gln; Xaa at position 417 is Ala, Ser
or Cys; Xaa at position 418 is Leu or Met; Xaa at position 422 is
Met or Val; Xaa at position 426 is Thr or Ser; Xaa at position 436
is Asp or Lys; Xaa at position 437 is Tyr or Val; Xaa at position
438 is Val or Arg; Xaa at position 440 is Val or Leu; Xaa at
position 442 is Gln, Lys or Glu; Xaa at position 445 is Cys, Leu or
Thr; Xaa at position 447 is Asp, Lys, Tyr, Ser, Glu, Ile, Gly, Pro,
Leu, Phe, Trp or Thr; Xaa at position 448 is Val or Ala; Xaa at
position 449 is Gln or Glu; Xaa at position 452 is Gln, Lys or Glu;
Xaa at position 453 is Asn or Asp; Xaa at position 454 is Arg, Tyr,
Met, Ser, Val, Ile, Lys, Phe, Trp, Gln, Gly, His, Asp, Leu, Thr,
Pro or Asn; Xaa at position 455 is Val or Ile; Xaa at position 457
is Trp or Asn; Xaa at position 459 is Lys, Met, Val, Trp, Gln, Ile,
Thr, Ser, His, Cys, Tyr, Pro, Asn, Ala, Arg or Glu; Xaa at position
460 is Gly or Ala; Xaa at position 461 is Thr or Ser; Xaa at
position 462 is Gly or Ala; Xaa at position 463 is Ala, Ser or Gly;
Xaa at position 464 is Arg, Gly, His, Gln, Thr or Phe; Xaa at
position 465 is Lys, Asn, Val, Met, Pro, Gly, Arg, Thr, His, Cys,
Trp, Phe or Leu; Xaa at position 466 is Asp or Arg; Xaa at position
471 is Gln, Lys or Glu; Xaa at position 497 is Asp or Gln; Xaa at
position 499 is Glu or Gln; Xaa at position 500 is Arg, Gln or Lys;
Xaa at position 502 is Arg, Glu or Gln; Xaa at position 509 is Lys,
Gln or Glu; Xaa at position 517 is Gln, Cys, Asn, Val or Pro; Xaa
at position 518 is Glu or Gln; Xaa at position 520 is Lys, Gln or
Glu; Xaa at position 525 is Gln or Lys; and Xaa at position 527 is
Gln, Lys, Pro, Cys, Glu, Ser, His, Phe or Trp; wherein one or more
amino acid(s) designated by Xaa in SEQ ID NO: 3 is an amino acid
different from the corresponding amino acid of SEQ ID NO: 35 and
wherein the PHI-4 polypeptide has increased insecticidal activity
compared to SEQ ID NO: 35.
3. The PHI-4 polypeptide of claim 1, wherein the PHI-4 polypeptide
comprises an amino acid sequence of the formula TABLE-US-00018 (SEQ
ID NO: 4) 5 10 15 Met Xaa Ser Ala Ala Asn Ala Gly Gln Leu Gly Asn
Leu Pro Gly 20 25 30 Val Thr Ser Met Gly Met Gly Tyr Xaa Val Asn
Gly Leu Tyr Ala 35 40 45 Ser Pro Glu Ser Leu Leu Gly Gln Pro Leu
Phe Xaa Xaa Gly Gly 50 55 60 Xaa Leu Asp Ser Ile Glu Ile Glu Gly
Arg Ser Tyr Thr Phe Pro 65 70 75 Arg Ser Met His Val His Thr Tyr
Phe His Ser Asp Phe Xaa Gln 80 85 90 Asp Val Ser Xaa Glu Ile Xaa
Glu Tyr Arg Glu Lys Met Ser Gln 95 100 105 His Val Gly Val Ser Gly
Xaa Xaa Xaa Leu Phe Ser Ala Ser Leu 110 115 120 Ser Val Asp Xaa Thr
Thr Thr Asp Gln Gln Leu Thr Glu Ile Thr 125 130 135 Tyr Ser Ser Thr
Arg Glu Ala His Val Leu Trp Tyr Ile Ser Leu 140 145 150 Pro Gly Ala
Ala Thr Leu Arg Ser Met Leu Arg Xaa Xaa Phe Xaa 155 160 165 Xaa Asp
Xaa Asn Asn Pro Asn Met Pro Ala Met Xaa Leu Phe Xaa 170 175 180 Xaa
Tyr Gly Pro Tyr Xaa Ile Ser Xaa Ala Ala Val Gly Gly Arg 185 190 195
Leu Xaa Tyr Ser Ala Ala Ser Lys Thr Leu Lys Met Asp Ser Ser 200 205
210 Xaa Ser Leu Ser Thr Thr Ala Xaa Met Ser Xaa Lys Ala Leu Val 215
220 225 Gly Glu Ile Lys Ile Xaa His Gly Ser Xaa Met Glu Lys Gln Val
230 235 240 Asn Ser Phe Arg Ser Asn Ser Thr Ile Arg Leu Thr Ala Thr
Gly 245 250 255 Gly Lys Pro Gly Met Thr Xaa Arg Ile Leu His Gly Pro
Asp Ser 260 265 270 Xaa Xaa Ala Phe Ser Xaa Trp Ala Glu Ser Leu Leu
Asp Tyr Ala 275 280 285 Thr Leu Met Asp Phe Ser Thr Xaa Ser Leu Xaa
Pro Ile Trp Ala 290 295 300 Leu Ala Asp Xaa Pro Glu Arg Xaa Val Glu
Leu Glu Asp Ala Phe 305 310 315 Pro Glu Phe Met Lys Gln Ser Gln Gln
Ser Ile Pro Xaa Val Asp 320 325 330 Lys Val Leu Leu Met Asp Ala Arg
Pro Pro Met Val Xaa Ala Gly 335 340 345 Glu Asp Xaa Xaa Ser Xaa Ala
Xaa Xaa Asp Leu Ala Xaa Phe Asn 350 355 360 Xaa Ser Thr Ser Asn Gly
Tyr Lys Met Xaa Gly Gln Phe Xaa Gln 365 370 375 Arg Asn His Ala Ser
Val Ala Asp Gly His Ala Pro Ile Phe Lys 380 385 390 Asp Leu Phe Asp
Leu Gly Val Leu Lys Ala Pro Val Gly Trp Gln 395 400 405 Xaa Val Trp
Asp Asp Xaa Gly Ser Gly Lys Xaa Xaa Xaa Tyr Ala 410 415 420 Cys Trp
Arg Ala Ile Xaa Xaa Gln Gly Tyr Xaa Xaa Xaa Gly Asp 425 430 435 Val
Met Met Leu Ala Xaa Ser Gly Tyr Asn Pro Pro Asn Leu Pro 440 445 450
Asp Tyr Val Cys Xaa His Gln Ser Leu Cys Ala Xaa Val Gln Thr 455 460
465 Leu Xaa Asn Xaa Xaa Trp Trp Asp Xaa Gly Xaa Xaa Xaa Xaa Xaa 470
475 480 Asp Val Ser Leu Trp Xaa Pro Gly Ala Ala Gly Ala Val Ala Ser
485 490 495 Ser Cys Phe Ala Gly Val Pro Asn Tyr Asn Asn Pro Pro Asn
Ser 500 505 510 Gly Asp Ile Glu Xaa Leu Arg Gly Ser Ile Ala Cys Val
Xaa Thr 515 520 525 Ser Ala Ile Ala Ser Met Gln Glu Met Xaa Ser Met
Leu Ser Gln 530 535 His Xaa Gly Met Glu Ala Met Met Ser Lys
Leu,
wherein Xaa at position 2 is Ala or Arg; Xaa at position 24 is Asp
or Asn; Xaa at position 42 is Asp or Asn; Xaa at position 43 is Phe
or Glu; Xaa at position 46 is Glu or Asn; Xaa at position 74 is
Lys, Glu or Gly; Xaa at position 79 is Lys or Glu; Xaa at position
82 is Glu, Ile, Leu or Tyr; Xaa at position 97 is Arg, Asn, Asp,
Glu, Gln or Gly; Xaa at position 98 is Tyr or Phe; Xaa at position
99 is Lys, Leu, Tyr, Ile or Met; Xaa at position 109 is Phe, Lys,
Gly, Met, Ser, Asp or Asn; Xaa at position 147 is Arg or Glu; Xaa
at position 148 is Asp, Phe or Pro; Xaa at position 150 is Arg or
Gln; Xaa at position 151 is Asp, Ser, Ala or Asn; Xaa at position
153 is Leu or Ile; Xaa at position 162 is Glu or Gln; Xaa at
position 165 is Lys, Glu or Gln; Xaa at position 166 is Arg or Gln;
Xaa at position 171 is Tyr or Phe; Xaa at position 174 is Glu or
Gln; Xaa at position 182 is Asp or Gln; Xaa at position 196 is Gln,
Lys, Asn or Asp; Xaa at position 203 is Glu, Thr or His; Xaa at
position 206 is Tyr or Phe; Xaa at position 216 is Glu or Gln; Xaa
at position 220 is Glu, His, Asp, Thr, Tyr, Val, Ser or Gln; Xaa at
position 247 is Asp or Tyr; Xaa at position 256 is Gln or Lys; Xaa
at position 257 is Gln or Ile; Xaa at position 261 is Gln or Glu;
Xaa at position 278 is Glu or Asn; Xaa at position 281 is Gln, Lys
or Glu; Xaa at position 289 is Lys, Leu, Val, Pro, Glu, Gln, Tyr,
Thr or Asp; Xaa at position 293 is Arg, Glu or Gln; Xaa at position
313 is Lys or Gln; Xaa at position 328 is Lys, Glu or Gln; Xaa at
position 333 is Ser, Gly, Lys, Val or Asn; Xaa at position 334 is
Gly, Arg, Lys or Ile; Xaa at position 336 is Gly or Ala; Xaa at
position 338 is Ser, His, Val, Lys or Ala; Xaa at position 339 is
Glu, Asn, Ile or Pro; Xaa at position 343 is Val or Ile; Xaa at
position 346 is Pro or Ala; Xaa at position 355 is Val or Ile; Xaa
at position 359 is Gly or Ala; Xaa at position 391 is Arg, Glu or
Gln; Xaa at position 396 is Ala, Leu, Lys, Asn or Gly; Xaa at
position 401 is Ser, His, Pro, Gly, Lys, Val or Arg; Xaa at
position 402 is Lys, Phe, His, Arg, Gly, Trp, Thr, Asn, Tyr or Met;
Xaa at position 403 is Asp or Tyr; Xaa at position 411 is Pro or
Ala; Xaa at position 412 is Pro or Ala; Xaa at position 416 is Arg
or Glu; Xaa at position 417 is Ala or Ser; Xaa at position 418 is
Leu or Met; Xaa at position 426 is Thr or Ser; Xaa at position 440
is Val or Leu; Xaa at position 447 is Asp, Lys, Tyr, Ser, Glu or
Ile; Xaa at position 452 is Gln, Lys or Glu; Xaa at position 454 is
Arg, Tyr, Met, Ser, Val, Ile, Lys, Phe, Trp or Gln; Xaa at position
455 is Val or Ile; Xaa at position 459 is Lys, Met, Val, Trp, Gln,
Ile or Tyr; Xaa at position 461 is Thr or Ser; Xaa at position 462
is Gly or Ala; Xaa at position 463 is Ala or Ser; Xaa at position
464 is Arg, Gly or His; Xaa at position 465 is Lys, Asn, Val, Met,
Pro, Gly or Arg; Xaa at position 471 is Gln, Lys or Glu; Xaa at
position 500 is Arg or Gln; Xaa at position 509 is Lys or Gln; Xaa
at position 520 is Lys, Gln or Glu; and Xaa at position 527 is Gln,
Lys, Pro, Cys or Glu; wherein one or more amino acid(s) designated
by Xaa in SEQ ID NO: 4 is an amino acid different from the
corresponding amino acid of SEQ ID NO: 35 and wherein the PHI-4
polypeptide has increased insecticidal activity compared to SEQ ID
NO: 35.
4. The PHI-4 polypeptide of claim 2 or 3, further comprising one or
more amino acid substitutions at position 86, 359, 399, 464, 465,
466, 467, 468, 499 or 517 of SEQ ID NO: 3 or SEQ ID NO: 4.
5. The PHI-4 polypeptide of claim 4, wherein the amino acid at
position 86 is Glu or Thr; the amino acid at position 359 is Gly or
Ala; the amino acid at position 399 is Gly or Ala; the amino acid
at position 464 is Arg, Ala, Lys, Asp or Asn; the amino acid at
position 465 is Lys or Met, the amino acid at position 467 is Val,
Ala, Leu or Thr; the amino acid at position 468 is Ser or Leu; the
amino acid at position 499 is Glu or Ala, or the amino acid at
position 517 is Glu or Arg.
6. The PHI-4 polypeptide of claim 2 or 3, further comprising one or
more amino acid substitution, insertion of one or more amino acids,
deletion of one or more amino acids, and combinations thereof.
7. The PHI-4 polypeptide of claim 2 or 3, wherein the insecticidal
activity is increased about 2 fold or greater compared to AXMI-205
(SEQ ID NO: 35).
8. The PHI-4 polypeptide of claim 2 or 3, wherein the insecticidal
activity is increased about 5 fold or greater compared to AXMI-205
(SEQ ID NO: 35).
9. The PHI-4 polypeptide of claim 2 or 3, wherein the improved
insecticidal activity compared to AXMI-205 (SEQ ID NO: 35) is
against Western Corn Root Worm (WCRW) larvae.
10. The PHI-4 polypeptide of claim 2 or 3, wherein the improved
insecticidal activity compared to AXMI-205 (SEQ ID NO: 35) is
quantitated as a Mean FAE Index.
11. The PHI-4 polypeptide of claim 2 or 3, wherein the improved
insecticidal activity compared to AXMI-205 (SEQ ID NO: 35) is
quantitated as an EC50 value.
12. The PHI-4 polypeptide of claim 2 or 3, wherein the improved
activity compared to AXMI-205 (SEQ ID NO: 35) is quantitated as a
Mean Deviation Score.
13. The PHI-4 polypeptide of claim 2 or 3, having 1 to 54 amino
acid substitutions at a position(s) designated as Xaa in SEQ ID NO:
3 or 4.
14. The PHI-4 polypeptide of claim 2 or 3, having 1 to 15 amino
acid substitutions at a position(s) designated as Xaa in SEQ ID NO:
3 or 4.
15. The PHI-4 polypeptide of claim 2 or 3, wherein 1-20 amino acids
are deleted from the C-terminus of the PHI-4 polypeptide.
16. A polynucleotide encoding a PHI-4 polypeptide, wherein the
PHI-4 polypeptide has improved insecticidal activity compared to
AXMI-205 (SEQ ID NO: 35).
17. The polynucleotide encoding a PHI-4 polypeptide of claim 16,
wherein the PHI-4 polypeptide comprises an amino acid sequence of
the formula, TABLE-US-00019 (SEQ ID NO: 3) 5 10 15 Met Xaa Ser Ala
Ala Asn Ala Gly Xaa Leu Gly Asn Leu Xaa Gly 20 25 30 Xaa Thr Ser
Xaa Gly Met Xaa Tyr Xaa Val Asn Gly Leu Tyr Ala 35 40 45 Ser Pro
Glu Ser Leu Xaa Gly Gln Pro Leu Phe Xaa Xaa Gly Gly 50 55 60 Xaa
Leu Asp Ser Xaa Xaa Ile Glu Gly Xaa Xaa Xaa Xaa Phe Pro 65 70 75
Xaa Ser Met His Val His Thr Tyr Phe His Ser Asp Xaa Xaa Gln 80 85
90 Xaa Val Ser Xaa Xaa Ile Xaa Xaa Xaa Arg Xaa Xaa Xaa Ser Xaa 95
100 105 His Val Gly Xaa Ser Gly Xaa Xaa Xaa Leu Phe Ser Xaa Ser Xaa
110 115 120 Ser Val Asp Xaa Thr Thr Xaa Xaa Gln Gln Leu Xaa Glu Ile
Thr 125 130 135 Xaa Ser Ser Thr Arg Glu Xaa His Val Leu Trp Tyr Ile
Ser Leu 140 145 150 Pro Gly Ala Ala Thr Leu Xaa Ser Met Leu Xaa Xaa
Xaa Xaa Xaa 155 160 165 Xaa Asp Xaa Xaa Xaa Pro Asn Met Xaa Ala Met
Xaa Leu Phe Xaa 170 175 180 Xaa Xaa Gly Pro Xaa Xaa Xaa Xaa Xaa Ala
Ala Val Gly Gly Arg 185 190 195 Leu Xaa Xaa Xaa Xaa Ala Ser Lys Xaa
Leu Xaa Met Xaa Ser Ser 200 205 210 Xaa Ser Leu Ser Thr Thr Xaa Xaa
Xaa Ser Xaa Xaa Ala Xaa Xaa 215 220 225 Gly Glu Ile Xaa Ile Xaa His
Gly Ser Xaa Met Glu Lys Gln Val 230 235 240 Asn Ser Phe Xaa Xaa Xaa
Ser Thr Ile Arg Xaa Thr Ala Thr Gly 245 250 255 Gly Lys Pro Gly Xaa
Thr Xaa Arg Ile Leu His Gly Pro Asp Ser 260 265 270 Xaa Xaa Ala Phe
Ser Xaa Trp Ala Xaa Ser Leu Leu Xaa Tyr Ala 275 280 285 Thr Leu Met
Asp Phe Xaa Thr Xaa Ser Leu Xaa Xaa Ile Xaa Ala 290 295 300 Leu Xaa
Asp Xaa Pro Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Ala Xaa 305 310 315 Pro
Xaa Xaa Met Xaa Xaa Ser Gln Xaa Ser Ile Pro Xaa Val Asp 320 325 330
Xaa Val Leu Leu Met Asp Ala Arg Pro Pro Met Val Xaa Ala Gly 335 340
345 Xaa Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Xaa Xaa Xaa 350
355 360 Xaa Ser Thr Ser Xaa Xaa Tyr Lys Xaa Xaa Gly Gln Phe Xaa Gln
365 370 375 Arg Xaa His Xaa Ser Val Ala Asp Gly His Xaa Pro Ile Xaa
Xaa 380 385 390 Asp Leu Phe Asp Xaa Gly Xaa Xaa Xaa Xaa Pro Val Gly
Xaa Gln 395 400 405 Xaa Val Trp Asp Xaa Xaa Xaa Xaa Gly Lys Xaa Xaa
Xaa Tyr Xaa 410 415 420 Cys Trp Arg Xaa Xaa Xaa Xaa Gln Gly Tyr Xaa
Xaa Xaa Gly Asp 425 430 435 Val Xaa Met Leu Ala Xaa Ser Gly Tyr Asn
Pro Pro Asn Leu Pro 440 445 450 Xaa Xaa Xaa Cys Xaa His Xaa Ser Leu
Xaa Ala Xaa Xaa Xaa Thr 455 460 465 Leu Xaa Xaa Xaa Xaa Trp Xaa Asp
Xaa Xaa Xaa Xaa Xaa Xaa Xaa 470 475 480 Xaa Val Ser Leu Trp Xaa Pro
Gly Ala Ala Gly Ala Val Ala Ser 485 490 495 Ser Cys Phe Ala Gly Val
Pro Asn Tyr Asn Asn Pro Pro Asn Ser 500 505 510 Gly Xaa Ile Xaa Xaa
Leu Xaa Gly Ser Ile Ala Cys Val Xaa Thr 515 520 525 Ser Ala Ile Ala
Ser Met Xaa Xaa Met Xaa Ser Met Leu Ser Xaa 530 535 His Xaa Gly Met
Glu Ala Met Met Ser Lys Leu,
wherein Xaa at position 2 is Ala or Arg; Xaa at position 9 is Gln,
Lys or Glu; Xaa at position 14 is Pro or Ala; Xaa at position 16 is
Val or Asp; Xaa at position 19 is Met or Leu; Xaa at position 22 is
Gly or Ser; Xaa at position 24 is Asp, Asn or Gln; Xaa at position
36 is Leu or Met; Xaa at position 42 is Asp, Asn or Gln; Xaa at
position 43 is Phe or Glu; Xaa at position 46 is Glu, Asp, Asn or
Gly; Xaa at position 50 is Ile or Val; Xaa at position 51 is Glu or
Gln; Xaa at position 55 is Arg or Lys; Xaa at position 56 is Ser or
Thr; Xaa at position 57 is Tyr or Phe; Xaa at position 58 is Thr or
Ser; Xaa at position 61 is Arg, Lys or Glu; Xaa at position 73 is
Phe or Tyr; Xaa at position 74 is Lys, Glu, Gly, Arg, Met, Leu, His
or Asp; Xaa at position 76 is Asp or Gln; Xaa at position 79 is Lys
or Glu; Xaa at position 80 is Glu or Ser; Xaa at position 82 is
Glu, Ile, Leu, Tyr or Gln; Xaa at position 83 is Glu or Gln; Xaa at
position 84 is Tyr or Phe; Xaa at position 86 is Glu or Gln; Xaa at
position 87 is Lys or Gln; Xaa at position 88 is Met, Ile or Leu;
Xaa at position 90 is Gln or Glu; Xaa at position 94 is Val or Ile;
Xaa at position 97 is Arg, Asn, Asp, Glu, Gln, Gly or Ser; Xaa at
position 98 is Tyr or Phe; Xaa at position 99 is Lys, Leu, Tyr,
Ile, Met, Phe, Cys, Val or Asn; Xaa at position 103 is Ala or Gly;
Xaa at position 105 is Leu or Ile; Xaa at position 109 is Phe, Lys,
Gly, Met, Ser, Asp, Asn, Glu, Cys, Ala or Arg; Xaa at position 112
is Thr or Ser; Xaa at position 113 is Asp, Glu or Met; Xaa at
position 117 is Thr or Ser; Xaa at position 121 is Tyr or Phe; Xaa
at position 127 is Ala or Thr; Xaa at position 142 is Arg or Glu;
Xaa at position 146 is Arg or Gln; Xaa at position 147 is Arg, Glu
or Gln; Xaa at position 148 is Asp, Phe, Pro, Val, Glu, His, Trp,
Ala, Arg, Leu, Ser, Gln or Gly; Xaa at position 149 is Phe or Val;
Xaa at position 150 is Arg, Gln or Glu; Xaa at position 151 is Asp,
Ser, Ala, Asn, Trp, Val, Gln, Cys, Met, Leu, Arg or Glu; Xaa at
position 153 is Leu or Ile; Xaa at position 154 is Asn or Asp; Xaa
at position 155 is Asn or Lys; Xaa at position 159 is Pro or Asp;
Xaa at position 162 is Glu, Asp or Gln; Xaa at position 165 is Lys,
Glu, Gln, Pro, Thr, Ala, Leu, Gly, Asp, Val, His, Ile, Met, Trp,
Phe, Tyr or Arg; Xaa at position 166 is Arg or Gln; Xaa at position
167 is Tyr, Trp or Cys; Xaa at position 170 is Tyr or His; Xaa at
position 171 is Tyr or Phe; Xaa at position 172 is Ile, Leu or Val;
Xaa at position 173 is Ser or Ala; Xaa at position 174 is Glu or
Gln; Xaa at position 182 is Asp or Gln; Xaa at position 183 is Tyr
or Val; Xaa at position 184 is Ser or Thr; Xaa at position 185 is
Ala or Ser; Xaa at position 189 is Thr, Lys or Ile; Xaa at position
191 is Lys or Gln; Xaa at position 193 is Asp or Asn; Xaa at
position 196 is Gln, Lys, Asn, Asp, Glu, Ala, Ile or Arg; Xaa at
position 202 is Ala or Val; Xaa at position 203 is Glu, Thr or His;
Xaa at position 204 is Met or Ala; Xaa at position 206 is Tyr or
Phe; Xaa at position 207 is Lys or Gln; Xaa at position 209 is Leu
or Pro; Xaa at position 210 is Val or Ile; Xaa at position 214 is
Lys, Ser or Gln; Xaa at position 216 is Glu, Gln, Phe, Val, Tyr or
Arg; Xaa at position 220 is Glu, His, Asp, Thr, Tyr, Val, Ser, Gln,
Arg, Trp, Met, Ala, Phe, Ile, Leu, Cys or Asn; Xaa at position 229
is Arg or Glu; Xaa at position 230 is Ser or Glu; Xaa at position
231 is Asn or Ser; Xaa at position 236 is Leu or Pro; Xaa at
position 245 is Met or Leu; Xaa at position 247 is Asp or Tyr; Xaa
at position 256 is Gln, Lys or Glu; Xaa at position 257 is Gln,
Ile, Glu, Cys, Ser, His, Trp or Met; Xaa at position 261 is Gln,
Glu or Lys; Xaa at position 264 is Glu or Gln; Xaa at position 268
is Asp or Asn; Xaa at position 276 is Ser or Ala; Xaa at position
278 is Glu, Asn or Gln; Xaa at position 281 is Gln, Lys or Glu; Xaa
at position 282 is Pro or Gly; Xaa at position 284 is Trp or Arg;
Xaa at position 287 is Ala or Cys; Xaa at position 289 is Lys, Leu,
Val, Pro, Glu, Gln, Tyr, Thr, Asp, Phe, Ser, Met, Arg, Trp, Ile,
His, Asn, Cys, Gly or Ala; Xaa at position 291 is Glu or Gln; Xaa
at position 292 is Arg or Gln; Xaa at position 293 is Arg, Glu or
Gln; Xaa at position 294 is Val or Ala; Xaa at position 296 is Leu
or Ile; Xaa at position 297 is Glu or Gln; Xaa at position 298 is
Asp or Gln; Xaa at position 300 is Phe or Tyr; Xaa at position 302
is Glu or Gln; Xaa at position 303 is Phe or Tyr; Xaa at position
305 is Lys or Gln; Xaa at position 306 is Gln or Lys; Xaa at
position 309 is Gln, Lys or Glu; Xaa at position 313 is Lys, Gln or
Arg; Xaa at position 316 is Lys or Gln; Xaa at position 328 is Lys,
Glu or Gln; Xaa at position 331 is Glu, Asn or Gln; Xaa at position
333 is Ser, Arg, Gly, Lys, Val, Asn, Ala, His, Gln, Thr, Asp, Ile,
Leu, Cys or Glu; Xaa at position 334 is Gly, Arg, Lys, Ile or Trp;
Xaa at position 335 is Ser or Ala; Xaa at position 336 is Gly or
Ala; Xaa at position 337 is Ala, Val or Gly; Xaa at position 338 is
Ser, His, Val, Lys, Ala, Gly, Thr, Ile, Glu, Met, Arg, Pro, Asp,
Asn or Leu; Xaa at position 339 is Glu, Asn, Gln, Ile, Pro, Met,
Ser, Ala, Cys, Phe, Val, Leu, Asp, Trp, His or Arg; Xaa at position
341 is Leu or Val; Xaa at position 342 is Ala, Ser or Val; Xaa at
position 343 is Val or Ile; Xaa at position 344 is Phe or Trp; Xaa
at position 345 is Asn or His; Xaa at position 346 is Pro or Ala;
Xaa at position 350 is Asn or Ser; Xaa at position 351 is Gly or
Val; Xaa at position 354 is Met or Leu; Xaa at position 355 is Val,
Ile or Leu; Xaa at position 359 is Gly or Ala; Xaa at position 362
is Asn or Ser; Xaa at position 364 is Ala or Ser; Xaa at position
371 is Ala, Gly or Thr; Xaa at position 374 is Phe or Ile; Xaa at
position 375 is Lys or Arg; Xaa at position 380 is Leu or Gly; Xaa
at position 382 is Val, Asp or Leu; Xaa at position 383 is Leu, Ile
or Val; Xaa at position 384 is Lys, Ala or Gly; Xaa at position 385
is Ala or Gly; Xaa at position 389 is Trp or Tyr; Xaa at position
391 is Arg, Leu, Glu, Gln or Asp; Xaa at position 395 is Asp or
Cys; Xaa at position 396 is Ala, Leu, Lys, Asn, Gly, Ile, Met, Arg,
Tyr, Gln or His; Xaa at position 397 is Gly, Arg or Ala; Xaa at
position 398 is Ser, Gln or Cys; Xaa at position 401 is Ser, His,
Pro, Gly, Lys, Val, Arg, Ile, Asn, Phe, Thr, Ala, Asp, Met, Gln or
Glu; Xaa at position 402 is Lys, Phe, His, Arg, Trp, Gly, Asn, Leu,
Tyr, Thr, Val, Met, Pro or Ala; Xaa at position 403 is Asp, Tyr,
Trp, Phe or Glu; Xaa at position 405 is Ala or Ser; Xaa at position
409 is Ala or Pro; Xaa at position 410 is Ile or Val; Xaa at
position 411 is Pro or Ala; Xaa at position 412 is Pro or Ala; Xaa
at position 416 is Arg, Glu or Gln; Xaa at position 417 is Ala, Ser
or Cys; Xaa at position 418 is Leu or Met; Xaa at position 422 is
Met or Val; Xaa at position 426 is Thr or Ser; Xaa at position 436
is Asp or Lys; Xaa at position 437 is Tyr or Val; Xaa at position
438 is Val or Arg; Xaa at position 440 is Val or Leu; Xaa at
position 442 is Gln, Lys or Glu; Xaa at position 445 is Cys, Leu or
Thr; Xaa at position 447 is Asp, Lys, Tyr, Ser, Glu, Ile, Gly, Pro,
Leu, Phe, Trp or Thr; Xaa at position 448 is Val or Ala; Xaa at
position 449 is Gln or Glu; Xaa at position 452 is Gln, Lys or Glu;
Xaa at position 453 is Asn or Asp; Xaa at position 454 is Arg, Tyr,
Met, Ser, Val, Ile, Lys, Phe, Trp, Gln, Gly, His, Asp, Leu, Thr,
Pro or Asn; Xaa at position 455 is Val or Ile; Xaa at position 457
is Trp or Asn; Xaa at position 459 is Lys, Met, Val, Trp, Gln, Ile,
Thr, Ser, His, Cys, Tyr, Pro, Asn, Ala, Arg or Glu; Xaa at position
460 is Gly or Ala; Xaa at position 461 is Thr or Ser; Xaa at
position 462 is Gly or Ala; Xaa at position 463 is Ala, Ser or Gly;
Xaa at position 464 is Arg, Gly, His, Gln, Thr or Phe; Xaa at
position 465 is Lys, Asn, Val, Met, Pro, Gly, Arg, Thr, His, Cys,
Trp, Phe or Leu; Xaa at position 466 is Asp or Arg; Xaa at position
471 is Gln, Lys or Glu; Xaa at position 497 is Asp or Gln; Xaa at
position 499 is Glu or Gln; Xaa at position 500 is Arg, Gln or Lys;
Xaa at position 502 is Arg, Glu or Gln; Xaa at position 509 is Lys,
Gln or Glu; Xaa at position 517 is Gln, Cys, Asn, Val or Pro; Xaa
at position 518 is Glu or Gln; Xaa at position 520 is Lys, Gln or
Glu; Xaa at position 525 is Gln or Lys; and Xaa at position 527 is
Gln, Lys, Pro, Cys, Glu, Ser, His, Phe or Trp; wherein one or more
amino acid(s) designated by Xaa in SEQ ID NO: 3 is an amino acid
different from the corresponding amino acid of SEQ ID NO: 35 and
wherein the PHI-4 polypeptide has increased insecticidal activity
compared to SEQ ID NO: 35.
18. The polynucleotide encoding a PHI-4 polypeptide of claim 16,
wherein the PHI-4 polypeptide comprises an amino acid sequence of
the formula, TABLE-US-00020 (SEQ ID NO: 4) 5 10 15 Met Xaa Ser Ala
Ala Asn Ala Gly Gln Leu Gly Asn Leu Pro Gly 20 25 30 Val Thr Ser
Met Gly Met Gly Tyr Xaa Val Asn Gly Leu Tyr Ala 35 40 45 Ser Pro
Glu Ser Leu Leu Gly Gln Pro Leu Phe Xaa Xaa Gly Gly 50 55 60 Xaa
Leu Asp Ser Ile Glu Ile Glu Gly Arg Ser Tyr Thr Phe Pro 65 70 75
Arg Ser Met His Val His Thr Tyr Phe His Ser Asp Phe Xaa Gln 80 85
90 Asp Val Ser Xaa Glu Ile Xaa Glu Tyr Arg Glu Lys Met Ser Gln 95
100 105 His Val Gly Val Ser Gly Xaa Xaa Xaa Leu Phe Ser Ala Ser Leu
110 115 120 Ser Val Asp Xaa Thr Thr Thr Asp Gln Gln Leu Thr Glu Ile
Thr 125 130 135 Tyr Ser Ser Thr Arg Glu Ala His Val Leu Trp Tyr Ile
Ser Leu 140 145 150 Pro Gly Ala Ala Thr Leu Arg Ser Met Leu Arg Xaa
Xaa Phe Xaa 155 160 165 Xaa Asp Xaa Asn Asn Pro Asn Met Pro Ala Met
Xaa Leu Phe Xaa 170 175 180 Xaa Tyr Gly Pro Tyr Xaa Ile Ser Xaa Ala
Ala Val Gly Gly Arg 185 190 195 Leu Xaa Tyr Ser Ala Ala Ser Lys Thr
Leu Lys Met Asp Ser Ser 200 205 210 Xaa Ser Leu Ser Thr Thr Ala Xaa
Met Ser Xaa Lys Ala Leu Val 215 220 225 Gly Glu Ile Lys Ile Xaa His
Gly Ser Xaa Met Glu Lys Gln Val 230 235 240 Asn Ser Phe Arg Ser Asn
Ser Thr Ile Arg Leu Thr Ala Thr Gly 245 250 255 Gly Lys Pro Gly Met
Thr Xaa Arg Ile Leu His Gly Pro Asp Ser 260 265 270 Xaa Xaa Ala Phe
Ser Xaa Trp Ala Glu Ser Leu Leu Asp Tyr Ala 275 280 285 Thr Leu Met
Asp Phe Ser Thr Xaa Ser Leu Xaa Pro Ile Trp Ala 290 295 300 Leu Ala
Asp Xaa Pro Glu Arg Xaa Val Glu Leu Glu Asp Ala Phe 305 310 315 Pro
Glu Phe Met Lys Gln Ser Gln Gln Ser Ile Pro Xaa Val Asp 320 325 330
Lys Val Leu Leu Met Asp Ala Arg Pro Pro Met Val Xaa Ala Gly 335 340
345 Glu Asp Xaa Xaa Ser Xaa Ala Xaa Xaa Asp Leu Ala Xaa Phe Asn 350
355 360 Xaa Ser Thr Ser Asn Gly Tyr Lys Met Xaa Gly Gln Phe Xaa Gln
365 370 375 Arg Asn His Ala Ser Val Ala Asp Gly His Ala Pro Ile Phe
Lys 380 385 390 Asp Leu Phe Asp Leu Gly Val Leu Lys Ala Pro Val Gly
Trp Gln 395 400 405 Xaa Val Trp Asp Asp Xaa Gly Ser Gly Lys Xaa Xaa
Xaa Tyr Ala 410 415 420 Cys Trp Arg Ala Ile Xaa Xaa Gln Gly Tyr Xaa
Xaa Xaa Gly Asp 425 430 435 Val Met Met Leu Ala Xaa Ser Gly Tyr Asn
Pro Pro Asn Leu Pro 440 445 450 Asp Tyr Val Cys Xaa His Gln Ser Leu
Cys Ala Xaa Val Gln Thr 455 460 465 Leu Xaa Asn Xaa Xaa Trp Trp Asp
Xaa Gly Xaa Xaa Xaa Xaa Xaa 470 475 480 Asp Val Ser Leu Trp Xaa Pro
Gly Ala Ala Gly Ala Val Ala Ser 485 490 495 Ser Cys Phe Ala Gly Val
Pro Asn Tyr Asn Asn Pro Pro Asn Ser 500 505 510 Gly Asp Ile Glu Xaa
Leu Arg Gly Ser Ile Ala Cys Val Xaa Thr 515 520 525 Ser Ala Ile Ala
Ser Met Gln Glu Met Xaa Ser Met Leu Ser Gln 530 535 His Xaa Gly Met
Glu Ala Met Met Ser Lys Leu,
wherein Xaa at position 2 is Ala or Arg; Xaa at position 24 is Asp
or Asn; Xaa at position 42 is Asp or Asn; Xaa at position 43 is Phe
or Glu; Xaa at position 46 is Glu or Asn; Xaa at position 74 is
Lys, Glu or Gly; Xaa at position 79 is Lys or Glu; Xaa at position
82 is Glu, Ile, Leu or Tyr; Xaa at position 97 is Arg, Asn, Asp,
Glu, Gln or Gly; Xaa at position 98 is Tyr or Phe; Xaa at position
99 is Lys, Leu, Tyr, Ile or Met; Xaa at position 109 is Phe, Lys,
Gly, Met, Ser, Asp or Asn; Xaa at position 147 is Arg or Glu; Xaa
at position 148 is Asp, Phe or Pro; Xaa at position 150 is Arg or
Gln; Xaa at position 151 is Asp, Ser, Ala or Asn; Xaa at position
153 is Leu or Ile; Xaa at position 162 is Glu or Gln; Xaa at
position 165 is Lys, Glu or Gln; Xaa at position 166 is Arg or Gln;
Xaa at position 171 is Tyr or Phe; Xaa at position 174 is Glu or
Gln; Xaa at position 182 is Asp or Gln; Xaa at position 196 is Gln,
Lys, Asn or Asp; Xaa at position 203 is Glu, Thr or His; Xaa at
position 206 is Tyr or Phe; Xaa at position 216 is Glu or Gln; Xaa
at position 220 is Glu, His, Asp, Thr, Tyr, Val, Ser or Gln; Xaa at
position 247 is Asp or Tyr; Xaa at position 256 is Gln or Lys; Xaa
at position 257 is Gln or Ile; Xaa at position 261 is Gln or Glu;
Xaa at position 278 is Glu or Asn; Xaa at position 281 is Gln, Lys
or Glu; Xaa at position 289 is Lys, Leu, Val, Pro, Glu, Gln, Tyr,
Thr or Asp; Xaa at position 293 is Arg, Glu or Gln; Xaa at position
313 is Lys or Gln; Xaa at position 328 is Lys, Glu or Gln; Xaa at
position 333 is Ser, Gly, Lys, Val or Asn; Xaa at position 334 is
Gly, Arg, Lys or Ile; Xaa at position 336 is Gly or Ala; Xaa at
position 338 is Ser, His, Val, Lys or Ala; Xaa at position 339 is
Glu, Asn, Ile or Pro; Xaa at position 343 is Val or Ile; Xaa at
position 346 is Pro or Ala; Xaa at position 355 is Val or Ile; Xaa
at position 359 is Gly or Ala; Xaa at position 391 is Arg, Glu or
Gln; Xaa at position 396 is Ala, Leu, Lys, Asn or Gly; Xaa at
position 401 is Ser, His, Pro, Gly, Lys, Val or Arg; Xaa at
position 402 is Lys, Phe, His, Arg, Gly, Trp, Thr, Asn, Tyr or Met;
Xaa at position 403 is Asp or Tyr; Xaa at position 411 is Pro or
Ala; Xaa at position 412 is Pro or Ala; Xaa at position 416 is Arg
or Glu; Xaa at position 417 is Ala or Ser; Xaa at position 418 is
Leu or Met; Xaa at position 426 is Thr or Ser; Xaa at position 440
is Val or Leu; Xaa at position 447 is Asp, Lys, Tyr, Ser, Glu or
Ile; Xaa at position 452 is Gln, Lys or Glu; Xaa at position 454 is
Arg, Tyr, Met, Ser, Val, Ile, Lys, Phe, Trp or Gln; Xaa at position
455 is Val or Ile; Xaa at position 459 is Lys, Met, Val, Trp, Gln,
Ile or Tyr; Xaa at position 461 is Thr or Ser; Xaa at position 462
is Gly or Ala; Xaa at position 463 is Ala or Ser; Xaa at position
464 is Arg, Gly or His; Xaa at position 465 is Lys, Asn, Val, Met,
Pro, Gly or Arg; Xaa at position 471 is Gln, Lys or Glu; Xaa at
position 500 is Arg or Gln; Xaa at position 509 is Lys or Gln; Xaa
at position 520 is Lys, Gln or Glu; and Xaa at position 527 is Gln,
Lys, Pro, Cys or Glu; wherein one or more amino acid(s) designated
by Xaa in SEQ ID NO: 4 is an amino acid different from the
corresponding amino acid of SEQ ID NO: 35 and wherein the PHI-4
polypeptide has increased insecticidal activity compared to SEQ ID
NO: 35.
19. The polynucleotide of claim 17 or 18, wherein the PHI-4
polypeptide further comprises one or more amino acid substitutions
at position 86, 359, 399, 464, 465, 466, 467, 468, 499 or 517 of
SEQ ID NO: 3 or SEQ ID NO: 4.
20. The polynucleotide of claim 19, wherein in the PHI-4
polypeptide the amino acid at position 86 is Glu or Thr; the amino
acid at position 359 is Gly or Ala; the amino acid at position 399
is Gly or Ala; the amino acid at position 464 is Arg, Ala, Lys, Asp
or Asn; the amino acid at position 465 is Lys or Met, the amino
acid at position 467 is Val, Ala, Leu or Thr; the amino acid at
position 468 is Ser or Leu; the amino acid at position 499 is Glu
or Ala, or the amino acid at position 517 is Glu or Arg.
21. The polynucleotide of claim 17 or 18, wherein the PHI-4
polypeptide further comprises one or more amino acid substitution,
insertion of one or more amino acids, deletion of one or more amino
acids, and combinations thereof.
22. The polynucleotide of claim 17 or 18, wherein the insecticidal
activity of the PHI-4 polypeptide is increased about 2 fold or
greater compared to AXMI-205 (SEQ ID NO: 35).
23. The polynucleotide of claim 17 or 18, wherein the insecticidal
activity of the PHI-4 polypeptide is increased about 5 fold or
greater compared to AXMI-205 (SEQ ID NO: 35).
24. A composition, comprising an insecticidally-effective amount of
the PHI-4 polypeptide of claim 1.
25. A method of inhibiting growth or killing an insect pest,
comprising contacting the insect pest with the composition of claim
24.
26. A method for controlling an insect pest population resistant to
a pesticidal protein, comprising contacting the resistant insect
pest population with the composition of claim 1.
27. The method of controlling an insect pest population resistant
to an pesticidal protein of claim 1, wherein the pesticidal protein
is selected from Cry1Ac, Cry1Ab, Cry1A.105, Cry1Ac, Cry1F, Cry1Fa2,
Cry1F, Cry2Ab, Cry3A, mCry3A, Cry3Bb1, Cry34Ab1, Cry35Ab1, Vip3A,
Cry9c, eCry3.1Ab and CBI-Bt.
28. A transgenic plant or progeny thereof, comprising the
polynucleotide of claim 16.
29. The transgenic plant or progeny thereof of claim 28, wherein
the transgenic plant is a monocotyledon.
30. The transgenic plant or progeny thereof of claim 29, further
comprising one or more additional transgenic traits.
31. Seed, grain or processed product thereof of the transgenic
plant of claim 28, wherein the seed, grain, or processed product
thereof comprises the polynucleotide of any one of claim 16.
32. An expression cassette, comprising the polynucleotide of claim
16 operably linked to one or more regulatory sequences directing
expression of the PHI-4 polypeptide.
33. A transgenic plant or plant cell, comprising the expression
cassette of claim 32.
34. A method for protecting a plant from an insect pest, comprising
expressing in the plant or cell thereof, an
insecticidally-effective amount of the PHI-4 polypeptide of claim
1.
35. A method for controlling an insect pest population, comprising
contacting the insect pest population with an
insecticidally-effective amount of the PHI-4 polypeptide of claim
1.
36. A method of inhibiting growth or killing an insect pest,
comprising contacting the insect pest with a composition comprising
an insecticidally-effective amount of the the PHI-4 polypeptide of
claim 1.
37. A method for controlling an insect pest population resistant to
a pesticidal protein, comprising contacting the insect pest
population with an insecticidally-effective amount of the PHI-4
polypeptide of claim 1.
38. A fusion protein comprising the PHI-4 polypeptide of claim 1.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. Non Provisional
application Ser. No. 13/839,702 filed Mar. 15, 2013 the contents of
which are herein incorporated by reference in their entirety.
REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
[0002] The official copy of the sequence listing is submitted
electronically via EFS-Web as an ASCII formatted sequence listing
with a file named "5192USCNT_Sequence_Listing" created on Jun. 8,
2016, and having a size of 3632 kilobytes and is filed concurrently
with the specification. The sequence listing contained in this
ASCII formatted document is part of the specification and is herein
incorporated by reference in its entirety.
LENGTHY TABLES
[0003] The patent application contains a lengthy table section as
an ASCII formatted document, which is part of the specification and
is herein incorporated by reference in its entirety. A copy of the
tables are available in electronic form from the USPTO web site
(http://seqdata.uspto.gov/). An electronic copy of the table will
also be available from the USPTO upon request and payment of the
fee set forth in 37 CFR 1.19(b)(3)
FIELD OF THE INVENTION
[0004] This disclosure relates to the field of molecular biology.
Provided are novel genes that encode pesticidal proteins. These
pesticidal proteins and the nucleic acid sequences encoding them
are useful in preparing pesticidal formulations and in the
production of transgenic pest-resistant plants.
BACKGROUND OF THE INVENTION
[0005] Biological control of insect pests of agricultural
significance using a microbial agent, such as fungi, bacteria, or
another species of insect affords an environmentally friendly and
commercially attractive alternative to synthetic chemical
pesticides. Generally speaking, the use of biopesticides presents a
lower risk of pollution and environmental hazards, and
biopesticides provide greater target specificity than is
characteristic of traditional broad-spectrum chemical insecticides.
In addition, biopesticides often cost less to produce and thus
improve economic yield for a wide variety of crops.
[0006] Certain species of microorganisms of the genus Bacillus are
known to possess pesticidal activity against a range of insect
pests including Lepidoptera, Diptera, Coleoptera, Hemiptera and
others. Bacillus thuringiensis (Bt) and Bacillus popilliae are
among the most successful biocontrol agents discovered to date.
Insect pathogenicity has also been attributed to strains of B.
larvae, B. lentimorbus, B. sphaericus and B. cereus. Microbial
insecticides, particularly those obtained from Bacillus strains,
have played an important role in agriculture as alternatives to
chemical pest control.
[0007] Crop plants have been developed with enhanced insect
resistance by genetically engineering crop plants to produce
pesticidal proteins from Bacillus. For example, corn and cotton
plants have been genetically engineered to produce pesticidal
proteins isolated from strains of Bt. These genetically engineered
crops are now widely used in agriculture and have provided the
farmer with an environmentally friendly alternative to traditional
insect-control methods. While they have proven to be very
successful commercially, these genetically engineered,
insect-resistant crop plants provide resistance to only a narrow
range of the economically important insect pests. In some cases,
insects can develop resistance to different insecticidal compounds,
which raises the need to identify alternative biological control
agents for pest control.
[0008] Accordingly, there remains a need for new pesticidal
proteins with different ranges of insecticidal activity against
insect pests, e.g., insecticidal proteins which are active against
a variety of insects in the order Lepidoptera and the order
Hemiptera including but not limited to species belonging to the
family Pentatomidae, the family Plataspidae and the family
Cydnidae. In addition, there remains a need for biopesticides
having activity against a variety of insect pests that have
developed resistance to existing pesticides.
SUMMARY OF THE INVENTION
[0009] Compositions and methods for conferring pesticidal activity
to bacteria, plants, plant cells, tissues and seeds are provided.
Compositions include nucleic acid molecules encoding sequences for
pesticidal and insecticidal polypeptides, vectors comprising those
nucleic acid molecules, and host cells comprising the vectors.
Compositions also include the pesticidal polypeptide sequences and
antibodies to those polypeptides. The nucleic acid sequences can be
used in DNA constructs or expression cassettes for transformation
and expression in organisms, including microorganisms and plants.
The nucleotide or amino acid sequences may be synthetic sequences
that have been designed for expression in an organism including,
but not limited to, a microorganism or a plant. Compositions also
comprise transformed bacteria, plants, plant cells, tissues and
seeds.
[0010] In particular, isolated or recombinant nucleic acid
molecules are provided encoding PHI-4 polypeptides including amino
acid substitutions, amino acid deletions, amino acid insertions,
and fragments thereof, and combinations thereof. Additionally,
amino acid sequences corresponding to the PHI-4 polypeptides are
encompassed. Nucleic acid sequences that are complementary to a
nucleic acid sequence of the embodiments, or that hybridize to a
sequence of the embodiments are also encompassed.
[0011] Methods are provided for producing the polypeptides and for
using those polypeptides for controlling, inhibiting growth or
killing a Lepidopteran, Coleopteran, nematode, fungi, Hemipteran
and/or Dipteran pests. The transgenic plants of the embodiments
express one or more of the pesticidal sequences disclosed herein.
In various embodiments, the transgenic plant further comprises one
or more additional genes for insect resistance, for example, one or
more additional genes for controlling coleopteran, lepidopteran,
hemipteran or nematode pests. It will be understood by one of skill
in the art that the transgenic plant may comprise any gene
imparting an agronomic trait of interest.
[0012] Methods for detecting the nucleic acids and polypeptides of
the embodiments in a sample are also included. A kit for detecting
the presence of a PHI-4 polypeptide or detecting the presence of a
nucleotide sequence encoding a PHI-4 polypeptide in a sample is
provided. The kit is provided along with all reagents and control
samples necessary for carrying out a method for detecting the
intended agent, as well as instructions for use.
[0013] The compositions and methods of the embodiments are useful
for the production of organisms with enhanced pest resistance or
tolerance. These organisms and compositions comprising the
organisms are desirable for agricultural purposes. The compositions
of the embodiments are also useful for generating altered or
improved proteins that have pesticidal activity, or for detecting
the presence of PHI-4 polypeptides or nucleic acids in products or
organisms.
[0014] The following embodiments are encompassed by the present
disclosure.
[0015] Embodiment 1 is a PHI-4 polypeptide having improved
insecticidal activity compared to AXMI-205 (SEQ ID NO: 35).
[0016] Embodiment 2 is the PHI-4 polypeptide of embodiment 1,
wherein the insecticidal activity is increased about 1.5 fold or
greater compared to AXMI-205 (SEQ ID NO: 35).
[0017] Embodiment 3 is the PHI-4 polypeptide of embodiment 1,
wherein the insecticidal activity is increased about 2 fold or
greater compared to AXMI-205 (SEQ ID NO: 35).
[0018] Embodiment 4 is the PHI-4 polypeptide of embodiment 1,
wherein the insecticidal activity is increased about 2.5 fold or
greater compared to AXMI-205 (SEQ ID NO: 35).
[0019] Embodiment 5 is the PHI-4 polypeptide of embodiment 1,
wherein the insecticidal activity is increased about 3 fold or
greater compared to AXMI-205 (SEQ ID NO: 35).
[0020] Embodiment 6 is the PHI-4 polypeptide of embodiment 1,
wherein the insecticidal activity is increased about 5 fold or
greater compared to AXMI-205 (SEQ ID NO: 35).
[0021] Embodiment 7 is the PHI-4 polypeptide of any one of
embodiments 1-6, wherein the improved insecticidal activity
compared to AXMI-205 (SEQ ID NO: 35) is against Western Corn Root
Worm (WCRW) larvae.
[0022] Embodiment 8 is the PHI-4 polypeptide of any one of
embodiments 1-7, wherein the improved insecticidal activity
compared to AXMI-205 (SEQ ID NO: 35) is quantified as a Mean FAE
Index.
[0023] Embodiment 9 is the PHI-4 polypeptide of any one of
embodiments 1-7, wherein the improved insecticidal activity
compared to AXMI-205 (SEQ ID NO: 35) is quantified as an EC50
value.
[0024] Embodiment 10 is the PHI-4 polypeptide of any one of
embodiments 1-7, wherein the improved activity compared to AXMI-205
(SEQ ID NO: 35) is quantified as a Mean Deviation Score.
[0025] Embodiment 11 is the PHI-4 polypeptide of any one of
embodiments 1-10, wherein the PHI-4 polypeptide comprises one or
more amino acid substitutions compared to the native amino acid at
position 40, 42, 43, 46, 52, 97, 98, 99, 145, 150, 151, 153, 163,
171, 172, 182, 196, 206, 210, 216, 220, 278, 283, 289, 293, 328,
333, 334, 336, 338, 339, 342, 346, 354, 355, 370, 389, 393, 396,
401, 402, 403, 410, 412, 416, 417, 426, 442, 447, 452, 454, 455,
457, 461, 462, 500, 509, 520 or 527 of SEQ ID NO: 35.
[0026] Embodiment 12 is the PHI-4 polypeptide of embodiment 11,
further comprising one or more amino acid substitutions at position
86, 359, 464, 465, 466, 467, 468, 499 or 517.
[0027] Embodiment 13 is the PHI-4 polypeptide of embodiment 11 or
12, wherein the amino acid at position 86 is Glu or Thr; the amino
acid at position 359 is Gly or Ala; the amino acid at position 464
is Arg, Ala, Lys, Asp or Asn; the amino acid at position 465 is Lys
or Met, the amino acid at position 467 is Val, Ala, Leu or Thr; the
amino acid at position 468 is Ser or Leu; the amino acid at
position 499 is Glu or Ala, or the amino acid at position 517 is
Glu or Arg.
[0028] Embodiment 14 is the PHI-4 polypeptide of embodiment 11, 12
or 13, wherein the amino acid at position 40 is Leu or Ile; the
amino acid at position 42 is Asp or Asn; the amino acid at position
43 is Phe or Glu; the amino acid at position 46 is Glu or Asn; the
amino acid at position 52 is Ile or Val; the amino acid at position
97 is Arg, Asp, Glu or Asn; the amino acid at position 98 is Tyr or
Phe; the amino acid at position 99 is Lys or Leu; the amino acid at
position 145 is Leu or Val; the amino acid at position 150 is Arg
or Gln; the amino acid at position 151 is Asp or Ser; the amino
acid at position 153 is Leu or Ile; the amino acid at position 163
is Leu or Val; the amino acid at position 171 is Tyr or Phe; the
amino acid at position 172 is Ile or Leu; the amino acid at
position 182 is Asp or Gln; the amino acid at position 196 is Gln
or Asn; the amino acid at position 206 is Tyr or Phe; the amino
acid at position 210 is Val or Ile; the amino acid at position 216
is Glu or Gln; the amino acid at position 220 is Glu, Gln, His or
Asp; the amino acid at position 278 is Glu or Asn; the amino acid
at position 283 is Ile or Val; the amino acid at position 289 is
Lys, Gln or Leu; the amino acid at position 293 is Arg, Gln or Glu;
the amino acid at position 328 is Lys or Glu; the amino acid at
position 333 is Ser, Lys or Val; the amino acid at position 334 is
Gly, Lys or Arg; the amino acid at position 336 is Gly or Ala; the
amino acid at position 338 is Ser or Val; the amino acid at
position 339 is Glu, Asn or Gln; the amino acid at position 342 is
Ala or Ser; the amino acid at position 346 is Pro or Ala; the amino
acid at position 354 is Met or Leu; the amino acid at position 355
is Val or Ile; the amino acid at position 370 is His or Arg; the
amino acid at position 389 is Trp or Leu; the amino acid at
position 393 is Trp or Leu; the amino acid at position 396 is Ala,
Leu, Lys, Thr or Gly; the amino acid at position 401 is Ser, His,
Gly, Lys or Pro; the amino acid at position 402 is Lys, His, Gly or
Trp; the amino acid at position 403 is Asp or Tyr; the amino acid
at position 410 is Ile or Val; the amino acid at position 412 is
Pro or Ala; the amino acid at position 416 is Arg or Glu; the amino
acid at position 417 is Ala or Ser; the amino acid at position 426
is Thr or Ser; the amino acid at position 442 is Gln or Glu; the
amino acid at position 447 is Asp or Lys; the amino acid at
position 452 is Gln or Lys; the amino acid at position 454 is Arg
or Gln; the amino acid at position 455 is Val or Ile; the amino
acid at position 457 is Trp or Asn; the amino acid at position 461
is Thr or Ser; the amino acid at position 462 is Gly or Ala; the
amino acid at position 500 is Arg or Gln; the amino acid at
position 509 is Lys or Gln; the amino acid at position 520 is Lys,
Glu or Gln; and the amino acid at position 527 is Gln or Lys.
[0029] Embodiment 15 is the PHI-4 polypeptide of any one of
embodiments 1-11 and 14, having 1 to 54 amino acid substitutions
compared to SEQ ID NO: 35.
[0030] Embodiment 16 is the PHI-4 polypeptide of any one of
embodiments 1-11 and 14, having 1 to 27 amino acid substitutions
compared to SEQ ID NO: 35.
[0031] Embodiment 17 is the PHI-4 polypeptide of any one of
embodiments 1-11 and 14, having 1 to 20 amino acid substitutions
compared to SEQ ID NO: 35.
[0032] Embodiment 18 is the PHI-4 polypeptide of any one of
embodiments 1-11 and 14, having 1 to 15 amino acid substitutions
compared to SEQ ID NO: 35.
[0033] Embodiment 19 is the PHI-4 polypeptide of any one of
embodiments 12 or 13, comprising 2 to 54 amino acid substitutions
compared to SEQ ID NO: 35.
[0034] Embodiment 20 is the PHI-4 polypeptide of any one of
embodiments 12 or 13, comprising 2 to 27 amino acid substitutions
compared to SEQ ID NO: 35.
[0035] Embodiment 21 is the PHI-4 polypeptide of any one of
embodiments 12 or 13, comprising 2 to 20 amino acid substitutions
compared to SEQ ID NO: 35.
[0036] Embodiment 22 is the PHI-4 polypeptide of any one of
embodiments 12 or 13, comprising 2 to 15 amino acid substitutions
compared to SEQ ID NO: 35.
[0037] Embodiment 23 is the PHI-4 polypeptide of any one of
embodiments 1-22, wherein the PHI-4 polypeptide has at least 80%
identity to SEQ ID NO: 35.
[0038] Embodiment 24 is the PHI-4 polypeptide of any one of
embodiments 1-22, wherein the PHI-4 polypeptide has at least 90%
identity to SEQ ID NO: 35.
[0039] Embodiment 25 is the PHI-4 polypeptide of any one of
embodiments 1-22, wherein the PHI-4 polypeptide has at least 95%
identity to SEQ ID NO: 35.
[0040] Embodiment 26 is the PHI-4 polypeptide of any one of
embodiments 1-22, wherein the PHI-4 polypeptide has at least 97%
identity to SEQ ID NO: 35.
[0041] Embodiment 27 is a PHI-4 polypeptide, comprising at least
one amino acid substitution at a residue relative to SEQ ID NO: 35
in structural domain selected from: [0042] a hydrophilic residue;
[0043] a residue in a membrane insertion initiation loop; [0044] a
residue in a receptor binding loop; and [0045] a residue in a
protease sensitive region,
[0046] wherein the PHI-4 polypeptide has increased insecticidal
activity compared to SEQ ID NO: 35.
[0047] Embodiment 28 is the PHI-4 polypeptide of embodiment 27,
wherein the hydrophilic residues are Asp, Glu, Lys, Arg, His, Ser,
Thr, Tyr, Trp, Asn, Gln, and Cys.
[0048] Embodiment 29 is the PHI-4 polypeptide of embodiment 27 or
28, wherein the membrane insertion loops are between about amino
acid at position 92 (Val) and 101 (Ala) and at position 211 (Gly)
and 220 (Glu) relative to SEQ ID NO: 35.
[0049] Embodiment 30 is the PHI-4 polypeptide of embodiment 29,
wherein the membrane insertion initiation loop residue is selected
from position 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103,
211, 212, 213, 214, 215, 216, 217, 218, 219, 220 of SEQ ID NO:
35.
[0050] Embodiment 31 is the PHI-4 polypeptide of any one of
embodiments 27-30, wherein the receptor binding loops are between
about amino acid 332 (Asp) and 340 (Asp), 395 (Asp) and 403 (Asp),
458 (Asp) and 466 (Asp) relative to SEQ ID NO: 35.
[0051] Embodiment 32 is the PHI-4 polypeptide of embodiment 31,
wherein the receptor binding loop residue is selected from
positions 332, 333, 334, 335, 336, 337, 338, 339, 340, 395, 396,
397, 398, 399, 400, 401, 402, 403, 458, 459, 460, 461, 462, 463,
464, 465, 466 of SEQ ID NO: 35.
[0052] Embodiment 33 is the PHI-4 polypeptide of any one of
embodiments 27-32, wherein the protease sensitive region residue is
selected from about amino acid residues between 305 (Lys) and 316
(Lys) and 500 (Arg) and 535 (Lys) relative to SEQ ID NO: 35.
[0053] Embodiment 34 is the PHI-4 polypeptide of embodiment 27,
wherein the protease is trypsin.
[0054] Embodiment 35 is the PHI-4 polypeptide of any one of
embodiments 27-34, wherein the PHI-4 polypeptide has at least 80%
sequence identity to SEQ ID NO: 35.
[0055] Embodiment 36 is the PHI-4 polypeptide of any one of
embodiments 27-34, wherein the PHI-4 polypeptide has at least 90%
sequence identity to SEQ ID NO: 35.
[0056] Embodiment 37 is the PHI-4 polypeptide of any one of
embodiments 27-34, wherein the PHI-4 polypeptide has at least 95%
sequence identity to SEQ ID NO: 35.
[0057] Embodiment 38 is the PHI-4 polypeptide of any one of
embodiments 27-34, wherein the PHI-4 polypeptide has at least 97%
sequence identity to SEQ ID NO: 35.
[0058] Embodiment 39 is a PHI-4 polypeptide, comprising an amino
acid sequence of the formula,
TABLE-US-00001 (SEQ ID NO: 3) 5 10 15 Met Xaa Ser Ala Ala Asn Ala
Gly Xaa Leu Gly Asn Leu Xaa Gly 20 25 30 Xaa Thr Ser Xaa Gly Met
Xaa Tyr Xaa Val Asn Gly Leu Tyr Ala 35 40 45 Ser Pro Glu Ser Leu
Xaa Gly Gln Pro Leu Phe Xaa Xaa Gly Gly 50 55 60 Xaa Leu Asp Ser
Xaa Xaa Ile Glu Gly Xaa Xaa Xaa Xaa Phe Pro 65 70 75 Xaa Ser Met
His Val His Thr Tyr Phe His Ser Asp Xaa Xaa Gln 80 85 90 Xaa Val
Ser Xaa Xaa Ile Xaa Xaa Xaa Arg Xaa Xaa Xaa Ser Xaa 95 100 105 His
Val Gly Xaa Ser Gly Xaa Xaa Xaa Leu Phe Ser Xaa Ser Xaa 110 115 120
Ser Val Asp Xaa Thr Thr Xaa Xaa Gln Gln Leu Xaa Glu Ile Thr 125 130
135 Xaa Ser Ser Thr Arg Glu Xaa His Val Leu Trp Tyr Ile Ser Leu 140
145 150 Pro Gly Ala Ala Thr Leu Xaa Ser Met Leu Xaa Xaa Xaa Xaa Xaa
155 160 165 Xaa Asp Xaa Xaa Xaa Pro Asn Met Xaa Ala Met Xaa Leu Phe
Xaa 170 175 180 Xaa Xaa Gly Pro Xaa Xaa Xaa Xaa Xaa Ala Ala Val Gly
Gly Arg 185 190 195 Leu Xaa Xaa Xaa Xaa Ala Ser Lys Xaa Leu Xaa Met
Xaa Ser Ser 200 205 210 Xaa Ser Leu Ser Thr Thr Xaa Xaa Xaa Ser Xaa
Xaa Ala Xaa Xaa 215 220 225 Gly Glu Ile Xaa Ile Xaa His Gly Ser Xaa
Met Glu Lys Gln Val 230 235 240 Asn Ser Phe Xaa Xaa Xaa Ser Thr Ile
Arg Xaa Thr Ala Thr Gly 245 250 255 Gly Lys Pro Gly Xaa Thr Xaa Arg
Ile Leu His Gly Pro Asp Ser 260 265 270 Xaa Xaa Ala Phe Ser Xaa Trp
Ala Xaa Ser Leu Leu Xaa Tyr Ala 275 280 285 Thr Leu Met Asp Phe Xaa
Thr Xaa Ser Leu Xaa Xaa Ile Xaa Ala 290 295 300 Leu Xaa Asp Xaa Pro
Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Ala Xaa 305 310 315 Pro Xaa Xaa Met
Xaa Xaa Ser Gln Xaa Ser Ile Pro Xaa Val Asp 320 325 330 Xaa Val Leu
Leu Met Asp Ala Arg Pro Pro Met Val Xaa Ala Gly 335 340 345 Xaa Asp
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Xaa Xaa Xaa 350 355 360 Xaa
Ser Thr Ser Xaa Xaa Tyr Lys Xaa Xaa Gly Gln Phe Xaa Gln 365 370 375
Arg Xaa His Xaa Ser Val Ala Asp Gly His Xaa Pro Ile Xaa Xaa 380 385
390 Asp Leu Phe Asp Xaa Gly Xaa Xaa Xaa Xaa Pro Val Gly Xaa Gln 395
400 405 Xaa Val Trp Asp Xaa Xaa Xaa Xaa Gly Lys Xaa Xaa Xaa Tyr Xaa
410 415 420 Cys Trp Arg Xaa Xaa Xaa Xaa Gln Gly Tyr Xaa Xaa Xaa Gly
Asp 425 430 435 Val Xaa Met Leu Ala Xaa Ser Gly Tyr Asn Pro Pro Asn
Leu Pro 440 445 450 Xaa Xaa Xaa Cys Xaa His Xaa Ser Leu Xaa Ala Xaa
Xaa Xaa Thr 455 460 465 Leu Xaa Xaa Xaa Xaa Trp Xaa Asp Xaa Xaa Xaa
Xaa Xaa Xaa Xaa 470 475 480 Xaa Val Ser Leu Trp Xaa Pro Gly Ala Ala
Gly Ala Val Ala Ser 485 490 495 Ser Cys Phe Ala Gly Val Pro Asn Tyr
Asn Asn Pro Pro Asn Ser 500 505 510 Gly Xaa Ile Xaa Xaa Leu Xaa Gly
Ser Ile Ala Cys Val Xaa Thr 515 520 525 Ser Ala Ile Ala Ser Met Xaa
Xaa Met Xaa Ser Met Leu Ser Xaa 530 535 His Xaa Gly Met Glu Ala Met
Met Ser Lys Leu,
wherein Xaa at position 2 is Ala or Arg; Xaa at position 9 is Gln,
Lys or Glu; Xaa at position 14 is Pro or Ala; Xaa at position 16 is
Val or Asp; Xaa at position 19 is Met or Leu; Xaa at position 22 is
Gly or Ser; Xaa at position 24 is Asp, Asn or Gln; Xaa at position
36 is Leu or Met; Xaa at position 42 is Asp, Asn or Gln; Xaa at
position 43 is Phe or Glu; Xaa at position 46 is Glu, Asp, Asn or
Gly; Xaa at position 50 is Ile or Val; Xaa at position 51 is Glu or
Gln; Xaa at position 55 is Arg or Lys; Xaa at position 56 is Ser or
Thr; Xaa at position 57 is Tyr or Phe; Xaa at position 58 is Thr or
Ser; Xaa at position 61 is Arg, Lys or Glu; Xaa at position 73 is
Phe or Tyr; Xaa at position 74 is Lys, Glu, Gly, Arg, Met, Leu, His
or Asp; Xaa at position 76 is Asp or Gln; Xaa at position 79 is Lys
or Glu; Xaa at position 80 is Glu or Ser; Xaa at position 82 is
Glu, Ile, Leu, Tyr or Gln; Xaa at position 83 is Glu or Gln; Xaa at
position 84 is Tyr or Phe; Xaa at position 86 is Glu or Gln; Xaa at
position 87 is Lys or Gln; Xaa at position 88 is Met, Ile or Leu;
Xaa at position 90 is Gln or Glu; Xaa at position 94 is Val or Ile;
Xaa at position 97 is Arg, Asn, Asp, Glu, Gln, Gly or Ser; Xaa at
position 98 is Tyr or Phe; Xaa at position 99 is Lys, Leu, Tyr,
Ile, Met, Phe, Cys, Val or Asn; Xaa at position 103 is Ala or Gly;
Xaa at position 105 is Leu or Ile; Xaa at position 109 is Phe, Lys,
Gly, Met, Ser, Asp, Asn, Glu, Cys, Ala or Arg; Xaa at position 112
is Thr or Ser; Xaa at position 113 is Asp, Glu or Met; Xaa at
position 117 is Thr or Ser; Xaa at position 121 is Tyr or Phe; Xaa
at position 127 is Ala or Thr; Xaa at position 142 is Arg or Glu;
Xaa at position 146 is Arg or Gln; Xaa at position 147 is Arg, Glu
or Gln; Xaa at position 148 is Asp, Phe, Pro, Val, Glu, His, Trp,
Ala, Arg, Leu, Ser, Gln or Gly; Xaa at position 149 is Phe or Val;
Xaa at position 150 is Arg, Gln or Glu; Xaa at position 151 is Asp,
Ser, Ala, Asn, Trp, Val, Gln, Cys, Met, Leu, Arg or Glu; Xaa at
position 153 is Leu or Ile; Xaa at position 154 is Asn or Asp; Xaa
at position 155 is Asn or Lys; Xaa at position 159 is Pro or Asp;
Xaa at position 162 is Glu, Asp or Gln; Xaa at position 165 is Lys,
Glu, Gln, Pro, Thr, Ala, Leu, Gly, Asp, Val, His, Ile, Met, Trp,
Phe, Tyr or Arg; Xaa at position 166 is Arg or Gln; Xaa at position
167 is Tyr, Trp or Cys; Xaa at position 170 is Tyr or His; Xaa at
position 171 is Tyr or Phe; Xaa at position 172 is Ile, Leu or Val;
Xaa at position 173 is Ser or Ala; Xaa at position 174 is Glu or
Gln; Xaa at position 182 is Asp or Gln; Xaa at position 183 is Tyr
or Val; Xaa at position 184 is Ser or Thr; Xaa at position 185 is
Ala or Ser; Xaa at position 189 is Thr, Lys or Ile; Xaa at position
191 is Lys or Gln; Xaa at position 193 is Asp or Asn; Xaa at
position 196 is Gln, Lys, Asn, Asp, Glu, Ala, Ile or Arg; Xaa at
position 202 is Ala or Val; Xaa at position 203 is Glu, Thr or His;
Xaa at position 204 is Met or Ala; Xaa at position 206 is Tyr or
Phe; Xaa at position 207 is Lys or Gln; Xaa at position 209 is Leu
or Pro; Xaa at position 210 is Val or Ile; Xaa at position 214 is
Lys, Ser or Gln; Xaa at position 216 is Glu, Gln, Phe, Val, Tyr or
Arg; Xaa at position 220 is Glu, His, Asp, Thr, Tyr, Val, Ser, Gln,
Arg, Trp, Met, Ala, Phe, Ile, Leu, Cys or Asn; Xaa at position 229
is Arg or Glu; Xaa at position 230 is Ser or Glu; Xaa at position
231 is Asn or Ser; Xaa at position 236 is Leu or Pro; Xaa at
position 245 is Met or Leu; Xaa at position 247 is Asp or Tyr; Xaa
at position 256 is Gln, Lys or Glu; Xaa at position 257 is Gln,
Ile, Glu, Cys, Ser, His, Trp or Met; Xaa at position 261 is Gln,
Glu or Lys; Xaa at position 264 is Glu or Gln; Xaa at position 268
is Asp or Asn; Xaa at position 276 is Ser or Ala; Xaa at position
278 is Glu, Asn or Gln; Xaa at position 281 is Gln, Lys or Glu; Xaa
at position 282 is Pro or Gly; Xaa at position 284 is Trp or Arg;
Xaa at position 287 is Ala or Cys; Xaa at position 289 is Lys, Leu,
Val, Pro, Glu, Gln, Tyr, Thr, Asp, Phe, Ser, Met, Arg, Trp, Ile,
His, Asn, Cys, Gly or Ala; Xaa at position 291 is Glu or Gln; Xaa
at position 292 is Arg or Gln; Xaa at position 293 is Arg, Glu or
Gln; Xaa at position 294 is Val or Ala; Xaa at position 296 is Leu
or Ile; Xaa at position 297 is Glu or Gln; Xaa at position 298 is
Asp or Gln; Xaa at position 300 is Phe or Tyr; Xaa at position 302
is Glu or Gln; Xaa at position 303 is Phe or Tyr; Xaa at position
305 is Lys or Gln; Xaa at position 306 is Gln or Lys; Xaa at
position 309 is Gln, Lys or Glu; Xaa at position 313 is Lys, Gln or
Arg; Xaa at position 316 is Lys or Gln; Xaa at position 328 is Lys,
Glu or Gln; Xaa at position 331 is Glu, Asn or Gln; Xaa at position
333 is Ser, Arg, Gly, Lys, Val, Asn, Ala, His, Gln, Thr, Asp, Ile,
Leu, Cys or Glu; Xaa at position 334 is Gly, Arg, Lys, Ile or Trp;
Xaa at position 335 is Ser or Ala; Xaa at position 336 is Gly or
Ala; Xaa at position 337 is Ala, Val or Gly; Xaa at position 338 is
Ser, His, Val, Lys, Ala, Gly, Thr, Ile, Glu, Met, Arg, Pro, Asp,
Asn or Leu; Xaa at position 339 is Glu, Asn, Gln, Ile, Pro, Met,
Ser, Ala, Cys, Phe, Val, Leu, Asp, Trp, His or Arg; Xaa at position
341 is Leu or Val; Xaa at position 342 is Ala, Ser or Val; Xaa at
position 343 is Val or Ile; Xaa at position 344 is Phe or Trp; Xaa
at position 345 is Asn or His; Xaa at position 346 is Pro or Ala;
Xaa at position 350 is Asn or Ser; Xaa at position 351 is Gly or
Val; Xaa at position 354 is Met or Leu; Xaa at position 355 is Val,
Ile or Leu; Xaa at position 359 is Gly or Ala; Xaa at position 362
is Asn or Ser; Xaa at position 364 is Ala or Ser; Xaa at position
371 is Ala, Gly or Thr; Xaa at position 374 is Phe or Ile; Xaa at
position 375 is Lys or Arg; Xaa at position 380 is Leu or Gly; Xaa
at position 382 is Val, Asp or Leu; Xaa at position 383 is Leu, Ile
or Val; Xaa at position 384 is Lys, Ala or Gly; Xaa at position 385
is Ala or Gly; Xaa at position 389 is Trp or Tyr; Xaa at position
391 is Arg, Leu, Glu, Gln or Asp; Xaa at position 395 is Asp or
Cys; Xaa at position 396 is Ala, Leu, Lys, Asn, Gly, Ile, Met, Arg,
Tyr, Gln or His; Xaa at position 397 is Gly, Arg or Ala; Xaa at
position 398 is Ser, Gln or Cys; Xaa at position 401 is Ser, His,
Pro, Gly, Lys, Val, Arg, Ile, Asn, Phe, Thr, Ala, Asp, Met, Gln or
Glu; Xaa at position 402 is Lys, Phe, His, Arg, Trp, Gly, Asn, Leu,
Tyr, Thr, Val, Met, Pro or Ala; Xaa at position 403 is Asp, Tyr,
Trp, Phe or Glu; Xaa at position 405 is Ala or Ser; Xaa at position
409 is Ala or Pro; Xaa at position 410 is Ile or Val; Xaa at
position 411 is Pro or Ala; Xaa at position 412 is Pro or Ala; Xaa
at position 416 is Arg, Glu or Gln; Xaa at position 417 is Ala, Ser
or Cys; Xaa at position 418 is Leu or Met; Xaa at position 422 is
Met or Val; Xaa at position 426 is Thr or Ser; Xaa at position 436
is Asp or Lys; Xaa at position 437 is Tyr or Val; Xaa at position
438 is Val or Arg; Xaa at position 440 is Val or Leu; Xaa at
position 442 is Gln, Lys or Glu; Xaa at position 445 is Cys, Leu or
Thr; Xaa at position 447 is Asp, Lys, Tyr, Ser, Glu, Ile, Gly, Pro,
Leu, Phe, Trp or Thr; Xaa at position 448 is Val or Ala; Xaa at
position 449 is Gln or Glu; Xaa at position 452 is Gln, Lys or Glu;
Xaa at position 453 is Asn or Asp; Xaa at position 454 is Arg, Tyr,
Met, Ser, Val, Ile, Lys, Phe, Trp, Gln, Gly, His, Asp, Leu, Thr,
Pro or Asn; Xaa at position 455 is Val or Ile; Xaa at position 457
is Trp or Asn; Xaa at position 459 is Lys, Met, Val, Trp, Gln, Ile,
Thr, Ser, His, Cys, Tyr, Pro, Asn, Ala, Arg or Glu; Xaa at position
460 is Gly or Ala; Xaa at position 461 is Thr or Ser; Xaa at
position 462 is Gly or Ala; Xaa at position 463 is Ala, Ser or Gly;
Xaa at position 464 is Arg, Gly, His, Gln, Thr or Phe; Xaa at
position 465 is Lys, Asn, Val, Met, Pro, Gly, Arg, Thr, His, Cys,
Trp, Phe or Leu; Xaa at position 466 is Asp or Arg; Xaa at position
471 is Gln, Lys or Glu; Xaa at position 497 is Asp or Gln; Xaa at
position 499 is Glu or Gln; Xaa at position 500 is Arg, Gln or Lys;
Xaa at position 502 is Arg, Glu or Gln; Xaa at position 509 is Lys,
Gln or Glu; Xaa at position 517 is Gln, Cys, Asn, Val or Pro; Xaa
at position 518 is Glu or Gln; Xaa at position 520 is Lys, Gln or
Glu; Xaa at position 525 is Gln or Lys; and Xaa at position 527 is
Gln, Lys, Pro, Cys, Glu, Ser, His, Phe or Trp; wherein one or more
amino acid(s) designated by Xaa in SEQ ID NO: 3 is an amino acid
different from the corresponding amino acid of SEQ ID NO: 35 and
wherein the PHI-4 polypeptide has increased insecticidal activity
compared to SEQ ID NO: 35.
[0059] Embodiment 40 is a PHI-4 polypeptide, comprising an amino
acid sequence of the formula
TABLE-US-00002 (SEQ ID NO: 4) 5 10 15 Met Xaa Ser Ala Ala Asn Ala
Gly Gln Leu Gly Asn Leu Pro Gly 20 25 30 Val Thr Ser Met Gly Met
Gly Tyr Xaa Val Asn Gly Leu Tyr Ala 35 40 45 Ser Pro Glu Ser Leu
Leu Gly Gln Pro Leu Phe Xaa Xaa Gly Gly 50 55 60 Xaa Leu Asp Ser
Ile Glu Ile Glu Gly Arg Ser Tyr Thr Phe Pro 65 70 75 Arg Ser Met
His Val His Thr Tyr Phe His Ser Asp Phe Xaa Gln 80 85 90 Asp Val
Ser Xaa Glu Ile Xaa Glu Tyr Arg Glu Lys Met Ser Gln 95 100 105 His
Val Gly Val Ser Gly Xaa Xaa Xaa Leu Phe Ser Ala Ser Leu 110 115 120
Ser Val Asp Xaa Thr Thr Thr Asp Gln Gln Leu Thr Glu Ile Thr 125 130
135 Tyr Ser Ser Thr Arg Glu Ala His Val Leu Trp Tyr Ile Ser Leu 140
145 150 Pro Gly Ala Ala Thr Leu Arg Ser Met Leu Arg Xaa Xaa Phe Xaa
155 160 165 Xaa Asp Xaa Asn Asn Pro Asn Met Pro Ala Met Xaa Leu Phe
Xaa 170 175 180 Xaa Tyr Gly Pro Tyr Xaa Ile Ser Xaa Ala Ala Val Gly
Gly Arg 185 190 195 Leu Xaa Tyr Ser Ala Ala Ser Lys Thr Leu Lys Met
Asp Ser Ser 200 205 210 Xaa Ser Leu Ser Thr Thr Ala Xaa Met Ser Xaa
Lys Ala Leu Val 215 220 225 Gly Glu Ile Lys Ile Xaa His Gly Ser Xaa
Met Glu Lys Gln Val 230 235 240 Asn Ser Phe Arg Ser Asn Ser Thr Ile
Arg Leu Thr Ala Thr Gly 245 250 255 Gly Lys Pro Gly Met Thr Xaa Arg
Ile Leu His Gly Pro Asp Ser 260 265 270 Xaa Xaa Ala Phe Ser Xaa Trp
Ala Glu Ser Leu Leu Asp Tyr Ala 275 280 285 Thr Leu Met Asp Phe Ser
Thr Xaa Ser Leu Xaa Pro Ile Trp Ala 290 295 300 Leu Ala Asp Xaa Pro
Glu Arg Xaa Val Glu Leu Glu Asp Ala Phe 305 310 315 Pro Glu Phe Met
Lys Gln Ser Gln Gln Ser Ile Pro Xaa Val Asp 320 325 330 Lys Val Leu
Leu Met Asp Ala Arg Pro Pro Met Val Xaa Ala Gly 335 340 345 Glu Asp
Xaa Xaa Ser Xaa Ala Xaa Xaa Asp Leu Ala Xaa Phe Asn 350 355 360 Xaa
Ser Thr Ser Asn Gly Tyr Lys Met Xaa Gly Gln Phe Xaa Gln 365 370 375
Arg Asn His Ala Ser Val Ala Asp Gly His Ala Pro Ile Phe Lys 380 385
390 Asp Leu Phe Asp Leu Gly Val Leu Lys Ala Pro Val Gly Trp Gln 395
400 405 Xaa Val Trp Asp Asp Xaa Gly Ser Gly Lys Xaa Xaa Xaa Tyr Ala
410 415 420 Cys Trp Arg Ala Ile Xaa Xaa Gln Gly Tyr Xaa Xaa Xaa Gly
Asp 425 430 435 Val Met Met Leu Ala Xaa Ser Gly Tyr Asn Pro Pro Asn
Leu Pro 440 445 450 Asp Tyr Val Cys Xaa His Gln Ser Leu Cys Ala Xaa
Val Gln Thr 455 460 465 Leu Xaa Asn Xaa Xaa Trp Trp Asp Xaa Gly Xaa
Xaa Xaa Xaa Xaa 470 475 480 Asp Val Ser Leu Trp Xaa Pro Gly Ala Ala
Gly Ala Val Ala Ser 485 490 495 Ser Cys Phe Ala Gly Val Pro Asn Tyr
Asn Asn Pro Pro Asn Ser 500 505 510 Gly Asp Ile Glu Xaa Leu Arg Gly
Ser Ile Ala Cys Val Xaa Thr 515 520 525 Ser Ala Ile Ala Ser Met Gln
Glu Met Xaa Ser Met Leu Ser Gln 530 535 His Xaa Gly Met Glu Ala Met
Met Ser Lys Leu,
wherein Xaa at position 2 is Ala or Arg; Xaa at position 24 is Asp
or Asn; Xaa at position 42 is Asp or Asn; Xaa at position 43 is Phe
or Glu; Xaa at position 46 is Glu or Asn; Xaa at position 74 is
Lys, Glu or Gly; Xaa at position 79 is Lys or Glu; Xaa at position
82 is Glu, Ile, Leu or Tyr; Xaa at position 97 is Arg, Asn, Asp,
Glu, Gln or Gly; Xaa at position 98 is Tyr or Phe; Xaa at position
99 is Lys, Leu, Tyr, Ile or Met; Xaa at position 109 is Phe, Lys,
Gly, Met, Ser, Asp or Asn; Xaa at position 147 is Arg or Glu; Xaa
at position 148 is Asp, Phe or Pro; Xaa at position 150 is Arg or
Gln; Xaa at position 151 is Asp, Ser, Ala or Asn; Xaa at position
153 is Leu or Ile; Xaa at position 162 is Glu or Gln; Xaa at
position 165 is Lys, Glu or Gln; Xaa at position 166 is Arg or Gln;
Xaa at position 171 is Tyr or Phe; Xaa at position 174 is Glu or
Gln; Xaa at position 182 is Asp or Gln; Xaa at position 196 is Gln,
Lys, Asn or Asp; Xaa at position 203 is Glu, Thr or His; Xaa at
position 206 is Tyr or Phe; Xaa at position 216 is Glu or Gln; Xaa
at position 220 is Glu, His, Asp, Thr, Tyr, Val, Ser or Gln; Xaa at
position 247 is Asp or Tyr; Xaa at position 256 is Gln or Lys; Xaa
at position 257 is Gln or Ile; Xaa at position 261 is Gln or Glu;
Xaa at position 278 is Glu or Asn; Xaa at position 281 is Gln, Lys
or Glu; Xaa at position 289 is Lys, Leu, Val, Pro, Glu, Gln, Tyr,
Thr or Asp; Xaa at position 293 is Arg, Glu or Gln; Xaa at position
313 is Lys or Gln; Xaa at position 328 is Lys, Glu or Gln; Xaa at
position 333 is Ser, Gly, Lys, Val or Asn; Xaa at position 334 is
Gly, Arg, Lys or Ile; Xaa at position 336 is Gly or Ala; Xaa at
position 338 is Ser, His, Val, Lys or Ala; Xaa at position 339 is
Glu, Asn, Ile or Pro; Xaa at position 343 is Val or Ile; Xaa at
position 346 is Pro or Ala; Xaa at position 355 is Val or Ile; Xaa
at position 359 is Gly or Ala; Xaa at position 391 is Arg, Glu or
Gln; Xaa at position 396 is Ala, Leu, Lys, Asn or Gly; Xaa at
position 401 is Ser, His, Pro, Gly, Lys, Val or Arg; Xaa at
position 402 is Lys, Phe, His, Arg, Gly, Trp, Thr, Asn, Tyr or Met;
Xaa at position 403 is Asp or Tyr; Xaa at position 411 is Pro or
Ala; Xaa at position 412 is Pro or Ala; Xaa at position 416 is Arg
or Glu; Xaa at position 417 is Ala or Ser; Xaa at position 418 is
Leu or Met; Xaa at position 426 is Thr or Ser; Xaa at position 440
is Val or Leu; Xaa at position 447 is Asp, Lys, Tyr, Ser, Glu or
Ile; Xaa at position 452 is Gln, Lys or Glu; Xaa at position 454 is
Arg, Tyr, Met, Ser, Val, Ile, Lys, Phe, Trp or Gln; Xaa at position
455 is Val or Ile; Xaa at position 459 is Lys, Met, Val, Trp, Gln,
Ile or Tyr; Xaa at position 461 is Thr or Ser; Xaa at position 462
is Gly or Ala; Xaa at position 463 is Ala or Ser; Xaa at position
464 is Arg, Gly or His; Xaa at position 465 is Lys, Asn, Val, Met,
Pro, Gly or Arg; Xaa at position 471 is Gln, Lys or Glu; Xaa at
position 500 is Arg or Gln; Xaa at position 509 is Lys or Gln; Xaa
at position 520 is Lys, Gln or Glu; and Xaa at position 527 is Gln,
Lys, Pro, Cys or Glu; wherein one or more amino acid(s) designated
by Xaa in SEQ ID NO: 4 is an amino acid different from the
corresponding amino acid of SEQ ID NO: 35 and wherein the PHI-4
polypeptide has increased insecticidal activity compared to SEQ ID
NO: 35.
[0060] Embodiment 41 is the PHI-4 polypeptide of embodiment 39 or
40, further comprising one or more amino acid substitutions at
position 86, 359, 464, 465, 466, 467, 468, 499 or 517 of SEQ ID NO:
3 or SEQ ID NO: 4.
[0061] Embodiment 42 is the PHI-4 polypeptide of embodiment 41,
wherein the amino acid at position 86 is Glu or Thr; the amino acid
at position 359 is Gly or Ala; the amino acid at position 464 is
Arg, Ala, Lys, Asp or Asn; the amino acid at position 465 is Lys or
Met, the amino acid at position 467 is Val, Ala, Leu or Thr; the
amino acid at position 468 is Ser or Leu; the amino acid at
position 499 is Glu or Ala, or the amino acid at position 517 is
Glu or Arg.
[0062] Embodiment 43 is the PHI-4 polypeptide of embodiment 39-42,
further comprising one or more conservative amino acid
substitution, insertion of one or more amino acids, deletion of one
or more amino acids, and combinations thereof.
[0063] Embodiment 44 is the PHI-4 polypeptide of any one of
embodiments 39-43, wherein the insecticidal activity is increased
about 1.5 fold or greater compared to AXMI-205 (SEQ ID NO: 35).
[0064] Embodiment 45 is the PHI-4 polypeptide of any one of
embodiments 39-43, wherein the insecticidal activity is increased
about 2 fold or greater compared to AXMI-205 (SEQ ID NO: 35).
[0065] Embodiment 46 is the PHI-4 polypeptide of any one of
embodiments 39-43, wherein the insecticidal activity is increased
about 2.5 fold or greater compared to AXMI-205 (SEQ ID NO: 35).
[0066] Embodiment 47 is the PHI-4 polypeptide of any one of
embodiments 39-43, wherein the insecticidal activity is increased
about 3 fold or greater compared to AXMI-205 (SEQ ID NO: 35).
[0067] Embodiment 48 is the PHI-4 polypeptide of any one of
embodiments 39-43, wherein the insecticidal activity is increased
about 5 fold or greater compared to AXMI-205 (SEQ ID NO: 35).
[0068] Embodiment 49 is the PHI-4 polypeptide of any one of
embodiments 39-48, wherein the improved insecticidal activity
compared to AXMI-205 (SEQ ID NO: 35) is against Western Corn Root
Worm (WCRW) larvae.
[0069] Embodiment 50 is the PHI-4 polypeptide of any one of
embodiments 39-49, wherein the improved insecticidal activity
compared to AXMI-205 (SEQ ID NO: 35) is quantified as a Mean FAE
Index.
[0070] Embodiment 51 is the PHI-4 polypeptide of any one of
embodiments 39-49, wherein the improved insecticidal activity
compared to AXMI-205 (SEQ ID NO: 35) is quantified as an EC50
value.
[0071] Embodiment 52 is the PHI-4 polypeptide of any one of
embodiments 39-49, wherein the improved activity compared to
AXMI-205 (SEQ ID NO: 35) is quantified as a Mean Deviation
Score.
[0072] Embodiment 53 is the PHI-4 polypeptide of any one of
embodiments 39-49, having 1 to 54 amino acid substitutions at a
position(s) designated as Xaa in SEQ ID NO: 3 or 4.
[0073] Embodiment 54 is the PHI-4 polypeptide of any one of
embodiments 39-49, having 1 to 27 amino acid substitutions at a
position(s) designated as Xaa in SEQ ID NO: 3 or 4.
[0074] Embodiment 55 is the PHI-4 polypeptide of any one of
embodiments 39-49, having 1 to 20 amino acid substitutions at a
position(s) designated as Xaa in SEQ ID NO: 3 or 4.
[0075] Embodiment 56 is the PHI-4 polypeptide of any one of
embodiments 39-49, having 1 to 15 amino acid substitutions at a
position(s) designated as Xaa in SEQ ID NO: 3 or 4.
[0076] Embodiment 57 is the PHI-4 polypeptide of any one of
embodiments 1-56, wherein 1-25 amino acids are deleted from the
N-terminus of the PHI-4 polypeptide and/or C-terminus of the PHI-4
polypeptide.
[0077] Embodiment 58 is the PHI-4 polypeptide of any one of
embodiments 1-53, wherein 1-20 amino acids are deleted from the
C-terminus of the PHI-4 polypeptide.
[0078] Embodiment 59 is a polynucleotide encoding a PHI-4
polypeptide, wherein the PHI-4 polypeptide has improved
insecticidal activity compared to AXMI-205 (SEQ ID NO: 35).
[0079] Embodiment 60 is the polynucleotide of embodiment 59,
wherein the insecticidal activity of the PHI-4 polypeptide is
increased about 1.5 fold or greater compared to AXMI-205 (SEQ ID
NO: 35).
[0080] Embodiment 61 is the polynucleotide of embodiment 59,
wherein the insecticidal activity of the PHI-4 polypeptide is
increased about 2 fold or greater compared to AXMI-205 (SEQ ID NO:
35).
[0081] Embodiment 62 is the polynucleotide of embodiment 59,
wherein the insecticidal activity of the PHI-4 polypeptide is
increased about 2.5 fold or greater compared to AXMI-205 (SEQ ID
NO: 35).
[0082] Embodiment 63 is the polynucleotide of embodiment 59,
wherein the insecticidal activity of the PHI-4 polypeptide is
increased about 3 fold or greater compared to AXMI-205 (SEQ ID NO:
35).
[0083] Embodiment 64 is the polynucleotide of embodiment 59,
wherein the insecticidal activity of the PHI-4 polypeptide is
increased about 5 fold or greater compared to AXMI-205 (SEQ ID NO:
35).
[0084] Embodiment 65 is the polynucleotide of any one of
embodiments 59-64, wherein the improved insecticidal activity
compared to AXMI-205 (SEQ ID NO: 35) is against Western Corn Root
Worm (WCRW) larvae.
[0085] Embodiment 66 is the polynucleotide of any one of
embodiments 59-64, wherein the improved insecticidal activity
compared to AXMI-205 (SEQ ID NO: 35) is quantified as a Mean FAE
Index.
[0086] Embodiment 67 is the polynucleotide of any one of
embodiments 59-64, wherein the improved insecticidal activity
compared to AXMI-205 (SEQ ID NO: 35) is quantified as an EC50
value.
[0087] Embodiment 68 is the polynucleotide of any one of
embodiments 59-64, wherein the improved activity compared to
AXMI-205 (SEQ ID NO: 35) is quantified as a Mean Deviation
Score.
[0088] Embodiment 69 is the polynucleotide of any one of
embodiments 59-68, wherein the PHI-4 polypeptide comprises one or
more amino acid substitutions compared to the native amino acid at
position 40, 42, 43, 46, 52, 97, 98, 99, 145, 150, 151, 153, 163,
171, 172, 182, 196, 206, 210, 216, 220, 278, 283, 289, 293, 328,
333, 334, 336, 338, 339, 342, 346, 354, 355, 370, 389, 393, 396,
401, 402, 403, 410, 412, 416, 417, 426, 442, 447, 452, 454, 455,
457, 461, 462, 500, 509, 520 or 527 of SEQ ID NO: 35.
[0089] Embodiment 70 is the polynucleotide of embodiment 69,
wherein the PHI-4 polypeptide further comprises one or more amino
acid substitutions compared to the native amino acid at position
86, 359, 464, 465, 466, 467, 468, 499 or 517 of SEQ ID NO: 35.
[0090] Embodiment 71 is the polynucleotide of embodiment 70,
wherein the amino acid at position 86 is Glu or Thr; the amino acid
at position 359 is Gly or Ala; the amino acid at position 464 is
Arg, Ala, Lys, Asp or Asn; the amino acid at position 465 is Lys or
Met, the amino acid at position 467 is Val, Ala, Leu or Thr; the
amino acid at position 468 is Ser or Leu; the amino acid at
position 499 is Glu or Ala, or the amino acid at position 517 is
Glu or Arg.
[0091] Embodiment 72 is the polynucleotide of any one of
embodiments 69-71, wherein the amino acid at position 40 is Leu or
Ile; the amino acid at position 42 is Asp or Asn; the amino acid at
position 43 is Phe or Glu; the amino acid at position 46 is Glu or
Asn; the amino acid at position 52 is Ile or Val; the amino acid at
position 97 is Arg, Asp, Glu or Asn; the amino acid at position 98
is Tyr or Phe; the amino acid at position 99 is Lys or Leu; the
amino acid at position 145 is Leu or Val; the amino acid at
position 150 is Arg or Gln; the amino acid at position 151 is Asp
or Ser; the amino acid at position 153 is Leu or Ile; the amino
acid at position 163 is Leu or Val; the amino acid at position 171
is Tyr or Phe; the amino acid at position 172 is Ile or Leu; the
amino acid at position 182 is Asp or Gln; the amino acid at
position 196 is Gln or Asn; the amino acid at position 206 is Tyr
or Phe; the amino acid at position 210 is Val or Ile; the amino
acid at position 216 is Glu or Gln; the amino acid at position 220
is Glu, Gln, His or Asp; the amino acid at position 278 is Glu or
Asn; the amino acid at position 283 is Ile or Val; the amino acid
at position 289 is Lys, Gln or Leu; the amino acid at position 293
is Arg, Gln or Glu; the amino acid at position 328 is Lys or Glu;
the amino acid at position 333 is Ser, Lys or Val; the amino acid
at position 334 is Gly, Lys or Arg; the amino acid at position 336
is Gly or Ala; the amino acid at position 338 is Ser or Val; the
amino acid at position 339 is Glu, Asn or Gln; the amino acid at
position 342 is Ala or Ser; the amino acid at position 346 is Pro
or Ala; the amino acid at position 354 is Met or Leu; the amino
acid at position 355 is Val or Ile; the amino acid at position 370
is His or Arg; the amino acid at position 389 is Trp or Leu; the
amino acid at position 393 is Trp or Leu; the amino acid at
position 396 is Ala, Leu, Lys, Thr or Gly; the amino acid at
position 401 is Ser, His, Gly, Lys or Pro; the amino acid at
position 402 is Lys, His, Gly or Trp; the amino acid at position
403 is Asp or Tyr; the amino acid at position 410 is Ile or Val;
the amino acid at position 412 is Pro or Ala; the amino acid at
position 416 is Arg or Glu; the amino acid at position 417 is Ala
or Ser; the amino acid at position 426 is Thr or Ser; the amino
acid at position 442 is Gln or Glu; the amino acid at position 447
is Asp or Lys; the amino acid at position 452 is Gln or Lys; the
amino acid at position 454 is Arg or Gln; the amino acid at
position 455 is Val or Ile; the amino acid at position 457 is Trp
or Asn; the amino acid at position 461 is Thr or Ser; the amino
acid at position 462 is Gly or Ala; the amino acid at position 500
is Arg or Gln; the amino acid at position 509 is Lys or Gln; the
amino acid at position 520 is Lys, Glu or Gln; and the amino acid
at position 527 is Gln or Lys.
[0092] Embodiment 73 is the polynucleotide of any one of
embodiments 59-69 and 72, wherein the PHI-4 polypeptide has 1 to 54
amino acid substitutions compared to SEQ ID NO: 35.
[0093] Embodiment 74 is the polynucleotide of any one of
embodiments 59-69 and 72, wherein the PHI-4 polypeptide has 1 to 27
amino acid substitutions compared to SEQ ID NO: 2.
[0094] Embodiment 75 is the polynucleotide of any one of
embodiments 59-69 and 72, wherein the PHI-4 polypeptide has 1 to 20
amino acid substitutions compared to SEQ ID NO: 35.
[0095] Embodiment 76 is the polynucleotide of any one of
embodiments 59-69 and 72, wherein the PHI-4 polypeptide has 1 to 15
amino acid substitutions compared to SEQ ID NO: 35.
[0096] Embodiment 77 is the polynucleotide of embodiments 70 or 71,
wherein the PHI-4 polypeptide has 2 to 54 amino acid substitutions
compared to SEQ ID NO: 35.
[0097] Embodiment 78 is the polynucleotide of embodiments 70 or 71,
wherein the PHI-4 polypeptide has 2 to 27 amino acid substitutions
compared to SEQ ID NO: 35.
[0098] Embodiment 79 is the polynucleotide of embodiments 70 or 71,
wherein the PHI-4 polypeptide has 2 to 20 amino acid substitutions
compared to SEQ ID NO: 35.
[0099] Embodiment 80 is the polynucleotide of embodiments 70 or 71,
wherein the PHI-4 polypeptide has 2 to 15 amino acid substitutions
compared to SEQ ID NO: 35.
[0100] Embodiment 81 is the polynucleotide of any one of
embodiments 59-80, wherein the PHI-4 polypeptide has at least 80%
identity to SEQ ID NO: 35.
[0101] Embodiment 82 is the polynucleotide of any one of
embodiments 59-80, wherein the PHI-4 polypeptide has at least 90%
identity to SEQ ID NO: 35.
[0102] Embodiment 83 is the polynucleotide of any one of
embodiments 59-80, wherein the PHI-4 polypeptide has at least 95%
identity to SEQ ID NO: 35.
[0103] Embodiment 84 is the polynucleotide of any one of
embodiments 59-80, wherein the PHI-4 polypeptide has at least 97%
identity to SEQ ID NO: 35.
[0104] Embodiment 85 is a polynucleotide encoding a PHI-4
polypeptide, wherein the PHI-4 polypeptide has at least one amino
acid substitution at a residue relative to SEQ ID NO: 35 in
structural domain selected from: [0105] a hydrophilic residue;
[0106] a residue in a membrane insertion initiation loop; [0107] a
residue in a receptor binding loop; and [0108] a residue in a
protease sensitive region,
[0109] wherein the PHI-4 polypeptide has increased insecticidal
activity compared to SEQ ID NO: 35.
[0110] Embodiment 86 is the polynucleotide of embodiment 85,
wherein the hydrophilic residues are Asp, Glu, Lys, Arg, His, Ser,
Thr, Tyr, Trp, Asn, Gln, and Cys. Embodiment 87 is the
polynucleotide of embodiment 85 or 86, wherein the membrane
insertion loops are between about amino acid at position 92 (Val)
and 101 (Ala) and at position 211 (Gly) and 220 (Glu) relative to
SEQ ID NO: 35.
[0111] Embodiment 88 is the polynucleotide of embodiment 87,
wherein the PHI-4 polypeptide has one or more amino substitution
compared to the native amino acid at position 92, 93, 94, 95, 96,
97, 98, 99, 100, 101, 102, 103, 211, 212, 213, 214, 215, 216, 217,
218, 219, and 220 of SEQ ID NO: 35.
[0112] Embodiment 89 is the polynucleotide of any one of
embodiments 85, 86, 87 or 88, wherein the receptor binding loops
are between about amino acid 332 (Asp) and 340 (Asp), 395 (Asp) and
403 (Asp), 458 (Asp) and 466 (Asp) relative to SEQ ID NO: 35.
[0113] Embodiment 90 is the polynucleotide of embodiment 89,
wherein the PHI-4 polypeptide has one or more amino substitution
compared to the native amino acid at position 332, 333, 334, 335,
336, 337, 338, 339, 340, 395, 396, 397, 398, 399, 400, 401, 402,
403, 458, 459, 460, 461, 462, 463, 464, 465, 466 of SEQ ID NO:
35.
[0114] Embodiment 91 is the polynucleotide of any one of
embodiments 85, 86, 87, 88, 89 or 90, wherein the protease
sensitive region residue is selected from about amino acid residues
between position 305 (Lys) and position 316 (Lys) and/or position
500 (Arg) and position 535 (Lys) relative to SEQ ID NO: 35.
[0115] Embodiment 92 is the polynucleotide of any one of
embodiments 85, 86, 87, 88, 89, 90 or 91, wherein the protease is
trypsin.
[0116] Embodiment 93 is the polynucleotide of any one of
embodiments 85-92, wherein the PHI-4 polypeptide has at least 80%
sequence identity to SEQ ID NO: 35.
[0117] Embodiment 94 is the polynucleotide of any one of
embodiments 85-92, wherein the PHI-4 polypeptide has at least 90%
sequence identity to SEQ ID NO: 35.
[0118] Embodiment 95 is the polynucleotide of any one of
embodiments 85-92, wherein the PHI-4 polypeptide has at least 95%
sequence identity to SEQ ID NO: 35.
[0119] Embodiment 96 is the polynucleotide of any one of
embodiments 85-92, wherein the PHI-4 polypeptide has at least 97%
sequence identity to SEQ ID NO: 35.
[0120] Embodiment 97 is a polynucleotide encoding a PHI-4
polypeptide, wherein the PHI-4 polypeptide comprises an amino acid
sequence of the formula,
TABLE-US-00003 (SEQ ID NO: 3) 5 10 15 Met Xaa Ser Ala Ala Asn Ala
Gly Xaa Leu Gly Asn Leu Xaa Gly 20 25 30 Xaa Thr Ser Xaa Gly Met
Xaa Tyr Xaa Val Asn Gly Leu Tyr Ala 35 40 45 Ser Pro Glu Ser Leu
Xaa Gly Gln Pro Leu Phe Xaa Xaa Gly Gly 50 55 60 Xaa Leu Asp Ser
Xaa Xaa Ile Glu Gly Xaa Xaa Xaa Xaa Phe Pro 65 70 75 Xaa Ser Met
His Val His Thr Tyr Phe His Ser Asp Xaa Xaa Gln 80 85 90 Xaa Val
Ser Xaa Xaa Ile Xaa Xaa Xaa Arg Xaa Xaa Xaa Ser Xaa 95 100 105 His
Val Gly Xaa Ser Gly Xaa Xaa Xaa Leu Phe Ser Xaa Ser Xaa 110 115 120
Ser Val Asp Xaa Thr Thr Xaa Xaa Gln Gln Leu Xaa Glu Ile Thr 125 130
135 Xaa Ser Ser Thr Arg Glu Xaa His Val Leu Trp Tyr Ile Ser Leu 140
145 150 Pro Gly Ala Ala Thr Leu Xaa Ser Met Leu Xaa Xaa Xaa Xaa Xaa
155 160 165 Xaa Asp Xaa Xaa Xaa Pro Asn Met Xaa Ala Met Xaa Leu Phe
Xaa 170 175 180 Xaa Xaa Gly Pro Xaa Xaa Xaa Xaa Xaa Ala Ala Val Gly
Gly Arg 185 190 195 Leu Xaa Xaa Xaa Xaa Ala Ser Lys Xaa Leu Xaa Met
Xaa Ser Ser 200 205 210 Xaa Ser Leu Ser Thr Thr Xaa Xaa Xaa Ser Xaa
Xaa Ala Xaa Xaa 215 220 225 Gly Glu Ile Xaa Ile Xaa His Gly Ser Xaa
Met Glu Lys Gln Val 230 235 240 Asn Ser Phe Xaa Xaa Xaa Ser Thr Ile
Arg Xaa Thr Ala Thr Gly 245 250 255 Gly Lys Pro Gly Xaa Thr Xaa Arg
Ile Leu His Gly Pro Asp Ser 260 265 270 Xaa Xaa Ala Phe Ser Xaa Trp
Ala Xaa Ser Leu Leu Xaa Tyr Ala 275 280 285 Thr Leu Met Asp Phe Xaa
Thr Xaa Ser Leu Xaa Xaa Ile Xaa Ala 290 295 300 Leu Xaa Asp Xaa Pro
Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Ala Xaa 305 310 315 Pro Xaa Xaa Met
Xaa Xaa Ser Gln Xaa Ser Ile Pro Xaa Val Asp 320 325 330 Xaa Val Leu
Leu Met Asp Ala Arg Pro Pro Met Val Xaa Ala Gly 335 340 345 Xaa Asp
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Xaa Xaa Xaa 350 355 360 Xaa
Ser Thr Ser Xaa Xaa Tyr Lys Xaa Xaa Gly Gln Phe Xaa Gln 365 370 375
Arg Xaa His Xaa Ser Val Ala Asp Gly His Xaa Pro Ile Xaa Xaa 380 385
390 Asp Leu Phe Asp Xaa Gly Xaa Xaa Xaa Xaa Pro Val Gly Xaa Gln 395
400 405 Xaa Val Trp Asp Xaa Xaa Xaa Xaa Gly Lys Xaa Xaa Xaa Tyr Xaa
410 415 420 Cys Trp Arg Xaa Xaa Xaa Xaa Gln Gly Tyr Xaa Xaa Xaa Gly
Asp 425 430 435 Val Xaa Met Leu Ala Xaa Ser Gly Tyr Asn Pro Pro Asn
Leu Pro 440 445 450 Xaa Xaa Xaa Cys Xaa His Xaa Ser Leu Xaa Ala Xaa
Xaa Xaa Thr 455 460 465 Leu Xaa Xaa Xaa Xaa Trp Xaa Asp Xaa Xaa Xaa
Xaa Xaa Xaa Xaa 470 475 480 Xaa Val Ser Leu Trp Xaa Pro Gly Ala Ala
Gly Ala Val Ala Ser 485 490 495 Ser Cys Phe Ala Gly Val Pro Asn Tyr
Asn Asn Pro Pro Asn Ser 500 505 510 Gly Xaa Ile Xaa Xaa Leu Xaa Gly
Ser Ile Ala Cys Val Xaa Thr 515 520 525 Ser Ala Ile Ala Ser Met Xaa
Xaa Met Xaa Ser Met Leu Ser Xaa 530 535 His Xaa Gly Met Glu Ala Met
Met Ser Lys Leu,
wherein Xaa at position 2 is Ala or Arg; Xaa at position 9 is Gln,
Lys or Glu; Xaa at position 14 is Pro or Ala; Xaa at position 16 is
Val or Asp; Xaa at position 19 is Met or Leu; Xaa at position 22 is
Gly or Ser; Xaa at position 24 is Asp, Asn or Gln; Xaa at position
36 is Leu or Met; Xaa at position 42 is Asp, Asn or Gln; Xaa at
position 43 is Phe or Glu; Xaa at position 46 is Glu, Asp, Asn or
Gly; Xaa at position 50 is Ile or Val; Xaa at position 51 is Glu or
Gln; Xaa at position 55 is Arg or Lys; Xaa at position 56 is Ser or
Thr; Xaa at position 57 is Tyr or Phe; Xaa at position 58 is Thr or
Ser; Xaa at position 61 is Arg, Lys or Glu; Xaa at position 73 is
Phe or Tyr; Xaa at position 74 is Lys, Glu, Gly, Arg, Met, Leu, His
or Asp; Xaa at position 76 is Asp or Gln; Xaa at position 79 is Lys
or Glu; Xaa at position 80 is Glu or Ser; Xaa at position 82 is
Glu, Ile, Leu, Tyr or Gln; Xaa at position 83 is Glu or Gln; Xaa at
position 84 is Tyr or Phe; Xaa at position 86 is Glu or Gln; Xaa at
position 87 is Lys or Gln; Xaa at position 88 is Met, Ile or Leu;
Xaa at position 90 is Gln or Glu; Xaa at position 94 is Val or Ile;
Xaa at position 97 is Arg, Asn, Asp, Glu, Gln, Gly or Ser; Xaa at
position 98 is Tyr or Phe; Xaa at position 99 is Lys, Leu, Tyr,
Ile, Met, Phe, Cys, Val or Asn; Xaa at position 103 is Ala or Gly;
Xaa at position 105 is Leu or Ile; Xaa at position 109 is Phe, Lys,
Gly, Met, Ser, Asp, Asn, Glu, Cys, Ala or Arg; Xaa at position 112
is Thr or Ser; Xaa at position 113 is Asp, Glu or Met; Xaa at
position 117 is Thr or Ser; Xaa at position 121 is Tyr or Phe; Xaa
at position 127 is Ala or Thr; Xaa at position 142 is Arg or Glu;
Xaa at position 146 is Arg or Gln; Xaa at position 147 is Arg, Glu
or Gln; Xaa at position 148 is Asp, Phe, Pro, Val, Glu, His, Trp,
Ala, Arg, Leu, Ser, Gln or Gly; Xaa at position 149 is Phe or Val;
Xaa at position 150 is Arg, Gln or Glu; Xaa at position 151 is Asp,
Ser, Ala, Asn, Trp, Val, Gln, Cys, Met, Leu, Arg or Glu; Xaa at
position 153 is Leu or Ile; Xaa at position 154 is Asn or Asp; Xaa
at position 155 is Asn or Lys; Xaa at position 159 is Pro or Asp;
Xaa at position 162 is Glu, Asp or Gln; Xaa at position 165 is Lys,
Glu, Gln, Pro, Thr, Ala, Leu, Gly, Asp, Val, His, Ile, Met, Trp,
Phe, Tyr or Arg; Xaa at position 166 is Arg or Gln; Xaa at position
167 is Tyr, Trp or Cys; Xaa at position 170 is Tyr or His; Xaa at
position 171 is Tyr or Phe; Xaa at position 172 is Ile, Leu or Val;
Xaa at position 173 is Ser or Ala; Xaa at position 174 is Glu or
Gln; Xaa at position 182 is Asp or Gln; Xaa at position 183 is Tyr
or Val; Xaa at position 184 is Ser or Thr; Xaa at position 185 is
Ala or Ser; Xaa at position 189 is Thr, Lys or Ile; Xaa at position
191 is Lys or Gln; Xaa at position 193 is Asp or Asn; Xaa at
position 196 is Gln, Lys, Asn, Asp, Glu, Ala, Ile or Arg; Xaa at
position 202 is Ala or Val; Xaa at position 203 is Glu, Thr or His;
Xaa at position 204 is Met or Ala; Xaa at position 206 is Tyr or
Phe; Xaa at position 207 is Lys or Gln; Xaa at position 209 is Leu
or Pro; Xaa at position 210 is Val or Ile; Xaa at position 214 is
Lys, Ser or Gln; Xaa at position 216 is Glu, Gln, Phe, Val, Tyr or
Arg; Xaa at position 220 is Glu, His, Asp, Thr, Tyr, Val, Ser, Gln,
Arg, Trp, Met, Ala, Phe, Ile, Leu, Cys or Asn; Xaa at position 229
is Arg or Glu; Xaa at position 230 is Ser or Glu; Xaa at position
231 is Asn or Ser; Xaa at position 236 is Leu or Pro; Xaa at
position 245 is Met or Leu; Xaa at position 247 is Asp or Tyr; Xaa
at position 256 is Gln, Lys or Glu; Xaa at position 257 is Gln,
Ile, Glu, Cys, Ser, His, Trp or Met; Xaa at position 261 is Gln,
Glu or Lys; Xaa at position 264 is Glu or Gln; Xaa at position 268
is Asp or Asn; Xaa at position 276 is Ser or Ala; Xaa at position
278 is Glu, Asn or Gln; Xaa at position 281 is Gln, Lys or Glu; Xaa
at position 282 is Pro or Gly; Xaa at position 284 is Trp or Arg;
Xaa at position 287 is Ala or Cys; Xaa at position 289 is Lys, Leu,
Val, Pro, Glu, Gln, Tyr, Thr, Asp, Phe, Ser, Met, Arg, Trp, Ile,
His, Asn, Cys, Gly or Ala; Xaa at position 291 is Glu or Gln; Xaa
at position 292 is Arg or Gln; Xaa at position 293 is Arg, Glu or
Gln; Xaa at position 294 is Val or Ala; Xaa at position 296 is Leu
or Ile; Xaa at position 297 is Glu or Gln; Xaa at position 298 is
Asp or Gln; Xaa at position 300 is Phe or Tyr; Xaa at position 302
is Glu or Gln; Xaa at position 303 is Phe or Tyr; Xaa at position
305 is Lys or Gln; Xaa at position 306 is Gln or Lys; Xaa at
position 309 is Gln, Lys or Glu; Xaa at position 313 is Lys, Gln or
Arg; Xaa at position 316 is Lys or Gln; Xaa at position 328 is Lys,
Glu or Gln; Xaa at position 331 is Glu, Asn or Gln; Xaa at position
333 is Ser, Arg, Gly, Lys, Val, Asn, Ala, His, Gln, Thr, Asp, Ile,
Leu, Cys or Glu; Xaa at position 334 is Gly, Arg, Lys, Ile or Trp;
Xaa at position 335 is Ser or Ala; Xaa at position 336 is Gly or
Ala; Xaa at position 337 is Ala, Val or Gly; Xaa at position 338 is
Ser, His, Val, Lys, Ala, Gly, Thr, Ile, Glu, Met, Arg, Pro, Asp,
Asn or Leu; Xaa at position 339 is Glu, Asn, Gln, Ile, Pro, Met,
Ser, Ala, Cys, Phe, Val, Leu, Asp, Trp, His or Arg; Xaa at position
341 is Leu or Val; Xaa at position 342 is Ala, Ser or Val; Xaa at
position 343 is Val or Ile; Xaa at position 344 is Phe or Trp; Xaa
at position 345 is Asn or His; Xaa at position 346 is Pro or Ala;
Xaa at position 350 is Asn or Ser; Xaa at position 351 is Gly or
Val; Xaa at position 354 is Met or Leu; Xaa at position 355 is Val,
Ile or Leu; Xaa at position 359 is Gly or Ala; Xaa at position 362
is Asn or Ser; Xaa at position 364 is Ala or Ser; Xaa at position
371 is Ala, Gly or Thr; Xaa at position 374 is Phe or Ile; Xaa at
position 375 is Lys or Arg; Xaa at position 380 is Leu or Gly; Xaa
at position 382 is Val, Asp or Leu; Xaa at position 383 is Leu, Ile
or Val; Xaa at position 384 is Lys, Ala or Gly; Xaa at position 385
is Ala or Gly; Xaa at position 389 is Trp or Tyr; Xaa at position
391 is Arg, Leu, Glu, Gln or Asp; Xaa at position 395 is Asp or
Cys; Xaa at position 396 is Ala, Leu, Lys, Asn, Gly, Ile, Met, Arg,
Tyr, Gln or His; Xaa at position 397 is Gly, Arg or Ala; Xaa at
position 398 is Ser, Gln or Cys; Xaa at position 401 is Ser, His,
Pro, Gly, Lys, Val, Arg, Ile, Asn, Phe, Thr, Ala, Asp, Met, Gln or
Glu; Xaa at position 402 is Lys, Phe, His, Arg, Trp, Gly, Asn, Leu,
Tyr, Thr, Val, Met, Pro or Ala; Xaa at position 403 is Asp, Tyr,
Trp, Phe or Glu; Xaa at position 405 is Ala or Ser; Xaa at position
409 is Ala or Pro; Xaa at position 410 is Ile or Val; Xaa at
position 411 is Pro or Ala; Xaa at position 412 is Pro or Ala; Xaa
at position 416 is Arg, Glu or Gln; Xaa at position 417 is Ala, Ser
or Cys; Xaa at position 418 is Leu or Met; Xaa at position 422 is
Met or Val; Xaa at position 426 is Thr or Ser; Xaa at position 436
is Asp or Lys; Xaa at position 437 is Tyr or Val; Xaa at position
438 is Val or Arg; Xaa at position 440 is Val or Leu; Xaa at
position 442 is Gln, Lys or Glu; Xaa at position 445 is Cys, Leu or
Thr; Xaa at position 447 is Asp, Lys, Tyr, Ser, Glu, Ile, Gly, Pro,
Leu, Phe, Trp or Thr; Xaa at position 448 is Val or Ala; Xaa at
position 449 is Gln or Glu; Xaa at position 452 is Gln, Lys or Glu;
Xaa at position 453 is Asn or Asp; Xaa at position 454 is Arg, Tyr,
Met, Ser, Val, Ile, Lys, Phe, Trp, Gln, Gly, His, Asp, Leu, Thr,
Pro or Asn; Xaa at position 455 is Val or Ile; Xaa at position 457
is Trp or Asn; Xaa at position 459 is Lys, Met, Val, Trp, Gln, Ile,
Thr, Ser, His, Cys, Tyr, Pro, Asn, Ala, Arg or Glu; Xaa at position
460 is Gly or Ala; Xaa at position 461 is Thr or Ser; Xaa at
position 462 is Gly or Ala; Xaa at position 463 is Ala, Ser or Gly;
Xaa at position 464 is Arg, Gly, His, Gln, Thr or Phe; Xaa at
position 465 is Lys, Asn, Val, Met, Pro, Gly, Arg, Thr, His, Cys,
Trp, Phe or Leu; Xaa at position 466 is Asp or Arg; Xaa at position
471 is Gln, Lys or Glu; Xaa at position 497 is Asp or Gln; Xaa at
position 499 is Glu or Gln; Xaa at position 500 is Arg, Gln or Lys;
Xaa at position 502 is Arg, Glu or Gln; Xaa at position 509 is Lys,
Gln or Glu; Xaa at position 517 is Gln, Cys, Asn, Val or Pro; Xaa
at position 518 is Glu or Gln; Xaa at position 520 is Lys, Gln or
Glu; Xaa at position 525 is Gln or Lys; and Xaa at position 527 is
Gln, Lys, Pro, Cys, Glu, Ser, His, Phe or Trp; wherein one or more
amino acid(s) designated by Xaa in SEQ ID NO: 3 is an amino acid
different from the corresponding amino acid of SEQ ID NO: 35 and
wherein the PHI-4 polypeptide has increased insecticidal activity
compared to SEQ ID NO: 35.
[0121] Embodiment 98 is a polynucleotide encoding a PHI-4
polypeptide, wherein the PHI-4 polypeptide comprises an amino acid
sequence of the formula,
TABLE-US-00004 (SEQ ID NO: 4) 5 10 15 Met Xaa Ser Ala Ala Asn Ala
Gly Gln Leu Gly Asn Leu Pro Gly 20 25 30 Val Thr Ser Met Gly Met
Gly Tyr Xaa Val Asn Gly Leu Tyr Ala 35 40 45 Ser Pro Glu Ser Leu
Leu Gly Gln Pro Leu Phe Xaa Xaa Gly Gly 50 55 60 Xaa Leu Asp Ser
Ile Glu Ile Glu Gly Arg Ser Tyr Thr Phe Pro 65 70 75 Arg Ser Met
His Val His Thr Tyr Phe His Ser Asp Phe Xaa Gln 80 85 90 Asp Val
Ser Xaa Glu Ile Xaa Glu Tyr Arg Glu Lys Met Ser Gln 95 100 105 His
Val Gly Val Ser Gly Xaa Xaa Xaa Leu Phe Ser Ala Ser Leu 110 115 120
Ser Val Asp Xaa Thr Thr Thr Asp Gln Gln Leu Thr Glu Ile Thr 125 130
135 Tyr Ser Ser Thr Arg Glu Ala His Val Leu Trp Tyr Ile Ser Leu 140
145 150 Pro Gly Ala Ala Thr Leu Arg Ser Met Leu Arg Xaa Xaa Phe Xaa
155 160 165 Xaa Asp Xaa Asn Asn Pro Asn Met Pro Ala Met Xaa Leu Phe
Xaa 170 175 180 Xaa Tyr Gly Pro Tyr Xaa Ile Ser Xaa Ala Ala Val Gly
Gly Arg 185 190 195 Leu Xaa Tyr Ser Ala Ala Ser Lys Thr Leu Lys Met
Asp Ser Ser 200 205 210 Xaa Ser Leu Ser Thr Thr Ala Xaa Met Ser Xaa
Lys Ala Leu Val 215 220 225 Gly Glu Ile Lys Ile Xaa His Gly Ser Xaa
Met Glu Lys Gln Val 230 235 240 Asn Ser Phe Arg Ser Asn Ser Thr Ile
Arg Leu Thr Ala Thr Gly 245 250 255 Gly Lys Pro Gly Met Thr Xaa Arg
Ile Leu His Gly Pro Asp Ser 260 265 270 Xaa Xaa Ala Phe Ser Xaa Trp
Ala Glu Ser Leu Leu Asp Tyr Ala 275 280 285 Thr Leu Met Asp Phe Ser
Thr Xaa Ser Leu Xaa Pro Ile Trp Ala 290 295 300 Leu Ala Asp Xaa Pro
Glu Arg Xaa Val Glu Leu Glu Asp Ala Phe 305 310 315 Pro Glu Phe Met
Lys Gln Ser Gln Gln Ser Ile Pro Xaa Val Asp 320 325 330 Lys Val Leu
Leu Met Asp Ala Arg Pro Pro Met Val Xaa Ala Gly 335 340 345 Glu Asp
Xaa Xaa Ser Xaa Ala Xaa Xaa Asp Leu Ala Xaa Phe Asn 350 355 360 Xaa
Ser Thr Ser Asn Gly Tyr Lys Met Xaa Gly Gln Phe Xaa Gln 365 370 375
Arg Asn His Ala Ser Val Ala Asp Gly His Ala Pro Ile Phe Lys 380 385
390 Asp Leu Phe Asp Leu Gly Val Leu Lys Ala Pro Val Gly Trp Gln 395
400 405 Xaa Val Trp Asp Asp Xaa Gly Ser Gly Lys Xaa Xaa Xaa Tyr Ala
410 415 420 Cys Trp Arg Ala Ile Xaa Xaa Gln Gly Tyr Xaa Xaa Xaa Gly
Asp 425 430 435 Val Met Met Leu Ala Xaa Ser Gly Tyr Asn Pro Pro Asn
Leu Pro 440 445 450 Asp Tyr Val Cys Xaa His Gln Ser Leu Cys Ala Xaa
Val Gln Thr 455 460 465 Leu Xaa Asn Xaa Xaa Trp Trp Asp Xaa Gly Xaa
Xaa Xaa Xaa Xaa 470 475 480 Asp Val Ser Leu Trp Xaa Pro Gly Ala Ala
Gly Ala Val Ala Ser 485 490 495 Ser Cys Phe Ala Gly Val Pro Asn Tyr
Asn Asn Pro Pro Asn Ser 500 505 510 Gly Asp Ile Glu Xaa Leu Arg Gly
Ser Ile Ala Cys Val Xaa Thr 515 520 525 Ser Ala Ile Ala Ser Met Gln
Glu Met Xaa Ser Met Leu Ser Gln 530 535 His Xaa Gly Met Glu Ala Met
Met Ser Lys Leu,
wherein Xaa at position 2 is Ala or Arg; Xaa at position 24 is Asp
or Asn; Xaa at position 42 is Asp or Asn; Xaa at position 43 is Phe
or Glu; Xaa at position 46 is Glu or Asn; Xaa at position 74 is
Lys, Glu or Gly; Xaa at position 79 is Lys or Glu; Xaa at position
82 is Glu, Ile, Leu or Tyr; Xaa at position 97 is Arg, Asn, Asp,
Glu, Gln or Gly; Xaa at position 98 is Tyr or Phe; Xaa at position
99 is Lys, Leu, Tyr, Ile or Met; Xaa at position 109 is Phe, Lys,
Gly, Met, Ser, Asp or Asn; Xaa at position 147 is Arg or Glu; Xaa
at position 148 is Asp, Phe or Pro; Xaa at position 150 is Arg or
Gln; Xaa at position 151 is Asp, Ser, Ala or Asn; Xaa at position
153 is Leu or Ile; Xaa at position 162 is Glu or Gln; Xaa at
position 165 is Lys, Glu or Gln; Xaa at position 166 is Arg or Gln;
Xaa at position 171 is Tyr or Phe; Xaa at position 174 is Glu or
Gln; Xaa at position 182 is Asp or Gln; Xaa at position 196 is Gln,
Lys, Asn or Asp; Xaa at position 203 is Glu, Thr or His; Xaa at
position 206 is Tyr or Phe; Xaa at position 216 is Glu or Gln; Xaa
at position 220 is Glu, His, Asp, Thr, Tyr, Val, Ser or Gln; Xaa at
position 247 is Asp or Tyr; Xaa at position 256 is Gln or Lys; Xaa
at position 257 is Gln or Ile; Xaa at position 261 is Gln or Glu;
Xaa at position 278 is Glu or Asn; Xaa at position 281 is Gln, Lys
or Glu; Xaa at position 289 is Lys, Leu, Val, Pro, Glu, Gln, Tyr,
Thr or Asp; Xaa at position 293 is Arg, Glu or Gln; Xaa at position
313 is Lys or Gln; Xaa at position 328 is Lys, Glu or Gln; Xaa at
position 333 is Ser, Gly, Lys, Val or Asn; Xaa at position 334 is
Gly, Arg, Lys or Ile; Xaa at position 336 is Gly or Ala; Xaa at
position 338 is Ser, His, Val, Lys or Ala; Xaa at position 339 is
Glu, Asn, Ile or Pro; Xaa at position 343 is Val or Ile; Xaa at
position 346 is Pro or Ala; Xaa at position 355 is Val or Ile; Xaa
at position 359 is Gly or Ala; Xaa at position 391 is Arg, Glu or
Gln; Xaa at position 396 is Ala, Leu, Lys, Asn or Gly; Xaa at
position 401 is Ser, His, Pro, Gly, Lys, Val or Arg; Xaa at
position 402 is Lys, Phe, His, Arg, Gly, Trp, Thr, Asn, Tyr or Met;
Xaa at position 403 is Asp or Tyr; Xaa at position 411 is Pro or
Ala; Xaa at position 412 is Pro or Ala; Xaa at position 416 is Arg
or Glu; Xaa at position 417 is Ala or Ser; Xaa at position 418 is
Leu or Met; Xaa at position 426 is Thr or Ser; Xaa at position 440
is Val or Leu; Xaa at position 447 is Asp, Lys, Tyr, Ser, Glu or
Ile; Xaa at position 452 is Gln, Lys or Glu; Xaa at position 454 is
Arg, Tyr, Met, Ser, Val, Ile, Lys, Phe, Trp or Gln; Xaa at position
455 is Val or Ile; Xaa at position 459 is Lys, Met, Val, Trp, Gln,
Ile or Tyr; Xaa at position 461 is Thr or Ser; Xaa at position 462
is Gly or Ala; Xaa at position 463 is Ala or Ser; Xaa at position
464 is Arg, Gly or His; Xaa at position 465 is Lys, Asn, Val, Met,
Pro, Gly or Arg; Xaa at position 471 is Gln, Lys or Glu; Xaa at
position 500 is Arg or Gln; Xaa at position 509 is Lys or Gln; Xaa
at position 520 is Lys, Gln or Glu; and Xaa at position 527 is Gln,
Lys, Pro, Cys or Glu; wherein one or more amino acid(s) designated
by Xaa in SEQ ID NO: 4 is an amino acid different from the
corresponding amino acid of SEQ ID NO: 35 and wherein the PHI-4
polypeptide has increased insecticidal activity compared to SEQ ID
NO: 35.
[0122] Embodiment 99 is the polynucleotide of embodiments 97 or 98,
wherein the PHI-4 polypeptide further comprises one or more amino
acid substitutions at position 86, 359, 464, 465, 466, 467, 468,
499 or 517 of SEQ ID NO: 3 or SEQ ID NO: 4.
[0123] Embodiment 100 is the polynucleotide of embodiment 99,
wherein the amino acid at position 86 is Glu or Thr; the amino acid
at position 359 is Gly or Ala; the amino acid at position 464 is
Arg, Ala, Lys, Asp or Asn; the amino acid at position 465 is Lys or
Met, the amino acid at position 467 is Val, Ala, Leu or Thr; the
amino acid at position 468 is Ser or Leu; the amino acid at
position 499 is Glu or Ala, or the amino acid at position 517 is
Glu or Arg.
[0124] Embodiment 101 is the polynucleotide of any one of
embodiments 97-100, wherein the PHI-4 polypeptide further comprises
one or more more conservative amino acid substitution, insertion of
one or more amino acids, deletion of one or more amino acids, and
combinations thereof.
[0125] Embodiment 102 is the polynucleotide of any one of
embodiments 97-101, wherein the insecticidal activity of the PHI-4
polypeptide is increased about 1.5 fold or greater compared to
AXMI-205 (SEQ ID NO: 35).
[0126] Embodiment 103 is the polynucleotide of any one of
embodiments 97-101, wherein the insecticidal activity of the PHI-4
polypeptide is increased about 2 fold or greater compared to
AXMI-205 (SEQ ID NO: 35).
[0127] Embodiment 104 is the polynucleotide of any one of
embodiments 97-101, wherein the insecticidal activity of the PHI-4
polypeptide is increased about 2.5 fold or greater compared to
AXMI-205 (SEQ ID NO: 35).
[0128] Embodiment 105 is the polynucleotide of any one of
embodiments 97-101, wherein the insecticidal activity of the PHI-4
polypeptide is increased about 3 fold or greater compared to
AXMI-205 (SEQ ID NO: 35).
[0129] Embodiment 106 is the polynucleotide of any one of
embodiments 97-101, wherein the insecticidal activity of the PHI-4
polypeptide is increased about 5 fold or greater compared to
AXMI-205 (SEQ ID NO: 35).
[0130] Embodiment 107 is the polynucleotide of any one of
embodiments 97-106, wherein the improved insecticidal activity
compared to AXMI-205 (SEQ ID NO: 35) is against Western Corn Root
Worm (WCRW) larvae.
[0131] Embodiment 108 is the polynucleotide of any one of
embodiments 97-107, wherein the improved insecticidal activity
compared to AXMI-205 (SEQ ID NO: 35) is quantified as a Mean FAE
Index.
[0132] Embodiment 109 is the polynucleotide of any one of
embodiments 97-107, wherein the improved insecticidal activity
compared to AXMI-205 (SEQ ID NO: 35) is quantified as an EC50
value.
[0133] Embodiment 110 is the polynucleotide of any one of
embodiments 97-107, wherein the improved activity compared to
AXMI-205 (SEQ ID NO: 35) is quantified as a Mean Deviation
Score.
[0134] Embodiment 111 is the polynucleotide of any one of
embodiments 97-110, wherein the PHI-4 polypeptide has 1 to 54 amino
acid substitutions at a position(s) designated as Xaa in SEQ ID NO:
3 or 4.
[0135] Embodiment 112 is the polynucleotide of any one of
embodiments 97-110, wherein the PHI-4 polypeptide has 1 to 27 amino
acid substitutions at a position(s) designated as Xaa in SEQ ID NO:
3 or 4.
[0136] Embodiment 113 is the polynucleotide of any one of
embodiments 97-110, wherein the PHI-4 polypeptide has 1 to 20 amino
acid substitutions at a position(s) designated as Xaa in SEQ ID NO:
3 or 4.
[0137] Embodiment 114 is the polynucleotide of any one of
embodiments 97-110, wherein the PHI-4 polypeptide has 1 to 15 amino
acid substitutions at a position(s) designated as Xaa in SEQ ID NO:
3 or 4.
[0138] Embodiment 115 is the polynucleotide of any one of
embodiments 97-114, wherein 1-25 amino acids are deleted from the
N-terminus of the PHI-4 polypeptide and/or C-terminus of the PHI-4
polypeptide.
[0139] Embodiment 116 is the polynucleotide of any one of
embodiments 97-114, wherein 1-20 amino acids are deleted from the
C-terminus of the PHI-4 polypeptide.
[0140] Embodiment 117 is a composition, comprising an
insecticidally-effective amount of the PHI-4 polypeptide of any one
of embodiments 1-58.
[0141] Embodiment 118 is a method of inhibiting growth or killing
an insect pest, comprising contacting the insect pest with the
composition of embodiment 117.
[0142] Embodiment 119 is a method for controlling an insect pest
population resistant to a pesticidal protein, comprising contacting
the resistant insect pest population with the composition of
embodiment 117.
[0143] Embodiment 120 is the method of controlling an insect pest
population resistant to an pesticidal protein of embodiment 119,
wherein the pesticidal protein is selected from Cry1Ac, Cry1Ab,
Cry1A.105, Cry1Ac, Cry1F, Cry1Fa2, Cry1F, Cry2Ab, Cry3A, mCry3A,
Cry3Bb1, Cry34Ab1, Cry35Ab1, Vip3A, Cry9c, eCry3.1Ab and
CBI-Bt.
[0144] Embodiment 121 is a transgenic plant or progeny thereof,
comprising the polynucleotide of any one of embodiments 59-116.
Embodiment 122 is the transgenic plant or progeny thereof of
embodiment 121, wherein the transgenic plant is a
monocotyledon.
[0145] Embodiment 123 is the transgenic plant or progeny thereof of
embodiment 122, wherein the plant is selected from barley, corn,
oat, rice, rye, sorghum, turf grass, sugarcane, wheat, alfalfa,
banana, broccoli, bean, cabbage, canola, carrot, cassava,
cauliflower, celery, citrus, cotton, a cucurbit, eucalyptus, flax,
garlic, grape, onion, lettuce, pea, peanut, pepper, potato, poplar,
pine, sunflower, safflower, soybean, strawberry, sugar beet, sweet
potato, tobacco, tomato ornamental, shrub, nut, chickpea, pigeon
pea, millets, hops and pasture grasses.
[0146] Embodiment 124 is the transgenic plant or progeny thereof of
embodiment 123, further comprising one or more additional
transgenic traits.
[0147] Embodiment 125 is the transgenic plant of embodiment 124,
wherein the one or more additional transgenic trait is selected
from insect resistance, herbicide resistance, fungal resistance,
viral resistance, stress tolerance, disease resistance, male
sterility, stalk strength, increased yield, modified starches,
improved oil profile, balanced amino acids, high lysine or
methionine, increased digestibility, improved fiber quality,
flowering, ear and seed development, enhancement of nitrogen
utilization efficiency, altered nitrogen responsiveness, drought
resistance or tolerance, cold resistance or tolerance, salt
resistance or tolerance and increased yield under stress.
[0148] Embodiment 126 is seed, grain or processed product thereof
of the transgenic plant of any one of embodiments 121-126, wherein
the seed, grain, or processed product thereof comprises the
polynucleotide of any one of embodiments 121-125.
[0149] Embodiment 127 is an expression cassette, comprising the
polynucleotide of any one of embodiments 59-116 operably linked to
one or more regulatory sequences directing expression of the PHI-4
polypeptide.
[0150] Embodiment 128 is a transgenic plant or plant cell,
comprising the expression cassette of embodiment 127.
[0151] Embodiment 129 is seed, grain or processed product thereof
of the transgenic plant of embodiment 128, wherein the seed, grain,
or processed product thereof comprises the recombinant nucleic acid
molecule of embodiment of 1 and the recombinant nucleic acid
molecule of 24.
[0152] Embodiment 130 is the seed of embodiment 129, wherein one or
more seed treatment has been applied to the seed.
[0153] Embodiment 131 is a method for expressing in a plant a
polynucleotide encoding an insecticidal protein, comprising
[0154] (a) inserting into a plant cell the polynucleotide of any
one of embodiment 59-116 encoding the PHI-4 polypeptide;
[0155] (b) obtaining a transformed plant cell comprising the
nucleic acid sequence of step (a); and
[0156] (c) generating from the transformed plant cell a plant
capable of expressing the polynucleotide encoding the PHI-4
polypeptide.
[0157] Embodiment 132 is a method for protecting a plant from an
insect pest, comprising expressing in the plant or cell thereof, an
insecticidally-effective amount of the PHI-4 polypeptide of any one
of embodiments 1-58.
[0158] Embodiment 133 is a method for controlling an insect pest
population, comprising contacting the insect pest population with
an insecticidally-effective amount of the PHI-4 polypeptide of any
one of embodiments 1-58.
[0159] Embodiment 134 is a method of inhibiting growth or killing
an insect pest, comprising contacting the insect pest with a
composition comprising an insecticidally-effective amount of the
the PHI-4 polypeptide of any one of embodiments 1-58.
[0160] Embodiment 135 is a method for controlling an insect pest
population resistant to a pesticidal protein, comprising contacting
the insect pest population with an insecticidally-effective amount
of the PHI-4 polypeptide of any one of embodiments 1-58.
[0161] Embodiment 136 is a fusion protein comprising the PHI-4
polypeptide of any one of embodiments 1-58.
[0162] Embodiment 137 is a fusion protein comprising the PHI-4
polypeptide of any one of embodiments 1-58 and a maltose binding
protein.
[0163] Embodiment 138 is the fusion protein of embodiment 137,
wherein the maltose binding protein has an amino acid sequence of
SEQ ID NO: 830 or SEQ ID NO: 831.
BRIEF DESCRIPTION OF THE FIGURES
[0164] FIG. 1 shows FAE analysis of MPB::PHI-4-SFR12-004 (SEQ ID NO
31). The reference protein is MBP::PHI-4 polypeptide of (SEQ ID NO:
6). The % Response is given on the y axis. The dose of the toxin
fragment is given on the x axis in parts per million (ppm). Half
dose (+) and full dose (*) indicate a mean response from six
replicate wells at the indicated concentration. All data are from a
single experiment.
[0165] FIG. 2 shows EC50 analysis of MBP::PHI-4 polypeptide of SEQ
ID NO 6 and MPB::PHI-4-SFR12-004 (SEQ ID NO 35). The % Response is
given on they axis. The dose of the toxin fragment is given on the
x axis in parts per million (ppm). The % Response is given on the y
axis. The dose of the toxin fragment is given on the x axis in
parts per million (ppm). The protein concentration (toxin portion
of the protein only) is given on the x axis. Each symbol indicates
a mean response from twenty-four replicate wells at the indicated
concentration. All data are from a single experiment. triangles:
MBP::PHI-4 (SEQ ID NO: 6); circles: MBP::PHI-4-SFR12-004 (SEQ ID
NO: 31).
[0166] FIG. 3 shows the amino acids sequence of the C-terminal
portion of the PHI-4 polypeptide (SEQ ID NO: 2) is given. Three
stretches of sequence corresponding to nine amino acid motifs that
align to the putative sugar binding loop motif
D-X-G-(S/T)-G-X.sub.3-D (SEQ ID NO:40) are highlighted in grey.
[0167] FIG. 4 shows EC50 data for SEQ ID NO: 610, SEQ ID NO: 595,
SEQ ID NO: 584, SEQ ID NO: 591, SEQ ID NO: 576, SEQ ID NO: 73, SEQ
ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO:
150, SEQ ID NO: 150, SEQ ID NO: 149, SEQ ID NO: 167, SEQ ID NO:
167, SEQ ID NO: 164, SEQ ID NO: 164, SEQ ID NO: 170, SEQ ID NO:
170, SEQ ID NO: 795, SEQ ID NO: 794, SEQ ID NO: 784, SEQ ID NO:
799, SEQ ID NO: 785, SEQ ID NO: 788, SEQ ID NO: 786, SEQ ID NO:
796, SEQ ID NO: 787. The x-axis corresponds to the mean fold
improvement in EC50, relative to MBP::PHI-4 (SEQ ID NO_: 6) from at
least three independent EC50 measurements. The y-axis corresponds
to the mean fold improvement of the mean FAE Index from at least
three independent measurements.
[0168] FIG. 5. TO seedlings in the V3-V4 growth stage were
challenged as described (Oleson J. et al J. Economic Entomology
98:1-8; 2005) and root nodal injury scores were recorded. The
groups indicated along the x axis were either controls or were
transformed with a plant vector of Example 18: 1, untransformed
control; 2, positive control transgenic expressing positive control
protein; 3, PHI-4 polypeptide (SEQ ID NO: 22); 4, PHI-4-B09
polypeptide (SEQ ID NO: 23); 5, PHI-4-D09 polypeptide (SEQ ID NO:
24); 6 PHI-4-H08 polypeptide (SEQ ID NO: 25).
DETAILED DESCRIPTION
[0169] It is to be understood that this invention is not limited to
the particular methodology, protocols, cell lines, genera, and
reagents described, as such may vary. It is also to be understood
that the terminology used herein is for the purpose of describing
particular embodiments only, and is not intended to limit the scope
of the present invention.
[0170] As used herein the singular forms "a", "and", and "the"
include plural referents unless the context clearly dictates
otherwise. Thus, for example, reference to "a cell" includes a
plurality of such cells and reference to "the protein" includes
reference to one or more proteins and equivalents thereof known to
those skilled in the art, and so forth. All technical and
scientific terms used herein have the same meaning as commonly
understood to one of ordinary skill in the art to which this
invention belongs unless clearly indicated otherwise.
[0171] The present disclosure is drawn to compositions and methods
for controlling pests. The methods involve transforming organisms
with a nucleic acid sequence encoding a PHI-4 polypeptide. In
particular, the nucleic acid sequences of the embodiments are
useful for preparing plants and microorganisms possessing
pesticidal activity. Thus, transformed bacteria, plants, plant
cells, plant tissues and seeds are provided. Compositions are
pesticidal nucleic acids and proteins of bacterial species. The
nucleic acid sequences find use in the construction of expression
vectors for subsequent transformation into organisms of interest,
as probes for the isolation of other homologous (or partially
homologous) genes, and for the generation of altered PHI-4
polypeptides by methods known in the art, such as site directed
mutagenesis, domain swapping or DNA shuffling. The PHI-4
polypeptides find use in controlling, inhibiting growth or killing
Lepidopteran, Coleopteran, Dipteran, fungal, Hemipteran, and
nematode pest populations and for producing compositions with
pesticidal activity. Insect pests of interest include, but are not
limited to, the superfamily of stink bugs and other related insects
including, but not limited to, species belonging to the family
Pentatomidae (Nezara viridula, Halyomorpha halys, Piezodorus
guildini, Euschistus servus, Acrosternum hilare, Euschistus heros,
Euschistus tristigmus, Acrosternum hilare, Dichelops furcatus,
Dichelops melacanthus, and Bagrada hilaris (Bagrada Bug)), the
family Plataspidae (Megacopta cribraria--Bean plataspid), and the
family Cydnidae (Scaptocoris castanea--Root stink bug) and
Lepidoptera species including but not limited to: diamond-back
moth, e.g., Helicoverpa zea Boddie; soybean looper, e.g.,
Pseudoplusia includens Walker and velvet bean caterpillar e.g.,
Anticarsia gemmatalis Hubner.
[0172] By "pesticidal toxin" or "pesticidal protein" is intended a
toxin that has toxic activity against one or more pests, including,
but not limited to, members of the Lepidoptera, Diptera, Hemiptera
and Coleoptera orders or the Nematoda phylum or a protein that has
homology to such a protein. Pesticidal proteins have been isolated
from organisms including, for example, Bacillus sp., Pseudomonas
sp., Photorhabdus sp., Xenorhabdus sp., Clostridium bifermentans
and Paenibacillus popilliae. Pesticidal proteins include but are
not limited to: insecticidal proteins from Pseudomonas sp. such as
PSEEN3174 (Monalysin, (2011) PLoS Pathogens, 7:1-13) from
Pseudomonas protegens strain CHAO and Pf-5 (previously fluorescens)
(Pechy-Tarr, (2008) Environmental Microbiology 10:2368-2386:
GenBank Accession No. EU400157); from Pseudomonas Taiwanensis (Liu,
et al., (2010) J. Agric. Food Chem. 58:12343-12349) and from
Pseudomonas pseudoalcligenes (Zhang, et al, (2009) Annals of
Microbiology 59:45-50 and Li, et al., (2007) Plant Cell Tiss. Organ
Cult. 89:159-168); insecticidal proteins from Photorhabdus sp. and
Xenorhabdus sp. (Hinchliffe, et al., (2010) The Open Toxinology
Journal 3:101-118 and Morgan, et al., (2001) Applied and Envir.
Micro. 67:2062-2069), U.S. Pat. Nos. 6,048,838, and 6,379,946; and
.delta.-endotoxins including, but not limited to, the cry1, cry2,
cry3, cry4, cry5, cry6, cry7, cry8, cry9, cry10, cry11, cry12,
cry13, cry14, cry15, cry16, cry17, cry18, cry19, cry20, cry21,
cry22, cry23, cry24, cry25, cry26, cry27, cry 28, cry 29, cry 30,
cry31, cry32, cry33, cry34, cry35,cry36, cry37, cry38, cry39,
cry40, cry41, cry42, cry43, cry44, cry45, cry 46, cry47, cry49, cry
51 and cry55 classes of .delta.-endotoxin genes and the B.
thuringiensis cytolytic cyt1 and cyt2 genes. Members of these
classes of B. thuringiensis insecticidal proteins include, but are
not limited to Cry1Aa1 (Accession #M11250), Cry1Aa2 (Accession
#M10917), Cry1Aa3 (Accession #D00348), Cry1Aa4 (Accession #X13535),
Cry1Aa5 (Accession #D17518), Cry1Aa6 (Accession #U43605), Cry1Aa7
(Accession #AF081790), Cry1Aa8 (Accession #126149), Cry1Aa9
(Accession #AB026261), Cry1Aa10 (Accession #AF154676), Cry1Aa11
(Accession #Y09663), Cry1Aa12 (Accession #AF384211), Cry1Aa13
(Accession #AF510713), Cry1Aa14 (Accession #AY197341), Cry1Aa15
(Accession #D0062690), Cry1Ab1 (Accession #M13898), Cry1Ab2
(Accession #M12661), Cry1Ab3 (Accession #M15271), Cry1Ab4
(Accession #D00117), Cry1Ab5 (Accession #X04698), Cry1Ab6
(Accession #M37263), Cry1Ab7 (Accession #X13233), Cry1Ab8
(Accession #M16463), Cry1Ab9 (Accession #X54939), Cry1Ab10
(Accession #A29125), Cry1Ab11 (Accession #112419), Cry1Ab12
(Accession #AF059670), Cry1Ab13 (Accession #AF254640), Cry1Ab14
(Accession #U94191), Cry1Ab15 (Accession #AF358861), Cry1Ab16
(Accession #AF375608), Cry1Ab17 (Accession #AAT46415), Cry1Ab18
(Accession #AAQ88259), Cry1Ab19 (Accession #AY847289), Cry1Ab20
(Accession #D0241675), Cry1Ab21 (Accession #EF683163), Cry1Ab22
(Accession #ABW87320), Cry1Ab-like (Accession #AF327924),
Cry1Ab-like (Accession #AF327925), Cry1Ab-like (Accession
#AF327926), Cry1Ab-like (Accession #D0781309), Cry1Ac1 (Accession
#M11068), Cry1Ac2 (Accession #M35524), Cry1Ac3 (Accession #X54159),
Cry1Ac4 (Accession #M73249), Cry1Ac5 (Accession #M73248), Cry1Ac6
(Accession #U43606), Cry1Ac7 (Accession #U87793), Cry1Ac8
(Accession #U87397), Cry1Ac9 (Accession #U89872), Cry1Ac10
(Accession #AJ002514), Cry1Ac11 (Accession #AJ130970), Cry1Ac12
(Accession #112418), Cry1Ac13 (Accession #AF148644), Cry1Ac14
(Accession #AF492767), Cry1Ac15 (Accession #AY122057), Cry1Ac16
(Accession #AY730621), Cry1Ac17 (Accession #AY925090), Cry1Ac18
(Accession #D0023296), Cry1Ac19 (Accession #D0195217), Cry1Ac20
(Accession #D0285666), Cry1Ac21 (Accession #D0062689), Cry1Ac22
(Accession #EU282379), Cry1Ac23 (Accession #AM949588), Cry1Ac24
(Accession #ABL01535), Cry1Ad1 (Accession #M73250), Cry1Ad2
(Accession #A27531), Cry1Ae1 (Accession #M65252), Cry1Af1
(Accession #U82003), Cry1Ag1 (Accession #AF081248), Cry1Ah1
(Accession #AF281866), Cry1Ah2 (Accession #D0269474), Cry1Ai1
(Accession #AY174873), Cry1A-like (Accession #AF327927), Cry1Ba1
(Accession #X06711), Cry1Ba2 (Accession #X95704), Cry1Ba3
(Accession #AF368257), Cry1 Ba4 (Accession #AF363025), Cry1 Ba5
(Accession #AB020894), Cry1 Ba6 (Accession #ABL60921), Cry1 Bb1
(Accession #L32020), Cry1Bc1 (Accession #Z46442), Cry1Bd1
(Accession #U70726), Cry1Bd2 (Accession #AY138457), Cry1Be1
(Accession #AF077326), Cry1Be2 (Accession #AAQ52387), Cry1Bf1
(Accession #AX189649), Cry1Bf2 (Accession #AAQ52380), Cry1Bg1
(Accession #AY176063), Cry1Ca1 (Accession #X07518), Cry1Ca2
(Accession #X13620), Cry1Ca3 (Accession #M73251), Cry1Ca4
(Accession #A27642), Cry1Ca5 (Accession #X96682), Cry1Ca6 [1]
(Accession #AF215647), Cry1Ca7 (Accession #AY015492), Cry1Ca8
(Accession #AF362020), Cry1Ca9 (Accession #AY078160), Cry1Ca10
(Accession #AF540014), Cry1Ca11 (Accession #AY955268), Cry1Cb1
(Accession #M97880), Cry1Cb2 (Accession #AY007686), Cry1Cb3
(Accession #EU679502), Cry1Cb-like (Accession #AAX63901), Cry1Da1
(Accession #X54160), Cry1Da2 (Accession #176415), Cry1Db1
(Accession #Z22511), Cry1Db2 (Accession #AF358862), Cry1Dc1
(Accession #EF059913), Cry1Ea1 (Accession #X53985), Cry1Ea2
(Accession #X56144), Cry1 Ea3 (Accession #M73252), Cry1 Ea4
(Accession #U94323), Cry1 Ea5 (Accession #A15535), Cry1 Ea6
(Accession #AF202531), Cry1 Ea7 (Accession #AAW72936), Cry1 Ea8
(Accession #ABX11258), Cry1Eb1 (Accession #M73253), Cry1Fa1
(Accession #M63897), Cry1Fa2 (Accession #M73254), Cry1Fb1
(Accession #Z22512), Cry1Fb2 (Accession #AB012288), Cry1Fb3
(Accession #AF062350), Cry1Fb4 (Accession #173895), Cry1Fb5
(Accession #AF336114), Cry1Fb6 (Accession #EU679500), Cry1Fb7
(Accession #EU679501), Cry1Ga1 (Accession #Z22510), Cry1Ga2
(Accession #Y09326), Cry1Gb1 (Accession #U70725), Cry1Gb2
(Accession #AF288683), Cry1Gc (Accession #AAQ52381), Cry1Ha1
(Accession #Z22513), Cry1Hb1 (Accession #U35780), Cry1H-like
(Accession #AF182196), Cry1Ia1 (Accession #X62821), Cry1Ia2
(Accession #M98544), Cry1Ia3 (Accession #L36338), Cry1Ia4
(Accession #L49391), Cry1Ia5 (Accession #Y08920), Cry1Ia6
(Accession #AF076953), Cry1Ia7 (Accession #AF278797), Cry1Ia8
(Accession #AF373207), Cry1Ia9 (Accession #AF521013), Cry1Ia10
(Accession #AY262167), Cry1Ia11 (Accession #AJ315121), Cry1Ia12
(Accession #AAV53390), Cry1Ia13 (Accession #ABF83202), Cry1Ia14
(Accession #EU887515), Cry1Ib1 (Accession #U07642), Cry1Ib2
(Accession #ABW88019), Cry1Ib3 (Accession #EU677422), Cry1Ic1
(Accession #AF056933), Cry1Ic2 (Accession #AAE71691), Cry1Id1
(Accession #AF047579), Cry1Ie1 (Accession #AF211190), Cry1If1
(Accession #AAQ52382), Cry1I-like (Accession #190732), Cry1I-like
(Accession #DQ781310), Cry1Ja1 (Accession #L32019), Cry1Jb1
(Accession #U31527), Cry1Jc1 (Accession #190730), Cry1Jc2
(Accession #AAQ52372), Cry1Jd1 (Accession #AX189651), Cry1Ka1
(Accession #U28801), Cry1La1 (Accession #AAS60191), Cry1-like
(Accession #190729), Cry2Aa1 (Accession #M31738), Cry2Aa2
(Accession #M23723), Cry2Aa3 (Accession #D86064), Cry2Aa4
(Accession #AF047038), Cry2Aa5 (Accession #AJ132464), Cry2Aa6
(Accession #AJ132465), Cry2Aa7 (Accession #AJ132463), Cry2Aa8
(Accession #AF252262), Cry2Aa9 (Accession #AF273218), Cry2Aa10
(Accession #AF433645), Cry2Aa11 (Accession #AAQ52384), Cry2Aa12
(Accession #DQ977646), Cry2Aa13 (Accession #ABL01536), Cry2Aa14
(Accession #ACF04939), Cry2Ab1 (Accession #M23724), Cry2Ab2
(Accession #X55416), Cry2Ab3 (Accession #AF164666), Cry2Ab4
(Accession #AF336115), Cry2Ab5 (Accession #AF441855), Cry2Ab6
(Accession #AY297091), Cry2Ab7 (Accession #DQ119823), Cry2Ab8
(Accession #DQ361266), Cry2Ab9 (Accession #DQ341378), Cry2Ab10
(Accession #EF157306), Cry2Ab11 (Accession #AM691748), Cry2Ab12
(Accession #ABM21764), Cry2Ab13 (Accession #EU909454), Cry2Ab14
(Accession #EU909455), Cry2Ac1 (Accession #X57252), Cry2Ac2
(Accession #AY007687), Cry2Ac3 (Accession #AAQ52385), Cry2Ac4
(Accession #DQ361267), Cry2Ac5 (Accession #DQ341379), Cry2Ac6
(Accession #DQ359137), Cry2Ac7 (Accession #AM292031), Cry2Ac8
(Accession #AM421903), Cry2Ac9 (Accession #AM421904), Cry2Ac10
(Accession #BI 877475), Cry2Ac11 (Accession #AM689531), Cry2Ac12
(Accession #AM689532), Cry2Ad1 (Accession #AF200816), Cry2Ad2
(Accession #DQ358053), Cry2Ad3 (Accession #AM268418), Cry2Ad4
(Accession #AM490199), Cry2Ad5 (Accession #AM765844), Cry2Ae1
(Accession #AAQ52362), Cry2Af1 (Accession #EF439818), Cry2Ag
(Accession #ACH91610), Cry2Ah (Accession #EU939453), Cry3Aa1
(Accession #M22472), Cry3Aa2 (Accession #J02978), Cry3Aa3
(Accession #Y00420), Cry3Aa4 (Accession #M30503), Cry3Aa5
(Accession #M37207), Cry3Aa6 (Accession #U10985), Cry3Aa7
(Accession #AJ237900), Cry3Aa8 (Accession #AAS79487), Cry3Aa9
(Accession #AAW05659), Cry3Aa10 (Accession #AAU29411), Cry3Aa11
(Accession #AY882576), Cry3Aa12 (Accession #ABY49136), Cry3Ba1
(Accession #X17123), Cry3Ba2 (Accession #A07234), Cry3Bb1
(Accession #M89794), Cry3Bb2 (Accession #U31633), Cry3Bb3
(Accession #115475), Cry3Ca1 (Accession #X59797), Cry4Aa1
(Accession #Y00423), Cry4Aa2 (Accession #D00248), Cry4Aa3
(Accession #AL731825), Cry4A-like (Accession #DQ078744), Cry4Ba1
(Accession #X07423), Cry4Ba2 (Accession #X07082), Cry4Ba3
(Accession #M20242), Cry4Ba4 (Accession #D00247), Cry4Ba5
(Accession #AL731825), Cry4Ba-like (Accession #ABC47686), Cry4Ca1
(Accession #EU646202), Cry5Aa1 (Accession #L07025), Cry5Ab1
(Accession #L07026), Cry5Ac1 (Accession #134543), Cry5Ad1
(Accession #EF219060), Cry5Ba1 (Accession #U19725), Cry5Ba2
(Accession #EU121522), Cry6Aa1 (Accession #L07022), Cry6Aa2
(Accession #AF499736), Cry6Aa3 (Accession #DQ835612), Cry6Ba1
(Accession #L07024), Cry7Aa1 (Accession #M64478), Cry7Ab1
(Accession #U04367), Cry7Ab2 (Accession #U04368), Cry7Ab3
(Accession #BI 1015188), Cry7Ab4 (Accession #EU380678), Cry7Ab5
(Accession #ABX79555), Cry7Ab6 (Accession #FJ194973), Cry7Ba1
(Accession #ABB70817), Cry7Ca1 (Accession #EF486523), Cry8Aa1
(Accession #U04364), Cry8Ab1 (Accession #EU044830), Cry8Ba1
(Accession #U04365), Cry8Bb1 (Accession #AX543924), Cry8Bc1
(Accession #AX543926), Cry8Ca1 (Accession #U04366), Cry8Ca2
(Accession #AAR98783), Cry8Ca3 (Accession #EU625349), Cry8Da1
(Accession #AB089299), Cry8Da2 (Accession #BD133574), Cry8Da3
(Accession #BD133575), Cry8Db1 (Accession #AB303980), Cry8Ea1
(Accession #AY329081), Cry8Ea2 (Accession #EU047597), Cry8Fa1
(Accession #AY551093), Cry8Ga1 (Accession #AY590188), Cry8Ga2
(Accession #DQ318860), Cry8Ga3 (Accession #FJ198072), Cry8Ha1
(Accession #EF465532), Cry8Ia1 (Accession #EU381044), Cry8Ja1
(Accession #EU625348), Cry8 like (Accession #ABS53003), Cry9Aa1
(Accession #X58120), Cry9Aa2 (Accession #X58534), Cry9Aa like
(Accession #AAQ52376), Cry9Ba1 (Accession #X75019), Cry9Bb1
(Accession #AY758316), Cry9Ca1 (Accession #Z37527), Cry9Ca2
(Accession #AAQ52375), Cry9Da1 (Accession #D85560), Cry9Da2
(Accession #AF042733), Cry9Db1 (Accession #AY971349), Cry9Ea1
(Accession #AB011496), Cry9Ea2 (Accession #AF358863), Cry9Ea3
(Accession #EF157307), Cry9Ea4 (Accession #EU760456), Cry9Ea5
(Accession #EU789519), Cry9Ea6 (Accession #EU887516), Cry9Eb1
(Accession #AX189653), Cry9Ec1 (Accession #AF093107), Cry9Ed1
(Accession #AY973867), Cry9 like (Accession #AF093107), Cry10Aa1
(Accession #M12662), Cry10Aa2 (Accession #E00614), Cry10Aa3
(Accession #AL731825), Cry10A like (Accession #DQ167578), Cry11Aa1
(Accession #M31737), Cry11Aa2 (Accession #M22860), Cry11Aa3
(Accession #AL731825), Cry11Aa-like (Accession #DQ166531), Cry11Ba1
(Accession #X86902), Cry11Bb1 (Accession #AF017416), Cry12Aa1
(Accession #L07027), Cry13Aa1 (Accession #L07023), Cry14Aa1
(Accession #U13955), Cry15Aa1 (Accession #M76442), Cry16Aa1
(Accession #X94146), Cry17Aa1 (Accession #X99478), Cry18Aa1
(Accession #X99049), Cry18Ba1 (Accession #AF169250), Cry18Ca1
(Accession #AF169251), Cry19Aa1 (Accession #Y07603), Cry19Ba1
(Accession #D88381), Cry20Aa1 (Accession #U82518), Cry21Aa1
(Accession #132932), Cry21Aa2 (Accession #166477), Cry21Ba1
(Accession #AB088406), Cry22Aa1 (Accession #134547), Cry22Aa2
(Accession #AX472772), Cry22Aa3 (Accession #EU715020), Cry22Ab1
(Accession #AAK50456), Cry22Ab2 (Accession #AX472764), Cry22Ba1
(Accession #AX472770), Cry23Aa1 (Accession #AAF76375), Cry24Aa1
(Accession #U88188), Cry24Ba1 (Accession #BAD32657), Cry24Ca1
(Accession #AM158318), Cry25Aa1 (Accession #U88189), Cry26Aa1
(Accession #AF122897), Cry27Aa1 (Accession #AB023293), Cry28Aa1
(Accession #AF132928), Cry28Aa2 (Accession #AF285775), Cry29Aa1
(Accession #AJ251977), Cry30Aa1 (Accession #AJ251978), Cry30Ba1
(Accession #BAD00052), Cry30Ca1 (Accession #BAD67157), Cry30Da1
(Accession #EF095955), Cry30Db1 (Accession #BAE80088), Cry30Ea1
(Accession #EU503140), Cry30Fa1 (Accession #EU751609), Cry30Ga1
(Accession #EU882064), Cry31Aa1 (Accession #AB031065), Cry31Aa2
(Accession #AY081052), Cry31Aa3 (Accession #AB250922), Cry31Aa4
(Accession #AB274826), Cry31Aa5 (Accession #AB274827), Cry31Ab1
(Accession #AB250923), Cry31Ab2 (Accession #AB274825), Cry31Ac1
(Accession #AB276125), Cry32Aa1 (Accession #AY008143), Cry32Ba1
(Accession #BAB78601), Cry32Ca1 (Accession #BAB78602), Cry32Da1
(Accession #BAB78603), Cry33Aa1 (Accession #AAL26871), Cry34Aa1
(Accession #AAG50341), Cry34Aa2 (Accession #AAK64560), Cry34Aa3
(Accession #AY536899), Cry34Aa4 (Accession #AY536897), Cry34Ab1
(Accession #AAG41671), Cry34Ac1 (Accession #AAG50118), Cry34Ac2
(Accession #AAK64562), Cry34Ac3 (Accession #AY536896), Cry34Ba1
(Accession #AAK64565), Cry34Ba2 (Accession #AY536900), Cry34Ba3
(Accession #AY536898), Cry35Aa1 (Accession #AAG50342), Cry35Aa2
(Accession #AAK64561), Cry35Aa3 (Accession #AY536895), Cry35Aa4
(Accession #AY536892), Cry35Ab1 (Accession #AAG41672), Cry35Ab2
(Accession #AAK64563), Cry35Ab3 (Accession #AY536891), Cry35Ac1
(Accession #AAG50117), Cry35Ba1 (Accession #AAK64566), Cry35Ba2
(Accession #AY536894), Cry35Ba3 (Accession #AY536893), Cry36Aa1
(Accession #AAK64558), Cry37Aa1 (Accession #AAF76376), Cry38Aa1
(Accession #AAK64559), Cry39Aa1 (Accession #BAB72016), Cry40Aa1
(Accession #BAB72018), Cry40Ba1 (Accession #BAC77648), Cry40Ca1
(Accession #EU381045), Cry40Da1 (Accession #EU596478), Cry41Aa1
(Accession #AB116649), Cry41Ab1 (Accession #AB116651), Cry42Aa1
(Accession #AB116652), Cry43Aa1 (Accession #AB115422), Cry43Aa2
(Accession #AB176668), Cry43Ba1 (Accession #AB115422), Cry43-like
(Accession #AB115422), Cry44Aa (Accession #BAD08532), Cry45Aa
(Accession #BAD22577), Cry46Aa (Accession #BAC79010), Cry46Aa2
(Accession #BAG68906), Cry46Ab (Accession #BAD35170), Cry47Aa
(Accession #AY950229), Cry48Aa (Accession #AJ841948), Cry48Aa2
(Accession #AM237205), Cry48Aa3 (Accession #AM237206), Cry48Ab
(Accession #AM237207), Cry48Ab2 (Accession #AM237208), Cry49Aa
(Accession #AJ841948), Cry49Aa2 (Accession #AM237201), Cry49Aa3
(Accession #AM237203), Cry49Aa4 (Accession #AM237204), Cry49Ab1
(Accession #AM237202), Cry50Aa1 (Accession #AB253419), Cry51Aa1
(Accession #DQ836184), Cry52Aa1 (Accession #EF613489), Cry53Aa1
(Accession #EF633476), Cry54Aa1 (Accession #EU339367), Cry55Aa1
(Accession #EU121521), Cry55Aa2 (Accession #AAE33526), Cyt1Aa
(GenBank Accession #X03182), Cyt1Ab (GenBank Accession #X98793),
Cyt1B (GenBank Accession #U37196), Cyt2A (GenBank Accession
#Z14147), Cyt2B (GenBank Accession #U52043).
[0173] Examples of .delta.-endotoxins also include but are not
limited to Cry1A proteins of U.S. Pat. Nos. 5,880,275 and
7,858,849; a DIG-3 or DIG-11 toxin (N-terminal deletion of
.alpha.-helix 1 and/or .alpha.-helix 2 variants of cry proteins
such as Cry1A, Cry3A) of U.S. Pat. Nos. 8,304,604 and 8,304,605,
Cry1B of U.S. patent application Ser. No. 10/525,318; Cry1C of U.S.
Pat. No. 6,033,874; Cry1F of U.S. Pat. Nos. 5,188,960, 6,218,188;
Cry1A/F chimeras of U.S. Pat. Nos. 7,070,982; 6,962,705 and
6,713,063); a Cry2 protein such as Cry2Ab protein of U.S. Pat. No.
7,064,249); a Cry3A protein including but not limited to an
engineered hybrid insecticidal protein (eHIP) created by fusing
unique combinations of variable regions and conserved blocks of at
least two different Cry proteins (US Patent Application Publication
Number 2010/0017914); a Cry4 protein; a Cry5 protein; a Cry6
protein; Cry8 proteins of U.S. Pat. Nos. 7,329,736, 7,449,552,
7,803,943, 7,476,781, 7,105,332, 7,378,499 and 7,462,760; a Cry9
protein such as such as members of the Cry9A, Cry9B, Cry9C, Cry9D,
Cry9E, and Cry9F families; a Cry15 protein of Naimov, et al.,
(2008) Applied and Environmental Microbiology 74:7145-7151; a
Cry22, a Cry34Ab1 protein of U.S. Pat. Nos. 6,127,180, 6,624,145
and 6,340,593; a CryET33 and cryET34 protein of U.S. Pat. Nos.
6,248,535, 6,326,351, 6,399,330, 6,949,626, 7,385,107 and
7,504,229; a CryET33 and CryET34 homologs of US Patent Publication
Number 2006/0191034, 2012/0278954, and PCT Publication Number WO
2012/139004; a Cry35Ab1 protein of U.S. Pat. Nos. 6,083,499,
6,548,291 and 6,340,593; a Cry46 protein, a Cry 51 protein, a Cry
binary toxin; a TIC901 or related toxin; TIC807 of US 2008/0295207;
ET29, ET37, TIC809, TIC810, TIC812, TIC127, TIC128 of PCT US
2006/033867; AXMI-027, AXMI-036, and AXMI-038 of U.S. Pat. No.
8,236,757; AXMI-031, AXMI-039, AXMI-040, AXMI-049 of U.S. Pat. No.
7,923,602; AXMI-018, AXMI-020, and AXMI-021 of WO 2006/083891;
AXMI-010 of WO 2005/038032; AXMI-003 of WO 2005/021585; AXMI-008 of
US 2004/0250311; AXMI-006 of US 2004/0216186; AXMI-007 of US
2004/0210965; AXMI-009 of US 2004/0210964; AXMI-014 of US
2004/0197917; AXMI-004 of US 2004/0197916; AXMI-028 and AXMI-029 of
WO 2006/119457; AXMI-007, AXMI-008, AXMI-0080rf2, AXMI-009,
AXMI-014 and AXMI-004 of WO 2004/074462; AXMI-150 of U.S. Pat. No.
8,084,416; AXMI-205 of US20110023184; AXMI-011, AXMI-012, AXMI-013,
AXMI-015, AXMI-019, AXMI-044, AXMI-037, AXMI-043, AXMI-033,
AXMI-034, AXMI-022, AXMI-023, AXMI-041, AXMI-063, and AXMI-064 of
US 2011/0263488; AXMI-R1 and related proteins of US 2010/0197592;
AXMI221Z, AXMI222z, AXMI223z, AXMI224z and AXMI225z of WO
2011/103248; AXMI218, AXMI219, AXMI220, AXMI226, AXMI227, AXMI228,
AXMI229, AXMI230, and AXMI231 of WO11/103247; AXMI-115, AXMI-113,
AXMI-005, AXMI-163 and AXMI-184 of U.S. Pat. No. 8,334,431;
AXMI-001, AXMI-002, AXMI-030, AXMI-035, and AXMI-045 of US
2010/0298211; AXMI-066 and AXMI-076 of US20090144852; AXMI128,
AXMI130, AXMI131, AXMI133, AXMI140, AXMI141, AXMI142, AXMI143,
AXMI144, AXMI146, AXMI148, AXMI149, AXMI152, AXMI153, AXMI154,
AXMI155, AXMI156, AXMI157, AXMI158, AXMI162, AXMI165, AXMI166,
AXMI167, AXMI168, AXMI169, AXMI170, AXMI171, AXMI172, AXMI173,
AXMI174, AXMI175, AXMI176, AXMI177, AXMI178, AXMI179, AXMI180,
AXMI181, AXMI182, AXMI185, AXMI186, AXMI187, AXMI188, AXMI189 of
U.S. Pat. No. 8,318,900; AXMI079, AXMI080, AXMI081, AXMI082,
AXMI091, AXMI092, AXMI096, AXMI097, AXMI098, AXMI099, AXMI100,
AXMI101, AXMI102, AXMI103, AXMI104, AXMI107, AXMI108, AXMI109,
AXMI110, AXMI111, AXMI112, AXMI114, AXMI116, AXMI117, AXMI118,
AXMI119, AXMI120, AXMI121, AXMI122, AXMI123, AXMI124, AXMI1257,
AXMI1268, AXMI127, AXMI129, AXMI164, AXMI151, AXMI161, AXMI183,
AXMI132, AXMI138, AXMI137 of US 2010/0005543; cry proteins such as
Cry1A and Cry3A having modified proteolytic sites of U.S. Pat. No.
8,319,019; a Cry1Ac, Cry2Aa and Cry1Ca toxin protein from Bacillus
thuringiensis strain VBTS 2528 of US Patent Application Publication
Number 2011/0064710. Other Cry proteins are well known to one
skilled in the art (see, Crickmore, et al., "Bacillus thuringiensis
toxin nomenclature" (2011), at
lifesci.sussex.ac.uk/home/Neil_Crickmore/Bt/ which can be accessed
on the world-wide web using the "www" prefix). The insecticidal
activity of Cry proteins is well known to one skilled in the art
(for review, see, van Frannkenhuyzen, (2009) J. Invert. Path.
101:1-16). The use of Cry proteins as transgenic plant traits is
well known to one skilled in the art and Cry-transgenic plants
including but not limited to Cry1Ac, Cry1Ac+Cry2Ab, Cry1Ab,
Cry1A.105, Cry1F, Cry1Fa2, Cry1F+Cry1Ac, Cry2Ab, Cry3A, mCry3A,
Cry3Bb1, Cry34Ab1, Cry35Ab1, Vip3A, mCry3A, Cry9c and CBI-Bt have
received regulatory approval (see, Sanahuja, (2011) Plant Biotech
Journal 9:283-300 and the CERA (2010) GM Crop Database Center for
Environmental Risk Assessment (CERA), ILSI Research Foundation,
Washington D.C. at cera-gmc.org/index.php?action=gm_crop_database
which can be accessed on the world-wide web using the "www"
prefix). More than one pesticidal proteins well known to one
skilled in the art can also be expressed in plants such as Vip3Ab
& Cry1Fa (US2012/0317682), Cry1BE & Cry1F (US2012/0311746),
Cry1CA & Cry1AB (US2012/0311745), Cry1F & CryCa
(US2012/0317681), Cry1DA & Cry1BE (US2012/0331590), Cry1DA
& Cry1Fa (US2012/0331589), Cry1AB & Cry1BE
(US2012/0324606), and Cry1Fa & Cry2Aa, Cry1I or Cry1E
(US2012/0324605). Pesticidal proteins also include insecticidal
lipases including lipid acyl hydrolases of U.S. Pat. No. 7,491,869,
and cholesterol oxidases such as from Streptomyces (Purcell et al.
(1993) Biochem Biophys Res Commun 15:1406-1413). Pesticidal
proteins also include VIP (vegetative insecticidal proteins) toxins
of U.S. Pat. Nos. 5,877,012, 6,107,279 6,137,033, 7,244,820,
7,615,686, and 8,237,020 and the like. Other VIP proteins are well
known to one skilled in the art (see,
lifesci.sussex.ac.uk/home/Neil_Crickmore/Bt/vip.html which can be
accessed on the world-wide web using the "www" prefix). Pesticidal
proteins also include toxin complex (TC) proteins, obtainable from
organisms such as Xenorhabdus, Photorhabdus and Paenibacillus (see,
U.S. Pat. Nos. 7,491,698 and 8,084,418). Some TC proteins have
"stand alone" insecticidal activity and other TC proteins enhance
the activity of the stand-alone toxins produced by the same given
organism. The toxicity of a "stand-alone" TC protein (from
Photorhabdus, Xenorhabdus or Paenibacillus, for example) can be
enhanced by one or more TC protein "potentiators" derived from a
source organism of a different genus. There are three main types of
TC proteins. As referred to herein, Class A proteins ("Protein A")
are stand-alone toxins. Class B proteins ("Protein B") and Class C
proteins ("Protein C") enhance the toxicity of Class A proteins.
Examples of Class A proteins are TcbA, TcdA, XptA1 and XptA2.
Examples of Class B proteins are TcaC, TcdB, XptB1Xb and XptC1Wi.
Examples of Class C proteins are TccC, XptC1Xb and XptB1Wi.
Pesticidal proteins also include spider, snake and scorpion venom
proteins. Examples of spider venom peptides include but not limited
to lycotoxin-1 peptides and mutants thereof (U.S. Pat. No.
8,334,366).
[0174] In some embodiments the PHI-4 polypeptides include amino
acid sequences deduced from the full-length nucleic acid sequences
disclosed herein, and amino acid sequences that are shorter than
the full-length sequences, either due to the use of an alternate
downstream start site or due to processing that produces a shorter
protein having pesticidal activity. Processing may occur in the
organism the protein is expressed in, or in the pest after
ingestion of the protein.
[0175] Thus, provided herein are novel isolated or recombinant
nucleic acid sequences that confer pesticidal activity. Also
provided are the amino acid sequences of PHI-4 polypeptides. The
protein resulting from translation of these PHI-4 polypeptide genes
allows cells to control or kill pests that ingest it.
Nucleic Acid Molecules, and Variants and Fragments Thereof
[0176] One aspect pertains to isolated or recombinant nucleic acid
molecules comprising nucleic acid sequences encoding PHI-4
polypeptides and polypeptides or biologically active portions
thereof, as well as nucleic acid molecules sufficient for use as
hybridization probes to identify nucleic acid molecules encoding
proteins with regions of sequence homology. As used herein, the
term "nucleic acid molecule" is intended to include DNA molecules
(e.g., recombinant DNA, cDNA, genomic DNA, plastid DNA,
mitochondrial DNA) and RNA molecules (e.g., mRNA) and analogs of
the DNA or RNA generated using nucleotide analogs. The nucleic acid
molecule can be single-stranded or double-stranded, but preferably
is double-stranded DNA.
[0177] An "isolated" or "recombinant" nucleic acid molecule (or
DNA) is used herein to refer to a nucleic acid sequence (or DNA)
that is no longer in its natural environment, for example in an in
vitro or in a recombinant bacterial or plant host cell. In some
embodiments, an "isolated" or "recombinant" nucleic acid is free of
sequences (preferably protein encoding sequences) that naturally
flank the nucleic acid (i.e., sequences located at the 5' and 3'
ends of the nucleic acid) in the genomic DNA of the organism from
which the nucleic acid is derived. For purposes of the disclosure,
"isolated" or "recombinant" when used to refer to nucleic acid
molecules excludes isolated chromosomes. For example, in various
embodiments, the recombinant nucleic acid molecule encoding a PHI-4
polypeptide can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1
kb, 0.5 kb, or 0.1 kb of nucleic acid sequences that naturally
flank the nucleic acid molecule in genomic DNA of the cell from
which the nucleic acid is derived.
[0178] A variety of polynucleotides encoding a PHI-4 polypeptide(s)
or related proteins are contemplated. Such polynucleotides are
useful for production of PHI-4 polypeptides in host cells when
operably linked to suitable promoter, transcription termination
and/or polyadenylation sequences. Such polynucleotides are also
useful as probes for isolating homologous or substantially
homologous polynucleotides encoding PHI-4 polypeptides or related
proteins.
[0179] The present invention provides isolated or recombinant
polynucleotides that encode any of the PHI-4 polypeptides disclosed
herein. Those having ordinary skill in the art will readily
appreciate that due to the degeneracy of the genetic code, a
multitude of nucleotide sequences encoding .beta.-glucosidase
polypeptides of the present invention exist. Table 1 is a Codon
Table that provides the synonymous codons for each amino acid. For
example, the codons AGA, AGG, CGA, CGC, CGG, and CGU all encode the
amino acid arginine. Thus, at every position in the nucleic acids
of the invention where an arginine is specified by a codon, the
codon can be altered to any of the corresponding codons described
above without altering the encoded polypeptide. It is understood
that U in an RNA sequence corresponds to T in a DNA sequence.
TABLE-US-00005 TABLE 1 Alanine Ala A GCA GCC GCG GCU Cysteine Cys C
UGC UGU Aspartic acid Asp D GAC GAU Glutamic acid Glu E GAA GAG
Phenylalanine Phe F UUC UUU Glycine Gly G GGA GGC GGG GGU Histidine
His H CAC CAU Isoleucine Ile I AUA AUC AUU Lysine Lys K AAA AAG
Leucine Leu L UUA UUG CUA CUC CUG CUU Methionine Met M AUG
Asparagine Asn N AAC AAU Proline Pro P CCA CCC CCG CCU Glutamine
Gln Q CAA CAG Arginine Arg R AGA AGG CGA CGC CGG CGU Serine Ser S
AGC AGU UCA UCC UCG UCU Threonine Thr T ACA ACC ACG ACU Valine Val
V GUA GUC GUG GUU Tryptophan Trp W UGG Tyrosine Tyr Y UAC UAU
[0180] Such "silent variations" are one species of "conservative"
variation. One of ordinary skill in the art will recognize that
each codon in a nucleic acid (except AUG, which is ordinarily the
only codon for methionine) can be modified by standard techniques
to encode a functionally identical polypeptide. Accordingly, each
silent variation of a nucleic acid which encodes a polypeptide is
implicit in any described sequence. The invention contemplates and
provides each and every possible variation of nucleic acid sequence
encoding a polypeptide of the invention that could be made by
selecting combinations based on possible codon choices. These
combinations are made in accordance with the standard triplet
genetic code (set forth in Table 1), as applied to the
polynucleotide sequences of the present invention.
[0181] A group of two or more different codons that, when
translated in the same context, all encode the same amino acid, are
referred to herein as "synonymous codons." Polynucleotides encoding
PHI-4 polypeptides of the present disclosure may be codon optimized
for expression in a particular host organism by modifying the
polynucleotides to conform with the optimum codon usage of the
desired host organism. Those having ordinary skill in the art will
recognize that tables and other references providing preference
information for a wide range of organisms are readily
available.
[0182] Polynucleotides encoding a PHI-4 polypeptide can also be
synthesized de novo from a PHI-4 polypeptide sequence. The sequence
of the polynucleotide gene can be deduced from a PHI-4 polypeptide
sequence through use of the genetic code. Computer programs such as
"BackTranslate" (GCG.TM. Package, Acclerys, Inc. San Diego, Calif.)
can be used to convert a peptide sequence to the corresponding
nucleotide sequence encoding the peptide. Examples of PHI-4
polypeptide sequences that can be used to obtain corresponding
nucleotide encoding sequences include, but are not limited to, the
PHI-4 polypeptide sequence of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID
NO: 4, SEQ ID NOs: 51-819. Furthermore, synthetic PHI-4
polynucleotide sequences of the invention can be designed so that
they will be expressed in plants. U.S. Pat. No. 5,500,365 describes
a method for synthesizing plant genes to improve the expression
level of the protein encoded by the synthesized gene. This method
relates to the modification of the structural gene sequences of the
exogenous transgene, to cause them to be more efficiently
transcribed, processed, translated and expressed by the plant.
Features of genes that are expressed well in plants include
elimination of sequences that can cause undesired intron splicing
or polyadenylation in the coding region of a gene transcript while
retaining substantially the amino acid sequence of the toxic
portion of the insecticidal protein. A similar method for obtaining
enhanced expression of transgenes in monocotyledonous plants is
disclosed in U.S. Pat. No. 5,689,052.
[0183] In some embodiments the nucleic acid molecule encoding a
PHI-4 polypeptide is a polynucleotide having the sequence set forth
in SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NOS: 24-30 and
variants, fragments and complements thereof. By "complement" is
intended a nucleic acid sequence that is sufficiently complementary
to a given nucleic acid sequence such that it can hybridize to the
given nucleic acid sequence to thereby form a stable duplex. In
some embodiments the nucleic acid molecule encoding a PHI-4
polypeptide is a nucleic acid molecule having the sequence set
forth in SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NOS:
24-30. The corresponding amino acid sequences for the insecticidal
protein encoded by these nucleic acid sequences are set forth in
SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NOS: 24-30.
[0184] In some embodiments the nucleic acid molecule encoding a
PHI-4 polypeptide is a polynucleotide having a nucleotide sequence
encoding a polypeptide comprising an amino acid sequence having at
least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater sequence identity
to the amino acid sequence of SEQ ID NO: 35, wherein the
polypeptide has pesticidal activity. In some embodiments the
nucleic acid molecule encoding a PHI-4 polypeptide is a
polynucleotide having a nucleotide sequence encoding a polypeptide
comprising an amino acid sequence having 80% and 95% identity, to
the amino acid sequence of SEQ ID NO: 35, wherein the polypeptide
has pesticidal activity.
[0185] In some embodiments the nucleic acid molecule encoding a
PHI-4 polypeptide is a polynucleotide having a nucleotide sequence
encoding a polypeptide comprising an amino acid sequence having at
least 80% identity, to the amino acid sequence of SEQ ID NO:
51-819, wherein the polypeptide has pesticidal activity.
[0186] In some embodiments the nucleic acid molecule encoding a
PHI-4 polypeptide is a polynucleotide having a nucleotide sequence
encoding a polypeptide comprising an amino acid sequence SEQ ID NO:
4, wherein Xaa at position 9 is Gln, Lys or Glu; Xaa at position 14
is Pro or Ala; Xaa at position 16 is Val or Asp; Xaa at position 19
is Met or Leu; Xaa at position 22 is Gly or Ser; Xaa at position 24
is Asp, Asn or Gln; Xaa at position 36 is Leu or Met; Xaa at
position 42 is Asp, Asn or Gln; Xaa at position 43 is Phe or Glu;
Xaa at position 46 is Glu, Asp, Asn or Gly; Xaa at position 50 is
Ile or Val; Xaa at position 51 is Glu or Gln; Xaa at position 55 is
Arg or Lys; Xaa at position 56 is Ser or Thr; Xaa at position 57 is
Tyr or Phe; Xaa at position 58 is Thr or Ser; Xaa at position 61 is
Arg, Lys or Glu; Xaa at position 73 is Phe or Tyr; Xaa at position
74 is Lys, Glu, Gly, Arg, Met, Leu, His or Asp; Xaa at position 76
is Asp or Gln; Xaa at position 79 is Lys or Glu; Xaa at position 80
is Glu or Ser; Xaa at position 82 is Glu, Ile, Leu, Tyr or Gln; Xaa
at position 83 is Glu or Gln; Xaa at position 84 is Tyr or Phe; Xaa
at position 86 is Glu or Gln; Xaa at position 87 is Lys or Gln; Xaa
at position 88 is Met, Ile or Leu; Xaa at position 90 is Gln or
Glu; Xaa at position 94 is Val or Ile; Xaa at position 97 is Arg,
Asn, Asp, Glu, Gln, Gly or Ser; Xaa at position 98 is Tyr or Phe;
Xaa at position 99 is Lys, Leu, Tyr, Ile, Met, Phe, Cys, Val or
Asn; Xaa at position 103 is Ala or Gly; Xaa at position 105 is Leu
or Ile; Xaa at position 109 is Phe, Lys, Gly, Met, Ser, Asp, Asn,
Glu, Cys, Ala or Arg; Xaa at position 112 is Thr or Ser; Xaa at
position 113 is Asp, Glu or Met; Xaa at position 117 is Thr or Ser;
Xaa at position 121 is Tyr or Phe; Xaa at position 127 is Ala or
Thr; Xaa at position 142 is Arg or Glu; Xaa at position 146 is Arg
or Gln; Xaa at position 147 is Arg, Glu or Gln; Xaa at position 148
is Asp, Phe, Pro, Val, Glu, His, Trp, Ala, Arg, Leu, Ser, Gln or
Gly; Xaa at position 149 is Phe or Val; Xaa at position 150 is Arg,
Gln or Glu; Xaa at position 151 is Asp, Ser, Ala, Asn, Trp, Val,
Gln, Cys, Met, Leu, Arg or Glu; Xaa at position 153 is Leu or Ile;
Xaa at position 154 is Asn or Asp; Xaa at position 155 is Asn or
Lys; Xaa at position 159 is Pro or Asp; Xaa at position 162 is Glu,
Asp or Gln; Xaa at position 165 is Lys, Glu, Gln, Pro, Thr, Ala,
Leu, Gly, Asp, Val, His, Ile, Met, Trp, Phe, Tyr or Arg; Xaa at
position 166 is Arg or Gln; Xaa at position 167 is Tyr, Trp or Cys;
Xaa at position 170 is Tyr or His; Xaa at position 171 is Tyr or
Phe; Xaa at position 172 is Ile, Leu or Val; Xaa at position 173 is
Ser or Ala; Xaa at position 174 is Glu or Gln; Xaa at position 182
is Asp or Gln; Xaa at position 183 is Tyr or Val; Xaa at position
184 is Ser or Thr; Xaa at position 185 is Ala or Ser; Xaa at
position 189 is Thr, Lys or Ile; Xaa at position 191 is Lys or Gln;
Xaa at position 193 is Asp or Asn; Xaa at position 196 is Gln, Lys,
Asn, Asp, Glu, Ala, Ile or Arg; Xaa at position 202 is Ala or Val;
Xaa at position 203 is Glu, Thr or His; Xaa at position 204 is Met
or Ala; Xaa at position 206 is Tyr or Phe; Xaa at position 207 is
Lys or Gln; Xaa at position 209 is Leu or Pro; Xaa at position 210
is Val or Ile; Xaa at position 214 is Lys, Ser or Gln; Xaa at
position 216 is Glu, Gln, Phe, Val, Tyr or Arg; Xaa at position 220
is Glu, His, Asp, Thr, Tyr, Val, Ser, Gln, Arg, Trp, Met, Ala, Phe,
Ile, Leu, Cys or Asn; Xaa at position 229 is Arg or Glu; Xaa at
position 230 is Ser or Glu; Xaa at position 231 is Asn or Ser; Xaa
at position 236 is Leu or Pro; Xaa at position 245 is Met or Leu;
Xaa at position 247 is Asp or Tyr; Xaa at position 256 is Gln, Lys
or Glu; Xaa at position 257 is Gln, Ile, Glu, Cys, Ser, His, Trp or
Met; Xaa at position 261 is Gln, Glu or Lys; Xaa at position 264 is
Glu or Gln; Xaa at position 268 is Asp or Asn; Xaa at position 276
is Ser or Ala; Xaa at position 278 is Glu, Asn or Gln; Xaa at
position 281 is Gln, Lys or Glu; Xaa at position 282 is Pro or Gly;
Xaa at position 284 is Trp or Arg; Xaa at position 287 is Ala or
Cys; Xaa at position 289 is Lys, Leu, Val, Pro, Glu, Gln, Tyr, Thr,
Asp, Phe, Ser, Met, Arg, Trp, Ile, His, Asn, Cys, Gly or Ala; Xaa
at position 291 is Glu or Gln; Xaa at position 292 is Arg or Gln;
Xaa at position 293 is Arg, Glu or Gln; Xaa at position 294 is Val
or Ala; Xaa at position 296 is Leu or Ile; Xaa at position 297 is
Glu or Gln; Xaa at position 298 is Asp or Gln; Xaa at position 300
is Phe or Tyr; Xaa at position 302 is Glu or Gln; Xaa at position
303 is Phe or Tyr; Xaa at position 305 is Lys or Gln; Xaa at
position 306 is Gln or Lys; Xaa at position 309 is Gln, Lys or Glu;
Xaa at position 313 is Lys, Gln or Arg; Xaa at position 316 is Lys
or Gln; Xaa at position 328 is Lys, Glu or Gln; Xaa at position 331
is Glu, Asn or Gln; Xaa at position 333 is Ser, Arg, Gly, Lys, Val,
Asn, Ala, His, Gln, Thr, Asp, Ile, Leu, Cys or Glu; Xaa at position
334 is Gly, Arg, Lys, Ile or Trp; Xaa at position 335 is Ser or
Ala; Xaa at position 336 is Gly or Ala; Xaa at position 337 is Ala,
Val or Gly; Xaa at position 338 is Ser, His, Val, Lys, Ala, Gly,
Thr, Ile, Glu, Met, Arg, Pro, Asp, Asn or Leu; Xaa at position 339
is Glu, Asn, Gln, Ile, Pro, Met, Ser, Ala, Cys, Phe, Val, Leu, Asp,
Trp, His or Arg; Xaa at position 341 is Leu or Val; Xaa at position
342 is Ala, Ser or Val; Xaa at position 343 is Val or Ile; Xaa at
position 344 is Phe or Trp; Xaa at position 345 is Asn or His; Xaa
at position 346 is Pro or Ala; Xaa at position 350 is Asn or Ser;
Xaa at position 351 is Gly or Val; Xaa at position 354 is Met or
Leu; Xaa at position 355 is Val, Ile or Leu; Xaa at position 359 is
Gly or Ala; Xaa at position 362 is Asn or Ser; Xaa at position 364
is Ala or Ser; Xaa at position 371 is Ala, Gly or Thr; Xaa at
position 374 is Phe or Ile; Xaa at position 375 is Lys or Arg; Xaa
at position 380 is Leu or Gly; Xaa at position 382 is Val, Asp or
Leu; Xaa at position 383 is Leu, Ile or Val; Xaa at position 384 is
Lys, Ala or Gly; Xaa at position 385 is Ala or Gly; Xaa at position
389 is Trp or Tyr; Xaa at position 391 is Arg, Leu, Glu, Gln or
Asp; Xaa at position 395 is Asp or Cys; Xaa at position 396 is Ala,
Leu, Lys, Asn, Gly, Ile, Met, Arg, Tyr, Gln or His; Xaa at position
397 is Gly, Arg or Ala; Xaa at position 398 is Ser, Gln or Cys; Xaa
at position 401 is Ser, His, Pro, Gly, Lys, Val, Arg, Ile, Asn,
Phe, Thr, Ala, Asp, Met, Gln or Glu; Xaa at position 402 is Lys,
Phe, His, Arg, Trp, Gly, Asn, Leu, Tyr, Thr, Val, Met, Pro or Ala;
Xaa at position 403 is Asp, Tyr, Trp, Phe or Glu; Xaa at position
405 is Ala or Ser; Xaa at position 409 is Ala or Pro; Xaa at
position 410 is Ile or Val; Xaa at position 411 is Pro or Ala; Xaa
at position 412 is Pro or Ala; Xaa at position 416 is Arg, Glu or
Gln; Xaa at position 417 is Ala, Ser or Cys; Xaa at position 418 is
Leu or Met; Xaa at position 422 is Met or Val; Xaa at position 426
is Thr or Ser; Xaa at position 436 is Asp or Lys; Xaa at position
437 is Tyr or Val; Xaa at position 438 is Val or Arg; Xaa at
position 440 is Val or Leu; Xaa at position 442 is Gln, Lys or Glu;
Xaa at position 445 is Cys, Leu or Thr; Xaa at position 447 is Asp,
Lys, Tyr, Ser, Glu, Ile, Gly, Pro, Leu, Phe, Trp or Thr; Xaa at
position 448 is Val or Ala; Xaa at position 449 is Gln or Glu; Xaa
at position 452 is Gln, Lys or Glu; Xaa at position 453 is Asn or
Asp; Xaa at position 454 is Arg, Tyr, Met, Ser, Val, Ile, Lys, Phe,
Trp, Gln, Gly, His, Asp, Leu, Thr, Pro or Asn; Xaa at position 455
is Val or Ile; Xaa at position 457 is Trp or Asn; Xaa at position
459 is Lys, Met, Val, Trp, Gln, Ile, Thr, Ser, His, Cys, Tyr, Pro,
Asn, Ala, Arg or Glu; Xaa at position 460 is Gly or Ala; Xaa at
position 461 is Thr or Ser; Xaa at position 462 is Gly or Ala; Xaa
at position 463 is Ala, Ser or Gly; Xaa at position 464 is Arg,
Gly, His, Gln, Thr or Phe; Xaa at position 465 is Lys, Asn, Val,
Met, Pro, Gly, Arg, Thr, His, Cys, Trp, Phe or Leu; Xaa at position
466 is Asp or Arg; Xaa at position 471 is Gln, Lys or Glu; Xaa at
position 497 is Asp or Gln; Xaa at position 499 is Glu or Gln; Xaa
at position 500 is Arg, Gln or Lys; Xaa at position 502 is Arg, Glu
or Gln; Xaa at position 509 is Lys, Gln or Glu; Xaa at position 517
is Gln, Cys, Asn, Val or Pro; Xaa at position 518 is Glu or Gln;
Xaa at position 520 is Lys, Gln or Glu; Xaa at position 525 is Gln
or Lys; and Xaa at position 527 is Gln, Lys, Pro, Cys, Glu, Ser,
His, Phe or Trp; and having one or more amino acid substitutions at
positions designated as Xaa in SEQ ID NO: 4 and wherein the PHI-4
polypeptide has increased insecticidal activity compared to SEQ ID
NO: 35.
[0187] In some embodiments the nucleic acid molecule encoding a
PHI-4 polypeptide is a polynucleotide having a nucleotide sequence
encoding a polypeptide comprising an amino acid sequence SEQ ID NO:
3, wherein Xaa at position 24 is Asp or Asn; Xaa at position 42 is
Asp or Asn; Xaa at position 43 is Phe or Glu; Xaa at position 46 is
Glu or Asn; Xaa at position 74 is Lys, Glu or Gly; Xaa at position
79 is Lys or Glu; Xaa at position 82 is Glu, Ile, Leu or Tyr; Xaa
at position 97 is Arg, Asn, Asp, Glu, Gln or Gly; Xaa at position
98 is Tyr or Phe; Xaa at position 99 is Lys, Leu, Tyr, Ile or Met;
Xaa at position 109 is Phe, Lys, Gly, Met, Ser, Asp or Asn; Xaa at
position 147 is Arg or Glu; Xaa at position 148 is Asp, Phe or Pro;
Xaa at position 150 is Arg or Gln; Xaa at position 151 is Asp, Ser,
Ala or Asn; Xaa at position 153 is Leu or Ile; Xaa at position 162
is Glu or Gln; Xaa at position 165 is Lys, Glu or Gln; Xaa at
position 166 is Arg or Gln; Xaa at position 171 is Tyr or Phe; Xaa
at position 174 is Glu or Gln; Xaa at position 182 is Asp or Gln;
Xaa at position 196 is Gln, Lys, Asn or Asp; Xaa at position 203 is
Glu, Thr or His; Xaa at position 206 is Tyr or Phe; Xaa at position
216 is Glu or Gln; Xaa at position 220 is Glu, His, Asp, Thr, Tyr,
Val, Ser or Gln; Xaa at position 247 is Asp or Tyr; Xaa at position
256 is Gln or Lys; Xaa at position 257 is Gln or Ile; Xaa at
position 261 is Gln or Glu; Xaa at position 278 is Glu or Asn; Xaa
at position 281 is Gln, Lys or Glu; Xaa at position 289 is Lys,
Leu, Val, Pro, Glu, Gln, Tyr, Thr or Asp; Xaa at position 293 is
Arg, Glu or Gln; Xaa at position 313 is Lys or Gln; Xaa at position
328 is Lys, Glu or Gln; Xaa at position 333 is Ser, Gly, Lys, Val
or Asn; Xaa at position 334 is Gly, Arg, Lys or Ile; Xaa at
position 336 is Gly or Ala; Xaa at position 338 is Ser, His, Val,
Lys or Ala; Xaa at position 339 is Glu, Asn, Ile or Pro; Xaa at
position 343 is Val or Ile; Xaa at position 346 is Pro or Ala; Xaa
at position 355 is Val or Ile; Xaa at position 359 is Gly or Ala;
Xaa at position 391 is Arg, Glu or Gln; Xaa at position 396 is Ala,
Leu, Lys, Asn or Gly; Xaa at position 401 is Ser, His, Pro, Gly,
Lys, Val or Arg; Xaa at position 402 is Lys, Phe, His, Arg, Gly,
Trp, Thr, Asn, Tyr or Met; Xaa at position 403 is Asp or Tyr; Xaa
at position 411 is Pro or Ala; Xaa at position 412 is Pro or Ala;
Xaa at position 416 is Arg or Glu; Xaa at position 417 is Ala or
Ser; Xaa at position 418 is Leu or Met; Xaa at position 426 is Thr
or Ser; Xaa at position 440 is Val or Leu; Xaa at position 447 is
Asp, Lys, Tyr, Ser, Glu or Ile; Xaa at position 452 is Gln, Lys or
Glu; Xaa at position 454 is Arg, Tyr, Met, Ser, Val, Ile, Lys, Phe,
Trp or Gln; Xaa at position 455 is Val or Ile; Xaa at position 459
is Lys, Met, Val, Trp, Gln, Ile or Tyr; Xaa at position 461 is Thr
or Ser; Xaa at position 462 is Gly or Ala; Xaa at position 463 is
Ala or Ser; Xaa at position 464 is Arg, Gly or His; Xaa at position
465 is Lys, Asn, Val, Met, Pro, Gly or Arg; Xaa at position 471 is
Gln, Lys or Glu; Xaa at position 500 is Arg or Gln; Xaa at position
509 is Lys or Gln; Xaa at position 520 is Lys, Gln or Glu; and Xaa
at position 527 is Gln, Lys, Pro, Cys or Glu; and having one or
more amino acid substitutions at positions designated as Xaa in SEQ
ID NO: 3 and wherein the PHI-4 polypeptide has increased
insecticidal activity compared to SEQ ID NO: 35.
[0188] In some embodiments exemplary nucleic acid molecules encode
a PHI-4 of SEQ ID NO: 51-819 as well as amino acid substitutions,
amino acid deletions, insertions and fragments thereof and
combinations thereof.
[0189] In some embodiments the nucleic acid molecules encode a
PHI-4 polypeptide of Table 3, Table 4, Table 5, Table 6, Table 7,
Megatable 1, and Megatable 2 and combinations of the amino acid
substitutions thereof and amino acid deletions and/or insertions
thereof.
[0190] Also provided are nucleic acid molecules that encode
transcription and/or translation products that are subsequently
spliced to ultimately produce functional PHI-4. Splicing can be
accomplished in vitro or in vivo, and can involve cis- or
trans-splicing. The substrate for splicing can be polynucleotides
(e.g., RNA transcripts) or polypeptides. An example of cis-splicing
of a polynucleotide is where an intron inserted into a coding
sequence is removed and the two flanking exon regions are spliced
to generate a PHI-4 encoding sequence. An example of trans splicing
would be where a polynucleotide is encrypted by separating the
coding sequence into two or more fragments that can be separately
transcribed and then spliced to form the full-length pesticidal
encoding sequence. The use of a splicing enhancer sequence, which
can be introduced into a construct, can facilitate splicing either
in cis or trans-splicing of polypeptides (U.S. Pat. Nos. 6,365,377
and 6,531,316). Thus, in some embodiments the polynucleotides do
not directly encode a full-length PHI-4, but rather encode a
fragment or fragments of a PHI-4. These polynucleotides can be used
to express a functional PHI-4 through a mechanism involving
splicing, where splicing can occur at the level of polynucleotide
(e.g., intron/exon) and/or polypeptide (e.g., intein/extein). This
can be useful, for example, in controlling expression of pesticidal
activity, since functional pesticidal polypeptide will only be
expressed if all required fragments are expressed in an environment
that permits splicing processes to generate functional product. In
another example, introduction of one or more insertion sequences
into a polynucleotide can facilitate recombination with a low
homology polynucleotide; use of an intron or intein for the
insertion sequence facilitates the removal of the intervening
sequence, thereby restoring function of the encoded variant.
[0191] Nucleic acid molecules that are fragments of these nucleic
acid sequences encoding PHI-4 are also encompassed by the
embodiments. By "fragment" is intended a portion of the nucleic
acid sequence encoding a PHI-4. A fragment of a nucleic acid
sequence may encode a biologically active portion of a PHI-4
polypeptide or it may be a fragment that can be used as a
hybridization probe or PCR primer using methods disclosed below.
Nucleic acid molecules that are fragments of a nucleic acid
sequence encoding a PHI-4 comprise at least about 50, 100, 200,
300, 400, 500, 600 or 700, contiguous nucleotides, or up to the
number of nucleotides present in a full-length nucleic acid
sequence encoding a PHI-4 disclosed herein, depending upon the
intended use. By "contiguous" nucleotides is intended nucleotide
residues that are immediately adjacent to one another. Fragments of
the nucleic acid sequences of the embodiments will encode protein
fragments that retain the biological activity of the PHI-4 and,
hence, retain insecticidal activity. By "retains activity" is
intended that the fragment will encode a polypeptide having at
least about 30%, at least about 50%, at least about 70%, 80%, 90%,
95% or higher of the insecticidal activity of the full-length
PHI-4. In one embodiment, the insecticidal activity is Lepodoptera
activity. In another embodiment, the insecticidal activity is
Hemiptera activity.
[0192] In some embodiments a fragment of a nucleic acid sequence
encoding a PHI-4 encoding a biologically active portion of a
protein will encode at least about 15, 25, 30, 50, 75, 100, 125,
150, 175, 200, or 250, contiguous amino acids, or up to the total
number of amino acids present in a full-length PHI-4 of the
embodiments. In some embodiments, the fragment is an N-terminal or
a C-terminal truncation of at least about 1, 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25 or more amino
acids relative to SEQ ID NO: 35, SEQ ID NOs: 51-819 or variants
thereof, e.g., by proteolysis, insertion of a start codon, deletion
of the codons encoding the deleted amino acids with the concomitant
insertion of a stop codon or by insertion of a stop codon in the
coding sequence. In some embodiments, the fragments encompassed
herein result from the removal of the N-terminal 1, 2, 3, 4, 5, 6,
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,
24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or more amino acids
relative to SEQ ID NO: 35, SEQ ID NOs: 51-819 or variants thereof,
e.g., by proteolysis or by insertion of a start codon in the coding
sequence.
[0193] In some embodiments the PHI-4 are encoded by a nucleic acid
sequence sufficiently identical to the nucleic acid sequence of SEQ
ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NOS: 24-30. By
"sufficiently identical" is intended an amino acid or nucleic acid
sequence that has at least about 60% or 65% sequence identity,
about 70% or 75% sequence identity, about 80%, 81%, 82%, 83%, 84%,
85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98%, 99% or greater sequence identity compared to a reference
sequence using one of the alignment programs described herein using
standard parameters. In some embodiments the sequence homology
identity is against the full length sequence of the polynucleotide
encoding a PHI-4 or against the full length sequence of a PHI-4
polypeptide. In some embodiments the polynucleotide encoding the
PHI-4 has at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%,
82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99% or greater sequence identity compared to
SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NOS: 24-30. One
of skill in the art will recognize that these values can be
appropriately adjusted to determine corresponding identity of
proteins encoded by two nucleic acid sequences by taking into
account codon degeneracy, amino acid similarity, reading frame
positioning, and the like.
[0194] To determine the percent identity of two amino acid
sequences or of two nucleic acids, the sequences are aligned for
optimal comparison purposes. The percent identity between the two
sequences is a function of the number of identical positions shared
by the sequences (i.e., percent identity=number of identical
positions/total number of positions (e.g., overlapping
positions).times.100). In one embodiment, the two sequences are the
same length. In another embodiment, the comparison is across the
entirety of the reference sequence (e.g., across the entirety of
SEQ ID NO: 35 or across the entirety of one of SEQ ID NO: 1, SEQ ID
NO: 7, SEQ ID NO: 11, SEQ ID NOS: 24-30). The percent identity
between two sequences can be determined using techniques similar to
those described below, with or without allowing gaps. In
calculating percent identity, typically exact matches are
counted.
[0195] The determination of percent identity between two sequences
can be accomplished using a mathematical algorithm. A non-limiting
example of a mathematical algorithm utilized for the comparison of
two sequences is the algorithm of Karlin and Altschul, (1990) Proc.
Natl. Acad. Sci. USA 87:2264, modified as in Karlin and Altschul,
(1993) Proc. Natl. Acad. Sci. USA 90:5873-5877. Such an algorithm
is incorporated into the BLASTN and BLASTX programs of Altschul, et
al., (1990) J. Mol. Biol. 215:403. BLAST nucleotide searches can be
performed with the BLASTN program, score=100, wordlength=12, to
obtain nucleic acid sequences homologous to pesticidal-like nucleic
acid molecules. BLAST protein searches can be performed with the
BLASTX program, score=50, wordlength=3, to obtain amino acid
sequences homologous to pesticidal protein molecules. To obtain
gapped alignments for comparison purposes, Gapped BLAST (in BLAST
2.0) can be utilized as described in Altschul, et al., (1997)
Nucleic Acids Res. 25:3389. Alternatively, PSI-Blast can be used to
perform an iterated search that detects distant relationships
between molecules. See, Altschul, et al., (1997) supra. When
utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default
parameters of the respective programs (e.g., BLASTX and BLASTN) can
be used. Alignment may also be performed manually by
inspection.
[0196] Another non-limiting example of a mathematical algorithm
utilized for the comparison of sequences is the ClustalW algorithm
(Higgins, et al., (1994) Nucleic Acids Res. 22:4673-4680). ClustalW
compares sequences and aligns the entirety of the amino acid or DNA
sequence and thus can provide data about the sequence conservation
of the entire amino acid sequence. The ClustalW algorithm is used
in several commercially available DNA/amino acid analysis software
packages, such as the ALIGNX.RTM. module of the Vector NTI.RTM.
Program Suite (Invitrogen Corporation, Carlsbad, Calif.). After
alignment of amino acid sequences with ClustalW, the percent amino
acid identity can be assessed. A non-limiting example of a software
program useful for analysis of ClustalW alignments is GENEDOC.TM..
GENEDOC.TM. (Karl Nicholas) allows assessment of amino acid (or
DNA) similarity and identity between multiple proteins. Another
non-limiting example of a mathematical algorithm utilized for the
comparison of sequences is the algorithm of Myers and Miller,
(1988) CABIOS 4:11-17. Such an algorithm is incorporated into the
ALIGN program (version 2.0), which is part of the GCG Wisconsin
Genetics Software Package, Version 10 (available from Accelrys,
Inc., 9685 Scranton Rd., San Diego, Calif., USA). When utilizing
the ALIGN program for comparing amino acid sequences, a PAM120
weight residue table, a gap length penalty of 12 and a gap penalty
of 4 can be used.
[0197] Another non-limiting example of a mathematical algorithm
utilized for the comparison of sequences is the algorithm of
Needleman and Wunsch, (1970) J. Mol. Biol. 48(3):443-453, used GAP
Version 10 software to determine sequence identity or similarity
using the following default parameters: % identity and % similarity
for a nucleic acid sequence using GAP Weight of 50 and Length
Weight of 3 and the nwsgapdna.cmpii scoring matrix; % identity or %
similarity for an amino acid sequence using GAP weight of 8 and
length weight of 2, and the BLOSUM62 scoring program. Equivalent
programs may also be used. By "equivalent program" is intended any
sequence comparison program that, for any two sequences in
question, generates an alignment having identical nucleotide
residue matches and an identical percent sequence identity when
compared to the corresponding alignment generated by GAP Version
10.
[0198] The embodiments also encompass nucleic acid molecules
encoding variants of PHI-4 polypeptide. "Variants" of the PHI-4
polypeptide encoding nucleic acid sequences include those sequences
that encode the PHI-4 polypeptides disclosed herein but that differ
conservatively because of the degeneracy of the genetic code as
well as those that are sufficiently identical as discussed above.
Naturally occurring allelic variants can be identified with the use
of well-known molecular biology techniques, such as polymerase
chain reaction (PCR) and hybridization techniques as outlined
below. Variant nucleic acid sequences also include synthetically
derived nucleic acid sequences that have been generated, for
example, by using site-directed mutagenesis but which still encode
the PHI-4 polypeptides disclosed as discussed below.
[0199] The skilled artisan will further appreciate that changes can
be introduced by mutation of the nucleic acid sequences thereby
leading to changes in the amino acid sequence of the encoded PHI-4
polypeptides, without altering the biological activity of the
proteins. Thus, variant nucleic acid molecules can be created by
introducing one or more nucleotide substitutions, nucleotide
additions and/or nucleotide deletions into the corresponding
nucleic acid sequence disclosed herein, such that one or more amino
acid substitutions, amino acid additions or amino acid deletions
are introduced into the encoded protein. Mutations can be
introduced by standard techniques, such as site-directed
mutagenesis and PCR-mediated mutagenesis. Such variant nucleic acid
sequences are also encompassed by the present invention.
[0200] Alternatively, variant nucleic acid sequences can be made by
introducing mutations randomly along all or part of the coding
sequence, such as by saturation mutagenesis and the resultant
mutants can be screened for ability to confer pesticidal activity
to identify mutants that retain activity. Following mutagenesis,
the encoded protein can be expressed recombinantly, and the
activity of the protein can be determined using standard assay
techniques.
[0201] The polynucleotides of the disclosure and fragments thereof
are optionally used as substrates for a variety of recombination
and recursive recombination reactions, in addition to standard
cloning methods as set forth in, e.g., Ausubel, Berger and
Sambrook, i.e., to produce additional pesticidal polypeptide
homologues and fragments thereof with desired properties. A variety
of such reactions are known, including those developed by the
inventors and their co-workers. Methods for producing a variant of
any nucleic acid listed herein comprising recursively recombining
such polynucleotide with a second (or more) polynucleotide, thus
forming a library of variant polynucleotides are also embodiments
of the disclosure, as are the libraries produced, the cells
comprising the libraries, and any recombinant polynucleotide
produces by such methods. Additionally, such methods optionally
comprise selecting a variant polynucleotide from such libraries
based on pesticidal activity, as is wherein such recursive
recombination is done in vitro or in vivo.
[0202] A variety of diversity generating protocols, including
nucleic acid recursive recombination protocols are available and
fully described in the art. The procedures can be used separately,
and/or in combination to produce one or more variants of a nucleic
acid or set of nucleic acids, as well as variants of encoded
proteins. Individually and collectively, these procedures provide
robust, widely applicable ways of generating diversified nucleic
acids and sets of nucleic acids (including, e.g., nucleic acid
libraries) useful, e.g., for the engineering or rapid evolution of
nucleic acids, proteins, pathways, cells and/or organisms with new
and/or improved characteristics.
[0203] While distinctions and classifications are made in the
course of the ensuing discussion for clarity, it will be
appreciated that the techniques are often not mutually exclusive.
Indeed, the various methods can be used singly or in combination,
in parallel or in series, to access diverse sequence variants.
[0204] The result of any of the diversity generating procedures
described herein can be the generation of one or more nucleic
acids, which can be selected or screened for nucleic acids with or
which confer desirable properties or that encode proteins with or
which confer desirable properties. Following diversification by one
or more of the methods herein, or otherwise available to one of
skill, any nucleic acids that are produced can be selected for a
desired activity or property, e.g. pesticidal activity, or, such
activity at a desired pH, etc. This can include identifying any
activity that can be detected, for example, in an automated or
automatable format, by any of the assays in the art, see, e.g.,
discussion of screening of insecticidal activity, infra. A variety
of related (or even unrelated) properties can be evaluated, in
serial or in parallel, at the discretion of the practitioner.
[0205] Descriptions of a variety of diversity generating procedures
for generating modified nucleic acid sequences, e.g., those coding
for polypeptides having pesticidal activity, or fragments thereof,
are found in the following publications and the references cited
therein: Soong, et al., (2000) Nat Genet 25(4):436-439; Stemmer, et
al., (1999) Tumor Targeting 4:1-4; Ness et al. (1999) Nat
Biotechnol 17:893-896; Chang et al. (1999) Nat Biotechnol
17:793-797; Minshull and Stemmer, (1999) Curr Opin Chem Biol
3:284-290; Christians, et al., (1999) Nat Biotechnol 17:259-264;
Crameri, et al., (1998) Nature 391:288-291; Crameri, et al., (1997)
Nat Biotechnol 15:436-438; Zhang, et al., (1997) PNAS USA
94:4504-4509; Patten, et al., (1997) Curr Opin Biotechnol
8:724-733; Crameri, et al, (1996) Nat Med 2:100-103; Crameri, et
al., (1996) Nat Biotechnol 14:315-319; Gates, et al., (1996) J Mol
Biol 255:373-386; Stemmer, (1996) "Sexual PCR and Assembly PCR" In:
The Encyclopedia of Molecular Biology. VCH Publishers, New York.
pp. 447-457; Crameri and Stemmer, (1995) Bio Techniques 18:194-195;
Stemmer, et al., (1995) Gene, 164:49-53; Stemmer, (1995) Science
270:1510; Stemmer, (1995) Bio/Technology 13:549-553; Stemmer,
(1994) Nature 370:389-391 and Stemmer, (1994) PNAS USA
91:10747-10751.
[0206] Mutational methods of generating diversity include, for
example, site-directed mutagenesis (Ling, et al., (1997) Anal
Biochem 254(2):157-178; Dale, et al., (1996) Methods Mol Biol
57:369-374; Smith, (1985) Ann Rev Genet 19:423-462; Botstein and
Shortle, (1985) Science 229:1193-1201; Carter, (1986) Biochem J
237:1-7 and Kunkel, (1987) "The efficiency of oligonucleotide
directed mutagenesis" in Nucleic Acids & Molecular Biology
(Eckstein and Lilley, eds., Springer Verlag, Berlin)); mutagenesis
using uracil containing templates (Kunkel, (1985) PNAS USA
82:488-492; Kunkel, et al, (1987) Methods Enzymol 154:367-382 and
Bass, et al., (1988) Science 242:240-245); oligonucleotide-directed
mutagenesis (Zoller and Smith, (1983) Methods Enzymol 100:468-500;
Zoller and Smith, (1987) Methods Enzymol 154:329-350; Zoller and
Smith, (1982) Nucleic Acids Res 10:6487-6500),
phosphorothioate-modified DNA mutagenesis (Taylor, et al, (1985)
Nucl Acids Res 13:8749-8764; Taylor, et al, (1985) Nucl Acids Res
13:8765-8787 (1985); Nakamaye and Eckstein (1986) Nucl Acids Res
14:9679-9698; Sayers, et al., (1988) Nucl Acids Res 16:791-802 and
Sayers, et al., (1988) Nucl Acids Res 16: 803-814); mutagenesis
using gapped duplex DNA (Kramer, et al., (1984) Nucl Acids Res
12:9441-9456; Kramer and Fritz, (1987) Methods Enzymol 154:350-367;
Kramer, et al., (1988) Nucl Acids Res 16:7207 and Fritz, et al.,
(1988) Nucl Acids Res 16:6987-6999).
[0207] Additional suitable methods include point mismatch repair
(Kramer, et al., (1984) Cell 38:879-887), mutagenesis using
repair-deficient host strains (Carter, et al., (1985) Nucl Acids
Res 13:4431-4443 and Carter, (1987) Methods in Enzymol
154:382-403), deletion mutagenesis (Eghtedarzadeh and Henikoff,
(1986) Nucl Acids Res 14:5115), restriction-selection and
restriction-purification (Wells, et al., (1986) Phil Trans R Soc
Lond A 317:415-423), mutagenesis by total gene synthesis (Nambiar,
et al., (1984) Science 223:1299-1301; Sakamar and Khorana, (1988)
Nucl Acids Res 14:6361-6372; Wells, et al., (1985) Gene 34:315-323
and Grundstrom, et al., (1985) Nucl Acids Res 13:3305-3316),
double-strand break repair (Mandecki, (1986) PNAS USA, 83:7177-7181
and Arnold, (1993) Curr Opin Biotech 4:450-455). Additional details
on many of the above methods can be found in Methods Enzymol Volume
154, which also describes useful controls for trouble-shooting
problems with various mutagenesis methods.
[0208] Additional details regarding various diversity generating
methods can be found in the following US Patents, PCT Publications
and Applications and EPO Publications: U.S. Pat. Nos. 5,723,323,
5,763,192, 5,814,476, 5,817,483, 5,824,514, 5,976,862, 5,605,793,
5,811,238, 5,830,721, 5,834,252, 5,837,458, WO 1995/22625, WO
1996/33207, WO 1997/20078, WO 1997/35966, WO 1999/41402, WO
1999/41383, WO 1999/41369, WO 1999/41368, EP 752008, EP 0932670, WO
1999/23107, WO 1999/21979, WO 1998/31837, WO 1998/27230, WO
1998/27230, WO 2000/00632, WO 2000/09679, WO 1998/42832, WO
1999/29902, WO 1998/41653, WO 1998/41622, WO 1998/42727, WO
2000/18906, WO 2000/04190, WO 2000/42561, WO 2000/42559, WO
2000/42560, WO 2001/23401, and PCT/US01/06775.
[0209] The nucleotide sequences of the embodiments can also be used
to isolate corresponding sequences from other organisms,
particularly other bacteria. In this manner, methods such as PCR,
hybridization and the like can be used to identify such sequences
based on their sequence homology to the sequences set forth herein.
Sequences that are selected based on their sequence identity to the
entire sequences set forth herein or to fragments thereof are
encompassed by the embodiments. Such sequences include sequences
that are orthologs of the disclosed sequences. The term "orthologs"
refers to genes derived from a common ancestral gene and which are
found in different species as a result of speciation. Genes found
in different species are considered orthologs when their nucleotide
sequences and/or their encoded protein sequences share substantial
identity as defined elsewhere herein. Functions of orthologs are
often highly conserved among species.
[0210] In a PCR approach, oligonucleotide primers can be designed
for use in PCR reactions to amplify corresponding DNA sequences
from cDNA or genomic DNA extracted from any organism of interest.
Methods for designing PCR primers and PCR cloning are generally
known in the art and are disclosed in Sambrook, et al., (1989)
Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor
Laboratory Press, Plainview, N.Y.), hereinafter "Sambrook". See
also, Innis, et al., eds. (1990) PCR Protocols: A Guide to Methods
and Applications (Academic Press, New York); Innis and Gelfand,
eds. (1995) PCR Strategies (Academic Press, New York); and Innis
and Gelfand, eds. (1999) PCR Methods Manual (Academic Press, New
York). Known methods of PCR include, but are not limited to,
methods using paired primers, nested primers, single specific
primers, degenerate primers, gene-specific primers, vector-specific
primers, partially-mismatched primers, and the like.
[0211] To identify potential PHI-4 polypeptides from bacterial
collections, the bacterial cell lysates can be screened with
antibodies generated against a PHI-4 polypeptide using Western
blotting and/or ELISA methods. This type of assays can be performed
in a high throughput fashion. Positive samples can be further
analyzed by various techniques such as antibody based protein
purification and identification. Methods of generating antibodies
are well known in the art as discussed infra.
[0212] Alternatively, mass spectrometry based protein
identification method can be used to identify homologs of a PHI-4
polypeptide using protocols in the literatures (Patterson, (1998),
10(22):1-24, Current Protocol in Molecular Biology published by
John Wiley & Son Inc). Specifically, LC-MS/MS based protein
identification method is used to associate the MS data of given
cell lysate or desired molecular weight enriched samples (excised
from SDS-PAGE gel of relevant molecular weight bands to a PHI-4
polypeptide) with sequence information of a PHI-4 polypeptide and
its homologs. Any match in peptide sequences indicates the
potential of having the homologous proteins in the samples.
Additional techniques (protein purification and molecular biology)
can be used to isolate the protein and identify the sequences of
the homologs.
[0213] In hybridization methods, all or part of the pesticidal
nucleic acid sequence can be used to screen cDNA or genomic
libraries. Methods for construction of such cDNA and genomic
libraries are generally known in the art and are disclosed in
Sambrook and Russell, (2001), supra. The so-called hybridization
probes may be genomic DNA fragments, cDNA fragments, RNA fragments
or other oligonucleotides, and may be labeled with a detectable
group such as 32P, or any other detectable marker, such as other
radioisotopes, a fluorescent compound, an enzyme, or an enzyme
co-factor. Probes for hybridization can be made by labeling
synthetic oligonucleotides based on the known PHI-4
polypeptide-encoding nucleic acid sequence disclosed herein.
Degenerate primers designed on the basis of conserved nucleotides
or amino acid residues in the nucleic acid sequence or encoded
amino acid sequence can additionally be used. The probe typically
comprises a region of nucleic acid sequence that hybridizes under
stringent conditions to at least about 12, at least about 25, at
least about 50, 75, 100, 125, 150, 175 or 200 consecutive
nucleotides of nucleic acid sequence encoding a PHI-4 polypeptide
of the disclosure or a fragment or variant thereof. Methods for the
preparation of probes for hybridization are generally known in the
art and are disclosed in Sambrook and Russell, (2001), supra,
herein incorporated by reference.
[0214] For example, an entire nucleic acid sequence, encoding a
PHI-4 polypeptide, disclosed herein, or one or more portions
thereof, may be used as a probe capable of specifically hybridizing
to corresponding nucleic acid sequences encoding PHI-4
polypeptide-like sequences and messenger RNAs. To achieve specific
hybridization under a variety of conditions, such probes include
sequences that are unique and are preferably at least about 10
nucleotides in length, or at least about 20 nucleotides in length.
Such probes may be used to amplify corresponding pesticidal
sequences from a chosen organism by PCR. This technique may be used
to isolate additional coding sequences from a desired organism or
as a diagnostic assay to determine the presence of coding sequences
in an organism. Hybridization techniques include hybridization
screening of plated DNA libraries (either plaques or colonies; see,
for example, Sambrook, et al., (1989) Molecular Cloning: A
Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, N.Y.).
[0215] Hybridization of such sequences may be carried out under
stringent conditions. By "stringent conditions" or "stringent
hybridization conditions" is intended conditions under which a
probe will hybridize to its target sequence to a detectably greater
degree than to other sequences (e.g., at least 2-fold over
background). Stringent conditions are sequence-dependent and will
be different in different circumstances. By controlling the
stringency of the hybridization and/or washing conditions, target
sequences that are 100% complementary to the probe can be
identified (homologous probing). Alternatively, stringency
conditions can be adjusted to allow some mismatching in sequences
so that lower degrees of similarity are detected (heterologous
probing). Generally, a probe is less than about 1000 nucleotides in
length, preferably less than 500 nucleotides in length.
[0216] Typically, stringent conditions will be those in which the
salt concentration is less than about 1.5 M Na ion, typically about
0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to
8.3 and the temperature is at least about 30.degree. C. for short
probes (e.g., 10 to 50 nucleotides) and at least about 60.degree.
C. for long probes (e.g., greater than 50 nucleotides). Stringent
conditions may also be achieved with the addition of destabilizing
agents such as formamide. Exemplary low stringency conditions
include hybridization with a buffer solution of 30 to 35%
formamide, 1 M NaCl, 1% SDS (sodium dodecyl sulphate) at 37.degree.
C., and a wash in 1.times. to 2.times.SSC (20.times.SSC=3.0 M
NaCl/0.3 M trisodium citrate) at 50 to 55.degree. C. Exemplary
moderate stringency conditions include hybridization in 40 to 45%
formamide, 1.0 M NaCl, 1% SDS at 37.degree. C., and a wash in
0.5.times. to 1.times.SSC at 55 to 60.degree. C. Exemplary high
stringency conditions include hybridization in 50% formamide, 1 M
NaCl, 1% SDS at 37.degree. C., and a wash in 0.1.times.SSC at 60 to
65.degree. C. Optionally, wash buffers may comprise about 0.1% to
about 1% SDS. Duration of hybridization is generally less than
about 24 hours, usually about 4 to about 12 hours.
[0217] Specificity is typically the function of post-hybridization
washes, the critical factors being the ionic strength and
temperature of the final wash solution. For DNA-DNA hybrids, the Tm
can be approximated from the equation of Meinkoth and Wahl, (1984)
Anal. Biochem. 138:267-284: Tm=81.5.degree. C.+16.6 (log M)+0.41 (%
GC)-0.61 (% form)-500/L; where M is the molarity of monovalent
cations, % GC is the percentage of guanosine and cytosine
nucleotides in the DNA, % form is the percentage of formamide in
the hybridization solution, and L is the length of the hybrid in
base pairs. The Tm is the temperature (under defined ionic strength
and pH) at which 50% of a complementary target sequence hybridizes
to a perfectly matched probe. Tm is reduced by about 1.degree. C.
for each 1% of mismatching; thus, Tm, hybridization, and/or wash
conditions can be adjusted to hybridize to sequences of the desired
identity. For example, if sequences with 90% identity are sought,
the Tm can be decreased 10.degree. C. Generally, stringent
conditions are selected to be about 5.degree. C. lower than the
thermal melting point (Tm) for the specific sequence and its
complement at a defined ionic strength and pH. However, severely
stringent conditions can utilize a hybridization and/or wash at 1,
2, 3 or 4.degree. C. lower than the thermal melting point (Tm);
moderately stringent conditions can utilize a hybridization and/or
wash at 6, 7, 8, 9 or 10.degree. C. lower than the thermal melting
point (Tm); low stringency conditions can utilize a hybridization
and/or wash at 11, 12, 13, 14, 15, or 20.degree. C. lower than the
thermal melting point (Tm). Using the equation, hybridization and
wash compositions, and desired Tm, those of ordinary skill will
understand that variations in the stringency of hybridization
and/or wash solutions are inherently described. If the desired
degree of mismatching results in a Tm of less than 45.degree. C.
(aqueous solution) or 32.degree. C. (formamide solution), it is
preferred to increase the SSC concentration so that a higher
temperature can be used. An extensive guide to the hybridization of
nucleic acids is found in Tijssen, (1993) Laboratory Techniques in
Biochemistry and Molecular Biology--Hybridization with Nucleic Acid
Probes, Part I, Chapter 2 (Elsevier, N.Y.); and Ausubel, et al.,
eds. (1995) Current Protocols in Molecular Biology, Chapter 2
(Greene Publishing and Wiley-Interscience, New York). See,
Sambrook, et al., (1989) Molecular Cloning: A Laboratory Manual (2d
ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
N.Y.).
Proteins and Variants and Fragments Thereof
[0218] PHI-4 polypeptides are encompassed by the disclosure. By
"PHI-4 polypeptide" or "PHI-4 protein" as used herein
interchangeably is intended a polypeptide that has increased
insecticidal activity against one or more insect pests of the
Lepidoptera and/or Coleoptera orders compared to the protein of SEQ
ID NO: 35, and is sufficiently identical to the protein of SEQ ID
NO: 35. A variety of PHI-4 polypeptides are contemplated.
[0219] The Western Corn Rootworm active protein AXMI-205 (SEQ ID
NO: 35) encoded by the polynucleotide of SEQ ID NO: 34 was
identified from the Chromobacterium Strain ATX 2024
(US20110023184). Synthetic genes encoding AXMI-205; AXMI-205
variants having a truncation of the last 10 and 20 amino acids from
the C-terminus (SEQ ID NO: 36 and SEQ ID NO: 37); and alanine
scanning at every other residue from residue 307-536 of AXMI-205
(SEQ ID NO: 35), with 5307A, D315A, V317A, S349A, G351A, K353A,
V355A, D395A, G399A, W407A, G419A, P435A, S443A, K465A, V467A,
F483A, P487A, S495A, D497A, E499A, K509A, and 1513A identified as
having WCRW activity; are disclosed in US20110023184. AXMI-205
variants evo 24 (E499A); evo25 (V467A--SEQ ID NO: 41); evo30
(V467L--SEQ ID NO: 42); PMlibl PoolIG2_p2al 1 (S468L--SEQ ID NO:
45); PMlibl PoolIG2_plcl (V467T--SEQ ID NO: 46), PMlibl
PoolIG2_pla4 (R464N--SEQ ID NO: 47), evo34 (E86T--SEQ ID NO: 43)
and evo35 (Q517R--SEQ ID NO: 44) having increased insecticidal
activity are disclosed in WO2013/016617.
[0220] As used herein, the terms "protein," "peptide molecule" or
"polypeptide" includes any molecule that comprises five or more
amino acids. It is well known in the art that protein, peptide or
polypeptide molecules may undergo modification, including
post-translational modifications, such as, but not limited to,
disulfide bond formation, glycosylation, phosphorylation or
oligomerization. Thus, as used herein, the terms "protein,"
"peptide molecule" or "polypeptide" includes any protein that is
modified by any biological or non-biological process. The terms
"amino acid" and "amino acids" refer to all naturally occurring
L-amino acids.
[0221] A "recombinant protein" is used to refer to a protein that
is no longer in its natural environment, for example in vitro or in
a recombinant bacterial or plant host cell. A PHI-4 polypeptide
that is substantially free of cellular material includes
preparations of protein having less than about 30%, 20%, 10% or 5%
(by dry weight) of non-pesticidal protein (also referred to herein
as a "contaminating protein").
[0222] By "improved activity" or "increased activity" is intended
an increase of at least about 10%, at least about 15%, at least
about 20%, at least about 25%, at least about 30%, at least about
35%, at least about 40%, at least about 50%, at least about 60%, at
least about 70%, at least about 80%, at least about 90%, at least
about 100%, at least about 110%, at least about 120%, at least
about 130%, at least about 140%, at least about 150%, at least
about 160%, at least about 170%, at least about 180%, at least
about 190%, at least about 200%, at least about 210% at least about
220%, at least about 230%, at least about 240%, at least about
250%, at least about 260%, at least about 270%, at least about
280%, at least about 290%, at least about 300%, at least about
310%, at least about 320%, at least about 330%, at least about
340%, at least about 350%, at least about 360%, at least about
370%, at least about 380%, at least about 390%, at least about
400%, at least about 410%, at least about 420%, at least about
430%, at least about 440%, at least about 450%, at least about
460%, at least about 470%, at least about 480%, at least about
490%, at least about 500%, at least about 510%, at least about
520%, at least about 530%, at least about 540%, at least about
550%, at least about 560%, at least about 570%, at least about
580%, at least about 590%, at least about 600%, at least about
650%, at least about 700%, at least about 750%, at least about
800%, at least about 850%, at least about 900%, at least about
950%, at least about 1000% or higher, or at least about 1.1-fold,
at least about 1.2-fold, at least about 1.3-fold, at least about
1.4-fold, or at least about 1.5-fold, at least about 1.6-fold, at
least about 1.7-fold, at least about 1.8-fold, at least about
1.9-fold, at least about 2-fold, at least about 2.1-fold, at least
about 2.2-fold, at least about 2.3-fold, at least about 2.4-fold,
at least about 2.5-fold, at least about 2.6-fold, at least about
2.7-fold, at least about 2.8-fold, at least about 2.9-fold, at
least about 3-fold, at least about 3.1-fold, at least about
3.2-fold, at least about 3.3-fold, at least about 3.4-fold, at
least about 3.5-fold, at least about 3.6-fold, at least about
3.7-fold, at least about 3.8-fold, at least about 3.9-fold, at
least about 4-fold, at least about 4.1-fold, at least about
4.2-fold, at least about 4.3-fold, at least about 4.4-fold, at
least about 4.5-fold, at least about 4.6-fold, at least about
4.7-fold, at least about 4.8-fold, at least about 4.9-fold, at
least about 5-fold, at least about 5.1-fold, at least about
5.2-fold, at least about 5.3-fold, at least about 5.4-fold, at
least about 5.5-fold, at least about 5.6-fold, at least about
5.7-fold, at least about 5.8-fold, at least about 5.9-fold, at
least about 6-fold, at least about 6.1-fold, at least about
6.2-fold, at least about 6.3-fold, at least about 6.4-fold, at
least about 6.5-fold, at least about 6.6-fold, at least about
6.7-fold, at least about 6.8-fold, at least about 6.9-fold, at
least about 7-fold, at least about 7.1-fold, at least about
7.2-fold, at least about 7.3-fold, at least about 7.4-fold, at
least about 7.5-fold, at least about 7.6-fold, at least about
7.7-fold, at least about 7.8-fold, at least about 7.9-fold, at
least about 8-fold, at least about 8.1-fold, at least about
8.2-fold, at least about 8.3-fold, at least about 8.4-fold, at
least about 8.5-fold, at least about 8.6-fold, at least about
8.7-fold, at least about 8.8-fold, at least about 8.9-fold, at
least about 9-fold, at least about 9.1-fold, at least about
9.2-fold, at least about 9.3-fold, at least about 9.4-fold, at
least about 9.5-fold, at least about 9.6-fold, at least about
9.7-fold, at least about 9.8-fold, at least about 9.9-fold, at
least about 10-fold, or higher increase in the pesticidal activity
of the variant protein relative to the pesticidal activity of
AXMI-205 (SEQ ID NO: 35).
[0223] In some embodiments, the improvement consists of a decrease
in the EC50 of at least about 10%, at least about 15%, at least
about 20%, at least about 25%, at least about 30%, at least about
35%, at least about 40%, at least about 50%, at least about 60%, at
least about 70%, at least about 80%, at least about 90%, at least
about 100%, at least about 110%, at least about 120%, at least
about 130%, at least about 140%, at least about 150%, at least
about 160%, at least about 170%, at least about 180%, at least
about 190%, at least about 200%, at least about 210% at least about
220%, at least about 230%, at least about 240%, at least about
250%, at least about 260%, at least about 270%, at least about
280%, at least about 290%, at least about 300%, at least about
310%, at least about 320%, at least about 330%, at least about
340%, at least about 350%, at least about 360%, at least about
370%, at least about 380%, at least about 390%, at least about
400%, at least about 410%, at least about 420%, at least about
430%, at least about 440%, at least about 450%, at least about
460%, at least about 470%, at least about 480%, at least about
490%, at least about 500%, at least about 510%, at least about
520%, at least about 530%, at least about 540%, at least about
550%, at least about 560%, at least about 570%, at least about
580%, at least about 590%, at least about 600%, at least about
650%, at least about 700%, at least about 750%, at least about
800%, at least about 850%, at least about 900%, at least about
950%, at least about 1000% or higher, or at least about 1.1-fold,
at least about 1.2-fold, at least about 1.3-fold, at least about
1.4-fold, or at least about 1.5-fold, at least about 1.6-fold, at
least about 1.7-fold, at least about 1.8-fold, at least about
1.9-fold, at least about 2-fold, at least about 2.1-fold, at least
about 2.2-fold, at least about 2.3-fold, at least about 2.4-fold,
at least about 2.5-fold, at least about 2.6-fold, at least about
2.7-fold, at least about 2.8-fold, at least about 2.9-fold, at
least about 3-fold, at least about 3.1-fold, at least about
3.2-fold, at least about 3.3-fold, at least about 3.4-fold, at
least about 3.5-fold, at least about 3.6-fold, at least about
3.7-fold, at least about 3.8-fold, at least about 3.9-fold, at
least about 4-fold, at least about 4.1-fold, at least about
4.2-fold, at least about 4.3-fold, at least about 4.4-fold, at
least about 4.5-fold, at least about 4.6-fold, at least about
4.7-fold, at least about 4.8-fold, at least about 4.9-fold, at
least about 5-fold, at least about 5.1-fold, at least about
5.2-fold, at least about 5.3-fold, at least about 5.4-fold, at
least about 5.5-fold, at least about 5.6-fold, at least about
5.7-fold, at least about 5.8-fold, at least about 5.9-fold, at
least about 6-fold, at least about 6.1-fold, at least about
6.2-fold, at least about 6.3-fold, at least about 6.4-fold, at
least about 6.5-fold, at least about 6.6-fold, at least about
6.7-fold, at least about 6.8-fold, at least about 6.9-fold, at
least about 7-fold, at least about 7.1-fold, at least about
7.2-fold, at least about 7.3-fold, at least about 7.4-fold, at
least about 7.5-fold, at least about 7.6-fold, at least about
7.7-fold, at least about 7.8-fold, at least about 7.9-fold, at
least about 8-fold, at least about 8.1-fold, at least about
8.2-fold, at least about 8.3-fold, at least about 8.4-fold, at
least about 8.5-fold, at least about 8.6-fold, at least about
8.7-fold, at least about 8.8-fold, at least about 8.9-fold, at
least about 9-fold, at least about 9.1-fold, at least about
9.2-fold, at least about 9.3-fold, at least about 9.4-fold, at
least about 9.5-fold, at least about 9.6-fold, at least about
9.7-fold, at least about 9.8-fold, at least about 9.9-fold, at
least about 10-fold, or greater reduction in the EC50 of the PHI-4
polypeptide relative to the pesticidal activity of AXMI-205 (SEQ ID
NO: 35).
[0224] In some embodiments the EC50 of the PHI-4 polypeptide is
<100 ppm, <90 ppm, <80 ppm, <70 ppm, <60 ppm, <50
ppm, <45 ppm, <40 ppm, <35 ppm, <30 ppm, <25 ppm,
<20 ppm, <19 ppm, <18 ppm, <17 ppm, <16 ppm, <15
ppm, <14 ppm, <13 ppm, <12 ppm, <11 ppm, <10 ppm,
<9 ppm, <8 ppm, <7 ppm, <6 ppm, <5 ppm, <4 ppm,
<3 ppm, <2 ppm, <1 ppm, <0.9 ppm, <0.8 ppm, <0.7
ppm, <0.6 ppm, <0.5 ppm, <0.4 ppm, <0.3 ppm, <0.2
ppm, <0.1 ppm,
[0225] In some embodiments, the improvement consists of an increase
in the Mean FAE Index of at least about 10%, at least about 15%, at
least about 20%, at least about 25%, at least about 30%, at least
about 35%, at least about 40%, at least about 50%, at least about
60%, at least about 70%, at least about 80%, at least about 90%, at
least about 100%, at least about 110%, at least about 120%, at
least about 130%, at least about 140%, at least about 150%, at
least about 160%, at least about 170%, at least about 180%, at
least about 190%, at least about 200%, at least about 210% at least
about 220%, at least about 230%, at least about 240%, at least
about 250%, at least about 260%, at least about 270%, at least
about 280%, at least about 290%, at least about 300%, at least
about 310%, at least about 320%, at least about 330%, at least
about 340%, at least about 350%, at least about 360%, at least
about 370%, at least about 380%, at least about 390%, at least
about 400%, at least about 410%, at least about 420%, at least
about 430%, at least about 440%, at least about 450%, at least
about 460%, at least about 470%, at least about 480%, at least
about 490%, at least about 500%, at least about 510%, at least
about 520%, at least about 530%, at least about 540%, at least
about 550%, at least about 560%, at least about 570%, at least
about 580%, at least about 590%, at least about 600%, at least
about 650%, at least about 700%, at least about 750%, at least
about 800%, at least about 850%, at least about 900%, at least
about 950%, at least about 1000% or higher, or at least about
1.1-fold, at least about 1.2-fold, at least about 1.3-fold, at
least about 1.4-fold, or at least about 1.5-fold, at least about
1.6-fold, at least about 1.7-fold, at least about 1.8-fold, at
least about 1.9-fold, at least about 2-fold, at least about
2.1-fold, at least about 2.2-fold, at least about 2.3-fold, at
least about 2.4-fold, at least about 2.5-fold, at least about
2.6-fold, at least about 2.7-fold, at least about 2.8-fold, at
least about 2.9-fold, at least about 3-fold, at least about
3.1-fold, at least about 3.2-fold, at least about 3.3-fold, at
least about 3.4-fold, at least about 3.5-fold, at least about
3.6-fold, at least about 3.7-fold, at least about 3.8-fold, at
least about 3.9-fold, at least about 4-fold, at least about
4.1-fold, at least about 4.2-fold, at least about 4.3-fold, at
least about 4.4-fold, at least about 4.5-fold, at least about
4.6-fold, at least about 4.7-fold, at least about 4.8-fold, at
least about 4.9-fold, at least about 5-fold, at least about
5.1-fold, at least about 5.2-fold, at least about 5.3-fold, at
least about 5.4-fold, at least about 5.5-fold, at least about
5.6-fold, at least about 5.7-fold, at least about 5.8-fold, at
least about 5.9-fold, at least about 6-fold, at least about
6.1-fold, at least about 6.2-fold, at least about 6.3-fold, at
least about 6.4-fold, at least about 6.5-fold, at least about
6.6-fold, at least about 6.7-fold, at least about 6.8-fold, at
least about 6.9-fold, at least about 7-fold, at least about
7.1-fold, at least about 7.2-fold, at least about 7.3-fold, at
least about 7.4-fold, at least about 7.5-fold, at least about
7.6-fold, at least about 7.7-fold, at least about 7.8-fold, at
least about 7.9-fold, at least about 8-fold, at least about
8.1-fold, at least about 8.2-fold, at least about 8.3-fold, at
least about 8.4-fold, at least about 8.5-fold, at least about
8.6-fold, at least about 8.7-fold, at least about 8.8-fold, at
least about 8.9-fold, at least about 9-fold, at least about
9.1-fold, at least about 9.2-fold, at least about 9.3-fold, at
least about 9.4-fold, at least about 9.5-fold, at least about
9.6-fold, at least about 9.7-fold, at least about 9.8-fold, at
least about 9.9-fold, at least about 10-fold, or higher increase in
the Mean FAE Index of the PHI-4 polypeptide relative to the
pesticidal activity of AXMI-205 (SEQ ID NO: 35).
[0226] In some embodiments, the improvement consists of an increase
in the Mean Deviation Score of at least about 10%, at least about
15%, at least about 20%, at least about 25%, at least about 30%, at
least about 35%, at least about 40%, at least about 50%, at least
about 60%, at least about 70%, at least about 80%, at least about
90%, at least about 100%, at least about 110%, at least about 120%,
at least about 130%, at least about 140%, at least about 150%, at
least about 160%, at least about 170%, at least about 180%, at
least about 190%, at least about 200%, at least about 210% at least
about 220%, at least about 230%, at least about 240%, at least
about 250%, at least about 260%, at least about 270%, at least
about 280%, at least about 290%, at least about 300%, at least
about 310%, at least about 320%, at least about 330%, at least
about 340%, at least about 350%, at least about 360%, at least
about 370%, at least about 380%, at least about 390%, at least
about 400%, at least about 410%, at least about 420%, at least
about 430%, at least about 440%, at least about 450%, at least
about 460%, at least about 470%, at least about 480%, at least
about 490%, at least about 500%, at least about 510%, at least
about 520%, at least about 530%, at least about 540%, at least
about 550%, at least about 560%, at least about 570%, at least
about 580%, at least about 590%, at least about 600%, at least
about 650%, at least about 700%, at least about 750%, at least
about 800%, at least about 850%, at least about 900%, at least
about 950%, at least about 1000% or higher, or at least about
1.1-fold, at least about 1.2-fold, at least about 1.3-fold, at
least about 1.4-fold, or at least about 1.5-fold, at least about
1.6-fold, at least about 1.7-fold, at least about 1.8-fold, at
least about 1.9-fold, at least about 2-fold, at least about
2.1-fold, at least about 2.2-fold, at least about 2.3-fold, at
least about 2.4-fold, at least about 2.5-fold, at least about
2.6-fold, at least about 2.7-fold, at least about 2.8-fold, at
least about 2.9-fold, at least about 3-fold, at least about
3.1-fold, at least about 3.2-fold, at least about 3.3-fold, at
least about 3.4-fold, at least about 3.5-fold, at least about
3.6-fold, at least about 3.7-fold, at least about 3.8-fold, at
least about 3.9-fold, at least about 4-fold, at least about
4.1-fold, at least about 4.2-fold, at least about 4.3-fold, at
least about 4.4-fold, at least about 4.5-fold, at least about
4.6-fold, at least about 4.7-fold, at least about 4.8-fold, at
least about 4.9-fold, at least about 5-fold, at least about
5.1-fold, at least about 5.2-fold, at least about 5.3-fold, at
least about 5.4-fold, at least about 5.5-fold, at least about
5.6-fold, at least about 5.7-fold, at least about 5.8-fold, at
least about 5.9-fold, at least about 6-fold, at least about
6.1-fold, at least about 6.2-fold, at least about 6.3-fold, at
least about 6.4-fold, at least about 6.5-fold, at least about
6.6-fold, at least about 6.7-fold, at least about 6.8-fold, at
least about 6.9-fold, at least about 7-fold, at least about
7.1-fold, at least about 7.2-fold, at least about 7.3-fold, at
least about 7.4-fold, at least about 7.5-fold, at least about
7.6-fold, at least about 7.7-fold, at least about 7.8-fold, at
least about 7.9-fold, at least about 8-fold, at least about
8.1-fold, at least about 8.2-fold, at least about 8.3-fold, at
least about 8.4-fold, at least about 8.5-fold, at least about
8.6-fold, at least about 8.7-fold, at least about 8.8-fold, at
least about 8.9-fold, at least about 9-fold, at least about
9.1-fold, at least about 9.2-fold, at least about 9.3-fold, at
least about 9.4-fold, at least about 9.5-fold, at least about
9.6-fold, at least about 9.7-fold, at least about 9.8-fold, at
least about 9.9-fold, at least about 10-fold, or higher increase in
the Mean Deviation Score of the PHI-4 polypeptide relative to the
pesticidal activity of AXMI-205 (SEQ ID NO: 35).
[0227] In some embodiments the improved activity of the PHI-4
polypeptide is relative to the pesticidal activity of
AXMI-205(evo25) (SEQ ID NO: 41), AXMI-205(evo30) (SEQ ID NO: 42),
Axmi205 PMlibl PoolIG2_p2al 1 (mutation S468L; SEQ ID NO: 45),
Axmi205 PMlibl PoolIG2_plcl (mutation V467T; SEQ ID NO: 46),
Axmi205 PMlibl PoolIG2_pla4 (mutation R464N; SEQ ID NO: 47),
AXMI-205(evo34) (SEQ ID NO: 43) or AXMI-205(evo35) (SEQ ID NO:
44).
[0228] "Mean FAE Index" (MFI) refers to the mean of multiple FAEGN
an arithmetic mean of FAEGN. As used herein, the "Mean Deviation
Score" refers to the arithmetic mean of multiple Deviation
Scores.
[0229] In some embodiments the PHI-4 polypeptides have increased
insecticidal activity against one or more insect pests of the order
Coleoptera.
[0230] In some embodiments the PHI-4 polypeptides have increased
insecticidal activity against Diabrotica virgifera larvae--Western
Corn Root Worm (WCRW).
[0231] "Fragments" or "biologically active portions" include
polypeptide fragments comprising amino acid sequences sufficiently
identical to a PHI-4 polypeptide and that exhibit insecticidal
activity. "Fragments" or "biologically active portions" include
polypeptide fragments comprising amino acid sequences sufficiently
identical to the amino acid sequence set forth in SEQ ID NO: 35 and
SEQ ID NOs: 51-819 and that exhibit insecticidal activity. A
biologically active portion of a PHI-4 polypeptide can be a
polypeptide that is, for example, 10, 25, 50, 100, 150, 200, 250,
300, 350, 400, 450, 500, 516, 517, 518, 519, 520, 521, 522, 523,
524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534 or 535 amino
acids in length. Such biologically active portions can be prepared
by recombinant techniques and evaluated for insecticidal activity.
As used here, a fragment comprises at least 8 contiguous amino
acids of a PHI-4 polypeptide. In some embodiments a fragment
comprises at least 8 contiguous amino acids of SEQ ID NO: 2 or SEQ
ID NOs: 51-819. In some embodiments a fragment comprises at least 8
contiguous amino acids of SEQ ID NO: 2 or SEQ ID NOs: 51-819. The
embodiments encompass other fragments, however, such as any
fragment in the protein greater than about 10, 20, 30, 50, 100,
150, 200, 250 or more amino acids.
[0232] In some embodiments, the fragment is an N-terminal and/or a
C-terminal truncation of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25 or more amino acids
relative to SEQ ID NO: 2, SEQ ID NO: 35 or SEQ ID NOs: 51-819 or
variants thereof e.g., by proteolysis, by insertion of a start
codon, by deletion of the codons encoding the deleted amino acids
and concomitant insertion of a start codon and/or insertion of a
stop codon. In some embodiments, the fragments encompassed herein
result from the removal of the C-terminal 1, 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,
26, 27, 28, or 29 amino acids relative to SEQ ID NO: 35, SEQ ID NO:
2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NOs: 51-819, and variants
thereof by proteolysis or by insertion of a start codon, by
deletion of the codons encoding the deleted amino acids and
concomitant insertion of a start codon. In particular embodiments
the proteolytic cleavage site is between Lys at 520 and Ser at 521
Ser or Lys at 313 and Val at 314 of SEQ ID NO: 35 or variants
thereof. It is well known in the art that polynucleotide encoding
the truncated PHI-4 polypeptide can be engineered to add a start
codon at the N-terminus such as ATG encoding methionine or
methionine followed by an alanine. It is also well known in the art
that depending on what host the PHI-4 polypeptide is expressed in
the methionine may be partially of completed processed off.
[0233] In some embodiments fragments, biologically active portions,
of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NOs: 51-819
as well as amino acid substitutions, amino acid deletions and/or
insertions thereof are also provided, and may be used to practice
the methods of the disclosure.
[0234] In some embodiments PHI-4 polypeptides are provided having
one or more amino acid substitution compared to AXMI-205 (SEQ ID
NO: 35). In some embodiments PHI-4 polypeptides are provided having
amino acid substitutions at solvent exposed surface residues to
modify the protein characteristics of AXMI-205 (SEQ ID NO: 35),
including but not limited to the ionic polarity of the protein
surface. In some embodiments PHI-4 polypeptides are provided having
amino acid substitutions at hydrophilic residues such as Asp, Glu,
Lys, Arg, His, Ser, Thr, Tyr, Trp, Asn, Gln, and Cys. In some
embodiments the PHI-4 polypeptides are provided having amino acid
substitutions changing a Lysine or Arginine to a Glutamine,
Glutamic Acid, Asparagine or Glutamic Acid; changing a Glutamic
Acid or Aspartic Acid to a Lysine, Asparagine or Glutamine; and
changing a Glutamine to a Asparagine or Lysine.
[0235] In some embodiments PHI-4 polypeptides are provided having
amino acid substitutions at residues in a membrane insertion loop.
In some embodiments PHI-4 polypeptides are provided having amino
acid substitutions in a membrane insertion loop between about amino
acid at position 92 (Val) and 101 (Ala) and/or at position 211
(Gly) and 220 (Glu) relative to SEQ ID NO: 35.
[0236] In some embodiments PHI-4 polypeptides are provided having
amino acid substitutions at residues and receptor binding loops. In
some embodiments PHI-4 polypeptides are provided having amino acid
substitutions at residues and receptor binding loops between about
amino acid 332 (Asp) and 340 (Asp), 395 (Asp) and 403 (Asp), 458
(Asp) and 466 (Asp) relative to SEQ ID NO: 35.
[0237] In some embodiments PHI-4 polypeptides are provided having
amino acid substitutions at residues in a protease sensitive
region. In some embodiments PHI-4 polypeptides are provided having
amino acid substitutions at residues in a protease sensitive region
from about amino acid residues between 305 (Lys) and 316 (Lys) and
500 (Arg) and 535 (Lys) relative to SEQ ID NO: 35.
[0238] By variants is intended proteins or polypeptides having an
amino acid sequence that is at least about 50%, 55%, 60%, 65%, 70%,
75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the parental
amino acid sequence. In some embodiments a PHI-4 polypeptide has at
least about 60%, 65%, about 70%, 75%, at least about 80%, 81%, 82%,
83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98% or 99% or greater identity across the entire length
of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NOs: 51-819.
In some embodiments a PHI-4 polypeptide has at least about 80%,
81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,
94%, 95%, 96%, 97%, 98% or 99% or greater identity across the
entire length of the amino acid sequence of SEQ ID NO: 2 or SEQ ID
NOs: 51-819.
[0239] In some embodiments a PHI-4 polypeptide comprises an amino
acid sequence having at least 80% identity, to the amino acid
sequence of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NOs:
51-819, wherein the polypeptide has insecticidal activity.
[0240] In some embodiments a PHI-4 polypeptide comprises an amino
acid sequence having at least 90% identity to the amino acid
sequence of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NOs:
51-819, wherein the polypeptide has insecticidal activity.
[0241] In some embodiments a PHI-4 polypeptide comprises an amino
acid sequence having at least 95% identity to the amino acid
sequence of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NOs:
51-819 wherein the polypeptide has insecticidal activity.
[0242] In some embodiments a PHI-4 polypeptide comprises an amino
acid sequence having at least 97% identity to the amino acid
sequence of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NOs:
51-819, wherein the polypeptide has insecticidal activity.
[0243] In some embodiments a PHI-4 polypeptide comprises an amino
acid sequence of SEQ ID NO: 4, wherein Xaa at position 9 is Gln,
Lys or Glu; Xaa at position 14 is Pro or Ala; Xaa at position 16 is
Val or Asp; Xaa at position 19 is Met or Leu; Xaa at position 22 is
Gly or Ser; Xaa at position 24 is Asp, Asn or Gln; Xaa at position
36 is Leu or Met; Xaa at position 42 is Asp, Asn or Gln; Xaa at
position 43 is Phe or Glu; Xaa at position 46 is Glu, Asp, Asn or
Gly; Xaa at position 50 is Ile or Val; Xaa at position 51 is Glu or
Gln; Xaa at position 55 is Arg or Lys; Xaa at position 56 is Ser or
Thr; Xaa at position 57 is Tyr or Phe; Xaa at position 58 is Thr or
Ser; Xaa at position 61 is Arg, Lys or Glu; Xaa at position 73 is
Phe or Tyr; Xaa at position 74 is Lys, Glu, Gly, Arg, Met, Leu, His
or Asp; Xaa at position 76 is Asp or Gln; Xaa at position 79 is Lys
or Glu; Xaa at position 80 is Glu or Ser; Xaa at position 82 is
Glu, Ile, Leu, Tyr or Gln; Xaa at position 83 is Glu or Gln; Xaa at
position 84 is Tyr or Phe; Xaa at position 86 is Glu or Gln; Xaa at
position 87 is Lys or Gln; Xaa at position 88 is Met, Ile or Leu;
Xaa at position 90 is Gln or Glu; Xaa at position 94 is Val or Ile;
Xaa at position 97 is Arg, Asn, Asp, Glu, Gln, Gly or Ser; Xaa at
position 98 is Tyr or Phe; Xaa at position 99 is Lys, Leu, Tyr,
Ile, Met, Phe, Cys, Val or Asn; Xaa at position 103 is Ala or Gly;
Xaa at position 105 is Leu or Ile; Xaa at position 109 is Phe, Lys,
Gly, Met, Ser, Asp, Asn, Glu, Cys, Ala or Arg; Xaa at position 112
is Thr or Ser; Xaa at position 113 is Asp, Glu or Met; Xaa at
position 117 is Thr or Ser; Xaa at position 121 is Tyr or Phe; Xaa
at position 127 is Ala or Thr; Xaa at position 142 is Arg or Glu;
Xaa at position 146 is Arg or Gln; Xaa at position 147 is Arg, Glu
or Gln; Xaa at position 148 is Asp, Phe, Pro, Val, Glu, His, Trp,
Ala, Arg, Leu, Ser, Gln or Gly; Xaa at position 149 is Phe or Val;
Xaa at position 150 is Arg, Gln or Glu; Xaa at position 151 is Asp,
Ser, Ala, Asn, Trp, Val, Gln, Cys, Met, Leu, Arg or Glu; Xaa at
position 153 is Leu or Ile; Xaa at position 154 is Asn or Asp; Xaa
at position 155 is Asn or Lys; Xaa at position 159 is Pro or Asp;
Xaa at position 162 is Glu, Asp or Gln; Xaa at position 165 is Lys,
Glu, Gln, Pro, Thr, Ala, Leu, Gly, Asp, Val, His, Ile, Met, Trp,
Phe, Tyr or Arg; Xaa at position 166 is Arg or Gln; Xaa at position
167 is Tyr, Trp or Cys; Xaa at position 170 is Tyr or His; Xaa at
position 171 is Tyr or Phe; Xaa at position 172 is Ile, Leu or Val;
Xaa at position 173 is Ser or Ala; Xaa at position 174 is Glu or
Gln; Xaa at position 182 is Asp or Gln; Xaa at position 183 is Tyr
or Val; Xaa at position 184 is Ser or Thr; Xaa at position 185 is
Ala or Ser; Xaa at position 189 is Thr, Lys or Ile; Xaa at position
191 is Lys or Gln; Xaa at position 193 is Asp or Asn; Xaa at
position 196 is Gln, Lys, Asn, Asp, Glu, Ala, Ile or Arg; Xaa at
position 202 is Ala or Val; Xaa at position 203 is Glu, Thr or His;
Xaa at position 204 is Met or Ala; Xaa at position 206 is Tyr or
Phe; Xaa at position 207 is Lys or Gln; Xaa at position 209 is Leu
or Pro; Xaa at position 210 is Val or Ile; Xaa at position 214 is
Lys, Ser or Gln; Xaa at position 216 is Glu, Gln, Phe, Val, Tyr or
Arg; Xaa at position 220 is Glu, His, Asp, Thr, Tyr, Val, Ser, Gln,
Arg, Trp, Met, Ala, Phe, Ile, Leu, Cys or Asn; Xaa at position 229
is Arg or Glu; Xaa at position 230 is Ser or Glu; Xaa at position
231 is Asn or Ser; Xaa at position 236 is Leu or Pro; Xaa at
position 245 is Met or Leu; Xaa at position 247 is Asp or Tyr; Xaa
at position 256 is Gln, Lys or Glu; Xaa at position 257 is Gln,
Ile, Glu, Cys, Ser, His, Trp or Met; Xaa at position 261 is Gln,
Glu or Lys; Xaa at position 264 is Glu or Gln; Xaa at position 268
is Asp or Asn; Xaa at position 276 is Ser or Ala; Xaa at position
278 is Glu, Asn or Gln; Xaa at position 281 is Gln, Lys or Glu; Xaa
at position 282 is Pro or Gly; Xaa at position 284 is Trp or Arg;
Xaa at position 287 is Ala or Cys; Xaa at position 289 is Lys, Leu,
Val, Pro, Glu, Gln, Tyr, Thr, Asp, Phe, Ser, Met, Arg, Trp, Ile,
His, Asn, Cys, Gly or Ala; Xaa at position 291 is Glu or Gln; Xaa
at position 292 is Arg or Gln; Xaa at position 293 is Arg, Glu or
Gln; Xaa at position 294 is Val or Ala; Xaa at position 296 is Leu
or Ile; Xaa at position 297 is Glu or Gln; Xaa at position 298 is
Asp or Gln; Xaa at position 300 is Phe or Tyr; Xaa at position 302
is Glu or Gln; Xaa at position 303 is Phe or Tyr; Xaa at position
305 is Lys or Gln; Xaa at position 306 is Gln or Lys; Xaa at
position 309 is Gln, Lys or Glu; Xaa at position 313 is Lys, Gln or
Arg; Xaa at position 316 is Lys or Gln; Xaa at position 328 is Lys,
Glu or Gln; Xaa at position 331 is Glu, Asn or Gln; Xaa at position
333 is Ser, Arg, Gly, Lys, Val, Asn, Ala, His, Gln, Thr, Asp, Ile,
Leu, Cys or Glu; Xaa at position 334 is Gly, Arg, Lys, Ile or Trp;
Xaa at position 335 is Ser or Ala; Xaa at position 336 is Gly or
Ala; Xaa at position 337 is Ala, Val or Gly; Xaa at position 338 is
Ser, His, Val, Lys, Ala, Gly, Thr, Ile, Glu, Met, Arg, Pro, Asp,
Asn or Leu; Xaa at position 339 is Glu, Asn, Gln, Ile, Pro, Met,
Ser, Ala, Cys, Phe, Val, Leu, Asp, Trp, His or Arg; Xaa at position
341 is Leu or Val; Xaa at position 342 is Ala, Ser or Val; Xaa at
position 343 is Val or Ile; Xaa at position 344 is Phe or Trp; Xaa
at position 345 is Asn or His; Xaa at position 346 is Pro or Ala;
Xaa at position 350 is Asn or Ser; Xaa at position 351 is Gly or
Val; Xaa at position 354 is Met or Leu; Xaa at position 355 is Val,
Ile or Leu; Xaa at position 359 is Gly or Ala; Xaa at position 362
is Asn or Ser; Xaa at position 364 is Ala or Ser; Xaa at position
371 is Ala, Gly or Thr; Xaa at position 374 is Phe or Ile; Xaa at
position 375 is Lys or Arg; Xaa at position 380 is Leu or Gly; Xaa
at position 382 is Val, Asp or Leu; Xaa at position 383 is Leu, Ile
or Val; Xaa at position 384 is Lys, Ala or Gly; Xaa at position 385
is Ala or Gly; Xaa at position 389 is Trp or Tyr; Xaa at position
391 is Arg, Leu, Glu, Gln or Asp; Xaa at position 395 is Asp or
Cys; Xaa at position 396 is Ala, Leu, Lys, Asn, Gly, Ile, Met, Arg,
Tyr, Gln or His; Xaa at position 397 is Gly, Arg or Ala; Xaa at
position 398 is Ser, Gln or Cys; Xaa at position 401 is Ser, His,
Pro, Gly, Lys, Val, Arg, Ile, Asn, Phe, Thr, Ala, Asp, Met, Gln or
Glu; Xaa at position 402 is Lys, Phe, His, Arg, Trp, Gly, Asn, Leu,
Tyr, Thr, Val, Met, Pro or Ala; Xaa at position 403 is Asp, Tyr,
Trp, Phe or Glu; Xaa at position 405 is Ala or Ser; Xaa at position
409 is Ala or Pro; Xaa at position 410 is Ile or Val; Xaa at
position 411 is Pro or Ala; Xaa at position 412 is Pro or Ala; Xaa
at position 416 is Arg, Glu or Gln; Xaa at position 417 is Ala, Ser
or Cys; Xaa at position 418 is Leu or Met; Xaa at position 422 is
Met or Val; Xaa at position 426 is Thr or Ser; Xaa at position 436
is Asp or Lys; Xaa at position 437 is Tyr or Val; Xaa at position
438 is Val or Arg; Xaa at position 440 is Val or Leu; Xaa at
position 442 is Gln, Lys or Glu; Xaa at position 445 is Cys, Leu or
Thr; Xaa at position 447 is Asp, Lys, Tyr, Ser, Glu, Ile, Gly, Pro,
Leu, Phe, Trp or Thr; Xaa at position 448 is Val or Ala; Xaa at
position 449 is Gln or Glu; Xaa at position 452 is Gln, Lys or Glu;
Xaa at position 453 is Asn or Asp; Xaa at position 454 is Arg, Tyr,
Met, Ser, Val, Ile, Lys, Phe, Trp, Gln, Gly, His, Asp, Leu, Thr,
Pro or Asn; Xaa at position 455 is Val or Ile; Xaa at position 457
is Trp or Asn; Xaa at position 459 is Lys, Met, Val, Trp, Gln, Ile,
Thr, Ser, His, Cys, Tyr, Pro, Asn, Ala, Arg or Glu; Xaa at position
460 is Gly or Ala; Xaa at position 461 is Thr or Ser; Xaa at
position 462 is Gly or Ala; Xaa at position 463 is Ala, Ser or Gly;
Xaa at position 464 is Arg, Gly, His, Gln, Thr or Phe; Xaa at
position 465 is Lys, Asn, Val, Met, Pro, Gly, Arg, Thr, His, Cys,
Trp, Phe or Leu; Xaa at position 466 is Asp or Arg; Xaa at position
471 is Gln, Lys or Glu; Xaa at position 497 is Asp or Gln; Xaa at
position 499 is Glu or Gln; Xaa at position 500 is Arg, Gln or Lys;
Xaa at position 502 is Arg, Glu or Gln; Xaa at position 509 is Lys,
Gln or Glu; Xaa at position 517 is Gln, Cys, Asn, Val or Pro; Xaa
at position 518 is Glu or Gln; Xaa at position 520 is Lys, Gln or
Glu; Xaa at position 525 is Gln or Lys; and Xaa at position 527 is
Gln, Lys, Pro, Cys, Glu, Ser, His, Phe or Trp; and having one or
more amino acid substitutions at positions designated as Xaa in SEQ
ID NO: 4 and wherein the PHI-4 polypeptide has increased
insecticidal activity compared to SEQ ID NO: 2; and amino acid
substitutions, deletions, insertions, and fragments thereof, and
combinations thereof.
[0244] In some embodiments a PHI-4 polypeptide comprises an amino
acid sequence of SEQ ID NO: 4 having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,
28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44,
45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 or
61 amino acid substitutions, in any combination, at residues
designated by Xaa in SEQ ID NO: 4 compared to the native amino acid
at the corresponding position of SEQ ID NO: 2.
[0245] In some embodiments a PHI-4 polypeptide comprises an amino
acid sequence of SEQ ID NO: 4 having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acid substitutions,
in any combination, at residues designated by Xaa in SEQ ID NO: 4
compared to the native amino acid at the corresponding position of
SEQ ID NO: 2.
[0246] In some embodiments a PHI-4 polypeptide comprises an amino
acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%,
87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or
greater sequence identity to the amino acid sequence of SEQ ID NO:
4.
[0247] In some embodiments a PHI-4 polypeptide comprises an amino
acid sequence of SEQ ID NO: 3, wherein Xaa at position 24 is Asp or
Asn; Xaa at position 42 is Asp or Asn; Xaa at position 43 is Phe or
Glu; Xaa at position 46 is Glu or Asn; Xaa at position 74 is Lys,
Glu or Gly; Xaa at position 79 is Lys or Glu; Xaa at position 82 is
Glu, Ile, Leu or Tyr; Xaa at position 97 is Arg, Asn, Asp, Glu, Gln
or Gly; Xaa at position 98 is Tyr or Phe; Xaa at position 99 is
Lys, Leu, Tyr, Ile or Met; Xaa at position 109 is Phe, Lys, Gly,
Met, Ser, Asp or Asn; Xaa at position 147 is Arg or Glu; Xaa at
position 148 is Asp, Phe or Pro; Xaa at position 150 is Arg or Gln;
Xaa at position 151 is Asp, Ser, Ala or Asn; Xaa at position 153 is
Leu or Ile; Xaa at position 162 is Glu or Gln; Xaa at position 165
is Lys, Glu or Gln; Xaa at position 166 is Arg or Gln; Xaa at
position 171 is Tyr or Phe; Xaa at position 174 is Glu or Gln; Xaa
at position 182 is Asp or Gln; Xaa at position 196 is Gln, Lys, Asn
or Asp; Xaa at position 203 is Glu, Thr or His; Xaa at position 206
is Tyr or Phe; Xaa at position 216 is Glu or Gln; Xaa at position
220 is Glu, His, Asp, Thr, Tyr, Val, Ser or Gln; Xaa at position
247 is Asp or Tyr; Xaa at position 256 is Gln or Lys; Xaa at
position 257 is Gln or Ile; Xaa at position 261 is Gln or Glu; Xaa
at position 278 is Glu or Asn; Xaa at position 281 is Gln, Lys or
Glu; Xaa at position 289 is Lys, Leu, Val, Pro, Glu, Gln, Tyr, Thr
or Asp; Xaa at position 293 is Arg, Glu or Gln; Xaa at position 313
is Lys or Gln; Xaa at position 328 is Lys, Glu or Gln; Xaa at
position 333 is Ser, Gly, Lys, Val or Asn; Xaa at position 334 is
Gly, Arg, Lys or Ile; Xaa at position 336 is Gly or Ala; Xaa at
position 338 is Ser, His, Val, Lys or Ala; Xaa at position 339 is
Glu, Asn, Ile or Pro; Xaa at position 343 is Val or Ile; Xaa at
position 346 is Pro or Ala; Xaa at position 355 is Val or Ile; Xaa
at position 359 is Gly or Ala; Xaa at position 391 is Arg, Glu or
Gln; Xaa at position 396 is Ala, Leu, Lys, Asn or Gly; Xaa at
position 401 is Ser, His, Pro, Gly, Lys, Val or Arg; Xaa at
position 402 is Lys, Phe, His, Arg, Gly, Trp, Thr, Asn, Tyr or Met;
Xaa at position 403 is Asp or Tyr; Xaa at position 411 is Pro or
Ala; Xaa at position 412 is Pro or Ala; Xaa at position 416 is Arg
or Glu; Xaa at position 417 is Ala or Ser; Xaa at position 418 is
Leu or Met; Xaa at position 426 is Thr or Ser; Xaa at position 440
is Val or Leu; Xaa at position 447 is Asp, Lys, Tyr, Ser, Glu or
Ile; Xaa at position 452 is Gln, Lys or Glu; Xaa at position 454 is
Arg, Tyr, Met, Ser, Val, Ile, Lys, Phe, Trp or Gln; Xaa at position
455 is Val or Ile; Xaa at position 459 is Lys, Met, Val, Trp, Gln,
Ile or Tyr; Xaa at position 461 is Thr or Ser; Xaa at position 462
is Gly or Ala; Xaa at position 463 is Ala or Ser; Xaa at position
464 is Arg, Gly or His; Xaa at position 465 is Lys, Asn, Val, Met,
Pro, Gly or Arg; Xaa at position 471 is Gln, Lys or Glu; Xaa at
position 500 is Arg or Gln; Xaa at position 509 is Lys or Gln; Xaa
at position 520 is Lys, Gln or Glu; and Xaa at position 527 is Gln,
Lys, Pro, Cys or Glu; and having one or more amino acid
substitutions at positions designated as Xaa in SEQ ID NO: 3 and
wherein the PHI-4 polypeptide has increased insecticidal activity
compared to SEQ ID NO: 35; and amino acid substitutions, deletions,
insertions, and fragments thereof, and combinations thereof.
[0248] In some embodiments a PHI-4 polypeptide comprises an amino
acid sequence of SEQ ID NO: 3 having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,
28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44,
45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61,
62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 or 76 amino
acid substitutions, in any combination, at residues designated by
Xaa in SEQ ID NO: 3 compared to the native amino acid at the
corresponding position of SEQ ID NO: 2.
[0249] In some embodiments PHI-4 polypeptide comprises an amino
acid sequence of SEQ ID NO: 3 having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,
28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44,
45, 46, 47, 48, 49, 50, 51, 52, 53 or 54 amino acid substitutions,
in any combination, at residues designated by Xaa in SEQ ID NO: 3
compared to the native amino acid at the corresponding position of
SEQ ID NO: 2.
[0250] In some embodiments PHI-4 polypeptide comprises an amino
acid sequence of SEQ ID NO: 3 having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
11, 12, 13, 14 or 15 amino acid substitutions, in any combination,
at residues designated by Xaa in SEQ ID NO: 3 compared to the
native amino acid at the corresponding position of SEQ ID NO:
2.
[0251] In some embodiments a PHI-4 polypeptide comprises an amino
acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%,
87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or
greater sequence identity to the amino acid sequence of SEQ ID NO:
3.
[0252] In some embodiments a PHI-4 polypeptide comprises one or
more amino acid substitutions compared to the native amino acid at
position 40, 42, 43, 46, 52, 97, 98, 99, 145, 150, 151, 153, 163,
171, 172, 182, 196, 206, 210, 216, 220, 278, 283, 289, 293, 328,
333, 334, 336, 338, 339, 342, 346, 354, 355, 370, 389, 393, 396,
401, 402, 403, 410, 412, 416, 417, 426, 442, 447, 452, 454, 455,
457, 461, 462, 500, 509, 520 or 527 of SEQ ID NO: 35.
[0253] In some embodiments a PHI-4 polypeptide comprises one or
more amino acid substitutions compared to the native amino acid at
position 40, 42, 43, 46, 52, 97, 98, 99, 145, 150, 151, 153, 163,
171, 172, 182, 196, 206, 210, 216, 220, 278, 283, 289, 293, 328,
333, 334, 336, 338, 339, 342, 346, 354, 355, 370, 389, 393, 396,
401, 402, 403, 410, 412, 416, 417, 426, 442, 447, 452, 454, 455,
457, 461, 462, 500, 509, 520 or 527 of SEQ ID NO: 35 wherein the
amino acid at position 40 is Leu or Ile; the amino acid at position
42 is Asp or Asn; the amino acid at position 43 is Phe or Glu; the
amino acid at position 46 is Glu or Asn; the amino acid at position
52 is Ile or Val; the amino acid at position 97 is Arg, Asp, Glu or
Asn; the amino acid at position 98 is Tyr or Phe; the amino acid at
position 99 is Lys or Leu; the amino acid at position 145 is Leu or
Val; the amino acid at position 150 is Arg or Gln; the amino acid
at position 151 is Asp or Ser; the amino acid at position 153 is
Leu or Ile; the amino acid at position 163 is Leu or Val; the amino
acid at position 171 is Tyr or Phe; the amino acid at position 172
is Ile or Leu; the amino acid at position 182 is Asp or Gln; the
amino acid at position 196 is Gln or Asn; the amino acid at
position 206 is Tyr or Phe; the amino acid at position 210 is Val
or Ile; the amino acid at position 216 is Glu or Gln; the amino
acid at position 220 is Glu, Gln, His or Asp; the amino acid at
position 278 is Glu or Asn; the amino acid at position 283 is Ile
or Val; the amino acid at position 289 is Lys, Gln or Leu; the
amino acid at position 293 is Arg, Gln or Glu; the amino acid at
position 328 is Lys or Glu; the amino acid at position 333 is Ser,
Lys or Val; the amino acid at position 334 is Gly, Lys or Arg; the
amino acid at position 336 is Gly or Ala; the amino acid at
position 338 is Ser or Val; the amino acid at position 339 is Glu,
Asn or Gln; the amino acid at position 342 is Ala or Ser; the amino
acid at position 346 is Pro or Ala; the amino acid at position 354
is Met or Leu; the amino acid at position 355 is Val or Ile; the
amino acid at position 370 is His or Arg; the amino acid at
position 389 is Trp or Leu; the amino acid at position 393 is Trp
or Leu; the amino acid at position 396 is Ala, Leu, Lys, Thr or
Gly; the amino acid at position 401 is Ser, His, Gly, Lys or Pro;
the amino acid at position 402 is Lys, His, Gly or Trp; the amino
acid at position 403 is Asp or Tyr; the amino acid at position 410
is Ile or Val; the amino acid at position 412 is Pro or Ala; the
amino acid at position 416 is Arg or Glu; the amino acid at
position 417 is Ala or Ser; the amino acid at position 426 is Thr
or Ser; the amino acid at position 442 is Gln or Glu; the amino
acid at position 447 is Asp or Lys; the amino acid at position 452
is Gln or Lys; the amino acid at position 454 is Arg or Gln; the
amino acid at position 455 is Val or Ile; the amino acid at
position 457 is Trp or Asn; the amino acid at position 461 is Thr
or Ser; the amino acid at position 462 is Gly or Ala; the amino
acid at position 500 is Arg or Gln; the amino acid at position 509
is Lys or Gln; the amino acid at position 520 is Lys, Glu or Gln;
and the amino acid at position 527 is Gln or Lys., and amino acid
deletions, insertions and fragments thereof, and combinations
thereof.
[0254] In some embodiments the PHI-4 polypeptide comprising one or
more amino acid substitutions at position 86, 359, 399, 464, 465,
466, 467, 468, 499 or 517.
[0255] In some embodiments the PHI-4 polypeptide comprising one or
more amino acid substitutions at position 86, 359, 399, 464, 465,
466, 467, 468, 499 or 517, wherein the amino acid at position 86 is
Glu or Thr; the amino acid at position 359 is Gly or Ala; the amino
acid at position 399 is Gly or Ala; the amino acid at position 464
is Arg, Ala, Lys, Asp or Asn; the amino acid at position 465 is Lys
or Met, the amino acid at position 467 is Val, Ala, Leu or Thr; the
amino acid at position 468 is Ser or Leu; the amino acid at
position 499 is Glu or Ala, or the amino acid at position 517 is
Glu or Arg.
[0256] In some embodiments exemplary PHI-4 polypeptides are encoded
by the polynucleotide sequence set forth in SEQ ID NO: 1, SEQ ID
NO: 7, SEQ ID NO: 11, SEQ ID NOS: 24-30.
[0257] In some embodiments a PHI-4 polypeptide includes variants
where an amino acid that is part of a proteolytic cleavage site is
changed to another amino acid to eliminate or alter the proteolytic
cleavage at that site. In some embodiments the proteolytic cleavage
is by a protease in the insect gut. In other embodiments the
proteolytic cleavage is by a plant protease in the transgenic
plant.
[0258] In some embodiments exemplary PHI-4 polypeptides are the
polypeptides shown in Table 3, Table 4, Table 5, Table 6, Table 7,
Megatable 1, and Megatable 2 and combinations of the amino
substitutions thereof as well as amino acid deletions, and or
insertions and fragments thereof.
[0259] In some embodiments a PHI-4 polypeptide is encoded by a
nucleic acid molecule that hybridizes under stringent conditions to
the nucleic acid molecule of SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO:
11, SEQ ID NOS: 24-30. Variants include polypeptides that differ in
amino acid sequence due to mutagenesis. Variant proteins
encompassed by the disclosure are biologically active, that is they
continue to possess the desired biological activity (i.e.
pesticidal activity) of the native protein. By "retains activity"
is intended that the variant will have at least about 30%, at least
about 50%, at least about 70% or at least about 80% of the
insecticidal activity of the native protein. In some embodiments,
the variants may have improved activity over the native
protein.
[0260] Bacterial genes quite often possess multiple methionine
initiation codons in proximity to the start of the open reading
frame. Often, translation initiation at one or more of these start
codons will lead to generation of a functional protein. These start
codons can include ATG codons. However, bacteria such as Bacillus
sp. also recognize the codon GTG as a start codon, and proteins
that initiate translation at GTG codons contain a methionine at the
first amino acid. On rare occasions, translation in bacterial
systems can initiate at a TTG codon, though in this event the TTG
encodes a methionine. Furthermore, it is not often determined a
priori which of these codons are used naturally in the bacterium.
Thus, it is understood that use of one of the alternate methionine
codons may also lead to generation of pesticidal proteins. These
pesticidal proteins are encompassed in the present disclosure and
may be used in the methods of the present disclosure. It will be
understood that, when expressed in plants, it will be necessary to
alter the alternate start codon to ATG for proper translation.
[0261] In another aspect the PHI-4 polypeptide may be expressed as
a precursor protein with an intervening sequence that catalyzes
multi-step, post translational protein splicing. Protein splicing
involves the excision of an intervening sequence from a polypeptide
with the concomitant joining of the flanking sequences to yield a
new polypeptide (Chong, et al., (1996) J. Biol. Chem.
271:22159-22168). This intervening sequence or protein splicing
element, referred to as inteins, which catalyze their own excision
through three coordinated reactions at the N-terminal and
C-terminal splice junctions: an acyl rearrangement of the
N-terminal cysteine or Serine; a transesterfication reaction
between the two termini to form a branched ester or thioester
intermediate and peptide bond cleavage coupled to cyclization of
the intein C-terminal asparagine to free the intein (Evans, et al.,
(2000) J. Biol. Chem. 275:9091-9094. The elucidation of the
mechanism of protein splicing has led to a number of intein-based
applications (Comb, et al., U.S. Pat. No. 5,496,714; Comb, et al.,
U.S. Pat. No. 5,834,247; Camarero and Muir, (1999) J. Amer. Chem.
Soc. 121:5597-5598; Chong, et al., (1997) Gene 192:271-281, Chong,
et al., (1998) Nucleic Acids Res. 26:5109-5115; Chong, et al.,
(1998) J. Biol. Chem. 273:10567-10577; Cotton, et al., (1999) J.
Am. Chem. Soc. 121:1100-1101; Evans, et al., (1999) J. Biol. Chem.
274:18359-18363; Evans, et al., (1999) J. Biol. Chem.
274:3923-3926; Evans, et al., (1998) Protein Sci. 7:2256-2264;
Evans, et al., (2000) J. Biol. Chem. 275:9091-9094; Iwai and
Pluckthun, (1999) FEBS Lett. 459:166-172; Mathys, et al., (1999)
Gene 231:1-13; Mills, et al., (1998) Proc. Natl. Acad. Sci. USA
95:3543-3548; Muir, et al., (1998) Proc. Natl. Acad. Sci. USA
95:6705-6710; Otomo, et al., (1999) Biochemistry 38:16040-16044;
Otomo, et al., (1999) J. Biolmol. NMR 14:105-114; Scott, et al.,
(1999) Proc. Natl. Acad. Sci. USA 96:13638-13643; Severinov and
Muir, (1998) J. Biol. Chem. 273:16205-16209; Shingledecker, et al.,
(1998) Gene 207:187-195; Southworth, et al., (1998) EMBO J.
17:918-926; Southworth, et al., (1999) Biotechniques 27:110-120;
Wood, et al., (1999) Nat. Biotechnol. 17:889-892; Wu, et al.,
(1998a) Proc. Natl. Acad. Sci. USA 95:9226-9231; Wu, et al.,
(1998b) Biochim Biophys Acta 1387:422-432; Xu, et al., (1999) Proc.
Natl. Acad. Sci. USA 96:388-393; Yamazaki, et al., (1998) J. Am.
Chem. Soc. 120:5591-5592). For the application of inteins in plant
transgenes see Yang, J, et al., (Transgene Res 15:583-593 (2006))
and Evans, et al., (Annu. Rev. Plant Biol. 56:375-392, (2005)).
[0262] In another aspect the PHI-4 polypeptide may be encoded by
two separate genes where the intein of the precursor protein comes
from the two genes, referred to as a split-intein and the two
portions of the precursor are joined by a peptide bond formation.
This peptide bond formation is accomplished by intein-mediated
trans-splicing. For this purpose, a first and a second expression
cassette comprising the two separate genes further code for inteins
capable of mediating protein trans-splicing. By trans-splicing, the
proteins and polypeptides encoded by the first and second fragments
may be linked by peptide bond formation. Trans-splicing inteins may
be selected from the nucleolar and organellar genomes of different
organisms including eukaryotes, archaebacteria and eubacteria.
Inteins that may be used for are listed at
neb.com/neb/inteins.html, which can be accessed on the world-wide
web using the "www" prefix). The nucleotide sequence coding for an
intein may be split into a 5' and a 3' part that code for the 5'
and the 3' part of the intein, respectively. Sequence portions not
necessary for intein splicing (e.g., homing endonuclease domain)
may be deleted. The intein coding sequence is split such that the
5' and the 3' parts are capable of trans-splicing. For selecting a
suitable splitting site of the intein coding sequence, the
considerations published by Southworth, et al., (1998) EMBO J.
17:918-926 may be followed. In constructing the first and the
second expression cassette, the 5' intein coding sequence is linked
to the 3' end of the first fragment coding for the N-terminal part
of the PHI-4 polypeptide and the 3' intein coding sequence is
linked to the 5' end of the second fragment coding for the
C-terminal part of the PHI-4 polypeptide.
[0263] In general, the trans-splicing partners can be designed
using any split intein, including any naturally-occurring or
artificially-split split intein. Several naturally-occurring split
inteins are known, for example: the split intein of the DnaE gene
of Synechocystis sp. PCC6803 (see, Wu, et al., (1998) Proc Natl
Acad Sci USA 95(16):9226-31 and Evans, et al., (2000) J Biol Chem
275(13):9091-4 and of the DnaE gene from Nostoc punctiforme (see,
Iwai, et al., (2006) FEBS Lett 580(7):1853-8). Non-split inteins
have been artificially split in the laboratory to create new split
inteins, for example: the artificially split Ssp DnaB intein (see,
Wu, et al., (1998) Biochim Biophys Acta 1387:422-32) and split Sce
VMA intein (see, Brenzel, et al., (2006) Biochemistry 45(6):1571-8)
and an artificially split fungal mini-intein (see, Elleuche, et
al., (2007) Biochem Biophys Res Commun 355(3):830-4). There are
also intein databases available that catalogue known inteins (see,
for example the online-database available at:
bioinformatics.weizmann.ac.il/pietro/inteins/Inteinstable.html,
which can be accessed on the world-wide web using the "www"
prefix).
[0264] Naturally-occurring non-split inteins may have endonuclease
or other enzymatic activities that can typically be removed when
designing an artificially-split split intein. Such mini-inteins or
minimized split inteins are well known in the art and are typically
less than 200 amino acid residues long (see, Wu, et al., (1998)
Biochim Biophys Acta 1387:422-32). Suitable split inteins may have
other purification enabling polypeptide elements added to their
structure, provided that such elements do not inhibit the splicing
of the split intein or are added in a manner that allows them to be
removed prior to splicing. Protein splicing has been reported using
proteins that comprise bacterial intein-like (BIL) domains (see,
Amitai, et al., (2003) Mol Microbiol 47:61-73) and hedgehog (Hog)
auto-processing domains (the latter is combined with inteins when
referred to as the Hog/intein superfamily or HINT family (see,
Dassa, et al., (2004) J Biol Chem. 279 32001-7) and domains such as
these may also be used to prepare artificially-split inteins. In
particular, non-splicing members of such families may be modified
by molecular biology methodologies to introduce or restore splicing
activity in such related species. Recent studies demonstrate that
splicing can be observed when a N-terminal split intein component
is allowed to react with a C-terminal split intein component not
found in nature to be its "partner"; for example, splicing has been
observed utilizing partners that have as little as 30 to 50%
homology with the "natural" splicing partner (see, Dassa, et al.,
(2007) Biochemistry 46(1):322-30). Other such mixtures of disparate
split intein partners have been shown to be unreactive one with
another (see, Brenzel, et al., 2006 Biochemistry 45(6):1571-8).
However, it is within the ability of a person skilled in the
relevant art to determine whether a particular pair of polypeptides
is able to associate with each other to provide a functional
intein, using routine methods and without the exercise of inventive
skill.
[0265] In another aspect the PHI-4 polypeptide is a circular
permuted variant. In certain embodiments the PHI-4 polypeptide is a
circular permuted variant of the polypeptide of SEQ ID NO: 2, SEQ
ID NO: 3, SEQ ID NO: 4 or SEQ ID NOs: 51-819. The development of
recombinant DNA methods has made it possible to study the effects
of sequence transposition on protein folding, structure and
function. The approach used in creating new sequences resembles
that of naturally occurring pairs of proteins that are related by
linear reorganization of their amino acid sequences (Cunningham, et
al., (1979) Proc. Natl. Acad. Sci. U.S.A. 76:3218-3222; Teather and
Erfle, (1990) J. Bacteriol. 172:3837-3841; Schimming, et al.,
(1992) Eur. J. Biochem. 204:13-19; Yamiuchi and Minamikawa, (1991)
FEBS Lett. 260:127-130; MacGregor, et al., (1996) FEBS Lett.
378:263-266). The first in vitro application of this type of
rearrangement to proteins was described by Goldenberg and Creighton
(J. Mol. Biol. 165:407-413, 1983). In creating a circular permuted
variant a new N-terminus is selected at an internal site
(breakpoint) of the original sequence, the new sequence having the
same order of amino acids as the original from the breakpoint until
it reaches an amino acid that is at or near the original
C-terminus. At this point the new sequence is joined, either
directly or through an additional portion of sequence (linker), to
an amino acid that is at or near the original N-terminus and the
new sequence continues with the same sequence as the original until
it reaches a point that is at or near the amino acid that was
N-terminal to the breakpoint site of the original sequence, this
residue forming the new C-terminus of the chain. The length of the
amino acid sequence of the linker can be selected empirically or
with guidance from structural information, or by using a
combination of the two approaches. When no structural information
is available, a small series of linkers can be prepared for testing
using a design whose length is varied in order to span a range from
0 to 50 .ANG. and whose sequence is chosen in order to be
consistent with surface exposure (hydrophilicity, Hopp and Woods,
(1983) Mol. Immunol. 20:483-489; Kyte and Doolittle, (1982) J. Mol.
Biol. 157:105-132; solvent exposed surface area, Lee and Richards,
(1971) J. Mol. Biol. 55:379-400) and the ability to adopt the
necessary conformation without deranging the configuration of the
pesticidal polypeptide (conformationally flexible; Karplus and
Schulz, (1985) Naturwissenschaften 72:212-213. Assuming an average
of translation of 2.0 to 3.8 .ANG. per residue, this would mean the
length to test would be between 0 to 30 residues, with 0 to 15
residues being the preferred range. Exemplary of such an empirical
series would be to construct linkers using a cassette sequence such
as Gly-Gly-Gly-Ser repeated n times, where n is 1, 2, 3 or 4. Those
skilled in the art will recognize that there are many such
sequences that vary in length or composition that can serve as
linkers with the primary consideration being that they be neither
excessively long nor short (cf., Sandhu, (1992) Critical Rev.
Biotech. 12:437-462); if they are too long, entropy effects will
likely destabilize the three-dimensional fold, and may also make
folding kinetically impractical, and if they are too short, they
will likely destabilize the molecule because of torsional or steric
strain. Those skilled in the analysis of protein structural
information will recognize that using the distance between the
chain ends, defined as the distance between the c-alpha carbons,
can be used to define the length of the sequence to be used, or at
least to limit the number of possibilities that must be tested in
an empirical selection of linkers. They will also recognize that it
is sometimes the case that the positions of the ends of the
polypeptide chain are ill-defined in structural models derived from
x-ray diffraction or nuclear magnetic resonance spectroscopy data,
and that when true, this situation will therefore need to be taken
into account in order to properly estimate the length of the linker
required. From those residues whose positions are well defined are
selected two residues that are close in sequence to the chain ends,
and the distance between their c-alpha carbons is used to calculate
an approximate length for a linker between them. Using the
calculated length as a guide, linkers with a range of number of
residues (calculated using 2 to 3.8 .ANG. per residue) are then
selected. These linkers may be composed of the original sequence,
shortened or lengthened as necessary, and when lengthened the
additional residues may be chosen to be flexible and hydrophilic as
described above; or optionally the original sequence may be
substituted for using a series of linkers, one example being the
Gly-Gly-Gly-Ser cassette approach mentioned above; or optionally a
combination of the original sequence and new sequence having the
appropriate total length may be used. Sequences of pesticidal
polypeptides capable of folding to biologically active states can
be prepared by appropriate selection of the beginning (amino
terminus) and ending (carboxyl terminus) positions from within the
original polypeptide chain while using the linker sequence as
described above. Amino and carboxyl termini are selected from
within a common stretch of sequence, referred to as a breakpoint
region, using the guidelines described below. A novel amino acid
sequence is thus generated by selecting amino and carboxyl termini
from within the same breakpoint region. In many cases the selection
of the new termini will be such that the original position of the
carboxyl terminus immediately preceded that of the amino terminus.
However, those skilled in the art will recognize that selections of
termini anywhere within the region may function, and that these
will effectively lead to either amino acid deletions or additions
to the amino or carboxyl portions of the new sequence. It is a
central tenet of molecular biology that the primary amino acid
sequence of a protein dictates folding to the three-dimensional
structure necessary for expression of its biological function.
Methods are known to those skilled in the art to obtain and
interpret three-dimensional structural information using x-ray
diffraction of single protein crystals or nuclear magnetic
resonance spectroscopy of protein solutions. Examples of structural
information that are relevant to the identification of breakpoint
regions include the location and type of protein secondary
structure (alpha and 3-10 helices, parallel and anti-parallel beta
sheets, chain reversals and turns, and loops; Kabsch and Sander,
(1983) Biopolymers 22:2577-2637; the degree of solvent exposure of
amino acid residues, the extent and type of interactions of
residues with one another (Chothia, (1984) Ann. Rev. Biochem.
53:537-572) and the static and dynamic distribution of
conformations along the polypeptide chain (Alber and Mathews,
(1987) Methods Enzymol. 154:511-533). In some cases additional
information is known about solvent exposure of residues; one
example is a site of post-translational attachment of carbohydrate
which is necessarily on the surface of the protein. When
experimental structural information is not available, or is not
feasible to obtain, methods are also available to analyze the
primary amino acid sequence in order to make predictions of protein
tertiary and secondary structure, solvent accessibility and the
occurrence of turns and loops. Biochemical methods are also
sometimes applicable for empirically determining surface exposure
when direct structural methods are not feasible; for example, using
the identification of sites of chain scission following limited
proteolysis in order to infer surface exposure (Gentile and
Salvatore, (1993) Eur. J. Biochem. 218:603-621). Thus using either
the experimentally derived structural information or predictive
methods (e.g., Srinivisan and Rose, (1995) Proteins: Struct.,
Funct. & Genetics 22:81-99) the parental amino acid sequence is
inspected to classify regions according to whether or not they are
integral to the maintenance of secondary and tertiary structure.
The occurrence of sequences within regions that are known to be
involved in periodic secondary structure (alpha and 3-10 helices,
parallel and anti-parallel beta sheets) are regions that should be
avoided. Similarly, regions of amino acid sequence that are
observed or predicted to have a low degree of solvent exposure are
more likely to be part of the so-called hydrophobic core of the
protein and should also be avoided for selection of amino and
carboxyl termini. In contrast, those regions that are known or
predicted to be in surface turns or loops, and especially those
regions that are known not to be required for biological activity,
are the preferred sites for location of the extremes of the
polypeptide chain. Continuous stretches of amino acid sequence that
are preferred based on the above criteria are referred to as a
breakpoint region. Polynucleotides encoding circular permuted PHI-4
polypeptides with new N-terminus/C-terminus which contain a linker
region separating the original C-terminus and N-terminus can be
made essentially following the method described in Mullins, et al.,
(1994) J. Am. Chem. Soc. 116:5529-5533. Multiple steps of
polymerase chain reaction (PCR) amplifications are used to
rearrange the DNA sequence encoding the primary amino acid sequence
of the protein. Polynucleotides encoding circular permuted PHI-4
polypeptides with new N-terminus/C-terminus which contain a linker
region separating the original C-terminus and N-terminus can be
made based on the tandem-duplication method described in Horlick,
et al., (1992) Protein Eng. 5:427-431. Polymerase chain reaction
(PCR) amplification of the new N-terminus/C-terminus genes is
performed using a tandemly duplicated template DNA.
[0266] In another aspect fusion proteins are provided that include
within its amino acid sequence an amino acid sequence comprising a
PHI-4 polypeptide including but not limited to the polypeptide of
SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NOs: 51-819 and
active fragments thereof.
[0267] In another aspect fusion proteins are provided comprising a
PHI-4 polypeptide and a second pesticidal polypeptide such a Cry
protein. Methods for design and construction of fusion proteins
(and polynucleotides encoding same) are known to those of skill in
the art. Polynucleotides encoding a PHI-4 polypeptide may be fused
to signal sequences which will direct the localization of the PHI-4
polypeptide to particular compartments of a prokaryotic or
eukaryotic cell and/or direct the secretion of the PHI-4
polypeptide of the embodiments from a prokaryotic or eukaryotic
cell. For example, in E. coli, one may wish to direct the
expression of the protein to the periplasmic space. Examples of
signal sequences or proteins (or fragments thereof) to which the
PHI-4 polypeptide may be fused in order to direct the expression of
the polypeptide to the periplasmic space of bacteria include, but
are not limited to, the pelB signal sequence, the maltose binding
protein (MBP) signal sequence, MBP, the ompA signal sequence, the
signal sequence of the periplasmic E. coli heat-labile enterotoxin
B-subunit, and the signal sequence of alkaline phosphatase. Several
vectors are commercially available for the construction of fusion
proteins which will direct the localization of a protein, such as
the pMAL series of vectors (particularly the pMAL-p series)
available from New England Biolabs. In a specific embodiment, the
PHI-4 polypeptide may be fused to the pelB pectate lyase signal
sequence to increase the efficiency of expression and purification
of such polypeptides in Gram-negative bacteria (see, U.S. Pat. Nos.
5,576,195 and 5,846,818). Plant plastid transit peptide/polypeptide
fusions are well known in the art (see, U.S. Pat. No. 7,193,133).
Apoplast transit peptides such as rice or barley alpha-amylase
secretion signal are also well known in the art. The plastid
transit peptide is generally fused N-terminal to the polypeptide to
be targeted (e.g., the fusion partner). In one embodiment, the
fusion protein consists essentially of the peptide transit plastid
and the PHI-4 polypeptide to be targeted. In another embodiment,
the fusion protein comprises the peptide transit plastid and the
polypeptide to be targeted. In such embodiments, the plastid
transit peptide is preferably at the N-terminus of the fusion
protein. However, additional amino acid residues may be N-terminal
to the plastid transit peptide providing that the fusion protein is
at least partially targeted to a plastid. In a specific embodiment,
the plastid transit peptide is in the N-terminal half, N-terminal
third or N-terminal quarter of the fusion protein. Most or all of
the plastid transit peptide is generally cleaved from the fusion
protein upon insertion into the plastid. The position of cleavage
may vary slightly between plant species, at different plant
developmental stages, as a result of specific intercellular
conditions or the particular combination of transit peptide/fusion
partner used. In one embodiment, the plastid transit peptide
cleavage is homogenous such that the cleavage site is identical in
a population of fusion proteins. In another embodiment, the plastid
transit peptide is not homogenous, such that the cleavage site
varies by 1-10 amino acids in a population of fusion proteins. The
plastid transit peptide can be recombinantly fused to a second
protein in one of several ways. For example, a restriction
endonuclease recognition site can be introduced into the nucleotide
sequence of the transit peptide at a position corresponding to its
C-terminal end and the same or a compatible site can be engineered
into the nucleotide sequence of the protein to be targeted at its
N-terminal end. Care must be taken in designing these sites to
ensure that the coding sequences of the transit peptide and the
second protein are kept "in frame" to allow the synthesis of the
desired fusion protein. In some cases, it may be preferable to
remove the initiator methionine codon of the second protein when
the new restriction site is introduced. The introduction of
restriction endonuclease recognition sites on both parent molecules
and their subsequent joining through recombinant DNA techniques may
result in the addition of one or more extra amino acids between the
transit peptide and the second protein. This generally does not
affect targeting activity as long as the transit peptide cleavage
site remains accessible and the function of the second protein is
not altered by the addition of these extra amino acids at its
N-terminus. Alternatively, one skilled in the art can create a
precise cleavage site between the transit peptide and the second
protein (with or without its initiator methionine) using gene
synthesis (Stemmer, et al., (1995) Gene 164:49-53) or similar
methods. In addition, the transit peptide fusion can intentionally
include amino acids downstream of the cleavage site. The amino
acids at the N-terminus of the mature protein can affect the
ability of the transit peptide to target proteins to plastids
and/or the efficiency of cleavage following protein import. This
may be dependent on the protein to be targeted. See, e.g., Comai,
et al., (1988) J. Biol. Chem. 263(29):15104-9.
[0268] In some embodiments fusion proteins are provide comprising a
PHI-4 polypeptide, a pesticidal protein such as a cry protein, and
an amino acid linker.
[0269] In some embodiments fusion proteins are provided represented
by a formula selected from the group consisting of
R.sup.1-L-R.sup.2,R.sup.2-L-R.sup.1,R.sup.1-R.sup.2 or
R.sup.2-R.sup.1
[0270] where R.sup.1 is a PHI-4 polypeptide, R.sup.2 is a
pesticidal protein with a different but complementary activity to
the PHI-4 polypeptide, including but not limited to cry proteins; a
polypeptide that increases the solubility and/or stability of the
PHI-4 polypeptide; or a transit peptide or leader sequence. The
R.sup.1 polypeptide is fused either directly or through a linker
segment to the R.sup.2 polypeptide. The term "directly" defines
fusions in which the polypeptides are joined without a peptide
linker. Thus L represents a chemical bound or polypeptide segment
to which both R.sup.1 and R.sup.2 are fused in frame, most commonly
L is a linear peptide to which R.sup.1 and R.sup.2 are bound by
amide bonds linking the carboxy terminus of R.sup.1 to the amino
terminus of L and carboxy terminus of L to the amino terminus of
R.sup.2. By "fused in frame" is meant that there is no translation
termination or disruption between the reading frames of R.sup.1 and
R.sup.2. The linking group (L) is generally a polypeptide of
between 1 and 500 amino acids in length. The linkers joining the
two molecules are preferably designed to (1) allow the two
molecules to fold and act independently of each other, (2) not have
a propensity for developing an ordered secondary structure which
could interfere with the functional domains of the two proteins,
(3) have minimal hydrophobic or charged characteristic which could
interact with the functional protein domains and (4) provide steric
separation of R.sup.1 and R.sup.2 such that R.sup.1 and R.sup.2
could interact simultaneously with their corresponding receptors on
a single cell. Typically surface amino acids in flexible protein
regions include Gly, Asn and Ser. Virtually any permutation of
amino acid sequences containing Gly, Asn and Ser would be expected
to satisfy the above criteria for a linker sequence. Other neutral
amino acids, such as Thr and Ala, may also be used in the linker
sequence. Additional amino acids may also be included in the
linkers due to the addition of unique restriction sites in the
linker sequence to facilitate construction of the fusions.
[0271] In some embodiments the linkers comprise sequences selected
from the group of formulas: (Gly.sub.3Ser).sub.n,
(Gly.sub.4Ser).sub.n, (Gly.sub.5Ser).sub.n, (Gly.sub.nSer).sub.n or
(AlaGlySer).sub.n where n is an integer. One example of a
highly-flexible linker is the (GlySer)-rich spacer region present
within the pill protein of the filamentous bacteriophages, e.g.,
bacteriophages M13 or fd (Schaller, et al., 1975). This region
provides a long, flexible spacer region between two domains of the
pill surface protein. Also included are linkers in which an
endopeptidase recognition sequence is included. Such a cleavage
site may be valuable to separate the individual components of the
fusion to determine if they are properly folded and active in
vitro. Examples of various endopeptidases include, but are not
limited to, Plasmin, Enterokinase, Kallikerin, Urokinase, Tissue
Plasminogen activator, clostripain, Chymosin, Collagenase,
Russell's Viper Venom Protease, Postproline cleavage enzyme, V8
protease, Thrombin and factor Xa. In some embodiments the linker
comprises the amino acids EEKKN from the multi-gene expression
vehicle (MGEV), which is cleaved by vacuolar proteases as disclosed
in US 2007/0277263. In other embodiments, peptide linker segments
from the hinge region of heavy chain immunoglobulins IgG, IgA, IgM,
IgD or IgE provide an angular relationship between the attached
polypeptides. Especially useful are those hinge regions where the
cysteines are replaced with serines. Preferred linkers of the
present invention include sequences derived from murine IgG gamma
2b hinge region in which the cysteines have been changed to
serines. The fusion proteins are not limited by the form, size or
number of linker sequences employed and the only requirement of the
linker is that functionally it does not interfere adversely with
the folding and function of the individual molecules of the
fusion.
[0272] In another aspect chimeric PHI-4 polypeptide are provided
that are created through joining two or more portions of genes,
which originally encoded separate insecticidal proteins from
different species, to create a chimeric gene. The translation of
the chimeric gene results in a single chimeric pesticidal
polypeptide with regions, motifs or domains derived from each of
the original polypeptides. In certain embodiments the chimeric
protein comprises portions, motifs, or domains of PHI-4
polypeptides in any combination. In certain embodiments the
chimeric insecticidal polypeptide includes but not limited to the
polypeptides of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID
NOs: 51-819.
[0273] It is recognized that DNA sequences may be altered by
various methods, and that these alterations may result in DNA
sequences encoding proteins with amino acid sequences different
than that encoded by the wild-type (or native) pesticidal protein.
These proteins may be altered in various ways including amino acid
substitutions, amino acid deletions, amino acid truncations, and
insertions of one or more amino acids, including up to 2, 3, 4, 5,
6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75,
80, 85, 90, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150,
155 or more amino acid substitutions, amino acid deletions and/or
insertions or combinations thereof compared to SEQ ID NO: 35 SEQ ID
NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NOs: 51-819. In some
embodiments a PHI-4 polypeptide comprises the deletion of 1, 2, 3,
4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,
22, 23, 24, 25, 26, 27, 28 or more amino acids from the C-terminus
of the PHI-4 polypeptide relative to the amino acid position of SEQ
ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NOs: 51-819. Methods
for such manipulations are generally known in the art. For example,
amino acid sequence variants of a PHI-4 polypeptide can be prepared
by mutations in the DNA. This may also be accomplished by one of
several forms of mutagenesis and/or in directed evolution. In some
aspects, the changes encoded in the amino acid sequence will not
substantially affect the function of the protein. Such variants
will possess the desired pesticidal activity. However, it is
understood that the ability of a PHI-4 polypeptide to confer
pesticidal activity may be improved by the use of such techniques
upon the compositions of this disclosure.
[0274] For example, conservative amino acid substitutions may be
made at one or more, predicted, nonessential amino acid residues. A
"nonessential" amino acid residue is a residue that can be altered
from the wild-type sequence of a PHI-4 polypeptide without altering
the biological activity. A "conservative amino acid substitution"
is one in which the amino acid residue is replaced with an amino
acid residue having a similar side chain. Families of amino acid
residues having similar side chains have been defined in the art.
These families include: amino acids with basic side chains (e.g.,
lysine, arginine, histidine); acidic side chains (e.g., aspartic
acid, glutamic acid); polar, negatively charged residues and their
amides (e.g., aspartic acid, asparagine, glutamic, acid, glutamine;
uncharged polar side chains (e.g., glycine, asparagine, glutamine,
serine, threonine, tyrosine, cysteine); small aliphatic, nonpolar
or slightly polar residues (e.g., Alanine, serine, threonine,
proline, glycine); nonpolar side chains (e.g., alanine, valine,
leucine, isoleucine, proline, phenylalanine, methionine,
tryptophan); large aliphatic, nonpolar residues (e.g., methionine,
leucine, isoleucine, valine, cystine); beta-branched side chains
(e.g., threonine, valine, isoleucine); aromatic side chains (e.g.,
tyrosine, phenylalanine, tryptophan, histidine); large aromatic
side chains (e.g., tyrosine, phenylalanine, tryptophan).
[0275] Amino acid substitutions may be made in nonconserved regions
that retain function. In general, such substitutions would not be
made for conserved amino acid residues, or for amino acid residues
residing within a conserved motif, where such residues are
essential for protein activity. Examples of residues that are
conserved and that may be essential for protein activity include,
for example, residues that are identical between all proteins
contained in an alignment of similar or related toxins to the
sequences of the embodiments (e.g., residues that are identical in
an alignment of homologous proteins). Examples of residues that are
conserved but that may allow conservative amino acid substitutions
and still retain activity include, for example, residues that have
only conservative substitutions between all proteins contained in
an alignment of similar or related toxins to the sequences of the
embodiments (e.g., residues that have only conservative
substitutions between all proteins contained in the alignment
homologous proteins). However, one of skill in the art would
understand that functional variants may have minor conserved or
nonconserved alterations in the conserved residues. Guidance as to
appropriate amino acid substitutions that do not affect biological
activity of the protein of interest may be found in the model of
Dayhoff, et al., (1978) Atlas of Protein Sequence and Structure
(Natl. Biomed. Res. Found., Washington, D.C.), herein incorporated
by reference.
[0276] In making such changes, the hydropathic index of amino acids
may be considered. The importance of the hydropathic amino acid
index in conferring interactive biologic function on a protein is
generally understood in the art (Kyte and Doolittle, (1982) J Mol
Biol. 157(1):105-32). It is accepted that the relative hydropathic
character of the amino acid contributes to the secondary structure
of the resultant protein, which in turn defines the interaction of
the protein with other molecules, for example, enzymes, substrates,
receptors, DNA, antibodies, antigens and the like.
[0277] It is known in the art that certain amino acids may be
substituted by other amino acids having a similar hydropathic index
or score and still result in a protein with similar biological
activity, i.e., still obtain a biological functionally equivalent
protein. Each amino acid has been assigned a hydropathic index on
the basis of its hydrophobicity and charge characteristics (Kyte
and Doolittle, ibid). These are: isoleucine (+4.5); valine (+4.2);
leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5);
methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine
(-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline
(-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5);
aspartate (-3.5); asparagine (-3.5); lysine (-3.9) and arginine
(-4.5). In making such changes, the substitution of amino acids
whose hydropathic indices are within +2 is preferred, those which
are within +1 are particularly preferred and those within +0.5 are
even more particularly preferred.
[0278] It is also understood in the art that the substitution of
like amino acids can be made effectively on the basis of
hydrophilicity. U.S. Pat. No. 4,554,101, states that the greatest
local average hydrophilicity of a protein, as governed by the
hydrophilicity of its adjacent amino acids, correlates with a
biological property of the protein.
[0279] As detailed in U.S. Pat. No. 4,554,101, the following
hydrophilicity values have been assigned to amino acid residues:
arginine (+3.0); lysine (+3.0); aspartate (+3.0.+0.1); glutamate
(+3.0.+0.1); serine (+0.3); asparagine (+0.2); glutamine (+0.2);
glycine (0); threonine (-0.4); proline (-0.5.+0.1); alanine (-0.5);
histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine
(-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3);
phenylalanine (-2.5); tryptophan (-3.4).
[0280] Alternatively, alterations may be made to the protein
sequence of many proteins at the amino or carboxy terminus without
substantially affecting activity. This can include amino acid
insertions, amino acid deletions, or amino acid alterations
introduced by modern molecular methods, such as PCR, including PCR
amplifications that alter or extend the protein coding sequence by
virtue of inclusion of amino acid encoding sequences in the
oligonucleotides utilized in the PCR amplification. Alternatively,
the protein sequences added can include entire protein-coding
sequences, such as those used commonly in the art to generate
protein fusions. Such fusion proteins are often used to (1)
increase expression of a protein of interest (2) introduce a
binding domain, enzymatic activity, or epitope to facilitate either
protein purification, protein detection, or other experimental uses
known in the art (3) target secretion or translation of a protein
to a subcellular organelle, such as the periplasmic space of
Gram-negative bacteria, mitochondria or chloroplasts of plants or
the endoplasmic reticulum of eukaryotic cells, the latter of which
often results in glycosylation of the protein.
[0281] In specific embodiments, the substitution is an alanine for
the native amino acid at the recited position(s). Also encompassed
are the nucleic acid sequence(s) encoding the variant protein or
polypeptide.
[0282] Variant nucleotide and amino acid sequences of the
disclosure also encompass sequences derived from mutagenic and
recombinogenic procedures such as DNA shuffling. With such a
procedure, one or more different PHI-4 polypeptide coding regions
can be used to create a new PHI-4 polypeptide possessing the
desired properties. In this manner, libraries of recombinant
polynucleotides are generated from a population of related sequence
polynucleotides comprising sequence regions that have substantial
sequence identity and can be homologously recombined in vitro or in
vivo. For example, using this approach, sequence motifs encoding a
domain of interest may be shuffled between a pesticidal gene and
other known pesticidal genes to obtain a new gene coding for a
protein with an improved property of interest, such as an increased
insecticidal activity. Strategies for such DNA shuffling are known
in the art. See, for example, Stemmer, (1994) Proc. Natl. Acad.
Sci. USA 91:10747-10751; Stemmer, (1994) Nature 370:389-391;
Crameri, et al., (1997) Nature Biotech. 15:436-438; Moore, et al.,
(1997) J. Mol. Biol. 272:336-347; Zhang, et al., (1997) Proc. Natl.
Acad. Sci. USA 94:4504-4509; Crameri, et al., (1998) Nature
391:288-291 and U.S. Pat. Nos. 5,605,793 and 5,837,458.
[0283] Domain swapping or shuffling is another mechanism for
generating altered PHI-4 polypeptides. Domains may be swapped
between PHI-4 polypeptides, resulting in hybrid or chimeric toxins
with improved pesticidal activity or target spectrum. Methods for
generating recombinant proteins and testing them for pesticidal
activity are well known in the art (see, for example, Naimov, et
al., (2001) Appl. Environ. Microbiol. 67:5328-5330; de Maagd, et
al., (1996) Appl. Environ. Microbiol. 62:1537-1543; Ge, et al.,
(1991) J. Biol. Chem. 266:17954-17958; Schnepf, et al., (1990) J.
Biol. Chem. 265:20923-20930; Rang, et al., 91999) Appl. Environ.
Microbiol. 65:2918-2925).
Antibodies
[0284] Antibodies to a PHI-4 polypeptide of the embodiments, or to
variants or fragments thereof, are also encompassed. Methods for
producing antibodies are well known in the art (see, for example,
Harlow and Lane, (1988) Antibodies: A Laboratory Manual, Cold
Spring Harbor Laboratory, Cold Spring Harbor, N.Y.; U.S. Pat. No.
4,196,265).
[0285] A kit for detecting the presence of a PHI-4 polypeptide, or
detecting the presence of a nucleotide sequence encoding a PHI-4
polypeptide, in a sample is provided. In one embodiment, the kit
provides antibody-based reagents for detecting the presence of a
PHI-4 polypeptide in a tissue sample. In another embodiment, the
kit provides labeled nucleic acid probes useful for detecting the
presence of one or more polynucleotides encoding PHI-4
polypeptide(s). The kit is provided along with appropriate reagents
and controls for carrying out a detection method, as well as
instructions for use of the kit."
Receptor Identification and Isolation
[0286] Receptors to the PHI-4 polypeptide of the embodiments, or to
variants or fragments thereof, are also encompassed. Methods for
identifying receptors are well known in the art (see, Hofmann, et.
al., (1988) Eur. J. Biochem. 173:85-91; Gill, et al., (1995) J.
Biol. Chem. 27277-27282) can be employed to identify and isolate
the receptor that recognizes the PHI-4 polypeptides using the
brush-border membrane vesicles from susceptible insects. In
addition to the radioactive labeling method listed in the cited
literatures, PHI-4 polypeptide can be labeled with fluorescent dye
and other common labels such as streptavidin. Brush-border membrane
vesicles (BBMV) of susceptible insects such as soybean looper and
stink bugs can be prepared according to the protocols listed in the
references and separated on SDS-PAGE gel and blotted on suitable
membrane. Labeled PHI-4 polypeptides can be incubated with blotted
membrane of BBMV and labeled the PHI-4 polypeptides can be
identified with the labeled reporters. Identification of protein
band(s) that interact with the PHI-4 polypeptides can be detected
by N-terminal amino acid gas phase sequencing or mass spectrometry
based protein identification method (Patterson, (1998) 10(22):1-24,
Current Protocol in Molecular Biology published by John Wiley &
Son Inc). Once the protein is identified, the corresponding gene
can be cloned from genomic DNA or cDNA library of the susceptible
insects and binding affinity can be measured directly with the
PHI-4 polypeptides. Receptor function for insecticidal activity by
the PHI-4 polypeptides can be verified by accomplished by RNAi type
of gene knock out method (Rajagopal, et al., (2002) J. Biol. Chem.
277:46849-46851).
Nucleotide Constructs, Expression Cassettes and Vectors
[0287] The use of the term "nucleotide constructs" herein is not
intended to limit the embodiments to nucleotide constructs
comprising DNA. Those of ordinary skill in the art will recognize
that nucleotide constructs particularly polynucleotides and
oligonucleotides composed of ribonucleotides and combinations of
ribonucleotides and deoxyribonucleotides may also be employed in
the methods disclosed herein. The nucleotide constructs, nucleic
acids, and nucleotide sequences of the embodiments additionally
encompass all complementary forms of such constructs, molecules and
sequences. Further, the nucleotide constructs, nucleotide molecules
and nucleotide sequences of the embodiments encompass all
nucleotide constructs, molecules and sequences which can be
employed in the methods of the embodiments for transforming plants
including, but not limited to, those comprised of
deoxyribonucleotides, ribonucleotides and combinations thereof.
Such deoxyribonucleotides and ribonucleotides include both
naturally occurring molecules and synthetic analogues. The
nucleotide constructs, nucleic acids, and nucleotide sequences of
the embodiments also encompass all forms of nucleotide constructs
including, but not limited to, single-stranded forms,
double-stranded forms, hairpins, stem-and-loop structures and the
like.
[0288] A further embodiment relates to a transformed organism such
as an organism selected from plant and insect cells, bacteria,
yeast, baculovirus, protozoa, nematodes and algae. The transformed
organism comprises a DNA molecule of the embodiments, an expression
cassette comprising the DNA molecule or a vector comprising the
expression cassette, which may be stably incorporated into the
genome of the transformed organism.
[0289] The sequences of the embodiments are provided in DNA
constructs for expression in the organism of interest. The
construct will include 5' and 3' regulatory sequences operably
linked to a sequence of the embodiments. The term "operably linked"
as used herein refers to a functional linkage between a promoter
and a second sequence, wherein the promoter sequence initiates and
mediates transcription of the DNA sequence corresponding to the
second sequence. Generally, operably linked means that the nucleic
acid sequences being linked are contiguous and where necessary to
join two protein coding regions in the same reading frame. The
construct may additionally contain at least one additional gene to
be cotransformed into the organism. Alternatively, the additional
gene(s) can be provided on multiple DNA constructs.
[0290] Such a DNA construct is provided with a plurality of
restriction sites for insertion of the PHI-4 polypeptide gene
sequence to be under the transcriptional regulation of the
regulatory regions. The DNA construct may additionally contain
selectable marker genes.
[0291] The DNA construct will generally include in the 5' to 3'
direction of transcription: a transcriptional and translational
initiation region (i.e., a promoter), a DNA sequence of the
embodiments and a transcriptional and translational termination
region (i.e., termination region) functional in the organism
serving as a host. The transcriptional initiation region (i.e., the
promoter) may be native, analogous, foreign or heterologous to the
host organism and/or to the sequence of the embodiments.
Additionally, the promoter may be the natural sequence or
alternatively a synthetic sequence. The term "foreign" as used
herein indicates that the promoter is not found in the native
organism into which the promoter is introduced. Where the promoter
is "foreign" or "heterologous" to the sequence of the embodiments,
it is intended that the promoter is not the native or naturally
occurring promoter for the operably linked sequence of the
embodiments. As used herein, a chimeric gene comprises a coding
sequence operably linked to a transcription initiation region that
is heterologous to the coding sequence. Where the promoter is a
native or natural sequence, the expression of the operably linked
sequence is altered from the wild-type expression, which results in
an alteration in phenotype.
[0292] In some embodiments the DNA construct may also include a
transcriptional enhancer sequence. As used herein, the term an
"enhancer" refers to a DNA sequence which can stimulate promoter
activity and may be an innate element of the promoter or a
heterologous element inserted to enhance the level or
tissue-specificity of a promoter. Various enhancers are known in
the art including for example, introns with gene expression
enhancing properties in plants (US Patent Application Publication
Number 2009/0144863, the ubiquitin intron (i.e., the maize
ubiquitin intron 1 (see, for example, NCBI sequence S94464)), the
omega enhancer or the omega prime enhancer (Gallie, et al., (1989)
Molecular Biology of RNA ed. Cech (Liss, New York) 237-256 and
Gallie, et al., (1987) Gene 60:217-25), the CaMV 35S enhancer (see,
e.g., Benfey, et al., (1990) EMBO J. 9:1685-96) and the enhancers
of U.S. Pat. No. 7,803,992 may also be used, each of which is
incorporated by reference. The above list of transcriptional
enhancers is not meant to be limiting. Any appropriate
transcriptional enhancer can be used in the embodiments.
[0293] The termination region may be native with the
transcriptional initiation region, may be native with the operably
linked DNA sequence of interest, may be native with the plant host,
or may be derived from another source (i.e., foreign or
heterologous to the promoter, the sequence of interest, the plant
host or any combination thereof).
[0294] Convenient termination regions are available from the
Ti-plasmid of A. tumefaciens, such as the octopine synthase and
nopaline synthase termination regions. See also, Guerineau, et al.,
(1991) Mol. Gen. Genet. 262:141-144; Proudfoot, (1991) Cell
64:671-674; Sanfacon, et al., (1991) Genes Dev. 5:141-149; Mogen,
et al., (1990) Plant Cell 2:1261-1272; Munroe, et al., (1990) Gene
91:151-158; Ballas, et al., (1989) Nucleic Acids Res. 17:7891-7903
and Joshi, et al., (1987) Nucleic Acid Res. 15:9627-9639.
[0295] Where appropriate, a nucleic acid may be optimized for
increased expression in the host organism. Thus, where the host
organism is a plant, the synthetic nucleic acids can be synthesized
using plant-preferred codons for improved expression. See, for
example, Campbell and Gowri, (1990) Plant Physiol. 92:1-11 for a
discussion of host-preferred codon usage. For example, although
nucleic acid sequences of the embodiments may be expressed in both
monocotyledonous and dicotyledonous plant species, sequences can be
modified to account for the specific codon preferences and GC
content preferences of monocotyledons or dicotyledons as these
preferences have been shown to differ (Murray et al. (1989) Nucleic
Acids Res. 17:477-498). Thus, the maize-preferred codon for a
particular amino acid may be derived from known gene sequences from
maize. Maize codon usage for 28 genes from maize plants is listed
in Table 4 of Murray, et al., supra. Methods are available in the
art for synthesizing plant-preferred genes. See, for example, U.S.
Pat. Nos. 5,380,831, and 5,436,391 and Murray, et al., (1989)
Nucleic Acids Res. 17:477-498, herein incorporated by
reference.
[0296] Additional sequence modifications are known to enhance gene
expression in a cellular host. These include elimination of
sequences encoding spurious polyadenylation signals, exon-intron
splice site signals, transposon-like repeats, and other
well-characterized sequences that may be deleterious to gene
expression. The GC content of the sequence may be adjusted to
levels average for a given cellular host, as calculated by
reference to known genes expressed in the host cell. The term "host
cell" as used herein refers to a cell which contains a vector and
supports the replication and/or expression of the expression vector
is intended. Host cells may be prokaryotic cells such as E. coli,
or eukaryotic cells such as yeast, insect, amphibian or mammalian
cells or monocotyledonous or dicotyledonous plant cells. An example
of a monocotyledonous host cell is a maize host cell. When
possible, the sequence is modified to avoid predicted hairpin
secondary mRNA structures.
[0297] The expression cassettes may additionally contain 5' leader
sequences. Such leader sequences can act to enhance translation.
Translation leaders are known in the art and include: picornavirus
leaders, for example, EMCV leader (Encephalomyocarditis 5'
noncoding region) (Elroy-Stein, et al., (1989) Proc. Natl. Acad.
Sci. USA 86:6126-6130); potyvirus leaders, for example, TEV leader
(Tobacco Etch Virus) (Gallie, et al., (1995) Gene 165(2):233-238),
MDMV leader (Maize Dwarf Mosaic Virus), human immunoglobulin
heavy-chain binding protein (BiP) (Macejak, et al., (1991) Nature
353:90-94); untranslated leader from the coat protein mRNA of
alfalfa mosaic virus (AMV RNA 4) (Jobling, et al., (1987) Nature
325:622-625); tobacco mosaic virus leader (TMV) (Gallie, et al.,
(1989) in Molecular Biology of RNA, ed. Cech (Liss, New York), pp.
237-256) and maize chlorotic mottle virus leader (MCMV) (Lommel, et
al., (1991) Virology 81:382-385). See also, Della-Cioppa, et al.,
(1987) Plant Physiol. 84:965-968. Such constructs may also contain
a "signal sequence" or "leader sequence" to facilitate
co-translational or post-translational transport of the peptide to
certain intracellular structures such as the chloroplast (or other
plastid), endoplasmic reticulum, or Golgi apparatus.
[0298] By "signal sequence" is intended a sequence that is known or
suspected to result in cotranslational or post-translational
peptide transport across the cell membrane. In eukaryotes, this
typically involves secretion into the Golgi apparatus, with some
resulting glycosylation. Insecticidal toxins of bacteria are often
synthesized as protoxins, which are protolytically activated in the
gut of the target pest (Chang, (1987) Methods Enzymol.
153:507-516). In some embodiments, the signal sequence is located
in the native sequence, or may be derived from a sequence of the
embodiments. By "leader sequence" is intended any sequence that
when translated, results in an amino acid sequence sufficient to
trigger co-translational transport of the peptide chain to a
subcellular organelle. Thus, this includes leader sequences
targeting transport and/or glycosylation by passage into the
endoplasmic reticulum, passage to vacuoles, plastids including
chloroplasts, mitochondria and the like. Nuclear-encoded proteins
targeted to the chloroplast thylakoid lumen compartment have a
characteristic bipartite transit peptide, composed of a stromal
targeting signal peptide and a lumen targeting signal peptide. The
stromal targeting information is in the amino-proximal portion of
the transit peptide. The lumen targeting signal peptide is in the
carboxyl-proximal portion of the transit peptide, and contains all
the information for targeting to the lumen. Recent research in
proteomics of the higher plant chloroplast has achieved in the
identification of numerous nuclear-encoded lumen proteins
(Kieselbach et al. FEBS LETT 480:271-276, 2000; Peltier et al.
Plant Cell 12:319-341, 2000; Bricker et al. Biochim. Biophys Acta
1503:350-356, 2001), the lumen targeting signal peptide of which
can potentially be used in accordance with the present invention.
About 80 proteins from Arabidopsis, as well as homologous proteins
from spinach and garden pea, are reported by Kieselbach et al.,
Photosynthesis Research, 78:249-264, 2003. In particular, table 2
of this publication, which is incorporated into the description
herewith by reference, discloses 85 proteins from the chloroplast
lumen, identified by their accession number (see also US Patent
Application Publication 2009/09044298). In addition, the recently
published draft version of the rice genome (Goff et al, Science
296:92-100, 2002) is a suitable source for lumen targeting signal
peptide which may be used in accordance with the present
invention.
[0299] Suitable chloroplast transit peptides (CTP) are well known
to one skilled in the art also include chimeric CTPs comprising but
not limited to, an N-terminal domain, a central domain or a
C-terminal domain from a CTP from Oryza sativa 1-deoxy-D
xyulose-5-Phosphate Synthase, Oryza sativa-Superoxide dismutase,
Oryza sativa-soluble starch synthase, Oryza sativa-NADP-dependent
Malic acid enzyme, Oryza sativa-Phospho-2-dehydro-3-deoxyheptonate
Aldolase 2, Oryza sativa-L-Ascorbate peroxidase 5, Oryza
sativa-Phosphoglucan water dikinase, Zea Mays ssRUBISCO, Zea
Mays-beta-glucosidase, Zea Mays-Malate dehydrogenase, Zea Mays
Thioredoxin M-type US Patent Application Publication
2012/0304336).
[0300] The PHI-4 polypeptide gene to be targeted to the chloroplast
may be optimized for expression in the chloroplast to account for
differences in codon usage between the plant nucleus and this
organelle. In this manner, the nucleic acids of interest may be
synthesized using chloroplast-preferred codons. See, for example,
U.S. Pat. No. 5,380,831, herein incorporated by reference.
[0301] In preparing the expression cassette, the various DNA
fragments may be manipulated so as to provide for the DNA sequences
in the proper orientation and, as appropriate, in the proper
reading frame. Toward this end, adapters or linkers may be employed
to join the DNA fragments or other manipulations may be involved to
provide for convenient restriction sites, removal of superfluous
DNA, removal of restriction sites, or the like. For this purpose,
in vitro mutagenesis, primer repair, restriction, annealing,
resubstitutions, e.g., transitions and transversions, may be
involved.
[0302] A number of promoters can be used in the practice of the
embodiments. The promoters can be selected based on the desired
outcome. The nucleic acids can be combined with constitutive,
tissue-preferred, inducible, or other promoters for expression in
the host organism. Suitable constitutive promoters for use in a
plant host cell include, for example, the core promoter of the
Rsyn7 promoter and other constitutive promoters disclosed in WO
1999/43838 and U.S. Pat. No. 6,072,050; the core CaMV 35S promoter
(Odell, et al., (1985) Nature 313:810-812); rice actin (McElroy, et
al., (1990) Plant Cell 2:163-171); ubiquitin (Christensen, et al.,
(1989) Plant Mol. Biol. 12:619-632 and Christensen, et al., (1992)
Plant Mol. Biol. 18:675-689); pEMU (Last, et al., (1991) Theor.
Appl. Genet. 81:581-588); MAS (Velten, et al., (1984) EMBO J.
3:2723-2730); ALS promoter (U.S. Pat. No. 5,659,026) and the like.
Other constitutive promoters include, for example, those discussed
in U.S. Pat. Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597;
5,466,785; 5,399,680; 5,268,463; 5,608,142 and 6,177,611.
[0303] Depending on the desired outcome, it may be beneficial to
express the gene from an inducible promoter. Of particular interest
for regulating the expression of the nucleotide sequences of the
embodiments in plants are wound-inducible promoters. Such
wound-inducible promoters, may respond to damage caused by insect
feeding, and include potato proteinase inhibitor (pin II) gene
(Ryan, (1990) Ann. Rev. Phytopath. 28:425-449; Duan, et al., (1996)
Nature Biotechnology 14:494-498); wun1 and wun2, U.S. Pat. No.
5,428,148; win1 and win2 (Stanford, et al., (1989) Mol. Gen. Genet.
215:200-208); systemin (McGurl, et al., (1992) Science
225:1570-1573); WIP1 (Rohmeier, et al., (1993) Plant Mol. Biol.
22:783-792; Eckelkamp, et al., (1993) FEBS Letters 323:73-76); MPI
gene (Corderok, et al., (1994) Plant J. 6(2):141-150) and the like,
herein incorporated by reference.
[0304] Additionally, pathogen-inducible promoters may be employed
in the methods and nucleotide constructs of the embodiments. Such
pathogen-inducible promoters include those from
pathogenesis-related proteins (PR proteins), which are induced
following infection by a pathogen; e.g., PR proteins, SAR proteins,
beta-1,3-glucanase, chitinase, etc. See, for example, Redolfi, et
al., (1983) Neth. J. Plant Pathol. 89:245-254; Uknes, et al.,
(1992) Plant Cell 4:645-656 and Van Loon, (1985) Plant Mol. Virol.
4:111-116. See also, WO 1999/43819, herein incorporated by
reference.
[0305] Of interest are promoters that are expressed locally at or
near the site of pathogen infection. See, for example, Marineau, et
al., (1987) Plant Mol. Biol. 9:335-342; Matton, et al., (1989)
Molecular Plant-Microbe Interactions 2:325-331; Somsisch, et al.,
(1986) Proc. Natl. Acad. Sci. USA 83:2427-2430; Somsisch, et al.,
(1988) Mol. Gen. Genet. 2:93-98 and Yang, (1996) Proc. Natl. Acad.
Sci. USA 93:14972-14977. See also, Chen, et al., (1996) Plant J.
10:955-966; Zhang, et al., (1994) Proc. Natl. Acad. Sci. USA
91:2507-2511; Warner, et al., (1993) Plant J. 3:191-201; Siebertz,
et al., (1989) Plant Cell 1:961-968; U.S. Pat. No. 5,750,386
(nematode-inducible) and the references cited therein. Of
particular interest is the inducible promoter for the maize PRms
gene, whose expression is induced by the pathogen Fusarium
moniliforme (see, for example, Cordero, et al., (1992) Physiol.
Mol. Plant Path. 41:189-200).
[0306] Chemical-regulated promoters can be used to modulate the
expression of a gene in a plant through the application of an
exogenous chemical regulator. Depending upon the objective, the
promoter may be a chemical-inducible promoter, where application of
the chemical induces gene expression, or a chemical-repressible
promoter, where application of the chemical represses gene
expression. Chemical-inducible promoters are known in the art and
include, but are not limited to, the maize In2-2 promoter, which is
activated by benzenesulfonamide herbicide safeners, the maize GST
promoter, which is activated by hydrophobic electrophilic compounds
that are used as pre-emergent herbicides, and the tobacco PR-1a
promoter, which is activated by salicylic acid. Other
chemical-regulated promoters of interest include steroid-responsive
promoters (see, for example, the glucocorticoid-inducible promoter
in Schena, et al., (1991) Proc. Natl. Acad. Sci. USA 88:10421-10425
and McNellis, et al., (1998) Plant J. 14(2):247-257) and
tetracycline-inducible and tetracycline-repressible promoters (see,
for example, Gatz, et al., (1991) Mol. Gen. Genet. 227:229-237 and
U.S. Pat. Nos. 5,814,618 and 5,789,156), herein incorporated by
reference.
[0307] Tissue-preferred promoters can be utilized to target
enhanced PHI-4 polypeptide expression within a particular plant
tissue. Tissue-preferred promoters include those discussed in
Yamamoto, et al., (1997) Plant J. 12(2)255-265; Kawamata, et al.,
(1997) Plant Cell Physiol. 38(7):792-803; Hansen, et al., (1997)
Mol. Gen Genet. 254(3):337-343; Russell, et al., (1997) Transgenic
Res. 6(2):157-168; Rinehart, et al., (1996) Plant Physiol.
112(3):1331-1341; Van Camp, et al., (1996) Plant Physiol.
112(2):525-535; Canevascini, et al., (1996) Plant Physiol.
112(2):513-524; Yamamoto, et al., (1994) Plant Cell Physiol.
35(5):773-778; Lam, (1994) Results Probl. Cell Differ. 20:181-196;
Orozco, et al., (1993) Plant Mol Biol. 23(6):1129-1138; Matsuoka,
et al., (1993) Proc Natl. Acad. Sci. USA 90(20):9586-9590 and
Guevara-Garcia, et al., (1993) Plant J. 4(3):495-505. Such
promoters can be modified, if necessary, for weak expression.
[0308] Leaf-preferred promoters are known in the art. See, for
example, Yamamoto, et al., (1997) Plant J. 12(2):255-265; Kwon, et
al., (1994) Plant Physiol. 105:357-67; Yamamoto, et al., (1994)
Plant Cell Physiol. 35(5):773-778; Gotor, et al., (1993) Plant J.
3:509-18; Orozco, et al., (1993) Plant Mol. Biol. 23(6):1129-1138
and Matsuoka, et al., (1993) Proc. Natl. Acad. Sci. USA
90(20):9586-9590.
[0309] Root-preferred or root-specific promoters are known and can
be selected from the many available from the literature or isolated
de novo from various compatible species. See, for example, Hire, et
al., (1992) Plant Mol. Biol. 20(2):207-218 (soybean root-specific
glutamine synthetase gene); Keller and Baumgartner, (1991) Plant
Cell 3(10):1051-1061 (root-specific control element in the GRP 1.8
gene of French bean); Sanger, et al., (1990) Plant Mol. Biol.
14(3):433-443 (root-specific promoter of the mannopine synthase
(MAS) gene of Agrobacterium tumefaciens) and Miao, et al., (1991)
Plant Cell 3(1):11-22 (full-length cDNA clone encoding cytosolic
glutamine synthetase (GS), which is expressed in roots and root
nodules of soybean). See also, Bogusz, et al., (1990) Plant Cell
2(7):633-641, where two root-specific promoters isolated from
hemoglobin genes from the nitrogen-fixing nonlegume Parasponia
andersonii and the related non-nitrogen-fixing nonlegume Trema
tomentosa are described. The promoters of these genes were linked
to a .beta.-glucuronidase reporter gene and introduced into both
the nonlegume Nicotiana tabacum and the legume Lotus corniculatus,
and in both instances root-specific promoter activity was
preserved. Leach and Aoyagi, (1991) describe their analysis of the
promoters of the highly expressed roIC and roID root-inducing genes
of Agrobacterium rhizogenes (see, Plant Science (Limerick)
79(1):69-76). They concluded that enhancer and tissue-preferred DNA
determinants are dissociated in those promoters. Teeri, et al.,
(1989) used gene fusion to lacZ to show that the Agrobacterium
T-DNA gene encoding octopine synthase is especially active in the
epidermis of the root tip and that the TR2' gene is root specific
in the intact plant and stimulated by wounding in leaf tissue, an
especially desirable combination of characteristics for use with an
insecticidal or larvicidal gene (see, EMBO J. 8(2):343-350). The
TR1' gene fused to nptII (neomycin phosphotransferase II) showed
similar characteristics. Additional root-preferred promoters
include the VfENOD-GRP3 gene promoter (Kuster, et al., (1995) Plant
Mol. Biol. 29(4):759-772) and rolB promoter (Capana, et al., (1994)
Plant Mol. Biol. 25(4):681-691. See also, U.S. Pat. Nos. 5,837,876;
5,750,386; 5,633,363; 5,459,252; 5,401,836; 5,110,732 and
5,023,179.
[0310] "Seed-preferred" promoters include both "seed-specific"
promoters (those promoters active during seed development such as
promoters of seed storage proteins) as well as "seed-germinating"
promoters (those promoters active during seed germination). See,
Thompson, et al., (1989) BioEssays 10:108, herein incorporated by
reference. Such seed-preferred promoters include, but are not
limited to, Cim1 (cytokinin-induced message); cZ19B1 (maize 19 kDa
zein); and milps (myo-inositol-1-phosphate synthase) (see, U.S.
Pat. No. 6,225,529, herein incorporated by reference). Gamma-zein
and Glb-1 are endosperm-specific promoters. For dicots,
seed-specific promoters include, but are not limited to, Kunitz
trypsin inhibitor 3 (KTi3) (Jofuku, K. D. and Goldberg, R. B. Plant
Cell 1:1079-1093, 1989), bean .beta.-phaseolin, napin,
.beta.-conglycinin, glycinin 1, soybean lectin, cruciferin, and the
like. For monocots, seed-specific promoters include, but are not
limited to, maize 15 kDa zein, 22 kDa zein, 27 kDa zein, g-zein,
waxy, shrunken 1, shrunken 2, globulin 1, etc. See also, WO
2000/12733, where seed-preferred promoters from end1 and end2 genes
are disclosed; herein incorporated by reference. In dicots, seed
specific promoters include but are not limited to seed coat
promoter from Arabidopsis, pBAN; and the early seed promoters from
Arabidopsis, p26, p63, and p63tr (U.S. Pat. Nos. 7,294,760 and
7,847,153). A promoter that has "preferred" expression in a
particular tissue is expressed in that tissue to a greater degree
than in at least one other plant tissue. Some tissue-preferred
promoters show expression almost exclusively in the particular
tissue.
[0311] Where low level expression is desired, weak promoters will
be used. Generally, the term "weak promoter" as used herein refers
to a promoter that drives expression of a coding sequence at a low
level. By low level expression at levels of about 1/1000
transcripts to about 1/100,000 transcripts to about 1/500,000
transcripts is intended. Alternatively, it is recognized that the
term "weak promoters" also encompasses promoters that drive
expression in only a few cells and not in others to give a total
low level of expression. Where a promoter drives expression at
unacceptably high levels, portions of the promoter sequence can be
deleted or modified to decrease expression levels.
[0312] Such weak constitutive promoters include, for example the
core promoter of the Rsyn7 promoter (WO 1999/43838 and U.S. Pat.
No. 6,072,050), the core 35S CaMV promoter, and the like. Other
constitutive promoters include, for example, those disclosed in
U.S. Pat. Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597;
5,466,785; 5,399,680; 5,268,463; 5,608,142 and 6,177,611, herein
incorporated by reference.
[0313] The above list of promoters is not meant to be limiting. Any
appropriate promoter can be used in the embodiments.
[0314] Generally, the expression cassette will comprise a
selectable marker gene for the selection of transformed cells.
Selectable marker genes are utilized for the selection of
transformed cells or tissues. Marker genes include genes encoding
antibiotic resistance, such as those encoding neomycin
phosphotransferase II (NEO) and hygromycin phosphotransferase
(HPT), as well as genes conferring resistance to herbicidal
compounds, such as glufosinate ammonium, bromoxynil, imidazolinones
and 2,4-dichlorophenoxyacetate (2,4-D). Additional examples of
suitable selectable marker genes include, but are not limited to,
genes encoding resistance to chloramphenicol (Herrera Estrella, et
al., (1983) EMBO J. 2:987-992); methotrexate (Herrera Estrella, et
al., (1983) Nature 303:209-213 and Meijer, et al., (1991) Plant
Mol. Biol. 16:807-820); streptomycin (Jones, et al., (1987) Mol.
Gen. Genet. 210:86-91); spectinomycin (Bretagne-Sagnard, et al.,
(1996) Transgenic Res. 5:131-137); bleomycin (Hille, et al., (1990)
Plant Mol. Biol. 7:171-176); sulfonamide (Guerineau, et al., (1990)
Plant Mol. Biol. 15:127-136); bromoxynil (Stalker, et al., (1988)
Science 242:419-423); glyphosate (Shaw, et al., (1986) Science
233:478-481 and U.S. patent application Ser. Nos. 10/004,357 and
10/427,692); phosphinothricin (DeBlock, et al., (1987) EMBO J.
6:2513-2518). See generally, Yarranton, (1992) Curr. Opin. Biotech.
3:506-511; Christopherson, et al., (1992) Proc. Natl. Acad. Sci.
USA 89:6314-6318; Yao, et al., (1992) Cell 71:63-72; Reznikoff,
(1992) Mol. Microbiol. 6:2419-2422; Barkley, et al., (1980) in The
Operon, pp. 177-220; Hu, et al., (1987) Cell 48:555-566; Brown, et
al., (1987) Cell 49:603-612; Figge, et al., (1988) Cell 52:713-722;
Deuschle, et al., (1989) Proc. Natl. Acad. Sci. USA 86:5400-5404;
Fuerst, et al., (1989) Proc. Natl. Acad. Sci. USA 86:2549-2553;
Deuschle, et al., (1990) Science 248:480-483; Gossen, (1993) Ph.D.
Thesis, University of Heidelberg; Reines, et al., (1993) Proc.
Natl. Acad. Sci. USA 90:1917-1921; Labow, et al., (1990) Mol. Cell.
Biol. 10:3343-3356; Zambretti, et al., (1992) Proc. Natl. Acad.
Sci. USA 89:3952-3956; Baim, et al., (1991) Proc. Natl. Acad. Sci.
USA 88:5072-5076; Wyborski, et al., (1991) Nucleic Acids Res.
19:4647-4653; Hillenand-Wissman, (1989) Topics Mol. Struc. Biol.
10:143-162; Degenkolb, et al., (1991) Antimicrob. Agents Chemother.
35:1591-1595; Kleinschnidt, et al., (1988) Biochemistry
27:1094-1104; Bonin, (1993) Ph.D. Thesis, University of Heidelberg;
Gossen, et al., (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551;
Oliva, et al., (1992) Antimicrob. Agents Chemother. 36:913-919;
Hlavka, et al., (1985) Handbook of Experimental Pharmacology, Vol.
78 (Springer-Verlag, Berlin) and Gill, et al., (1988) Nature
334:721-724. Such disclosures are herein incorporated by
reference.
[0315] The above list of selectable marker genes is not meant to be
limiting. Any selectable marker gene can be used in the
embodiments.
Plant Transformation
[0316] The methods of the embodiments involve introducing a
polypeptide or polynucleotide into a plant. "Introducing" is
intended to mean presenting to the plant the polynucleotide or
polypeptide in such a manner that the sequence gains access to the
interior of a cell of the plant. The methods of the embodiments do
not depend on a particular method for introducing a polynucleotide
or polypeptide into a plant, only that the polynucleotide or
polypeptides gains access to the interior of at least one cell of
the plant. Methods for introducing polynucleotide or polypeptides
into plants are known in the art including, but not limited to,
stable transformation methods, transient transformation methods and
virus-mediated methods.
[0317] "Stable transformation" is intended to mean that the
nucleotide construct introduced into a plant integrates into the
genome of the plant and is capable of being inherited by the
progeny thereof. "Transient transformation" is intended to mean
that a polynucleotide is introduced into the plant and does not
integrate into the genome of the plant or a polypeptide is
introduced into a plant. By "plant" is intended whole plants, plant
organs (e.g., leaves, stems, roots, etc.), seeds, plant cells,
propagules, embryos and progeny of the same. Plant cells can be
differentiated or undifferentiated (e.g. callus, suspension culture
cells, protoplasts, leaf cells, root cells, phloem cells, and
pollen).
[0318] Transformation protocols as well as protocols for
introducing nucleotide sequences into plants may vary depending on
the type of plant or plant cell, i.e., monocot or dicot, targeted
for transformation. Suitable methods of introducing nucleotide
sequences into plant cells and subsequent insertion into the plant
genome include microinjection (Crossway, et al., (1986)
Biotechniques 4:320-334), electroporation (Riggs, et al., (1986)
Proc. Natl. Acad. Sci. USA 83:5602-5606), Agrobacterium-mediated
transformation (U.S. Pat. Nos. 5,563,055 and 5,981,840), direct
gene transfer (Paszkowski, et al., (1984) EMBO J. 3:2717-2722) and
ballistic particle acceleration (see, for example, U.S. Pat. Nos.
4,945,050; 5,879,918; 5,886,244 and 5,932,782; Tomes, et al.,
(1995) in Plant Cell, Tissue, and Organ Culture: Fundamental
Methods, ed. Gamborg and Phillips, (Springer-Verlag, Berlin) and
McCabe, et al., (1988) Biotechnology 6:923-926) and Lecl
transformation (WO 2000/28058). For potato transformation see, Tu,
et al., (1998) Plant Molecular Biology 37:829-838 and Chong, et
al., (2000) Transgenic Research 9:71-78. Additional transformation
procedures can be found in Weissinger, et al., (1988) Ann. Rev.
Genet. 22:421-477; Sanford, et al., (1987) Particulate Science and
Technology 5:27-37 (onion); Christou, et al., (1988) Plant Physiol.
87:671-674 (soybean); McCabe, et al., (1988) Bio/Technology
6:923-926 (soybean); Finer and McMullen, (1991) In Vitro Cell Dev.
Biol. 27P:175-182 (soybean); Singh, et al., (1998) Theor. Appl.
Genet. 96:319-324 (soybean); Datta, et al., (1990) Biotechnology
8:736-740 (rice); Klein, et al., (1988) Proc. Natl. Acad. Sci. USA
85:4305-4309 (maize); Klein, et al., (1988) Biotechnology 6:559-563
(maize); U.S. Pat. Nos. 5,240,855; 5,322,783 and 5,324,646; Klein,
et al., (1988) Plant Physiol. 91:440-444 (maize); Fromm, et al.,
(1990) Biotechnology 8:833-839 (maize); Hooykaas-Van Slogteren, et
al., (1984) Nature (London) 311:763-764; U.S. Pat. No. 5,736,369
(cereals); Bytebier, et al., (1987) Proc. Natl. Acad. Sci. USA
84:5345-5349 (Liliaceae); De Wet, et al., (1985) in The
Experimental Manipulation of Ovule Tissues, ed. Chapman, et al.,
(Longman, N.Y.), pp. 197-209 (pollen); Kaeppler, et al., (1990)
Plant Cell Reports 9:415-418 and Kaeppler, et al., (1992) Theor.
Appl. Genet. 84:560-566 (whisker-mediated transformation);
D'Halluin, et al., (1992) Plant Cell 4:1495-1505 (electroporation);
Li, et al., (1993) Plant Cell Reports 12:250-255 and Christou and
Ford, (1995) Annals of Botany 75:407-413 (rice); Osjoda, et al.,
(1996) Nature Biotechnology 14:745-750 (maize via Agrobacterium
tumefaciens); all of which are herein incorporated by
reference.
[0319] In specific embodiments, the sequences of the embodiments
can be provided to a plant using a variety of transient
transformation methods. Such transient transformation methods
include, but are not limited to, the introduction of the PHI-4
polypeptide or variants and fragments thereof directly into the
plant or the introduction of the PHI-4 polypeptide transcript into
the plant. Such methods include, for example, microinjection or
particle bombardment. See, for example, Crossway, et al., (1986)
Mol Gen. Genet. 202:179-185; Nomura, et al., (1986) Plant Sci.
44:53-58; Hepler, et al., (1994) Proc. Natl. Acad. Sci.
91:2176-2180 and Hush, et al., (1994) The Journal of Cell Science
107:775-784, all of which are herein incorporated by reference.
Alternatively, the PHI-4 polypeptide polynucleotide can be
transiently transformed into the plant using techniques known in
the art. Such techniques include viral vector system and the
precipitation of the polynucleotide in a manner that precludes
subsequent release of the DNA. Thus, transcription from the
particle-bound DNA can occur, but the frequency with which it is
released to become integrated into the genome is greatly reduced.
Such methods include the use of particles coated with
polyethylimine (PEI; Sigma #P3143).
[0320] Methods are known in the art for the targeted insertion of a
polynucleotide at a specific location in the plant genome. In one
embodiment, the insertion of the polynucleotide at a desired
genomic location is achieved using a site-specific recombination
system. See, for example, WO 1999/25821, WO 1999/25854, WO
1999/25840, WO 1999/25855 and WO 1999/25853, all of which are
herein incorporated by reference. Briefly, the polynucleotide of
the embodiments can be contained in transfer cassette flanked by
two non-identical recombination sites. The transfer cassette is
introduced into a plant have stably incorporated into its genome a
target site which is flanked by two non-identical recombination
sites that correspond to the sites of the transfer cassette. An
appropriate recombinase is provided and the transfer cassette is
integrated at the target site. The polynucleotide of interest is
thereby integrated at a specific chromosomal position in the plant
genome.
[0321] Plant transformation vectors may be comprised of one or more
DNA vectors needed for achieving plant transformation. For example,
it is a common practice in the art to utilize plant transformation
vectors that are comprised of more than one contiguous DNA segment.
These vectors are often referred to in the art as "binary vectors".
Binary vectors as well as vectors with helper plasmids are most
often used for Agrobacterium-mediated transformation, where the
size and complexity of DNA segments needed to achieve efficient
transformation is quite large, and it is advantageous to separate
functions onto separate DNA molecules. Binary vectors typically
contain a plasmid vector that contains the cis-acting sequences
required for T-DNA transfer (such as left border and right border),
a selectable marker that is engineered to be capable of expression
in a plant cell, and a "gene of interest" (a gene engineered to be
capable of expression in a plant cell for which generation of
transgenic plants is desired). Also present on this plasmid vector
are sequences required for bacterial replication. The cis-acting
sequences are arranged in a fashion to allow efficient transfer
into plant cells and expression therein. For example, the
selectable marker gene and the pesticidal gene are located between
the left and right borders. Often a second plasmid vector contains
the trans-acting factors that mediate T-DNA transfer from
Agrobacterium to plant cells. This plasmid often contains the
virulence functions (Vir genes) that allow infection of plant cells
by Agrobacterium, and transfer of DNA by cleavage at border
sequences and vir-mediated DNA transfer, as is understood in the
art (Hellens and Mullineaux, (2000) Trends in Plant Science
5:446-451). Several types of Agrobacterium strains (e.g. LBA4404,
GV3101, EHA101, EHA105, etc.) can be used for plant transformation.
The second plasmid vector is not necessary for transforming the
plants by other methods such as microprojection, microinjection,
electroporation, polyethylene glycol, etc.
[0322] In general, plant transformation methods involve
transferring heterologous DNA into target plant cells (e.g.,
immature or mature embryos, suspension cultures, undifferentiated
callus, protoplasts, etc.), followed by applying a maximum
threshold level of appropriate selection (depending on the
selectable marker gene) to recover the transformed plant cells from
a group of untransformed cell mass. Following integration of
heterologous foreign DNA into plant cells, one then applies a
maximum threshold level of appropriate selection in the medium to
kill the untransformed cells and separate and proliferate the
putatively transformed cells that survive from this selection
treatment by transferring regularly to a fresh medium. By
continuous passage and challenge with appropriate selection, one
identifies and proliferates the cells that are transformed with the
plasmid vector. Molecular and biochemical methods can then be used
to confirm the presence of the integrated heterologous gene of
interest into the genome of the transgenic plant.
[0323] Explants are typically transferred to a fresh supply of the
same medium and cultured routinely. Subsequently, the transformed
cells are differentiated into shoots after placing on regeneration
medium supplemented with a maximum threshold level of selecting
agent. The shoots are then transferred to a selective rooting
medium for recovering rooted shoot or plantlet. The transgenic
plantlet then grows into a mature plant and produces fertile seeds
(e.g., Hiei, et al., (1994) The Plant Journal 6:271-282; Ishida, et
al., (1996) Nature Biotechnology 14:745-750). Explants are
typically transferred to a fresh supply of the same medium and
cultured routinely. A general description of the techniques and
methods for generating transgenic plants are found in Ayres and
Park, (1994) Critical Reviews in Plant Science 13:219-239 and
Bommineni and Jauhar, (1997) Maydica 42:107-120. Since the
transformed material contains many cells; both transformed and
non-transformed cells are present in any piece of subjected target
callus or tissue or group of cells. The ability to kill
non-transformed cells and allow transformed cells to proliferate
results in transformed plant cultures. Often, the ability to remove
non-transformed cells is a limitation to rapid recovery of
transformed plant cells and successful generation of transgenic
plants.
[0324] The cells that have been transformed may be grown into
plants in accordance with conventional ways. See, for example,
McCormick, et al., (1986) Plant Cell Reports 5:81-84. These plants
may then be grown, and either pollinated with the same transformed
strain or different strains and the resulting hybrid having
constitutive or inducible expression of the desired phenotypic
characteristic identified. Two or more generations may be grown to
ensure that expression of the desired phenotypic characteristic is
stably maintained and inherited and then seeds harvested to ensure
that expression of the desired phenotypic characteristic has been
achieved.
[0325] The nucleotide sequences of the embodiments may be provided
to the plant by contacting the plant with a virus or viral nucleic
acids. Generally, such methods involve incorporating the nucleotide
construct of interest within a viral DNA or RNA molecule. It is
recognized that the recombinant proteins of the embodiments may be
initially synthesized as part of a viral polyprotein, which later
may be processed by proteolysis in vivo or in vitro to produce the
desired PHI-4 polypeptide. It is also recognized that such a viral
polyprotein, comprising at least a portion of the amino acid
sequence of a PHI-4 polypeptide of the embodiments, may have the
desired pesticidal activity. Such viral polyproteins and the
nucleotide sequences that encode for them are encompassed by the
embodiments. Methods for providing plants with nucleotide
constructs and producing the encoded proteins in the plants, which
involve viral DNA or RNA molecules are known in the art. See, for
example, U.S. Pat. Nos. 5,889,191; 5,889,190; 5,866,785; 5,589,367
and 5,316,931, herein incorporated by reference.
[0326] Methods for transformation of chloroplasts are known in the
art. See, for example, Svab, et al., (1990) Proc. Natl. Acad. Sci.
USA 87:8526-8530; Svab and Maliga, (1993) Proc. Natl. Acad. Sci.
USA 90:913-917; Svab and Maliga, (1993) EMBO J. 12:601-606. The
method relies on particle gun delivery of DNA containing a
selectable marker and targeting of the DNA to the plastid genome
through homologous recombination. Additionally, plastid
transformation can be accomplished by transactivation of a silent
plastid-borne transgene by tissue-preferred expression of a
nuclear-encoded and plastid-directed RNA polymerase. Such a system
has been reported in McBride, et al., (1994) Proc. Natl. Acad. Sci.
USA 91:7301-7305.
[0327] The embodiments further relate to plant-propagating material
of a transformed plant of the embodiments including, but not
limited to, seeds, tubers, corms, bulbs, leaves, and cuttings of
roots and shoots.
[0328] The embodiments may be used for transformation of any plant
species, including, but not limited to, monocots and dicots.
Examples of plants of interest include, but are not limited to,
corn (Zea mays), Brassica sp. (e.g., B. napus, B. rapa, B. juncea),
particularly those Brassica species useful as sources of seed oil,
alfalfa (Medicago sativa), rice (Oryza sativa), rye (Secale
cereale), sorghum (Sorghum bicolor, Sorghum vulgare), millet (e.g.,
pearl millet (Pennisetum glaucum), proso millet (Panicum
miliaceum), foxtail millet (Setaria italica), finger millet
(Eleusine coracana)), sunflower (Helianthus annuus), safflower
(Carthamus tinctorius), wheat (Triticum aestivum), soybean (Glycine
max), tobacco (Nicotiana tabacum), potato (Solanum tuberosum),
peanuts (Arachis hypogaea), cotton (Gossypium barbadense, Gossypium
hirsutum), sweet potato (Ipomoea batatus), cassava (Manihot
esculenta), coffee (Coffea spp.), coconut (Cocos nucifera),
pineapple (Ananas comosus), citrus trees (Citrus spp.), cocoa
(Theobroma cacao), tea (Camellia sinensis), banana (Musa spp.),
avocado (Persea americana), fig (Ficus casica), guava (Psidium
guajava), mango (Mangifera indica), olive (Olea europaea), papaya
(Carica papaya), cashew (Anacardium occidentale), macadamia
(Macadamia integrifolia), almond (Prunus amygdalus), sugar beets
(Beta vulgaris), sugarcane (Saccharum spp.), oats, barley,
vegetables, ornamentals and conifers.
[0329] Vegetables include tomatoes (Lycopersicon esculentum),
lettuce (e.g., Lactuca sativa), green beans (Phaseolus vulgaris),
lima beans (Phaseolus limensis), peas (Lathyrus spp.), and members
of the genus Cucumis such as cucumber (C. sativus), cantaloupe (C.
cantalupensis), and musk melon (C. melo). Ornamentals include
azalea (Rhododendron spp.), hydrangea (Macrophylla hydrangea),
hibiscus (Hibiscus rosasanensis), roses (Rosa spp.), tulips (Tulipa
spp.), daffodils (Narcissus spp.), petunias (Petunia hybrida),
carnation (Dianthus caryophyllus), poinsettia (Euphorbia
pulcherrima), and chrysanthemum. Conifers that may be employed in
practicing the embodiments include, for example, pines such as
loblolly pine (Pinus taeda), slash pine (Pinus elliotii), ponderosa
pine (Pinus ponderosa), lodgepole pine (Pinus contorta) and
Monterey pine (Pinus radiata); Douglas-fir (Pseudotsuga menziesii);
Western hemlock (Tsuga canadensis); Sitka spruce (Picea glauca);
redwood (Sequoia sempervirens); true firs such as silver fir (Abies
amabilis) and balsam fir (Abies balsamea); and cedars such as
Western red cedar (Thuja plicata) and Alaska yellow-cedar
(Chamaecyparis nootkatensis). Plants of the embodiments include
crop plants (for example, corn, alfalfa, sunflower, Brassica,
soybean, cotton, safflower, peanut, sorghum, wheat, millet,
tobacco, etc.), such as corn and soybean plants.
[0330] Turf grasses include, but are not limited to: annual
bluegrass (Poa annua); annual ryegrass (Lolium multiflorum); Canada
bluegrass (Poa compressa); Chewing's fescue (Festuca rubra);
colonial bentgrass (Agrostis tenuis); creeping bentgrass (Agrostis
palustris); crested wheatgrass (Agropyron desertorum); fairway
wheatgrass (Agropyron cristatum); hard fescue (Festuca longifolia);
Kentucky bluegrass (Poa pratensis); orchardgrass (Dactylis
glomerata); perennial ryegrass (Lolium perenne); red fescue
(Festuca rubra); redtop (Agrostis alba); rough bluegrass (Poa
trivialis); sheep fescue (Festuca ovina); smooth bromegrass (Bromus
inermis); tall fescue (Festuca arundinacea); timothy (Phleum
pratense); velvet bentgrass (Agrostis canina); weeping alkaligrass
(Puccinellia distans); western wheatgrass (Agropyron smithii);
Bermuda grass (Cynodon spp.); St. Augustine grass (Stenotaphrum
secundatum); zoysia grass (Zoysia spp.); Bahia grass (Paspalum
notatum); carpet grass (Axonopus affinis); centipede grass
(Eremochloa ophiuroides); kikuyu grass (Pennisetum clandesinum);
seashore paspalum (Paspalum vaginatum); blue gramma (Bouteloua
gracilis); buffalo grass (Buchloe dactyloids); sideoats gramma
(Bouteloua curtipendula).
[0331] Plants of interest include grain plants that provide seeds
of interest, oil-seed plants, and leguminous plants. Seeds of
interest include grain seeds, such as corn, wheat, barley, rice,
sorghum, rye, millet, etc. Oil-seed plants include cotton, soybean,
safflower, sunflower, Brassica, maize, alfalfa, palm, coconut,
flax, castor, olive etc. Leguminous plants include beans and peas.
Beans include guar, locust bean, fenugreek, soybean, garden beans,
cowpea, mungbean, lima bean, fava bean, lentils, chickpea, etc.
Evaluation of Plant Transformation
[0332] Following introduction of heterologous foreign DNA into
plant cells, the transformation or integration of heterologous gene
in the plant genome is confirmed by various methods such as
analysis of nucleic acids, proteins and metabolites associated with
the integrated gene.
[0333] PCR analysis is a rapid method to screen transformed cells,
tissue or shoots for the presence of incorporated gene at the
earlier stage before transplanting into the soil (Sambrook and
Russell, (2001) Molecular Cloning: A Laboratory Manual. Cold Spring
Harbor Laboratory Press, Cold Spring Harbor, N.Y.). PCR is carried
out using oligonucleotide primers specific to the gene of interest
or Agrobacterium vector background, etc.
[0334] Plant transformation may be confirmed by Southern blot
analysis of genomic DNA (Sambrook and Russell, (2001) supra). In
general, total DNA is extracted from the transformant, digested
with appropriate restriction enzymes, fractionated in an agarose
gel and transferred to a nitrocellulose or nylon membrane. The
membrane or "blot" is then probed with, for example, radiolabeled
32P target DNA fragment to confirm the integration of introduced
gene into the plant genome according to standard techniques
(Sambrook and Russell, (2001) supra).
[0335] In Northern blot analysis, RNA is isolated from specific
tissues of transformant, fractionated in a formaldehyde agarose
gel, and blotted onto a nylon filter according to standard
procedures that are routinely used in the art (Sambrook and
Russell, (2001) supra). Expression of RNA encoded by the pesticidal
gene is then tested by hybridizing the filter to a radioactive
probe derived from a pesticidal gene, by methods known in the art
(Sambrook and Russell, (2001) supra).
[0336] Western blot, biochemical assays and the like may be carried
out on the transgenic plants to confirm the presence of protein
encoded by the pesticidal gene by standard procedures (Sambrook and
Russell, 2001, supra) using antibodies that bind to one or more
epitopes present on the PHI-4 polypeptide.
Stacking of Traits in Transgenic Plant
[0337] Transgenic plants may comprise a stack of one or more
insecticidal polynucleotides disclosed herein with one or more
additional polynucleotides resulting in the production or
suppression of multiple polypeptide sequences. Transgenic plants
comprising stacks of polynucleotide sequences can be obtained by
either or both of traditional breeding methods or through genetic
engineering methods. These methods include, but are not limited to,
breeding individual lines each comprising a polynucleotide of
interest, transforming a transgenic plant comprising a gene
disclosed herein with a subsequent gene, and co-transformation of
genes into a single plant cell. As used herein, the term "stacked"
includes having the multiple traits present in the same plant
(i.e., both traits are incorporated into the nuclear genome, one
trait is incorporated into the nuclear genome and one trait is
incorporated into the genome of a plastid, or both traits are
incorporated into the genome of a plastid). In one non-limiting
example, "stacked traits" comprise a molecular stack where the
sequences are physically adjacent to each other. A trait, as used
herein, refers to the phenotype derived from a particular sequence
or groups of sequences. Co-transformation of genes can be carried
out using single transformation vectors comprising multiple genes
or genes carried separately on multiple vectors. If the sequences
are stacked by genetically transforming the plants, the
polynucleotide sequences of interest can be combined at any time
and in any order. The traits can be introduced simultaneously in a
co-transformation protocol with the polynucleotides of interest
provided by any combination of transformation cassettes. For
example, if two sequences will be introduced, the two sequences can
be contained in separate transformation cassettes (trans) or
contained on the same transformation cassette (cis). Expression of
the sequences can be driven by the same promoter or by different
promoters. In certain cases, it may be desirable to introduce a
transformation cassette that will suppress the expression of the
polynucleotide of interest. This may be combined with any
combination of other suppression cassettes or overexpression
cassettes to generate the desired combination of traits in the
plant. It is further recognized that polynucleotide sequences can
be stacked at a desired genomic location using a site-specific
recombination system. See, for example, WO 1999/25821, WO
1999/25854, WO 1999/25840, WO 1999/25855 and WO 1999/25853, all of
which are herein incorporated by reference.
[0338] In some embodiments the polynucleotides encoding the PHI-4
polypeptides disclosed herein, alone or stacked with one or more
additional insect resistance traits can be stacked with one or more
additional input traits (e.g., herbicide resistance, fungal
resistance, virus resistance or stress tolerance, disease
resistance, male sterility, stalk strength, and the like) or output
traits (e.g., increased yield, modified starches, improved oil
profile, balanced amino acids, high lysine or methionine, increased
digestibility, improved fiber quality, drought resistance, and the
like). Thus, the polynucleotide embodiments can be used to provide
a complete agronomic package of improved crop quality with the
ability to flexibly and cost effectively control any number of
agronomic pests.
[0339] Transgenes useful for stacking include but are not limited
to:
1. Transgenes that Confer Resistance to Insects or Disease and that
Encode:
[0340] (A) Plant disease resistance genes. Plant defenses are often
activated by specific interaction between the product of a disease
resistance gene (R) in the plant and the product of a corresponding
avirulence (Avr) gene in the pathogen. A plant variety can be
transformed with cloned resistance gene to engineer plants that are
resistant to specific pathogen strains. See, for example, Jones, et
al., (1994) Science 266:789 (cloning of the tomato Cf-9 gene for
resistance to Cladosporium fulvum); Martin, et al., (1993) Science
262:1432 (tomato Pto gene for resistance to Pseudomonas syringae
pv. tomato encodes a protein kinase); Mindrinos, et al., (1994)
Cell 78:1089 (Arabidopsis RSP2 gene for resistance to Pseudomonas
syringae), McDowell and Woffenden, (2003) Trends Biotechnol.
21(4):178-83 and Toyoda, et al., (2002) Transgenic Res.
11(6):567-82. A plant resistant to a disease is one that is more
resistant to a pathogen as compared to the wild type plant.
[0341] (B) Genes encoding a Bacillus thuringiensis protein, a
derivative thereof or a synthetic polypeptide modeled thereon. See,
for example, Geiser, et al., (1986) Gene 48:109, who disclose the
cloning and nucleotide sequence of a Bt delta-endotoxin gene.
Moreover, DNA molecules encoding delta-endotoxin genes can be
purchased from American Type Culture Collection (Rockville, Md.),
for example, under ATCC Accession Numbers 40098, 67136, 31995 and
31998. Other non-limiting examples of Bacillus thuringiensis
transgenes being genetically engineered are given in the following
patents and patent applications and hereby are incorporated by
reference for this purpose: U.S. Pat. Nos. 5,188,960; 5,689,052;
5,880,275; 5,986,177; 6,023,013, 6,060,594, 6,063,597, 6,077,824,
6,620,988, 6,642,030, 6,713,259, 6,893,826, 7,105,332; 7,179,965,
7,208,474; 7,227,056, 7,288,643, 7,323,556, 7,329,736, 7,449,552,
7,468,278, 7,510,878, 7,521,235, 7,544,862, 7,605,304, 7,696,412,
7,629,504, 7,705,216, 7,772,465, 7,790,846, 7,858,849 and WO
1991/14778; WO 1999/31248; WO 2001/12731; WO 1999/24581 and WO
1997/40162.
[0342] (C) A polynucleotide encoding an insect-specific hormone or
pheromone such as an ecdysteroid and juvenile hormone, a variant
thereof, a mimetic based thereon or an antagonist or agonist
thereof. See, for example, the disclosure by Hammock, et al.,
(1990) Nature 344:458, of baculovirus expression of cloned juvenile
hormone esterase, an inactivator of juvenile hormone.
[0343] (D) A polynucleotide encoding an insect-specific peptide
which, upon expression, disrupts the physiology of the affected
pest. For example, see the disclosures of, Regan, (1994) J. Biol.
Chem. 269:9 (expression cloning yields DNA coding for insect
diuretic hormone receptor); Pratt, et al., (1989) Biochem. Biophys.
Res. Comm. 163:1243 (an allostatin is identified in Diploptera
puntata); Chattopadhyay, et al., (2004) Critical Reviews in
Microbiology 30(1):33-54; Zjawiony, (2004) J Nat Prod
67(2):300-310; Carlini and Grossi-de-Sa, (2002) Toxicon
40(11):1515-1539; Ussuf, et al., (2001) Curr 80(7):847-853 and
Vasconcelos and Oliveira, (2004) Toxicon 44(4):385-403. See also,
U.S. Pat. No. 5,266,317 to Tomalski, et al., who disclose genes
encoding insect-specific toxins.
[0344] (E) A polynucleotide encoding an enzyme responsible for a
hyperaccumulation of a monoterpene, a sesquiterpene, a steroid,
hydroxamic acid, a phenylpropanoid derivative or another
non-protein molecule with insecticidal activity.
[0345] (F) A polynucleotide encoding an enzyme involved in the
modification, including the post-translational modification, of a
biologically active molecule; for example, a glycolytic enzyme, a
proteolytic enzyme, a lipolytic enzyme, a nuclease, a cyclase, a
transaminase, an esterase, a hydrolase, a phosphatase, a kinase, a
phosphorylase, a polymerase, an elastase, a chitinase and a
glucanase, whether natural or synthetic. See, PCT Application WO
1993/02197 in the name of Scott, et al., which discloses the
nucleotide sequence of a callase gene. DNA molecules which contain
chitinase-encoding sequences can be obtained, for example, from the
ATCC under Accession Numbers 39637 and 67152. See also, Kramer, et
al., (1993) Insect Biochem. Molec. Biol. 23:691, who teach the
nucleotide sequence of a cDNA encoding tobacco hookworm chitinase
and Kawalleck, et al., (1993) Plant Molec. Biol. 21:673, who
provide the nucleotide sequence of the parsley ubi4-2 polyubiquitin
gene, and U.S. Pat. Nos. 6,563,020; 7,145,060 and 7,087,810.
[0346] (G) A polynucleotide encoding a molecule that stimulates
signal transduction. For example, see the disclosure by Botella, et
al., (1994) Plant Molec. Biol. 24:757, of nucleotide sequences for
mung bean calmodulin cDNA clones, and Griess, et al., (1994) Plant
Physiol. 104:1467, who provide the nucleotide sequence of a maize
calmodulin cDNA clone.
[0347] (H) A polynucleotide encoding a hydrophobic moment peptide.
See, PCT Application WO 1995/16776 and U.S. Pat. No. 5,580,852
disclosure of peptide derivatives of Tachyplesin which inhibit
fungal plant pathogens) and PCT Application WO 1995/18855 and U.S.
Pat. No. 5,607,914 (teaches synthetic antimicrobial peptides that
confer disease resistance).
[0348] (I) A polynucleotide encoding a membrane permease, a channel
former or a channel blocker. For example, see the disclosure by
Jaynes, et al., (1993) Plant Sci. 89:43, of heterologous expression
of a cecropin-beta lytic peptide analog to render transgenic
tobacco plants resistant to Pseudomonas solanacearum.
[0349] (J) A gene encoding a viral-invasive protein or a complex
toxin derived therefrom. For example, the accumulation of viral
coat proteins in transformed plant cells imparts resistance to
viral infection and/or disease development effected by the virus
from which the coat protein gene is derived, as well as by related
viruses. See, Beachy, et al., (1990) Ann. Rev. Phytopathol. 28:451.
Coat protein-mediated resistance has been conferred upon
transformed plants against alfalfa mosaic virus, cucumber mosaic
virus, tobacco streak virus, potato virus X, potato virus Y,
tobacco etch virus, tobacco rattle virus and tobacco mosaic virus.
Id.
[0350] (K) A gene encoding an insect-specific antibody or an
immunotoxin derived therefrom. Thus, an antibody targeted to a
critical metabolic function in the insect gut would inactivate an
affected enzyme, killing the insect. Cf. Taylor, et al., Abstract
#497, SEVENTH INT'L SYMPOSIUM ON MOLECULAR PLANT-MICROBE
INTERACTIONS (Edinburgh, Scotland, 1994) (enzymatic inactivation in
transgenic tobacco via production of single-chain antibody
fragments).
[0351] (L) A gene encoding a virus-specific antibody. See, for
example, Tavladoraki, et al., (1993) Nature 366:469, who show that
transgenic plants expressing recombinant antibody genes are
protected from virus attack.
[0352] (M) A polynucleotide encoding a developmental-arrestive
protein produced in nature by a pathogen or a parasite. Thus,
fungal endo alpha-1,4-D-polygalacturonases facilitate fungal
colonization and plant nutrient release by solubilizing plant cell
wall homo-alpha-1,4-D-galacturonase. See, Lamb, et al., (1992)
Bio/Technology 10:1436. The cloning and characterization of a gene
which encodes a bean endopolygalacturonase-inhibiting protein is
described by Toubart, et al., (1992) Plant J. 2:367.
[0353] (N) A polynucleotide encoding a developmental-arrestive
protein produced in nature by a plant. For example, Logemann, et
al., (1992) Bio/Technology 10:305, have shown that transgenic
plants expressing the barley ribosome-inactivating gene have an
increased resistance to fungal disease.
[0354] (O) Genes involved in the Systemic Acquired Resistance (SAR)
Response and/or the pathogenesis related genes. Briggs, (1995)
Current Biology 5(2), Pieterse and Van Loon, (2004) Curr. Opin.
Plant Bio. 7(4):456-64 and Somssich, (2003) Cell 113(7):815-6.
[0355] (P) Antifungal genes (Cornelissen and Melchers, (1993) Pl.
Physiol. 101:709-712 and Parijs, et al., (1991) Planta 183:258-264
and Bushnell, et al., (1998) Can. J. of Plant Path. 20(2):137-149.
Also see, U.S. patent application Ser. Nos. 09/950,933; 11/619,645;
11/657,710; 11/748,994; 11/774,121 and U.S. Pat. Nos. 6,891,085 and
7,306,946. LysM Receptor-like kinases for the perception of chitin
fragments as a first step in plant defense response against fungal
pathogens (US 2012/0110696).
[0356] (Q) Detoxification genes, such as for fumonisin,
beauvericin, moniliformin and zearalenone and their structurally
related derivatives. For example, see, U.S. Pat. Nos. 5,716,820;
5,792,931; 5,798,255; 5,846,812; 6,083,736; 6,538,177; 6,388,171
and 6,812,380.
[0357] (R) A polynucleotide encoding a Cystatin and cysteine
proteinase inhibitors. See, U.S. Pat. No. 7,205,453.
[0358] (S) Defensin genes. See, WO 2003/000863 and U.S. Pat. Nos.
6,911,577; 6,855,865; 6,777,592 and 7,238,781.
[0359] (T) Genes conferring resistance to nematodes. See, e.g., PCT
Application WO 1996/30517; PCT Application WO 1993/19181, WO
2003/033651 and Urwin, et al., (1998) Planta 204:472-479,
Williamson, (1999) Curr Opin Plant Bio. 2(4):327-31; U.S. Pat. Nos.
6,284,948 and 7,301,069 and miR164 genes (WO 2012/058266).
[0360] (U) Genes that confer resistance to Phytophthora Root Rot,
such as the Rps 1, Rps 1-a, Rps 1-b, Rps 1-c, Rps 1-d, Rps 1-e, Rps
1-k, Rps 2, Rps 3-a, Rps 3-b, Rps 3-c, Rps 4, Rps 5, Rps 6, Rps 7
and other Rps genes. See, for example, Shoemaker, et al.,
Phytophthora Root Rot Resistance Gene Mapping in Soybean, Plant
Genome IV Conference, San Diego, Calif. (1995).
[0361] (V) Genes that confer resistance to Brown Stem Rot, such as
described in U.S. Pat. No. 5,689,035 and incorporated by reference
for this purpose.
[0362] (W) Genes that confer resistance to Colletotrichum, such as
described in US Patent Application Publication US 2009/0035765 and
incorporated by reference for this purpose. This includes the Rcg
locus that may be utilized as a single locus conversion.
2. Transgenes that Confer Resistance to a Herbicide, for
Example:
[0363] (A) A polynucleotide encoding resistance to a herbicide that
inhibits the growing point or meristem, such as an imidazolinone or
a sulfonylurea. Exemplary genes in this category code for mutant
ALS and AHAS enzyme as described, for example, by Lee, et al.,
(1988) EMBO J. 7:1241 and Miki, et al., (1990) Theor. Appl. Genet.
80:449, respectively. See also, U.S. Pat. Nos. 5,605,011;
5,013,659; 5,141,870; 5,767,361; 5,731,180; 5,304,732; 4,761,373;
5,331,107; 5,928,937 and 5,378,824; U.S. Pat. application Ser. No.
11/683,737 and International Publication WO 1996/33270.
[0364] (B) A polynucleotide encoding a protein for resistance to
Glyphosate (resistance imparted by mutant
5-enolpyruvl-3-phosphikimate synthase (EPSP) and aroA genes,
respectively) and other phosphono compounds such as glufosinate
(phosphinothricin acetyl transferase (PAT) and Streptomyces
hygroscopicus phosphinothricin acetyl transferase (bar) genes), and
pyridinoxy or phenoxy proprionic acids and cyclohexones (ACCase
inhibitor-encoding genes). See, for example, U.S. Pat. No.
4,940,835 to Shah, et al., which discloses the nucleotide sequence
of a form of EPSPS which can confer glyphosate resistance. U.S.
Pat. No. 5,627,061 to Barry, et al., also describes genes encoding
EPSPS enzymes. See also, U.S. Pat. Nos. 6,566,587; 6,338,961;
6,248,876 B1; 6,040,497; 5,804,425; 5,633,435; 5,145,783;
4,971,908; 5,312,910; 5,188,642; 5,094,945, 4,940,835; 5,866,775;
6,225,114 B1; 6,130,366; 5,310,667; 4,535,060; 4,769,061;
5,633,448; 5,510,471; Re. 36,449; RE 37,287 E and U.S. Pat. No.
5,491,288 and International Publications EP 1173580; WO 2001/66704;
EP 1173581 and EP 1173582, which are incorporated herein by
reference for this purpose. Glyphosate resistance is also imparted
to plants that express a gene encoding a glyphosate oxido-reductase
enzyme as described more fully in U.S. Pat. Nos. 5,776,760 and
5,463,175, which are incorporated herein by reference for this
purpose. In addition glyphosate resistance can be imparted to
plants by the over expression of genes encoding glyphosate
N-acetyltransferase. See, for example, U.S. Pat. Nos. 7,462,481;
7,405,074 and US Patent Application Publication Number US
2008/0234130. A DNA molecule encoding a mutant aroA gene can be
obtained under ATCC Accession Number 39256, and the nucleotide
sequence of the mutant gene is disclosed in U.S. Pat. No. 4,769,061
to Comai. EP Application Number 0 333 033 to Kumada, et al., and
U.S. Pat. No. 4,975,374 to Goodman, et al., disclose nucleotide
sequences of glutamine synthetase genes which confer resistance to
herbicides such as L-phosphinothricin. The nucleotide sequence of a
phosphinothricin-acetyl-transferase gene is provided in EP
Application Numbers 0 242 246 and 0 242 236 to Leemans, et al., De
Greef, et al., (1989) Bio/Technology 7:61, describe the production
of transgenic plants that express chimeric bar genes coding for
phosphinothricin acetyl transferase activity. See also, U.S. Pat.
Nos. 5,969,213; 5,489,520; 5,550,318; 5,874,265; 5,919,675;
5,561,236; 5,648,477; 5,646,024; 6,177,616 B1 and 5,879,903, which
are incorporated herein by reference for this purpose. Exemplary
genes conferring resistance to phenoxy proprionic acids and
cyclohexones, such as sethoxydim and haloxyfop, are the Acc1-S1,
Acc1-S2 and Acc1-S3 genes described by Marshall, et al., (1992)
Theor. Appl. Genet. 83:435.
[0365] (C) A polynucleotide encoding a protein for resistance to
herbicide that inhibits photosynthesis, such as a triazine (psbA
and gs+genes) and a benzonitrile (nitrilase gene). Przibilla, et
al., (1991) Plant Cell 3:169, describe the transformation of
Chlamydomonas with plasmids encoding mutant psbA genes. Nucleotide
sequences for nitrilase genes are disclosed in U.S. Pat. No.
4,810,648 to Stalker and DNA molecules containing these genes are
available under ATCC Accession Numbers 53435, 67441 and 67442.
Cloning and expression of DNA coding for a glutathione
S-transferase is described by Hayes, et al., (1992) Biochem. J.
285:173.
[0366] (D) A polynucleotide encoding a protein for resistance to
Acetohydroxy acid synthase, which has been found to make plants
that express this enzyme resistant to multiple types of herbicides,
has been introduced into a variety of plants (see, e.g., Hattori,
et al., (1995) Mol Gen Genet. 246:419). Other genes that confer
resistance to herbicides include: a gene encoding a chimeric
protein of rat cytochrome P4507A1 and yeast NADPH-cytochrome P450
oxidoreductase (Shiota, et al., (1994) Plant Physiol 106:17), genes
for glutathione reductase and superoxide dismutase (Aono, et al.,
(1995) Plant Cell Physiol 36:1687) and genes for various
phosphotransferases (Datta, et al., (1992) Plant Mol Biol
20:619).
[0367] (E) A polynucleotide encoding resistance to a herbicide
targeting Protoporphyrinogen oxidase (protox) which is necessary
for the production of chlorophyll. The protox enzyme serves as the
target for a variety of herbicidal compounds. These herbicides also
inhibit growth of all the different species of plants present,
causing their total destruction. The development of plants
containing altered protox activity which are resistant to these
herbicides are described in U.S. Pat. Nos. 6,288,306 B1; 6,282,837
B1 and 5,767,373 and International Publication WO 2001/12825.
[0368] (F) The aad-1 gene (originally from Sphingobium
herbicidovorans) encodes the aryloxyalkanoate dioxygenase (AAD-1)
protein. The trait confers tolerance to 2,4-dichlorophenoxyacetic
acid and aryloxyphenoxypropionate (commonly referred to as "fop"
herbicides such as quizalofop) herbicides. The aad-1 gene, itself,
for herbicide tolerance in plants was first disclosed in WO
2005/107437 (see also, US 2009/0093366). The aad-12 gene, derived
from Delftia acidovorans, which encodes the aryloxyalkanoate
dioxygenase (AAD-12) protein that confers tolerance to
2,4-dichlorophenoxyacetic acid and pyridyloxyacetate herbicides by
deactivating several herbicides with an aryloxyalkanoate moiety,
including phenoxy auxin (e.g., 2,4-D, MCPA), as well as pyridyloxy
auxins (e.g., fluroxypyr, triclopyr).
[0369] (G) A polynucleotide encoding a herbicide resistant dicamba
monooxygenase disclosed in US Patent Application Publication
2003/0135879 for imparting dicamba tolerance;
[0370] (H) A polynucleotide molecule encoding bromoxynil nitrilase
(Bxn) disclosed in U.S. Pat. No. 4,810,648 for imparting bromoxynil
tolerance;
[0371] (I) A polynucleotide molecule encoding phytoene (crtl)
described in Misawa, et al., (1993) Plant J. 4:833-840 and in
Misawa, et al., (1994) Plant J. 6:481-489 for norflurazon
tolerance.
3. Transgenes that Confer or Contribute to an Altered Grain
Characteristic
Such as:
[0372] (A) Altered fatty acids, for example, by
[0373] (1) Down-regulation of stearoyl-ACP to increase stearic acid
content of the plant. See, Knultzon, et al., (1992) Proc. Natl.
Acad. Sci. USA 89:2624 and WO 1999/64579 (Genes to Alter Lipid
Profiles in Corn).
[0374] (2) Elevating oleic acid via FAD-2 gene modification and/or
decreasing linolenic acid via FAD-3 gene modification (see, U.S.
Pat. Nos. 6,063,947; 6,323,392; 6,372,965 and WO 1993/11245).
[0375] (3) Altering conjugated linolenic or linoleic acid content,
such as in WO 2001/12800.
[0376] (4) Altering LEC1, AGP, Dek1, Superal1, mi1 ps, various Ipa
genes such as Ipa1, Ipa3, hpt or hggt. For example, see, WO
2002/42424, WO 1998/22604, WO 2003/011015, WO 2002/057439, WO
2003/011015, U.S. Pat. Nos. 6,423,886, 6,197,561, 6,825,397 and US
Patent Application Publication Numbers US 2003/0079247, US
2003/0204870 and Rivera-Madrid, et al., (1995) Proc. Natl. Acad.
Sci. 92:5620-5624.
[0377] (5) Genes encoding delta-8 desaturase for making long-chain
polyunsaturated fatty acids (U.S. Pat. Nos. 8,058,571 and
8,338,152), delta-9 desaturase for lowering saturated fats (U.S.
Pat. No. 8,063,269), Primula .DELTA.6-desaturase for improving
omega-3 fatty acid profiles.
[0378] (6) Isolated nucleic acids and proteins associated with
lipid and sugar metabolism regulation, in particular, lipid
metabolism protein (LMP) used in methods of producing transgenic
plants and modulating levels of seed storage compounds including
lipids, fatty acids, starches or seed storage proteins and use in
methods of modulating the seed size, seed number, seed weights,
root length and leaf size of plants (EP 2404499).
[0379] (7) Altering expression of a High-Level Expression of
Sugar-Inducible 2 (HSI2) protein in the plant to increase or
decrease expression of HSI2 in the plant. Increasing expression of
HSI2 increases oil content while decreasing expression of HSI2
decreases abscisic acid sensitivity and/or increases drought
resistance (US Patent Application Publication Number
2012/0066794).
[0380] (8) Expression of cytochrome b5 (Cb5) alone or with FAD2 to
modulate oil content in plant seed, particular to increase the
levels of omega-3 fatty acids and improve the ratio of omega-6 to
omega-3 fatty acids (US Patent Application Publication Number
2011/0191904).
[0381] (9) Nucleic acid molecules encoding wrinkled1-like
polypeptides for modulating sugar metabolism (U.S. Pat. No.
8,217,223).
[0382] (B) Altered phosphorus content, for example, by the
[0383] (1) Introduction of a phytase-encoding gene would enhance
breakdown of phytate, adding more free phosphate to the transformed
plant. For example, see, Van Hartingsveldt, et al., (1993) Gene
127:87, for a disclosure of the nucleotide sequence of an
Aspergillus niger phytase gene.
[0384] (2) Modulating a gene that reduces phytate content. In
maize, this, for example, could be accomplished, by cloning and
then re-introducing DNA associated with one or more of the alleles,
such as the LPA alleles, identified in maize mutants characterized
by low levels of phytic acid, such as in WO 2005/113778 and/or by
altering inositol kinase activity as in WO 2002/059324, US Patent
Application Publication Number 2003/0009011, WO 2003/027243, US
Patent Application Publication Number 2003/0079247, WO 1999/05298,
U.S. Pat. Nos. 6,197,561, 6,291,224, 6,391,348, WO 2002/059324, US
Patent Application Publication Number 2003/0079247, WO 1998/45448,
WO 1999/55882, WO 2001/04147.
[0385] (C) Altered carbohydrates affected, for example, by altering
a gene for an enzyme that affects the branching pattern of starch
or, a gene altering thioredoxin such as NTR and/or TRX (see, U.S.
Pat. No. 6,531,648. which is incorporated by reference for this
purpose) and/or a gamma zein knock out or mutant such as cs27 or
TUSC27 or en27 (see, U.S. Pat. No. 6,858,778 and US Patent
Application Publication Number 2005/0160488, US Patent Application
Publication Number 2005/0204418, which are incorporated by
reference for this purpose). See, Shiroza, et al., (1988) J.
Bacteriol. 170:810 (nucleotide sequence of Streptococcus mutant
fructosyltransferase gene), Steinmetz, et al., (1985) Mol. Gen.
Genet. 200:220 (nucleotide sequence of Bacillus subtilis
levansucrase gene), Pen, et al., (1992) Bio/Technology 10:292
(production of transgenic plants that express Bacillus
licheniformis alpha-amylase), Elliot, et al., (1993) Plant Molec.
Biol. 21:515 (nucleotide sequences of tomato invertase genes),
Sogaard, et al., (1993) J. Biol. Chem. 268:22480 (site-directed
mutagenesis of barley alpha-amylase gene) and Fisher, et al.,
(1993) Plant Physiol. 102:1045 (maize endosperm starch branching
enzyme II), WO 1999/10498 (improved digestibility and/or starch
extraction through modification of UDP-D-xylose 4-epimerase,
Fragile 1 and 2, Ref1, HCHL, C4H), U.S. Pat. No. 6,232,529 (method
of producing high oil seed by modification of starch levels (AGP)).
The fatty acid modification genes mentioned herein may also be used
to affect starch content and/or composition through the
interrelationship of the starch and oil pathways.
[0386] (D) Altered antioxidant content or composition, such as
alteration of tocopherol or tocotrienols. For example, see, U.S.
Pat. No. 6,787,683, US Patent Application Publication Number
2004/0034886 and WO 2000/68393 involving the manipulation of
antioxidant levels and WO 2003/082899 through alteration of a
homogentisate geranyl geranyl transferase (hggt).
[0387] (E) Altered essential seed amino acids. For example, see,
U.S. Pat. No. 6,127,600 (method of increasing accumulation of
essential amino acids in seeds), U.S. Pat. No. 6,080,913 (binary
methods of increasing accumulation of essential amino acids in
seeds), U.S. Pat. No. 5,990,389 (high lysine), WO 1999/40209
(alteration of amino acid compositions in seeds), WO 1999/29882
(methods for altering amino acid content of proteins), U.S. Pat.
No. 5,850,016 (alteration of amino acid compositions in seeds), WO
1998/20133 (proteins with enhanced levels of essential amino
acids), U.S. Pat. No. 5,885,802 (high methionine), U.S. Pat. No.
5,885,801 (high threonine), U.S. Pat. No. 6,664,445 (plant amino
acid biosynthetic enzymes), U.S. Pat. No. 6,459,019 (increased
lysine and threonine), U.S. Pat. No. 6,441,274 (plant tryptophan
synthase beta subunit), U.S. Pat. No. 6,346,403 (methionine
metabolic enzymes), U.S. Pat. No. 5,939,599 (high sulfur), U.S.
Pat. No. 5,912,414 (increased methionine), WO 1998/56935 (plant
amino acid biosynthetic enzymes), WO 1998/45458 (engineered seed
protein having higher percentage of essential amino acids), WO
1998/42831 (increased lysine), U.S. Pat. No. 5,633,436 (increasing
sulfur amino acid content), U.S. Pat. No. 5,559,223 (synthetic
storage proteins with defined structure containing programmable
levels of essential amino acids for improvement of the nutritional
value of plants), WO 1996/01905 (increased threonine), WO
1995/15392 (increased lysine), US Patent Application Publication
Number 2003/0163838, US Patent Application Publication Number
2003/0150014, US Patent Application Publication Number
2004/0068767, U.S. Pat. No. 6,803,498, WO 2001/79516.
4. Genes that Control Male-Sterility:
[0388] There are several methods of conferring genetic male
sterility available, such as multiple mutant genes at separate
locations within the genome that confer male sterility, as
disclosed in U.S. Pat. Nos. 4,654,465 and 4,727,219 to Brar, et
al., and chromosomal translocations as described by Patterson in
U.S. Pat. Nos. 3,861,709 and 3,710,511. In addition to these
methods, Albertsen, et al., U.S. Pat. No. 5,432,068, describe a
system of nuclear male sterility which includes: identifying a gene
which is critical to male fertility; silencing this native gene
which is critical to male fertility; removing the native promoter
from the essential male fertility gene and replacing it with an
inducible promoter; inserting this genetically engineered gene back
into the plant; and thus creating a plant that is male sterile
because the inducible promoter is not "on" resulting in the male
fertility gene not being transcribed. Fertility is restored by
inducing or turning "on", the promoter, which in turn allows the
gene that confers male fertility to be transcribed.
[0389] (A) Introduction of a deacetylase gene under the control of
a tapetum-specific promoter and with the application of the
chemical N-Ac-PPT (WO 2001/29237).
[0390] (B) Introduction of various stamen-specific promoters (WO
1992/13956, WO 1992/13957).
[0391] (C) Introduction of the barnase and the barstar gene (Paul,
et al., (1992) Plant Mol. Biol. 19:611-622).
[0392] For additional examples of nuclear male and female sterility
systems and genes, see also, U.S. Pat. Nos. 5,859,341; 6,297,426;
5,478,369; 5,824,524; 5,850,014 and 6,265,640, all of which are
hereby incorporated by reference.
5. Genes that Create a Site for Site Specific DNA Integration.
[0393] This includes the introduction of FRT sites that may be used
in the FLP/FRT system and/or Lox sites that may be used in the
Cre/Loxp system. For example, see, Lyznik, et al., (2003) Plant
Cell Rep 21:925-932 and WO 1999/25821, which are hereby
incorporated by reference. Other systems that may be used include
the Gin recombinase of phage Mu (Maeser, et al., (1991) Vicki
Chandler, The Maize Handbook ch. 118 (Springer-Verlag 1994), the
Pin recombinase of E. coli (Enomoto, et al., 1983) and the R/RS
system of the pSRi plasmid (Araki, et al., 1992).
6. Genes that Affect Abiotic Stress Resistance
[0394] Including but not limited to flowering, ear and seed
development, enhancement of nitrogen utilization efficiency,
altered nitrogen responsiveness, drought resistance or tolerance,
cold resistance or tolerance and salt resistance or tolerance and
increased yield under stress.
[0395] (A) For example, see: WO 2000/73475 where water use
efficiency is altered through alteration of malate; U.S. Pat. Nos.
5,892,009, 5,965,705, 5,929,305, 5,891,859, 6,417,428, 6,664,446,
6,706,866, 6,717,034, 6,801,104, WO 2000/060089, WO 2001/026459, WO
2001/035725, WO 2001/034726, WO 2001/035727, WO 2001/036444, WO
2001/036597, WO 2001/036598, WO 2002/015675, WO 2002/017430, WO
2002/077185, WO 2002/079403, WO 2003/013227, WO 2003/013228, WO
2003/014327, WO 2004/031349, WO 2004/076638, WO 199809521.
[0396] (B) WO 199938977 describing genes, including CBF genes and
transcription factors effective in mitigating the negative effects
of freezing, high salinity and drought on plants, as well as
conferring other positive effects on plant phenotype.
[0397] (C) US Patent Application Publication Number 2004/0148654
and WO 2001/36596 where abscisic acid is altered in plants
resulting in improved plant phenotype such as increased yield
and/or increased tolerance to abiotic stress.
[0398] (D) WO 2000/006341, WO 2004/090143, U.S. Pat. Nos. 7,531,723
and 6,992,237 where cytokinin expression is modified resulting in
plants with increased stress tolerance, such as drought tolerance,
and/or increased yield. Also see, WO 2002/02776, WO 2003/052063, JP
2002/281975, U.S. Pat. No. 6,084,153, WO 2001/64898, U.S. Pat. Nos.
6,177,275 and 6,107,547 (enhancement of nitrogen utilization and
altered nitrogen responsiveness).
[0399] (E) For ethylene alteration, see, US Patent Application
Publication Number 2004/0128719, US Patent Application Publication
Number 2003/0166197 and WO 2000/32761.
[0400] (F) For plant transcription factors or transcriptional
regulators of abiotic stress, see, e.g., US Patent Application
Publication Number 2004/0098764 or US Patent Application
Publication Number 2004/0078852.
[0401] (G) Genes that increase expression of vacuolar
pyrophosphatase such as AVP1 (U.S. Pat. No. 8,058,515) for
increased yield; nucleic acid encoding a HSFA4 or a HSFA5 (Heat
Shock Factor of the class A4 or A5) polypeptides, an oligopeptide
transporter protein (OPT4-like) polypeptide; a plastochron2-like
(PLA2-like) polypeptide or a Wuschel related homeobox 1-like
(WOX1-like) polypeptide (U.S. Patent Application Publication Number
US 2011/0283420).
[0402] (H) Down regulation of polynucleotides encoding poly
(ADP-ribose) polymerase (PARP) proteins to modulate programmed cell
death (U.S. Pat. No. 8,058,510) for increased vigor.
[0403] (I) Polynucleotide encoding DTP21 polypeptides for
conferring drought resistance (US Patent Application Publication
Number US 2011/0277181).
[0404] (J) Nucleotide sequences encoding ACC Synthase 3 (ACS3)
proteins for modulating development, modulating response to stress,
and modulating stress tolerance (US Patent Application Publication
Number US 2010/0287669).
[0405] (K) Polynucleotides that encode proteins that confer a
drought tolerance phenotype (DTP) for conferring drought resistance
(WO 2012/058528).
[0406] (L) Tocopherol cyclase (TC) genes for conferring drought and
salt tolerance (US Patent Application Publication Number
2012/0272352).
[0407] (M) CAAX amino terminal family proteins for stress tolerance
(U.S. Pat. No. 8,338,661).
[0408] (N) Mutations in the SAL1 encoding gene have increased
stress tolerance, including increased drought resistant (US Patent
Application Publication Number 2010/0257633).
[0409] (O) Expression of a nucleic acid sequence encoding a
polypeptide selected from the group consisting of: GRF polypeptide,
RAA1-like polypeptide, SYR polypeptide, ARKL polypeptide, and YTP
polypeptide increasing yield-related traits (US Patent Application
Publication Number 2011/0061133).
[0410] (P) Modulating expression in a plant of a nucleic acid
encoding a Class III Trehalose Phosphate Phosphatase (TPP)
polypeptide for enhancing yield-related traits in plants,
particularly increasing seed yield (US Patent Application
Publication Number 2010/0024067).
[0411] Other genes and transcription factors that affect plant
growth and agronomic traits such as yield, flowering, plant growth
and/or plant structure, can be introduced or introgressed into
plants, see e.g., WO 1997/49811 (LHY), WO 1998/56918 (ESD4), WO
1997/10339 and U.S. Pat. No. 6,573,430 (TFL), U.S. Pat. No.
6,713,663 (FT), WO 1996/14414 (CON), WO 1996/38560, WO 2001/21822
(VRN1), WO 2000/44918 (VRN2), WO 1999/49064 (GI), WO 2000/46358
(FR1), WO 1997/29123, U.S. Pat. Nos. 6,794,560, 6,307,126 (GAI), WO
1999/09174 (D8 and Rht) and WO 2004/076638 and WO 2004/031349
(transcription factors).
7. Genes that Confer Increased Yield
[0412] (A) A transgenic crop plant transformed by a
1-AminoCyclopropane-1-Carboxylate Deaminase-like Polypeptide
(ACCDP) coding nucleic acid, wherein expression of the nucleic acid
sequence in the crop plant results in the plant's increased root
growth, and/or increased yield, and/or increased tolerance to
environmental stress as compared to a wild type variety of the
plant (U.S. Pat. No. 8,097,769).
[0413] (B) Over-expression of maize zinc finger protein gene
(Zm-ZFP1) using a seed preferred promoter has been shown to enhance
plant growth, increase kernel number and total kernel weight per
plant (US Patent Application Publication Number 2012/0079623).
[0414] (C) Constitutive over-expression of maize lateral organ
boundaries (LOB) domain protein (Zm-LOBDP1) has been shown to
increase kernel number and total kernel weight per plant (US Patent
Application Publication Number 2012/0079622).
[0415] (D) Enhancing yield-related traits in plants by modulating
expression in a plant of a nucleic acid encoding a VIM1 (Variant in
Methylation 1)-like polypeptide or a VTC2-like (GDP-L-galactose
phosphorylase) polypeptide or a DUF1685 polypeptide or an ARF6-like
(Auxin Responsive Factor) polypeptide (WO 2012/038893).
[0416] (E) Modulating expression in a plant of a nucleic acid
encoding a Ste20-like polypeptide or a homologue thereof gives
plants having increased yield relative to control plants (EP
2431472).
[0417] (F) Genes encoding nucleoside diphosphatase kinase (NDK)
polypeptides and homologs thereof for modifying the plant's root
architecture (US Patent Application Publication Number
2009/0064373).
8. Genes that Confer Plant Digestibility
[0418] (A) Altering the level of xylan present in the cell wall of
a plant by modulating expression of xylan synthase (U.S. Pat. No.
8,173,866).
[0419] In some embodiment the stacked trait may be a trait or event
that has received regulatory approval including but not limited to
the events in Table 2A-1F.
TABLE-US-00006 TABLE 2A Triticum aestivum Wheat Event Company
Description AP205CL BASF Inc. Selection for a mutagenized version
of the enzyme acetohydroxyacid synthase (AHAS), also known as
acetolactate synthase (ALS) or acetolactate pyruvate-lyase. AP602CL
BASF Inc. Selection for a mutagenized version of the enzyme
acetohydroxyacid synthase (AHAS), also known as acetolactate
synthase (ALS) or acetolactate pyruvate-lyase. BW255-2, BASF Inc.
Selection for a mutagenized version of the BW238-3 enzyme
acetohydroxyacid synthase (AHAS), also known as acetolactate
synthase (ALS) or acetolactate pyruvate- lyase. BW7 BASF Inc.
Tolerance to imidazolinone herbicides induced by chemical
mutagenesis of the acetohydroxyacid synthase (AHAS) gene using
sodium azide. MON71800 Monsanto Glyphosate tolerant wheat variety
Company produced by inserting a modified 5-enolpyruvylshikimate-
3-phosphate synthase (EPSPS) encoding gene from the soil bacterium
Agrobacterium tumefaciens, strain CP4. SWP965001 Cyanamid Selection
for a mutagenized version of the Crop enzyme acetohydroxyacid
synthase Protection (AHAS), also known as acetolactate synthase
(ALS) or acetolactate pyruvate-lyase. Teal 11A BASF Inc. Selection
for a mutagenized version of the enzyme acetohydroxyacid synthase
(AHAS), also known as acetolactate synthase (ALS) or acetolactate
pyruvate-lyase. A2704-12, Bayer Glufosinate ammonium herbicide
tolerant A2704-21, CropScience soybean produced by inserting a
modified A5547-35 (Aventis phosphinothricin acetyltransferase (PAT)
CropScience encoding gene from the soil bacterium (AgrEvo))
Streptomyces viridochromogenes.
TABLE-US-00007 TABLE 2B Glycine max L. Soybean Event Compay
Description A5547-127 Bayer Glufosinate ammonium herbicide tolerant
CropScience soybean produced by inserting a modified (Aventis
phosphinothricin acetyltransferase (PAT) CropScience encoding gene
from the soil bacterium (AgrEvo)) Streptomyces viridochromogenes.
BPS- BASF Inc. The introduced csr1-2 gene from CV127-9 Arabidopsis
thaliana encodes an acetohydroxyacid synthase protein that confers
tolerance to imidazolinone herbicides due to a point mutation that
results in a single amino acid substitution in which the serine
residue at position 653 is replaced by asparagine (S653N).
DP-305423 Pioneer High oleic acid soybean produced by Hi-Bred
inserting additional copies of a portion of International the
omega-6 desaturase encoding gene, Inc. gm-fad2-1 resulting in
silencing of the endogenous omega-6 desaturase gene (FAD2-1).
DP356043 Pioneer Soybean event with two herbicide tolerance Hi-Bred
genes: glyphosate N-acetlytransferase, which International
detoxifies glyphosate, and a modified Inc. acetolactate synthase
(ALS) gene which is tolerant to ALS-inhibiting herbicides. G94-1,
DuPont High oleic acid soybean produced by G94-19, Canada inserting
a second copy of the fatty acid G168 Agricultural desaturase
(GmFad2-1) encoding gene Products from soybean, which resulted in
"silencing" of the endogenous host gene. GTS 40-3-2 Monsanto
Glyphosate tolerant soybean variety Company produced by inserting a
modified 5-enolpyruvylshikimate-3- phosphate synthase (EPSPS)
encoding gene from the soil bacterium Agrobacterium tumefaciens.
GU262 Bayer Glufosinate ammonium herbicide tolerant CropScience
soybean produced by inserting a modified (Aventis phosphinothricin
acetyltransferase (PAT) CropScience encoding gene from the soil
bacterium (AgrEvo)) Streptomyces viridochromogenes. MON87701
Monsanto Resistance to lepidopteran pests of soybean Company
including velvetbean caterpillar (Anticarsia gemmatalis) and
soybean looper (Pseudoplusia includens). MON87701 x Monsanto
Glyphosate herbicide tolerance through MON89788 Company expression
of the EPSPS encoding gene from A. tumefaciens strain CP4, and
resistance to lepidopteran pests of soybean including velvetbean
caterpillar (Anticarsia gemmatalis) and soybean looper
(Pseudoplusia includens) via expression of the Cry1Ac encoding gene
from B. thuringiensis. MON89788 Monsanto Glyphosate-tolerant
soybean produced by Company inserting a modified
5-enolpyruvylshikimate- 3-phosphate synthase (EPSPS) encoding aroA
(epsps) gene from Agrobacterium tumefaciens CP4. OT96-15
Agriculture & Low linolenic acid soybean produced Agri-Food
through traditional cross-breeding to Canada incorporate the novel
trait from a naturally occurring fan1 gene mutant that was selected
for low linolenic acid. W62, W98 Bayer Glufosinate ammonium
herbicide tolerant CropScience soybean produced by inserting a
modified (Aventis phosphinothricin acetyltransferase (PAT)
CropScience encoding gene from the soil bacterium (AgrEvo))
Streptomyces hygroscopicus.
TABLE-US-00008 TABLE 2C Helianthus annuus Sunflower Event Company
Description X81359 BASF Inc. Tolerance to imidazolinone herbicides
by selection of a naturally occurring mutant.
TABLE-US-00009 TABLE 2D Medicago sativa Alfalfa Event Company
Description J101, J163 Monsanto Glyphosate herbicide tolerant
alfalfa (lucerne) Company produced by inserting a gene encoding the
and Forage enzyme 5-enolypyruvylshikimate-3-phosphate Genetics
synthase (EPSPS) from the CP4 strain of International Agrobacterium
tumefaciens.
TABLE-US-00010 TABLE 2E Oryza sativa Rice Event Company Description
CL121, BASF Inc. Tolerance to the imidazolinone herbicide, CL141,
imazethapyr, induced by chemical CFX51 mutagenesis of the
acetolactate synthase (ALS) enzyme using ethyl methanesulfonate
(EMS). IMINTA-1, BASF Inc. Tolerance to imidazolinone herbicides
IMINTA-4 induced by chemical mutagenesis of the acetolactate
synthase (ALS) enzyme using sodium azide. LLRICE06, Aventis
Glufosinate ammonium herbicide tolerant LLRICE62 CropScience rice
produced by inserting a modified phosphinothricin acetyltransferase
(PAT) encoding gene from the soil bacterium Streptomyces
hygroscopicus). LLRICE601 Bayer Glufosinate ammonium herbicide
tolerant CropScience rice produced by inserting a modified (Aventis
phosphinothricin acetyltransferase (PAT) CropScience encoding gene
from the soil bacterium (AgrEvo)) Streptomyces hygroscopicus).
PWC16 BASF Inc. Tolerance to the imidazolinone herbicide,
imazethapyr, induced by chemical mutagenesis of the acetolactate
synthase (ALS) enzyme using ethyl methanesulfonate (EMS).
TABLE-US-00011 TABLE 2F Zea mays L. Maize Event Company Description
176 Syngenta Insect-resistant maize produced by inserting the
Seeds, cry1Ab gene from Bacillus thuringiensis subsp. Inc.
kurstaki. The genetic modification affords resistance to attack by
the European corn borer (ECB). 3751IR Pioneer Selection of
somaclonal variants by culture of Hi-Bred embryos on imidazolinone
containing media. Inter- national Inc. 676, 678, Pioneer
Male-sterile and glufosinate ammonium 680 Hi-Bred herbicide
tolerant maize produced by inserting Inter- genes encoding DNA
adenine methylase and national phosphinothricin acetyltransferase
(PAT) Inc. from Escherichia coli and Streptomyces
viridochromogenes, respectively. B16 Dekalb Glufosinate ammonium
herbicide tolerant (DLL25) Genetics maize produced by inserting the
gene Cor- encoding phosphinothricin acetyltransferase poration
(PAT) from Streptomyces hygroscopicus. BT11 Syngenta
Insect-resistant and herbicide tolerant maize (X4334CBR, Seeds,
produced by inserting the cry1Ab gene from X4734CBR) Inc. Bacillus
thuringiensis subsp. kurstaki, and the phosphinothricin
N-acetyltransferase (PAT) encoding gene from S. viridochromogenes.
BT11 x Syngenta Stacked insect resistant and herbicide tolerant
GA21 Seeds, maize produced by conventional cross breeding Inc. of
parental lines BT11 (OECD unique identifier: SYN-BTO11-1) and GA21
(OECD unique identifier: MON-OOO21-9). BT11 x Syngenta Stacked
insect resistant and herbicide tolerant MIR162 Seeds, maize
produced by conventional cross breeding Inc. of parental lines BT11
(OECD unique identifier: SYN-BTO11-1) and MIR162 (OECD unique
identifier: SYN-IR162-4). Resistance to the European Corn Borer and
tolerance to the herbicide glufosinate ammonium (Liberty) is
derived from BT11, which contains the cry1Ab gene from Bacillus
thuringiensis subsp. kurstaki, and the phosphinothricin N-
acetyltransferase (PAT) encoding gene from S. viridochromogenes.
Resistance to other lepidopteran pests, including H. zea, S.
frugiperda, A. ipsilon, and S. albicosta, is derived from MIR162,
which contains the vip3Aa gene from Bacillus thuringiensis strain
AB88. BT11 x Syngenta Bacillus thuringiensis Cry1Ab delta-endotoxin
MIR162 x Seeds, protein and the genetic material necessary for its
MIR604 Inc. production (via elements of vector pZO1502) in Event
Bt11 corn (OECD Unique Identifier: SYN-BTO11-1) x Bacillus
thuringiensis Vip3Aa20 insecticidal protein and the genetic
material necessary for its production (via elements of vector
pNOV1300) in Event MIR162 maize (OECD Unique Identifier:
SYN-IR162-4) x modified Cry3A protein and the genetic material
necessary for its production (via elements of vector pZM26) in
Event MIR604 corn (OECD Unique Identifier: SYN-IR6O4-5). BT11 x
Syngenta Resistance to coleopteran pests, particularly MIR162 x
Seeds, corn rootworm pests (Diabrotica spp.) and MIR604 x Inc.
several lepidopteran pests of corn, including GA21 European corn
borer (ECB, Ostrinia nubilalis), corn earworm (CEW, Helicoverpa
zea), fall army worm (FAW, Spodoptera frugiperda), and black
cutworm (BCW, Agrotis ipsilon); tolerance to glyphosate and
glufosinate- ammonium containing herbicides. BT11 x Syngenta
Stacked insect resistant and herbicide tolerant MIR604 Seeds, maize
produced by conventional cross breeding Inc. of parental lines BT11
(OECD unique identifier: SYN-BTO11-1) and MIR604 (OECD unique
identifier: SYN-IR605-5). Resistance to the European Corn Borer and
tolerance to the herbicide glufosinate ammonium (Liberty) is
derived from BT11, which contains the cry1Ab gene from Bacillus
thuringiensis subsp. kurstaki, and the phosphinothricin
N-acetyltransferase (PAT) encoding gene from S. viridochromogenes.
Corn rootworm-resistance is derived from MIR604 which contains the
mcry3A gene from Bacillus thuringiensis. BT11 x Syngenta Stacked
insect resistant and herbicide tolerant MIR604 x Seeds, maize
produced by conventional cross GA21 Inc. breeding of parental lines
BT11 (OECD unique identifier: SYN-BTO11-1), MIR604 (OECD unique
identifier: SYN-IR605-5) and GA21 (OECD unique identifier:
MON-OOO21-9). Resistance to the European Corn Borer and tolerance
to the herbicide glufosinate ammonium (Liberty) is derived from
BT11, which contains the cry1Ab gene from Bacillus thuringiensis
subsp. kurstaki, and the phosphinothricin N- acetyltransferase
(PAT) encoding gene from S. viridochromogenes. Corn
rootworm-resistance is derived from MIR604 which contains the
mcry3A gene from Bacillus thuringiensis. Tolerance to glyphosate
herbicide is derived from GA21 which contains a modified EPSPS gene
from maize. CBH-351 Aventis Insect-resistant and glufosinate
ammonium Crop- herbicide tolerant maize developed by inserting
Science genes encoding Cry9C protein from Bacillus thuringiensis
subsp tolworthi and phosphinothricin acetyltransferase (PAT) from
Streptomyces hygroscopicus. DAS- DOW Lepidopteran insect resistant
and glufosinate 06275-8 Agro- ammonium herbicide-tolerant maize
variety Sciences produced by inserting the cry1F gene from LLC
Bacillus thuringiensis var aizawai and the phosphinothricin
acetyltransferase (PAT) from Streptomyces hygroscopicus. DAS- DOW
Corn rootworm-resistant maize produced by 59122-7 Agro- inserting
the cry34Ab1 and cry35Ab1 genes Sciences from Bacillus
thuringiensis strain P5149B1. LLC and The PAT encoding gene from
Streptomyces Pioneer viridochromogenes was introduced as a Hi-Bred
selectable marker. Inter- national Inc. DAS- DOW Stacked insect
resistant and herbicide tolerant 59122-7 x Agro- maize produced by
conventional cross breeding NK603 Sciences of parental lines
DAS-59122-7 (OECD unique LLC and identifier: DAS-59122-7) with
NK603 (OECD Pioneer unique identifier: MON-OO6O3-6). Corn Hi-Bred
rootworm-resistance is derived from DAS- Inter- 59122-7 which
contains the cry34Ab1 and national cry35Ab1 genes from Bacillus
thuringiensis Inc. strain PS149B1. Tolerance to glyphosate
herbicide is derived from NK603. DAS- DOW Stacked insect resistant
and herbicide tolerant 59122-7 x Agro- maize produced by
conventional cross breeding TC1507 x Sciences of parental lines
DAS-59122-7 (OECD unique NK603 LLC and identifier: DAS-59122-7) and
TC1507 (OECD Pioneer unique identifier: DAS-O15O7-1) with NK603
Hi-Bred (OECD unique identifier: MON-OO6O3-6). Inter- Corn
rootworm-resistance is derived from national DAS-59122-7 which
contains the cry34Ab1 Inc. and cry35Ab1 genes from Bacillus
thuringiensis strain PS149B1. Lepidopteran resistance and tolerance
to glufosinate ammonium herbicide is derived from TC1507. Tolerance
to glyphosate herbicide is derived from NK603. DBT418 Dekalb
Insect-resistant and glufosinate ammonium Genetics herbicide
tolerant maize developed by inserting Cor- genes encoding Cry1AC
protein from poration Bacillus thuringiensis subsp kurstaki and
phosphinothricin acetyltransferase (PAT) from Streptomyces
hygroscopicus DK404SR BASF Somaclonal variants with a modified Inc.
acetyl-CoA-carboxylase (ACCase) were selected by culture of embryos
on sethoxydim enriched medium. Event Syngenta Maize line expressing
a heat stable alpha- 3272 Seeds, amylase gene amy797E for use in
the dry-grind Inc. ethanol process. The phosphomannose isomerase
gene from E. coli was used as a selectable marker. Event Pioneer
Maize event expressing tolerance to glyphosate 98140 Hi-Bred
herbicide, via expression of a modified Inter- bacterial glyphosate
N-acetlytransferase, and national ALS-inhibiting herbicides, vial
expression of Inc. a modified form of the maize acetolactate
synthase enzyme. EXP1910IT Syngenta Tolerance to the imidazolinone
herbicide, Seeds, imazethapyr, induced by chemical mutagenesis Inc.
of the acetolactate synthase (ALS) enzyme (formerly using ethyl
methanesulfonate (EMS). Zeneca Seeds) GA21 Syngenta Introduction,
by particle bombardment, of a Seeds, modified 5-enolpyruvyl
shikimate-3-phosphate Inc. synthase (EPSPS), an enzyme involved in
(formerly the shikimate biochemical pathway for the Zeneca
production of the aromatic amino acids. Seeds) GA21 x Monsanto
Stacked insect resistant and herbicide tolerant MON810 Company corn
hybrid derived from conventional cross- breeding of the parental
lines GA21 (OECD identifier: MONOOO21-9) and MON810 (OECD
identifier: MON-OO81O-6). IT Pioneer Tolerance to the imidazolinone
herbicide, Hi-Bred imazethapyr, was obtained by in vitro Inter-
selection of somaclonal variants. national Inc. LY038 Monsanto
Altered amino acid composition, specifically Company elevated
levels of lysine, through the introduction of the cordapA gene,
derived from Corynebacterium glutamicum, encoding the enzyme
dihydrodipicolinate synthase (cDHDPS). MIR162 Syngenta
Insect-resistant maize event expressing a Seeds, Vip3A protein from
Bacillus thuringiensis Inc. and the Escherichia coli PMI selectable
marker MIR604 Syngenta Corn rootworm resistant maize produced
Seeds, Inc. by transformation with a modified cry3A gene. The
phosphomannose isomerase gene from E. coli was used as a selectable
marker. MIR604 x Syngenta Stacked insect resistant and herbicide
tolerant GA21 Seeds, maize produced by conventional cross Inc.
breeding of parental lines MIR604 (OECD unique identifier:
SYN-IR6O5-5) and GA21 (OECD unique identifier: MON-OOO21-9). Corn
rootworm-resistance is derived from MIR604 which contains the
mcry3A gene from Bacillus thuringiensis. Tolerance to glyphosate
herbicide is derived from GA21. MON80100 Monsanto Insect-resistant
maize produced by inserting Company the cry1Ab gene from Bacillus
thuringiensis subsp. kurstaki. The genetic modification affords
resistance to attack by the European corn borer (ECB). MPN802
Monsanto Insect-resistant and glyphosate herbicide Company tolerant
maize produced by inserting the genes encoding the Cry1Ab protein
from Bacillus thuringiensis and the 5-
enolpyruvylshikimate-3-phosphate synthase (EPSPS) from A.
tumefaciens strain CP4. MON809 Pioneer Resistance to European corn
borer (Ostrinia Hi- nubilalis) by introduction of a synthetic Bred
cry1Ab gene. Glyphosate resistance via Inter- introduction of the
bacterial version of a national plant enzyme, 5-enolpyruvyl Inc.
shikimate-3-phosphate synthase (EPSPS). MON810 Monsanto
Insect-resistant maize produced by inserting Company a truncated
form of the cry1Ab gene from Bacillus thuringiensis subsp. kurstaki
HD-1. The genetic modification affords resistance to attack by the
European corn borer (ECB). MON810 x Monsanto Stacked insect
resistant and enhanced lysine LY038 Company content maize derived
from conventional cross-breeding of the parental lines MON810 (OECD
identifier: MON-OO81O-6) and LY038 (OECD identifier: REN-OOO38-3).
MON810 x Monsanto Stacked insect resistant and glyphosate MON88017
Company tolerant maize derived from conventional cross-breeding of
the parental lines MON810
(OECD identifier: MON-OO81O-6) and MON88017 (OECD identifier:
MON-88O17-3). European corn borer (ECB) resistance is derived from
a truncated form of the cry1Ab gene from Bacillus thuringiensis
subsp. kurstaki HD-1 present in MON810. Corn rootworm resistance is
derived from the cry3Bb1 gene from Bacillus thuringiensis
subspecies kumamotoensis strain EG4691 present in MON88017.
Glyphosate tolerance is derived from a 5-enolpyruvylshikimate-3-
phosphate synthase (EPSPS) encoding gene from Agrobacterium
tumefaciens strain CP4 present in MON88017. MON832 Monsanto
Introduction, by particle bombardment, of Company glyphosate
oxidase (GOX) and a modified 5-enolpyruvyl shikimate-3-phosphate
synthase (EPSPS), an enzyme involved in the shikimate biochemical
pathway for the production of the aromatic amino acids. MON863
Monsanto Corn root worm resistant maize produced by Company
inserting the cry3Bb1 gene from Bacillus thuringiensis subsp.
kumamotoensis. MON863 x Monsanto Stacked insect resistant corn
hybrid derived MON810 Company from conventional cross-breeding of
the parental lines MON863 (OECD identifier: MON-OO863-5) and MON810
(OECD identifier: MON-OO81O-6) MON863 x Monsanto Stacked insect
resistant and herbicide MON810 x Company tolerant corn hybrid
derived from conventional NK603 cross-breeding of the stacked
hybrid MON- OO863-5 x MON-OO81O-6 and NK603 (OECD identifier:
MON-OO6O3-6). MON863 x Monsanto Stacked insect resistant and
herbicide tolerant NK603 Company corn hybrid derived from
conventional cross- breeding of the parental lines MON863 (OECD
identifier:MON-OO863-5) and NK603 (OECD identifier: MON-OO6O3-6).
MON87460 Monsanto MON 87460 was developed to provide Company
reduced yield loss under water-limited conditions compared to
conventional maize. Efficacy in MON 87460 is derived by expression
of the inserted Bacillus subtilis cold shock protein B (CspB).
MON88017 Monsanto Corn rootworm-resistant maize produced by Company
inserting the cry3Bb1 gene from Bacillus thuringiensis subspecies
kumamotoensis strain EG4691. Glyphosate tolerance derived by
inserting a 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS)
encoding gene from Agrobacterium tumefaciens strain CP4. MON89034
Monsanto Maize event expressing two different Company insecticidal
proteins from Bacillus thuringiensis providing resistance to number
of lepidopteran pests. MON89034 x Monsanto Stacked insect resistant
and glyphosate tolerant MON88017 Company maize derived from
conventional cross-breeding of the parental lines MON89034 (OECD
identifier: MON-89O34-3) and MON88017 (OECD identifier:
MON-88O17-3). Resistance to Lepidopteran insects is derived from
two cry genes present in MON89043. Corn rootworm resistance is
derived from a single cry genes and glyphosate tolerance is derived
from the 5- enolpyruvylshikimate-3-phosphate synthase (EPSPS)
encoding gene from Agrobacterium tumefaciens present in MON88017.
M0N89034 x Monsanto Stacked insect resistant and herbicide tolerant
NK603 Company maize produced by conventional cross breeding of
parental lines MON89034 (OECD identifier: MON-89O34-3) with NK603
(OECD unique identifier: MON-OO603-6). Resistance to Lepidopteran
insects is derived from two cry genes present in MON89043.
Tolerance to glyphosate herbicide is derived from NK603. MON89034 x
Monsanto Stacked insect resistant and herbicide tolerant TC1507 x
Company maize produced by conventional cross breeding MON88017 x
and of parental lines: MON89034, TC1507, DAS- Mycogen MON88017, and
DAS-59122. Resistance to the 59122-7 Seeds above-ground and
below-ground insect pests c/o and tolerance to glyphosate and
glufosinate- Dow ammonium containing herbicides. Agro- Sciences LLC
MS3 Bayer Male sterility caused by expression of the Crop- barnase
ribonuclease gene from Bacillus Science amyloliquefaciens; PPT
resistance was via (Aventis PPT-acetyltransferase (PAT). Crop-
Science (AgrEvo)) MS6 Bayer Male sterility caused by expression of
the Crop- barnase ribonuclease gene from Bacillus Science
amyloliquefaciens; PPT resistance was via (Aventis
PPT-acetyltransferase (PAT). Crop Science (AgrEvo)) NK603 Monsanto
Introduction, by particle bombardment, of a Company modified
5-enolpyruvyl shikimate-3-phosphate synthase (EPSPS), an enzyme
involved in the shikimate biochemical pathway for the production of
the aromatic amino acids. NK603 x Monsanto Stacked insect resistant
and herbicide tolerant MON810 Company corn hybrid derived from
conventional cross- breeding of the parental lines NK603 (OECD
identifier: MON-OO6O3-6) and MON810 (OECD identifier: MON-OO81O-6).
NK603 x Monsanto Stacked glufosinate ammonium and T25 Company
glyphosate herbicide tolerant maize hybrid derived from
conventional cross-breeding of the parental lines NK603 (OECD
identifier: MON-OO6O3-6) and T25 (OECD identifier: ACS-ZM003-2).
T14, T25 Bayer Glufosinate herbicide tolerant maize Crop- produced
by inserting the phosphinothricin Science N-acetyltransferase
(Aventis (PAT) encoding gene from the aerobic Crop- actinomycete
Streptomyces Science viridochromogenes. (AgrEvo)) T25 x Bayer
Stacked insect resistant and herbicide tolerant MON810 Crop- corn
hybrid derived from conventional cross- Science breeding of the
parental lines T25 (OECD (Aventis identifier: ACS-ZMOO3-2) and
MON810 Crop- (OECD identifier: MONOO81O-6). Science (AgrEvo))
TC1507 Mycogen Insect-resistant and glufosinate ammonium (c/o Dow
herbicide tolerant maize produced by inserting Agro- the cry1F gene
from Bacillus thuringiensis var. Sciences); aizawai and the
phosphinothricin N- Pioneer acetyltransferase encoding gene from
(c/o Streptomyces viridochromogenes. DuPont) TC1507 x DOW Stacked
insect resistant and herbicide tolerant DAS- Agro- maize produced
by conventional cross 59122-7 Sciences breeding of parental lines
TC1507 (OECD LLC and unique identifier: DAS-O15O7-1) with Pioneer
DAS-59122-7 (OECD unique identifier: Hi-Bred DAS-59122-7).
Resistance to lepidopteran Inter- insects is derived from TC1507
due national the presence of the cry1F gene from Bacillus Inc.
thuringiensis var. aizawai. Corn rootworm- resistance is derived
from DAS-59122-7 which contains the cry34Ab1 and cry35Ab1 genes
from Bacillus thuringiensis strain PS149B1. Tolerance to
glufosinate ammonium herbicide is derived from TC1507 from the
phosphinothricin N- acetyltransferase encoding gene from
Streptomyces viridochromogenes. TC1507 x DOW Stacked insect
resistant and herbicide tolerant NK603 Agro- corn hybrid derived
from conventional cross- Sciences breeding of the parental lines
1507 (OECD LLC identifier: DAS-O15O7-1) and NK603 (OECD identifier:
MON-OO6O3-6).
[0420] Other events with regulatory approval are well known to one
skilled in the art and can be found at the Center for Environmental
Risk Assessment (cera-gmc.org/?action=gm_crop_database, which can
be accessed using the www prefix).
Gene Silencing
[0421] In some embodiments the stacked trait may be in the form of
silencing of one or more polynucleotides of interest resulting in
suppression of one or more target pest polypeptides. In some
embodiments the silencing is achieved through the use of a
suppression DNA construct.
[0422] In some embodiments one or more of the PHI-4 polypeptides or
fragments or variants thereof may be stacked with one or more
polynucleotides encoding one or more polypeptides having
insecticidal activity or agronomic traits as set forth supra and
optionally may further include one or more polynucleotides
providing for gene silencing of one or more target polynucleotides
as discussed infra.
[0423] "Suppression DNA construct" is a recombinant DNA construct
which when transformed or stably integrated into the genome of the
plant, results in "silencing" of a target gene in the plant. The
target gene may be endogenous or transgenic to the plant.
"Silencing," as used herein with respect to the target gene, refers
generally to the suppression of levels of mRNA or protein/enzyme
expressed by the target gene, and/or the level of the enzyme
activity or protein functionality. The term "suppression" includes
lower, reduce, decline, decrease, inhibit, eliminate and prevent.
"Silencing" or "gene silencing" does not specify mechanism and is
inclusive, and not limited to, anti-sense, cosuppression,
viral-suppression, hairpin suppression, stem-loop suppression,
RNAi-based approaches and small RNA-based approaches.
[0424] A suppression DNA construct may comprise a region derived
from a target gene of interest and may comprise all or part of the
nucleic acid sequence of the sense strand (or antisense strand) of
the target gene of interest. Depending upon the approach to be
utilized, the region may be 100% identical or less than 100%
identical (e.g., at least 50% or any integer between 51% and 100%
identical) to all or part of the sense strand (or antisense strand)
of the gene of interest.
[0425] Suppression DNA constructs are well-known in the art, are
readily constructed once the target gene of interest is selected,
and include, without limitation, cosuppression constructs,
antisense constructs, viral-suppression constructs, hairpin
suppression constructs, stem-loop suppression constructs,
double-stranded RNA-producing constructs, and more generally, RNAi
(RNA interference) constructs and small RNA constructs such as
siRNA (short interfering RNA) constructs and miRNA (microRNA)
constructs.
[0426] "Antisense inhibition" refers to the production of antisense
RNA transcripts capable of suppressing the expression of the target
protein.
[0427] "Antisense RNA" refers to an RNA transcript that is
complementary to all or part of a target primary transcript or mRNA
and that blocks the expression of a target isolated nucleic acid
fragment (U.S. Pat. No. 5,107,065). The complementarity of an
antisense RNA may be with any part of the specific gene transcript,
i.e., at the 5' non-coding sequence, 3' non-coding sequence,
introns or the coding sequence.
[0428] "Cosuppression" refers to the production of sense RNA
transcripts capable of suppressing the expression of the target
protein. "Sense" RNA refers to RNA transcript that includes the
mRNA and can be translated into protein within a cell or in vitro.
Cosuppression constructs in plants have been previously designed by
focusing on overexpression of a nucleic acid sequence having
homology to a native mRNA, in the sense orientation, which results
in the reduction of all RNA having homology to the overexpressed
sequence (see, Vaucheret, et al. (1998) Plant J. 16:651-659 and
Gura, (2000) Nature 404:804-808).
[0429] Another variation describes the use of plant viral sequences
to direct the suppression of proximal mRNA encoding sequences (PCT
Publication WO 1998/36083).
[0430] Recent work has described the use of "hairpin" structures
that incorporate all, or part, of an mRNA encoding sequence in a
complementary orientation that results in a potential "stem-loop"
structure for the expressed RNA (PCT Publication Number WO
1999/53050). In this case the stem is formed by polynucleotides
corresponding to the gene of interest inserted in either sense or
anti-sense orientation with respect to the promoter and the loop is
formed by some polynucleotides of the gene of interest, which do
not have a complement in the construct. This increases the
frequency of cosuppression or silencing in the recovered transgenic
plants. For review of hairpin suppression see, Wesley, et al.,
(2003) Methods in Molecular Biology, Plant Functional Genomics:
Methods and Protocols 236:273-286.
[0431] A construct where the stem is formed by at least 30
nucleotides from a gene to be suppressed and the loop is formed by
a random nucleotide sequence has also effectively been used for
suppression (WO 1999/61632).
[0432] The use of poly-T and poly-A sequences to generate the stem
in the stem-loop structure has also been described (WO
2002/00894).
[0433] Yet another variation includes using synthetic repeats to
promote formation of a stem in the stem-loop structure. Transgenic
organisms prepared with such recombinant DNA fragments have been
shown to have reduced levels of the protein encoded by the
nucleotide fragment forming the loop as described in PCT
Publication Number WO 2002/00904.
[0434] RNA interference refers to the process of sequence-specific
post-transcriptional gene silencing in animals mediated by short
interfering RNAs (siRNAs) (Fire, et al., (1998) Nature 391:806).
The corresponding process in plants is commonly referred to as
post-transcriptional gene silencing (PTGS) or RNA silencing and is
also referred to as quelling in fungi. The process of
post-transcriptional gene silencing is thought to be an
evolutionarily-conserved cellular defense mechanism used to prevent
the expression of foreign genes and is commonly shared by diverse
flora and phyla (Fire, et al., (1999) Trends Genet. 15:358). Such
protection from foreign gene expression may have evolved in
response to the production of double-stranded RNAs (dsRNAs) derived
from viral infection or from the random integration of transposon
elements into a host genome via a cellular response that
specifically destroys homologous single-stranded RNA of viral
genomic RNA. The presence of dsRNA in cells triggers the RNAi
response through a mechanism that has yet to be fully
characterized.
[0435] The presence of long dsRNAs in cells stimulates the activity
of a ribonuclease III enzyme referred to as dicer. Dicer is
involved in the processing of the dsRNA into short pieces of dsRNA
known as short interfering RNAs (siRNAs) (Berstein, et al., (2001)
Nature 409:363). Short interfering RNAs derived from dicer activity
are typically about 21 to about 23 nucleotides in length and
comprise about 19 base pair duplexes (Elbashir, et al., (2001)
Genes Dev. 15:188). Dicer has also been implicated in the excision
of 21- and 22-nucleotide small temporal RNAs (stRNAs) from
precursor RNA of conserved structure that are implicated in
translational control (Hutvagner, et al., (2001) Science 293:834).
The RNAi response also features an endonuclease complex, commonly
referred to as an RNA-induced silencing complex (RISC), which
mediates cleavage of single-stranded RNA having sequence
complementarity to the antisense strand of the siRNA duplex.
Cleavage of the target RNA takes place in the middle of the region
complementary to the antisense strand of the siRNA duplex
(Elbashir, et al., (2001) Genes Dev. 15:188). In addition, RNA
interference can also involve small RNA (e.g., miRNA) mediated gene
silencing, presumably through cellular mechanisms that regulate
chromatin structure and thereby prevent transcription of target
gene sequences (see, e.g., Allshire, (2002) Science 297:1818-1819;
Volpe, et al., (2002) Science 297:1833-1837; Jenuwein, (2002)
Science 297:2215-2218; and Hall, et al., (2002) Science
297:2232-2237). As such, miRNA molecules of the invention can be
used to mediate gene silencing via interaction with RNA transcripts
or alternately by interaction with particular gene sequences,
wherein such interaction results in gene silencing either at the
transcriptional or post-transcriptional level.
[0436] Methods and compositions are further provided which allow
for an increase in RNAi produced from the silencing element. In
such embodiments, the methods and compositions employ a first
polynucleotide comprising a silencing element for a target pest
sequence operably linked to a promoter active in the plant cell;
and, a second polynucleotide comprising a suppressor enhancer
element comprising the target pest sequence or an active variant or
fragment thereof operably linked to a promoter active in the plant
cell. The combined expression of the silencing element with
suppressor enhancer element leads to an increased amplification of
the inhibitory RNA produced from the silencing element over that
achievable with only the expression of the silencing element alone.
In addition to the increased amplification of the specific RNAi
species itself, the methods and compositions further allow for the
production of a diverse population of RNAi species that can enhance
the effectiveness of disrupting target gene expression. As such,
when the suppressor enhancer element is expressed in a plant cell
in combination with the silencing element, the methods and
composition can allow for the systemic production of RNAi
throughout the plant; the production of greater amounts of RNAi
than would be observed with just the silencing element construct
alone; and, the improved loading of RNAi into the phloem of the
plant, thus providing better control of phloem feeding insects by
an RNAi approach. Thus, the various methods and compositions
provide improved methods for the delivery of inhibitory RNA to the
target organism. See, for example, US 2009/0188008.
[0437] As used herein, a "suppressor enhancer element" comprises a
polynucleotide comprising the target sequence to be suppressed or
an active fragment or variant thereof. It is recognize that the
suppressor enhancer element need not be identical to the target
sequence, but rather, the suppressor enhancer element can comprise
a variant of the target sequence, so long as the suppressor
enhancer element has sufficient sequence identity to the target
sequence to allow for an increased level of the RNAi produced by
the silencing element over that achievable with only the expression
of the silencing element. Similarly, the suppressor enhancer
element can comprise a fragment of the target sequence, wherein the
fragment is of sufficient length to allow for an increased level of
the RNAi produced by the silencing element over that achievable
with only the expression of the silencing element.
[0438] It is recognized that multiple suppressor enhancer elements
from the same target sequence or from different target sequences,
or from different regions of the same target sequence can be
employed. For example, the suppressor enhancer elements employed
can comprise fragments of the target sequence derived from
different region of the target sequence (i.e., from the 3'UTR,
coding sequence, intron, and/or 5'UTR). Further, the suppressor
enhancer element can be contained in an expression cassette, as
described elsewhere herein, and in specific embodiments, the
suppressor enhancer element is on the same or on a different DNA
vector or construct as the silencing element. The suppressor
enhancer element can be operably linked to a promoter as disclosed
herein. It is recognized that the suppressor enhancer element can
be expressed constitutively or alternatively, it may be produced in
a stage-specific manner employing the various inducible or
tissue-preferred or developmentally regulated promoters that are
discussed elsewhere herein.
[0439] In specific embodiments, employing both a silencing element
and the suppressor enhancer element the systemic production of RNAi
occurs throughout the entire plant. In further embodiments, the
plant or plant parts of the invention have an improved loading of
RNAi into the phloem of the plant than would be observed with the
expression of the silencing element construct alone and, thus
provide better control of phloem feeding insects by an RNAi
approach. In specific embodiments, the plants, plant parts, and
plant cells of the invention can further be characterized as
allowing for the production of a diversity of RNAi species that can
enhance the effectiveness of disrupting target gene expression.
[0440] In specific embodiments, the combined expression of the
silencing element and the suppressor enhancer element increases the
concentration of the inhibitory RNA in the plant cell, plant, plant
part, plant tissue or phloem over the level that is achieved when
the silencing element is expressed alone.
[0441] As used herein, an "increased level of inhibitory RNA"
comprises any statistically significant increase in the level of
RNAi produced in a plant having the combined expression when
compared to an appropriate control plant. For example, an increase
in the level of RNAi in the plant, plant part or the plant cell can
comprise at least about a 1%, about a 1%-5%, about a 5%-10%, about
a 10%-20%, about a 20%-30%, about a 30%-40%, about a 40%-50%, about
a 50%-60%, about 60-70%, about 70%-80%, about a 80%-90%, about a
90%-100% or greater increase in the level of RNAi in the plant,
plant part, plant cell, or phloem when compared to an appropriate
control. In other embodiments, the increase in the level of RNAi in
the plant, plant part, plant cell, or phloem can comprise at least
about a 1 fold, about a 1 fold-5 fold, about a 5 fold-10 fold,
about a 10 fold-20 fold, about a 20 fold-30 fold, about a 30
fold-40 fold, about a 40 fold-50 fold, about a 50 fold-60 fold,
about 60 fold-70 fold, about 70 fold-80 fold, about a 80 fold-90
fold, about a 90 fold-100 fold or greater increase in the level of
RNAi in the plant, plant part, plant cell or phloem when compared
to an appropriate control. Examples of combined expression of the
silencing element with suppressor enhancer element for the control
of Stinkbugs and Lygus can be found in US 2011/0301223 and US
2009/0192117.
[0442] Some embodiments relate to down-regulation of expression of
target genes in insect pest species by interfering ribonucleic acid
(RNA) molecules. WO 2007/074405 describes methods of inhibiting
expression of target genes in invertebrate pests including Colorado
potato beetle. WO 2005/110068 describes methods of inhibiting
expression of target genes in invertebrate pests including in
particular Western corn rootworm as a means to control insect
infestation. Furthermore, WO 2009/091864 describes compositions and
methods for the suppression of target genes from insect pest
species including pests from the Lygus genus. Nucleic acid
molecules including RNAi for targeting the vacuolar ATPase H
subunit, useful for controlling a coleopteran pest population and
infestation as described in US Patent Application Publication
2012/0198586. WO 2012/055982 describes ribonucleic acid (RNA or
double stranded RNA) that inhibits or down regulates the expression
of a target gene that encodes: an insect ribosomal protein such as
the ribosomal protein L19, the ribosomal protein L40 or the
ribosomal protein S27A; an insect proteasome subunit such as the
Rpn6 protein, the Pros 25, the Rpn2 protein, the proteasome beta 1
subunit protein or the Pros beta 2 protein; an insect
.beta.-coatomer of the COPI vesicle, the .gamma.-coatomer of the
COPI vesicle, the .beta.'-coatomer protein or the .zeta.-coatomer
of the COPI vesicle; an insect Tetraspanine 2 .ANG. protein which
is a putative transmembrane domain protein; an insect protein
belonging to the actin family such as Actin 5C; an insect
ubiquitin-5E protein; an insect Sec23 protein which is a GTPase
activator involved in intracellular protein transport; an insect
crinkled protein which is an unconventional myosin which is
involved in motor activity; an insect crooked neck protein which is
involved in the regulation of nuclear alternative mRNA splicing; an
insect vacuolar H+-ATPase G-subunit protein; and an insect Tbp-1
such as Tat-binding protein. US Patent Application Publications
2012/029750, US 20120297501, and 2012/0322660 describe interfering
ribonucleic acids (RNA or double stranded RNA) that functions upon
uptake by an insect pest species to down-regulate expression of a
target gene in said insect pest, wherein the RNA comprises at least
one silencing element wherein the silencing element is a region of
double-stranded RNA comprising annealed complementary strands, one
strand of which comprises or consists of a sequence of nucleotides
which is at least partially complementary to a target nucleotide
sequence within the target gene. US Patent Application Publication
2012/0164205 describe potential targets for interfering double
stranded ribonucleic acids for inhibiting invertebrate pests
including: a Chd3 Homologous Sequence, a Beta-Tubulin Homologous
Sequence, a 40 kDa V-ATPase Homologous Sequence, a EF1a Homologous
Sequence, a 26S Proteosome Subunit p28 Homologous Sequence, a
Juvenile Hormone Epoxide Hydrolase Homologous Sequence, a Swelling
Dependent Chloride Channel Protein Homologous Sequence, a
Glucose-6-Phosphate 1-Dehydrogenase Protein Homologous Sequence, an
Act42A Protein Homologous Sequence, a ADP-Ribosylation Factor 1
Homologous Sequence, a Transcription Factor IIB Protein Homologous
Sequence, a Chitinase Homologous Sequences, a Ubiquitin Conjugating
Enzyme Homologous Sequence, a Glyceraldehyde-3-Phosphate
Dehydrogenase Homologous Sequence, an Ubiquitin B Homologous
Sequence, a Juvenile Hormone Esterase Homolog, and an Alpha
Tubuliln Homologous Sequence.
Use in Pesticidal Control
[0443] General methods for employing strains comprising a nucleic
acid sequence of the embodiments, or a variant thereof, in
pesticide control or in engineering other organisms as pesticidal
agents are known in the art. See, for example U.S. Pat. No.
5,039,523 and EP 0480762A2.
[0444] Microorganism hosts that are known to occupy the
"phytosphere" (phylloplane, phyllosphere, rhizosphere, and/or
rhizoplana) of one or more crops of interest may be selected. These
microorganisms are selected so as to be capable of successfully
competing in the particular environment with the wild-type
microorganisms, provide for stable maintenance and expression of
the gene expressing the PHI-4 polypeptide, and desirably, provide
for improved protection of the pesticide from environmental
degradation and inactivation.
[0445] Such microorganisms include bacteria, algae, and fungi. Of
particular interest are microorganisms such as bacteria, e.g.,
Pseudomonas, Erwinia, Serratia, Klebsiella, Xanthomonas,
Streptomyces, Rhizobium, Rhodopseudomonas, Methylius,
Agrobacterium, Acetobacter, Lactobacillus, Arthrobacter,
Azotobacter, Leuconostoc, and Alcaligenes, fungi, particularly
yeast, e.g., Saccharomyces, Cryptococcus, Kluyveromyces,
Sporobolomyces, Rhodotorula, and Aureobasidium. Of particular
interest are such phytosphere bacterial species as Pseudomonas
syringae, Pseudomonas fluorescens, Pseudomonas chlororaphis,
Serratia marcescens, Acetobacter xylinum, Agrobacteria,
Rhodopseudomonas spheroides, Xanthomonas campestris, Rhizobium
melioti, Alcaligenes entrophus, Clavibacter xyli and Azotobacter
vinelandii and phytosphere yeast species such as Rhodotorula rubra,
R. glutinis, R. marina, R. aurantiaca, Cryptococcus albidus, C.
diffluens, C. laurentii, Saccharomyces rosei, S. pretoriensis, S.
cerevisiae, Sporobolomyces roseus, S. odorus, Kluyveromyces
veronae, and Aureobasidium pollulans. Of particular interest are
the pigmented microorganisms. Host organisms of particular interest
include yeast, such as Rhodotorula spp., Aureobasidium spp.,
Saccharomyces spp. (such as S. cerevisiae), Sporobolomyces spp.,
phylloplane organisms such as Pseudomonas spp. (such as P.
aeruginosa, P. fluorescens, P. chlororaphis), Erwinia spp., and
Flavobacterium spp., and other such organisms, including
Agrobacterium tumefaciens, E. coli, Bacillus subtilis, Bacillus
cereus and the like.
[0446] Genes encoding the PHI-4 polypeptides of the embodiments can
be introduced into microorganisms that multiply on plants
(epiphytes) to deliver PHI-4 polypeptides to potential target
pests. Epiphytes, for example, can be gram-positive or
gram-negative bacteria.
[0447] Root-colonizing bacteria, for example, can be isolated from
the plant of interest by methods known in the art. Specifically, a
Bacillus cereus strain that colonizes roots can be isolated from
roots of a plant (see, for example, Handelsman, et al., (1991)
Appl. Environ. Microbiol. 56:713-718). Genes encoding the PHI-4
polypeptides of the embodiments can be introduced into a
root-colonizing Bacillus cereus by standard methods known in the
art.
[0448] Genes encoding PHI-4 polypeptides can be introduced, for
example, into the root-colonizing Bacillus by means of electro
transformation. Specifically, genes encoding the PHI-4 polypeptides
can be cloned into a shuttle vector, for example, pHT3101
(Lerecius, et al., (1989) FEMS Microbiol. Letts. 60:211-218. The
shuttle vector pHT3101 containing the coding sequence for the
particular PHI-4 polypeptide gene can, for example, be transformed
into the root-colonizing Bacillus by means of electroporation
(Lerecius, et al., (1989) FEMS Microbiol. Letts. 60:211-218).
[0449] Expression systems can be designed so that PHI-4
polypeptides are secreted outside the cytoplasm of gram-negative
bacteria, such as E. coli, for example. Advantages of having PHI-4
polypeptides secreted are: (1) avoidance of potential cytotoxic
effects of the PHI-4 polypeptide expressed; and (2) improvement in
the efficiency of purification of the PHI-4 polypeptide, including,
but not limited to, increased efficiency in the recovery and
purification of the protein per volume cell broth and decreased
time and/or costs of recovery and purification per unit
protein.
[0450] PHI-4 polypeptides can be made to be secreted in E. coli,
for example, by fusing an appropriate E. coli signal peptide to the
amino-terminal end of the PHI-4 polypeptide. Signal peptides
recognized by E. coli can be found in proteins already known to be
secreted in E. coli, for example the OmpA protein (Ghrayeb, et al.,
(1984) EMBO J, 3:2437-2442). OmpA is a major protein of the E. coli
outer membrane, and thus its signal peptide is thought to be
efficient in the translocation process. Also, the OmpA signal
peptide does not need to be modified before processing as may be
the case for other signal peptides, for example lipoprotein signal
peptide (Duffaud, et al., (1987) Meth. Enzymol. 153:492).
[0451] PHI-4 polypeptides of the embodiments can be fermented in a
bacterial host and the resulting bacteria processed and used as a
microbial spray in the same manner that Bt strains have been used
as insecticidal sprays. In the case of a PHI-4 polypeptide that is
secreted from Bacillus, the secretion signal is removed or mutated
using procedures known in the art. Such mutations and/or deletions
prevent secretion of the PHI-4 polypeptide into the growth medium
during the fermentation process. The PHI-4 polypeptides are
retained within the cell, and the cells are then processed to yield
the encapsulated PHI-4 polypeptides. Any suitable microorganism can
be used for this purpose. Pseudomonas has been used to express Bt
toxins as encapsulated proteins and the resulting cells processed
and sprayed as an insecticide (Gaertner, et al., (1993), in:
Advanced Engineered Pesticides, ed. Kim).
[0452] Alternatively, the PHI-4 polypeptides are produced by
introducing a heterologous gene into a cellular host. Expression of
the heterologous gene results, directly or indirectly, in the
intracellular production and maintenance of the pesticide. These
cells are then treated under conditions that prolong the activity
of the toxin produced in the cell when the cell is applied to the
environment of target pest(s). The resulting product retains the
toxicity of the toxin. These naturally encapsulated PHI-4
polypeptides may then be formulated in accordance with conventional
techniques for application to the environment hosting a target
pest, e.g., soil, water, and foliage of plants. See, for example
EPA 0192319, and the references cited therein.
Pesticidal Compositions
[0453] In some embodiments the active ingredients can be applied in
the form of compositions and can be applied to the crop area or
plant to be treated, simultaneously or in succession, with other
compounds. These compounds can be fertilizers, weed killers,
cryoprotectants, surfactants, detergents, pesticidal soaps, dormant
oils, polymers, and/or time-release or biodegradable carrier
formulations that permit long-term dosing of a target area
following a single application of the formulation. They can also be
selective herbicides, chemical insecticides, virucides,
microbicides, amoebicides, pesticides, fungicides, bacteriocides,
nematocides, molluscicides or mixtures of several of these
preparations, if desired, together with further agriculturally
acceptable carriers, surfactants or application-promoting adjuvants
customarily employed in the art of formulation. Suitable carriers
and adjuvants can be solid or liquid and correspond to the
substances ordinarily employed in formulation technology, e.g.
natural or regenerated mineral substances, solvents, dispersants,
wetting agents, tackifiers, binders or fertilizers. Likewise the
formulations may be prepared into edible "baits" or fashioned into
pest "traps" to permit feeding or ingestion by a target pest of the
pesticidal formulation.
[0454] Methods of applying an active ingredient or an agrochemical
composition that contains at least one of the PHI-4 polypeptides
produced by the bacterial strains include leaf application, seed
coating and soil application. The number of applications and the
rate of application depend on the intensity of infestation by the
corresponding pest.
[0455] The composition may be formulated as a powder, dust, pellet,
granule, spray, emulsion, colloid, solution, or such like, and may
be prepared by such conventional means as desiccation,
lyophilization, homogenation, extraction, filtration,
centrifugation, sedimentation, or concentration of a culture of
cells comprising the polypeptide. In all such compositions that
contain at least one such pesticidal polypeptide, the polypeptide
may be present in a concentration of from about 1% to about 99% by
weight.
[0456] Lepidopteran, dipteran, heteropteran, nematode, hemiptera,
or coleopteran pests may be killed or reduced in numbers in a given
area by the methods of the disclosure, or may be prophylactically
applied to an environmental area to prevent infestation by a
susceptible pest. Preferably the pest ingests, or is contacted
with, a pesticidally-effective amount of the polypeptide. By
"pesticidally-effective amount" is intended an amount of the
pesticide that is able to bring about death to at least one pest,
or to noticeably reduce pest growth, feeding, or normal
physiological development. This amount will vary depending on such
factors as, for example, the specific target pests to be
controlled, the specific environment, location, plant, crop or
agricultural site to be treated, the environmental conditions, and
the method, rate, concentration, stability, and quantity of
application of the pesticidally-effective polypeptide composition.
The formulations may also vary with respect to climatic conditions,
environmental considerations, and/or frequency of application
and/or severity of pest infestation.
[0457] The pesticide compositions described may be made by
formulating either the bacterial cell, crystal and/or spore
suspension, or isolated protein component with the desired
agriculturally-acceptable carrier. The compositions may be
formulated prior to administration in an appropriate means such as
lyophilized, freeze-dried, desiccated, or in an aqueous carrier,
medium or suitable diluent, such as saline or other buffer. The
formulated compositions may be in the form of a dust or granular
material, or a suspension in oil (vegetable or mineral), or water
or oil/water emulsions, or as a wettable powder, or in combination
with any other carrier material suitable for agricultural
application. Suitable agricultural carriers can be solid or liquid
and are well known in the art. The term "agriculturally-acceptable
carrier" covers all adjuvants, inert components, dispersants,
surfactants, tackifiers, binders, etc. that are ordinarily used in
pesticide formulation technology; these are well known to those
skilled in pesticide formulation. The formulations may be mixed
with one or more solid or liquid adjuvants and prepared by various
means, e.g., by homogeneously mixing, blending and/or grinding the
pesticidal composition with suitable adjuvants using conventional
formulation techniques. Suitable formulations and application
methods are described in U.S. Pat. No. 6,468,523, herein
incorporated by reference. The plants can also be treated with one
or more chemical compositions, including one or more herbicide,
insecticides, or fungicides. Exemplary chemical compositions
include: Fruits/Vegetables Herbicides: Atrazine, Bromacil, Diuron,
Glyphosate, Linuron, Metribuzin, Simazine, Trifluralin, Fluazifop,
Glufosinate, Halo sulfuron Gowan, Paraquat, Propyzamide,
Sethoxydim, Butafenacil, Halosulfuron, Indaziflam;
Fruits/Vegetables Insecticides: Aldicarb, Bacillus thuriengiensis,
Carbaryl, Carbofuran, Chlorpyrifos, Cypermethrin, Deltamethrin,
Diazinon, Malathion, Abamectin, Cyfluthrin/beta-cyfluthrin,
Esfenvalerate, Lambda-cyhalothrin, Acequinocyl, Bifenazate,
Methoxyfenozide, Novaluron, Chromafenozide, Thiacloprid,
Dinotefuran, Fluacrypyrim, Tolfenpyrad, Clothianidin,
Spirodiclofen, Gamma-cyhalothrin, Spiromesifen, Spinosad,
Rynaxypyr, Cyazypyr, Spinoteram, Triflumuron, Spirotetramat,
Imidacloprid, Flubendiamide, Thiodicarb, Metaflumizone,
Sulfoxaflor, Cyflumetofen, Cyanopyrafen, Imidacloprid,
Clothianidin, Thiamethoxam, Spinotoram, Thiodicarb, Flonicamid,
Methiocarb, Emamectin-benzoate, Indoxacarb, Forthiazate,
Fenamiphos, Cadusaphos, Pyriproxifen, Fenbutatin-oxid, Hexthiazox,
Methomyl,
4-[[(6-Chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino]furan-2(5H)-on;
Fruits/Vegetables Fungicides: Carbendazim, Chlorothalonil, EBDCs,
Sulphur, Thiophanate-methyl, Azoxystrobin, Cymoxanil, Fluazinam,
Fosetyl, Iprodione, Kresoxim-methyl, Metalaxyl/mefenoxam,
Trifloxystrobin, Ethaboxam, Iprovalicarb, Trifloxystrobin,
Fenhexamid, Oxpoconazole fumarate, Cyazofamid, Fenamidone,
Zoxamide, Picoxystrobin, Pyraclostrobin, Cyflufenamid, Boscalid;
Cereals Herbicides: Isoproturon, Bromoxynil, Ioxynil, Phenoxies,
Chlorsulfuron, Clodinafop, Diclofop, Diflufenican, Fenoxaprop,
Florasulam, Fluoroxypyr, Metsulfuron, Triasulfuron, Flucarbazone,
Iodosulfuron, Propoxycarbazone, Picolinafen, Mesosulfuron,
Beflubutamid, Pinoxaden, Amidosulfuron, Thifensulfuron Methyl,
Tribenuron, Flupyrsulfuron, Sulfosulfuron, Pyrasulfotole,
Pyroxsulam, Flufenacet, Tralkoxydim, Pyroxasulfon; Cereals
Fungicides: Carbendazim, Chlorothalonil, Azoxystrobin,
Cyproconazole, Cyprodinil, Fenpropimorph, Epoxiconazole,
Kresoxim-methyl, Quinoxyfen, Tebuconazole, Trifloxystrobin,
Simeconazole, Picoxystrobin, Pyraclostrobin, Dimoxystrobin,
Prothioconazole, Fluoxastrobin; Cereals Insecticides: Dimethoate,
Lambda-cyhalthrin, Deltamethrin, alpha-Cypermethrin,
.beta.-cyfluthrin, Bifenthrin, Imidacloprid, Clothianidin,
Thiamethoxam, Thiacloprid, Acetamiprid, Dinetofuran, Clorphyriphos,
Metamidophos, Oxidemethon-methyl, Pirimicarb, Methiocarb; Maize
Herbicides: Atrazine, Alachlor, Bromoxynil, Acetochlor, Dicamba,
Clopyralid, (S-) Dimethenamid, Glufosinate, Glyphosate,
Isoxaflutole, (S-)Metolachlor, Mesotrione, Nicosulfuron,
Primisulfuron, Rimsulfuron, Sulcotrione, Foramsulfuron,
Topramezone, Tembotrione, Saflufenacil, Thiencarbazone, Flufenacet,
Pyroxasulfon; Maize Insecticides: Carbofuran, Chlorpyrifos,
Bifenthrin, Fipronil, Imidacloprid, Lambda-Cyhalothrin, Tefluthrin,
Terbufos, Thiamethoxam, Clothianidin, Spiromesifen, Flubendiamide,
Triflumuron, Rynaxypyr, Deltamethrin, Thiodicarb,
.beta.-Cyfluthrin, Cypermethrin, Bifenthrin, Lufenuron,
Triflumoron, Tefluthrin, Tebupirimphos, Ethiprole, Cyazypyr,
Thiacloprid, Acetamiprid, Dinetofuran, Avermectin, Methiocarb,
Spirodiclofen, Spirotetramat; Maize Fungicides: Fenitropan, Thiram,
Prothioconazole, Tebuconazole, Trifloxystrobin; Rice Herbicides:
Butachlor, Propanil, Azimsulfuron, Bensulfuron, Cyhalofop,
Daimuron, Fentrazamide, Imazosulfuron, Mefenacet, Oxaziclomefone,
Pyrazosulfuron, Pyributicarb, Quinclorac, Thiobencarb, Indanofan,
Flufenacet, Fentrazamide, Halosulfuron, Oxaziclomefone,
Benzobicyclon, Pyriftalid, Penoxsulam, Bispyribac, Oxadiargyl,
Ethoxysulfuron, Pretilachlor, Mesotrione, Tefuryltrione,
Oxadiazone, Fenoxaprop, Pyrimisulfan; Rice Insecticides: Diazinon,
Fenitrothion, Fenobucarb, Monocrotophos, Benfuracarb, Buprofezin,
Dinotefuran, Fipronil, Imidacloprid, Isoprocarb, Thiacloprid,
Chromafenozide, Thiacloprid, Dinotefuran, Clothianidin, Ethiprole,
Flubendiamide, Rynaxypyr, Deltamethrin, Acetamiprid, Thiamethoxam,
Cyazypyr, Spinosad, Spinotoram, Emamectin-Benzoate, Cypermethrin,
Chlorpyriphos, Cartap, Methamidophos, Etofenprox, Triazophos,
4-[[(6-Chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino]furan-2(5H)-on,
Carbofuran, Benfuracarb; Rice Fungicides: Thiophanate-methyl,
Azoxystrobin, Carpropamid, Edifenphos, Ferimzone, Iprobenfos,
Isoprothiolane, Pencycuron, Probenazole, Pyroquilon, Tricyclazole,
Trifloxystrobin, Diclocymet, Fenoxanil, Simeconazole, Tiadinil;
Cotton Herbicides: Diuron, Fluometuron, MSMA, Oxyfluorfen,
Prometryn, Trifluralin, Carfentrazone, Clethodim, Fluazifop-butyl,
Glyphosate, Norflurazon, Pendimethalin, Pyrithiobac-sodium,
Trifloxysulfuron, Tepraloxydim, Glufosinate, Flumioxazin,
Thidiazuron; Cotton Insecticides: Acephate, Aldicarb, Chlorpyrifos,
Cypermethrin, Deltamethrin, Malathion, Monocrotophos, Abamectin,
Acetamiprid, Emamectin Benzoate, Imidacloprid, Indoxacarb,
Lambda-Cyhalothrin, Spinosad, Thiodicarb, Gamma-Cyhalothrin,
Spiromesifen, Pyridalyl, Flonicamid, Flubendiamide, Triflumuron,
Rynaxypyr, Beta-Cyfluthrin, Spirotetramat, Clothianidin,
Thiamethoxam, Thiacloprid, Dinetofuran, Flubendiamide, Cyazypyr,
Spinosad, Spinotoram, gamma Cyhalothrin,
4-[[(6-Chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino]furan-2(5H)-on,
Thiodicarb, Avermectin, Flonicamid, Pyridalyl, Spiromesifen,
Sulfoxaflor, Profenophos, Thriazophos, Endosulfan; Cotton
Fungicides: Etridiazole, Metalaxyl, Quintozene; Soybean Herbicides:
Alachlor, Bentazone, Trifluralin, Chlorimuron-Ethyl,
Cloransulam-Methyl, Fenoxaprop, Fomesafen, Fluazifop, Glyphosate,
Imazamox, Imazaquin, Imazethapyr, (S-)Metolachlor, Metribuzin,
Pendimethalin, Tepraloxydim, Glufosinate; Soybean Insecticides:
Lambda-cyhalothrin, Methomyl, Parathion, Thiocarb, Imidacloprid,
Clothianidin, Thiamethoxam, Thiacloprid, Acetamiprid, Dinetofuran,
Flubendiamide, Rynaxypyr, Cyazypyr, Spinosad, Spinotoram,
Emamectin-Benzoate, Fipronil, Ethiprole, Deltamethrin,
.delta.-Cyfluthrin, gamma and lambda Cyhalothrin,
4-[[(6-Chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino]furan-2(5H)-on,
Spirotetramat, Spinodiclofen, Triflumuron, Flonicamid, Thiodicarb,
beta-Cyfluthrin; Soybean Fungicides: Azoxystrobin, Cyproconazole,
Epoxiconazole, Flutriafol, Pyraclostrobin, Tebuconazole,
Trifloxystrobin, Prothioconazole, Tetraconazole; Sugarbeet
Herbicides: Chloridazon, Desmedipham, Ethofumesate, Phenmedipham,
Triallate, Clopyralid, Fluazifop, Lenacil, Metamitron, Quinmerac,
Cycloxydim, Triflusulfuron, Tepraloxydim, Quizalofop; Sugarbeet
Insecticides: Imidacloprid, Clothianidin, Thiamethoxam,
Thiacloprid, Acetamiprid, Dinetofuran, Deltamethrin,
.delta.-Cyfluthrin, gamma/lambda Cyhalothrin,
4-[[(6-Chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino]furan-2(5H)-on,
Tefluthrin, Rynaxypyr, Cyaxypyr, Fipronil, Carbofuran; Canola
Herbicides: Clopyralid, Diclofop, Fluazifop, Glufosinate,
Glyphosate, Metazachlor, Trifluralin Ethametsulfuron, Quinmerac,
Quizalofop, Clethodim, Tepraloxydim; Canola Fungicides:
Azoxystrobin, Carbendazim, Fludioxonil, Iprodione, Prochloraz,
Vinclozolin; Canola Insecticides: Carbofuran, Organophosphates,
Pyrethroids, Thiacloprid, Deltamethrin, Imidacloprid, Clothianidin,
Thiamethoxam, Acetamiprid, Dinetofuran, .beta.-Cyfluthrin, gamma
and lambda Cyhalothrin, tau-Fluvaleriate, Ethiprole, Spinosad,
Spinotoram, Flubendiamide, Rynaxypyr, Cyazypyr,
4-[[(6-Chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino]furan-2(5H)-on.
[0458] In some embodiments the herbicide is Atrazine, Bromacil,
Diuron, Chlorsulfuron, Metsulfuron, Thifensulfuron Methyl,
Tribenuron, Acetochlor, Dicamba, Isoxaflutole, Nicosulfuron,
Rimsulfuron, Pyrithiobac-sodium, Flumioxazin, Chlorimuron-Ethyl,
Metribuzin, Quizalofop, S-metolachlor, Hexazinne or combinations
thereof.
[0459] In some embodiments the insecticide is Esfenvalerate,
Chlorantraniliprole, Methomyl, Indoxacarb, Oxamyl, or combinations
thereof.
Pesticidal and Insecticidal Activity
[0460] "Pest" includes but is not limited to, insects, fungi,
bacteria, nematodes, mites, ticks, and the like. Insect pests
include insects selected from the orders Coleoptera, Diptera,
Hymenoptera, Lepidoptera, Mallophaga, Homoptera, Hemiptera,
Orthroptera, Thysanoptera, Dermaptera, Isoptera, Anoplura,
Siphonaptera, Trichoptera, etc., particularly Lepidoptera, and
Hemiptera.
[0461] Those skilled in the art will recognize that not all
compounds are equally effective against all pests. Compounds of the
embodiments display activity against insect pests, which may
include economically important agronomic, forest, greenhouse,
nursery, ornamentals, food and fiber, public and animal health,
domestic and commercial structure, household and stored product
pests.
[0462] Larvae of the order Lepidoptera include, but are not limited
to, armyworms, cutworms, loopers, and heliothines in the family
Noctuidae Spodoptera frugiperda JE Smith (fall armyworm); S. exigua
Hubner (beet armyworm); S. litura Fabricius (tobacco cutworm,
cluster caterpillar); Mamestra configurata Walker (bertha
armyworm); M. brassicae Linnaeus (cabbage moth); Agrotis ipsilon
Hufnagel (black cutworm); A. orthogonia Morrison (western cutworm);
A. subterranea Fabricius (granulate cutworm); Alabama argillacea
Hubner (cotton leaf worm); Trichoplusia ni Hubner (cabbage looper);
Pseudoplusia includens Walker (soybean looper); Anticarsia
gemmatalis Hubner (velvetbean caterpillar); Hypena scabra Fabricius
(green cloverworm); Heliothis virescens Fabricius (tobacco
budworm); Pseudaletia unipuncta Haworth (armyworm); Athetis mindara
Barnes and Mcdunnough (rough skinned cutworm); Euxoa messoria
Harris (darksided cutworm); Earias insulana Boisduval (spiny
bollworm); E. vittella Fabricius (spotted bollworm); Helicoverpa
armigera Hubner (American bollworm); H. zea Boddie (corn earworm or
cotton bollworm); Melanchra picta Harris (zebra caterpillar); Egira
(Xylomyges) curialis Grote (citrus cutworm); borers, casebearers,
webworms, coneworms, and skeletonizers from the family Pyralidae
Ostrinia nubilalis Hubner (European corn borer); Amyelois
transitella Walker (naval orangeworm); Anagasta kuehniella Zeller
(Mediterranean flour moth); Cadra cautella Walker (almond moth);
Chilo suppressalis Walker (rice stem borer); C. partellus, (sorghum
borer); Corcyra cephalonica Stainton (rice moth); Crambus
caliginosellus Clemens (corn root webworm); C. teterrellus Zincken
(bluegrass webworm); Cnaphalocrocis medinalis Guenee (rice leaf
roller); Desmia funeralis Hubner (grape leaffolder); Diaphania
hyalinata Linnaeus (melon worm); D. nitidalis Stoll (pickleworm);
Diatraea grandiosella Dyar (southwestern corn borer), D.
saccharalis Fabricius (surgarcane borer); Eoreuma loftini Dyar
(Mexican rice borer); Ephestia elutella Hubner (tobacco (cacao)
moth); Galleria mellonella Linnaeus (greater wax moth);
Herpetogramma licarsisalis Walker (sod webworm); Homoeosoma
electellum Hulst (sunflower moth); Elasmopalpus lignosellus Zeller
(lesser cornstalk borer); Achroia grisella Fabricius (lesser wax
moth); Loxostege sticticalis Linnaeus (beet webworm); Orthaga
thyrisalis Walker (tea tree web moth); Maruca testulalis Geyer
(bean pod borer); Plodia interpunctella Hubner (Indian meal moth);
Scirpophaga incertulas Walker (yellow stem borer); Udea rubigalis
Guenee (celery leaftier); and leafrollers, budworms, seed worms,
and fruit worms in the family Tortricidae Acleris gloverana
Walsingham (Western blackheaded budworm); A. variana Fernald
(Eastern blackheaded budworm); Archips argyrospila Walker (fruit
tree leaf roller); A. rosana Linnaeus (European leaf roller); and
other Archips species, Adoxophyes orana Fischer von Rosslerstamm
(summer fruit tortrix moth); Cochylis hospes Walsingham (banded
sunflower moth); Cydia latiferreana Walsingham (filbertworm); C.
pomonella Linnaeus (coding moth); Platynota flavedana Clemens
(variegated leafroller); P. stultana Walsingham (omnivorous
leafroller); Lobesia botrana Denis & Schiffermuller (European
grape vine moth); Spilonota ocellana Denis & Schiffermuller
(eyespotted bud moth); Endopiza viteana Clemens (grape berry moth);
Eupoecilia ambiguella Hubner (vine moth); Bonagota salubricola
Meyrick (Brazilian apple leafroller); Grapholita molesta Busck
(oriental fruit moth); Suleima helianthana Riley (sunflower bud
moth); Argyrotaenia spp.; Choristoneura spp.
[0463] Selected other agronomic pests in the order Lepidoptera
include, but are not limited to, Alsophila pometaria Harris (fall
cankerworm); Anarsia lineatella Zeller (peach twig borer); Anisota
senatoria J. E. Smith (orange striped oakworm); Antheraea pernyi
Guerin-Meneville (Chinese Oak Tussah Moth); Bombyx mori Linnaeus
(Silkworm); Bucculatrix thurberiella Busck (cotton leaf
perforator); Collas eurytheme Boisduval (alfalfa caterpillar);
Datana integerrima Grote & Robinson (walnut caterpillar);
Dendrolimus sibiricus Tschetwerikov (Siberian silk moth), Ennomos
subsignaria Hubner (elm spanworm); Erannis tiliaria Harris (linden
looper); Euproctis chrysorrhoea Linnaeus (browntail moth);
Harrisina americana Guerin-Meneville (grapeleaf skeletonizer);
Hemileuca oliviae Cockrell (range caterpillar); Hyphantria cunea
Drury (fall webworm); Keiferia lycopersicella Walsingham (tomato
pinworm); Lambdina fiscellaria fiscellaria Hulst (Eastern hemlock
looper); L. fiscellaria lugubrosa Hulst (Western hemlock looper);
Leucoma salicis Linnaeus (satin moth); Lymantria dispar Linnaeus
(gypsy moth); Manduca quinquemaculata Haworth (five spotted hawk
moth, tomato hornworm); M. sexta Haworth (tomato hornworm, tobacco
hornworm); Operophtera brumata Linnaeus (winter moth); Paleacrita
vemata Peck (spring cankerworm); Papilio cresphontes Cramer (giant
swallowtail, orange dog); Phryganidia californica Packard
(California oakworm); Phyllocnistis citrella Stainton (citrus
leafminer); Phyllonorycter blancardella Fabricius (spotted
tentiform leafminer); Pieris brassicae Linnaeus (large white
butterfly); P. rapae Linnaeus (small white butterfly); P. napi
Linnaeus (green veined white butterfly); Platyptilia carduidactyla
Riley (artichoke plume moth); Plutella xylostella Linnaeus
(diamondback moth); Pectinophora gossypiella Saunders (pink
bollworm); Pontia protodice Boisduval & Leconte (Southern
cabbageworm); Sabulodes aegrotata Guenee (omnivorous looper);
Schizura concinna J. E. Smith (red humped caterpillar); Sitotroga
cerealella Olivier (Angoumois grain moth); Thaumetopoea pityocampa
Schiffermuller (pine processionary caterpillar); Tineola
bisselliella Hummel (webbing clothesmoth); Tuta absoluta Meyrick
(tomato leafminer); Yponomeuta padella Linnaeus (ermine moth);
Heliothis subflexa Guenee; Malacosoma spp. and Orgyia spp.
[0464] Of interest are larvae and adults of the order Coleoptera
including weevils from the families Anthribidae, Bruchidae, and
Curculionidae (including, but not limited to: Anthonomus grandis
Boheman (boll weevil); Lissorhoptrus oryzophilus Kuschel (rice
water weevil); Sitophilus granarius Linnaeus (granary weevil); S.
oryzae Linnaeus (rice weevil); Hypera punctata Fabricius (clover
leaf weevil); Cylindrocopturus adspersus LeConte (sunflower stem
weevil); Smicronyx fulvus LeConte (red sunflower seed weevil); S.
sordidus LeConte (gray sunflower seed weevil); Sphenophorus maidis
Chittenden (maize billbug)); flea beetles, cucumber beetles,
rootworms, leaf beetles, potato beetles, and leafminers in the
family Chrysomelidae (including, but not limited to: Leptinotarsa
decemlineata Say (Colorado potato beetle); Diabrotica virgifera
virgifera LeConte (western corn rootworm); D. barberi Smith &
Lawrence (northern corn rootworm); D. undecimpunctata howardi
Barber (southern corn rootworm); Chaetocnema pulicaria Melsheimer
(corn flea beetle); Phyllotreta cruciferae Goeze (corn flea
beetle); Colaspis brunnea Fabricius (grape colaspis); Oulema
melanopus Linnaeus (cereal leaf beetle); Zygogramma exclamationis
Fabricius (sunflower beetle)); beetles from the family
Coccinellidae (including, but not limited to: Epilachna varivestis
Mulsant (Mexican bean beetle)); chafers and other beetles from the
family Scarabaeidae (including, but not limited to: Popillia
japonica Newman (Japanese beetle); Cyclocephala borealis Arrow
(northern masked chafer, white grub); C. immaculata Olivier
(southern masked chafer, white grub); Rhizotrogus majalis
Razoumowsky (European chafer); Phyllophaga crinita Burmeister
(white grub); Ligyrus gibbosus De Geer (carrot beetle)); carpet
beetles from the family Dermestidae; wireworms from the family
Elateridae, Eleodes spp., Melanotus spp.; Conoderus spp.; Limonius
spp.; Agriotes spp.; Ctenicera spp.; Aeolus spp.; bark beetles from
the family Scolytidae and beetles from the family
Tenebrionidae.
[0465] Adults and immatures of the order Diptera are of interest,
including leafminers Agromyza parvicornis Loew (corn blotch
leafminer); midges (including, but not limited to: Contarinia
sorghicola Coquillett (sorghum midge); Mayetiola destructor Say
(Hessian fly); Sitodiplosis mosellana Gehin (wheat midge);
Neolasioptera murtfeldtiana Felt, (sunflower seed midge)); fruit
flies (Tephritidae), Oscinella frit Linnaeus (fruit flies); maggots
(including, but not limited to: Delia platura Meigen (seedcorn
maggot); D. coarctata Fallen (wheat bulb fly); and other Delia
spp., Meromyza americana Fitch (wheat stem maggot); Musca domestica
Linnaeus (house flies); Fannia canicularis Linnaeus, F. femoralis
Stein (lesser house flies); Stomoxys calcitrans Linnaeus (stable
flies)); face flies, horn flies, blow flies, Chrysomya spp.;
Phormia spp.; and other muscoid fly pests, horse flies Tabanus
spp.; bot flies Gastrophilus spp.; Oestrus spp.; cattle grubs
Hypoderma spp.; deer flies Chrysops spp.; Melophagus ovinus
Linnaeus (keds); and other Brachycera, mosquitoes Aedes spp.;
Anopheles spp.; Culex spp.; black flies Prosimulium spp.; Simulium
spp.; biting midges, sand flies, sciarids, and other
Nematocera.
[0466] Included as insects of interest are adults and nymphs of the
orders Hemiptera and Homoptera such as, but not limited to,
adelgids from the family Adelgidae, plant bugs from the family
Miridae, cicadas from the family Cicadidae, leafhoppers, Empoasca
spp.; from the family Cicadellidae, planthoppers from the families
Cixiidae, Flatidae, Fulgoroidea, lssidae and Delphacidae,
treehoppers from the family Membracidae, psyllids from the family
Psyllidae, whiteflies from the family Aleyrodidae, aphids from the
family Aphididae, Phylloxera from the family Phylloxeridae,
mealybugs from the family Pseudococcidae, scales from the families
Asterolecanidae, Coccidae, Dactylopiidae, Diaspididae,
Eriococcidae, Ortheziidae, Phoenicococcidae and Margarodidae, lace
bugs from the family Tingidae, stink bugs from the family
Pentatomidae, cinch bugs, Blissus spp.; and other seed bugs from
the family Lygaeidae, spittlebugs from the family Cercopidae squash
bugs from the family Coreidae, and red bugs and cotton stainers
from the family Pyrrhocoridae.
[0467] Agronomically important members from the order Homoptera
further include, but are not limited to: Acyrthisiphon pisum Harris
(pea aphid); Aphis craccivora Koch (cowpea aphid); A. fabae Scopoli
(black bean aphid); A. gossypii Glover (cotton aphid, melon aphid);
A. maidiradicis Forbes (corn root aphid); A. pomi De Geer (apple
aphid); A. spiraecola Patch (spirea aphid); Aulacorthum solani
Kaltenbach (foxglove aphid); Chaetosiphon fragaefolii Cockerell
(strawberry aphid); Diuraphis noxia Kurdjumov/Mordvilko (Russian
wheat aphid); Dysaphis plantaginea Paaserini (rosy apple aphid);
Eriosoma lanigerum Hausmann (woolly apple aphid); Brevicoryne
brassicae Linnaeus (cabbage aphid); Hyalopterus pruni Geoffroy
(mealy plum aphid); Lipaphis erysimi Kaltenbach (turnip aphid);
Metopolophium dirrhodum Walker (cereal aphid); Macrosiphum
euphorbiae Thomas (potato aphid); Myzus persicae Sulzer
(peach-potato aphid, green peach aphid); Nasonovia ribisnigri
Mosley (lettuce aphid); Pemphigus spp. (root aphids and gall
aphids); Rhopalosiphum maidis Fitch (corn leaf aphid); R. padi
Linnaeus (bird cherry-oat aphid); Schizaphis graminum Rondani
(greenbug); Sipha flava Forbes (yellow sugarcane aphid); Sitobion
avenae Fabricius (English grain aphid); Therioaphis maculata
Buckton (spotted alfalfa aphid); Toxoptera aurantii Boyer de
Fonscolombe (black citrus aphid); and T. citricida Kirkaldy (brown
citrus aphid); Adelges spp. (adelgids); Phylloxera devastatrix
Pergande (pecan phylloxera); Bemisia tabaci Gennadius (tobacco
whitefly, sweetpotato whitefly); B. argentifolii Bellows &
Perring (silverleaf whitefly); Dialeurodes citri Ashmead (citrus
whitefly); Trialeurodes abutiloneus (bandedwinged whitefly) and T.
vaporariorum Westwood (greenhouse whitefly); Empoasca fabae Harris
(potato leafhopper); Laodelphax striatellus Fallen (smaller brown
planthopper); Macrolestes quadrilineatus Forbes (aster leafhopper);
Nephotettix cinticeps Uhler (green leafhopper); N. nigropictus
St{dot over (a)}l (rice leafhopper); Nilaparvata lugens St{dot over
(a)}l (brown planthopper); Peregrinus maidis Ashmead (corn
planthopper); Sogatella furcifera Horvath (white-backed
planthopper); Sogatodes orizicola Muir (rice delphacid); Typhlocyba
pomaria McAtee (white apple leafhopper); Erythroneoura spp. (grape
leafhoppers); Magicicada septendecim Linnaeus (periodical cicada);
Icerya purchasi Maskell (cottony cushion scale); Quadraspidiotus
perniciosus Comstock (San Jose scale); Planococcus citri Risso
(citrus mealybug); Pseudococcus spp. (other mealybug complex);
Cacopsylla pyricola Foerster (pear psylla); Trioza diospyri Ashmead
(persimmon psylla).
[0468] Agronomically important species of interest from the order
Hemiptera include, but are not limited to: Acrosternum hilare Say
(green stink bug); Anasa tristis De Geer (squash bug); Blissus
leucopterus leucopterus Say (chinch bug); Corythuca gossypii
Fabricius (cotton lace bug); Cyrtopeltis modesta Distant (tomato
bug); Dysdercus suturellus Herrich-Schaffer (cotton stainer);
Euschistus servus Say (brown stink bug); E. variolarius Palisot de
Beauvois (one-spotted stink bug); Graptostethus spp. (complex of
seed bugs); Leptoglossus corculus Say (leaf-footed pine seed bug);
Lygus lineolaris Palisot de Beauvois (tarnished plant bug); L.
Hesperus Knight (Western tarnished plant bug); L. pratensis
Linnaeus (common meadow bug); L. rugulipennis Poppius (European
tarnished plant bug); Lygocoris pabulinus Linnaeus (common green
capsid); Nezara viridula Linnaeus (southern green stink bug);
Oebalus pugnax Fabricius (rice stink bug); Oncopeltus fasciatus
Dallas (large milkweed bug); Pseudatomoscelis seriatus Reuter
(cotton fleahopper).
[0469] Furthermore, embodiments may be effective against Hemiptera
such, Calocoris norvegicus Gmelin (strawberry bug); Orthops
campestris Linnaeus; Plesiocoris rugicollis Fallen (apple capsid);
Cyrtopeltis modestus Distant (tomato bug); Cyrtopeltis notatus
Distant (suckfly); Spanagonicus albofasciatus Reuter (whitemarked
fleahopper); Diaphnocoris chlorionis Say (honeylocust plant bug);
Labopidicola allii Knight (onion plant bug); Pseudatomoscelis
seriatus Reuter (cotton fleahopper); Adelphocoris rapidus Say
(rapid plant bug); Poecilocapsus lineatus Fabricius (four-lined
plant bug); Nysius ericae Schilling (false chinch bug); Nysius
raphanus Howard (false chinch bug); Nezara viridula Linnaeus
(Southern green stink bug); Eurygaster spp.; Coreidae spp.;
Pyrrhocoridae spp.; Tinidae spp.; Blostomatidae spp.; Reduviidae
spp.; and Cimicidae spp.
[0470] Also included are adults and larvae of the order Acari
(mites) such as Aceria tosichella Keifer (wheat curl mite);
Petrobia latens Muller (brown wheat mite); spider mites and red
mites in the family Tetranychidae, Panonychus ulmi Koch (European
red mite); Tetranychus urticae Koch (two spotted spider mite); (T.
mcdanieli McGregor (McDaniel mite); T. cinnabarinus Boisduval
(carmine spider mite); T. turkestani Ugarov & Nikolski
(strawberry spider mite); flat mites in the family Tenuipalpidae,
Brevipalpus lewisi McGregor (citrus flat mite); rust and bud mites
in the family Eriophyidae and other foliar feeding mites and mites
important in human and animal health, i.e. dust mites in the family
Epidermoptidae, follicle mites in the family Demodicidae, grain
mites in the family Glycyphagidae, ticks in the order Ixodidae.
Ixodes scapularis Say (deer tick); I. holocyclus Neumann
(Australian paralysis tick); Dermacentor variabilis Say (American
dog tick); Amblyomma americanum Linnaeus (lone star tick); and scab
and itch mites in the families Psoroptidae, Pyemotidae, and
Sarcoptidae.
[0471] Insect pests of the order Thysanura are of interest, such as
Lepisma saccharina Linnaeus (silverfish); Thermobia domestica
Packard (firebrat).
[0472] Additional arthropod pests covered include: spiders in the
order Araneae such as Loxosceles reclusa Gertsch & Mulaik
(brown recluse spider); and the Latrodectus mactans Fabricius
(black widow spider); and centipedes in the order Scutigeromorpha
such as Scutigera coleoptrata Linnaeus (house centipede).
[0473] Insect pest of interest include the superfamily of stink
bugs and other related insects including but not limited to species
belonging to the family Pentatomidae (Nezara viridula, Halyomorpha
halys, Piezodorus guildini, Euschistus servus, Acrosternum hilare,
Euschistus heros, Euschistus tristigmus, Acrosternum hilare,
Dichelops furcatus, Dichelops melacanthus, and Bagrada hilaris
(Bagrada Bug)), the family Plataspidae (Megacopta cribraria--Bean
plataspid), and the family Cydnidae (Scaptocoris castanea--Root
stink bug); and Lepidoptera species including but not limited to:
diamond-back moth, e.g., Helicoverpa zea Boddie; soybean looper,
e.g., Pseudoplusia includens Walker; and velvet bean caterpillar
e.g., Anticarsia gemmatalis Hubner.
[0474] Methods for measuring pesticidal activity are well known in
the art. See, for example, Czapla and Lang, (1990) J. Econ.
Entomol. 83:2480-2485; Andrews, et al., (1988) Biochem. J.
252:199-206; Marrone, et al., (1985) J. of Economic Entomology
78:290-293 and U.S. Pat. No. 5,743,477, all of which are herein
incorporated by reference in their entirety. Generally, the protein
is mixed and used in feeding assays. See, for example Marrone, et
al., (1985) J. of Economic Entomology 78:290-293. Such assays can
include contacting plants with one or more pests and determining
the plant's ability to survive and/or cause the death of the
pests.
[0475] Nematodes include parasitic nematodes such as root-knot,
cyst, and lesion nematodes, including Heterodera spp., Meloidogyne
spp., and Globodera spp.; particularly members of the cyst
nematodes, including, but not limited to, Heterodera glycines
(soybean cyst nematode); Heterodera schachtii (beet cyst nematode);
Heterodera avenae (cereal cyst nematode); and Globodera
rostochiensis and Globodera pailida (potato cyst nematodes). Lesion
nematodes include Pratylenchus spp.
Seed Treatment
[0476] To protect and to enhance yield production and trait
technologies, seed treatment options can provide additional crop
plan flexibility and cost effective control against insects, weeds
and diseases. Seed material can be treated, typically surface
treated, with a composition comprising combinations of chemical or
biological herbicides, herbicide safeners, insecticides,
fungicides, germination inhibitors and enhancers, nutrients, plant
growth regulators and activators, bactericides, nematocides,
avicides and/or molluscicides. These compounds are typically
formulated together with further carriers, surfactants or
application-promoting adjuvants customarily employed in the art of
formulation. The coatings may be applied by impregnating
propagation material with a liquid formulation or by coating with a
combined wet or dry formulation. Examples of the various types of
compounds that may be used as seed treatments are provided in The
Pesticide Manual: A World Compendium, C.D.S. Tomlin Ed., Published
by the British Crop Production Council, which is hereby
incorporated by reference.
[0477] Some seed treatments that may be used on crop seed include,
but are not limited to, one or more of abscisic acid,
acibenzolar-S-methyl, avermectin, amitrol, azaconazole,
azospirillum, azadirachtin, azoxystrobin, Bacillus spp. (including
one or more of cereus, firmus, megaterium, pumilis, sphaericus,
subtilis and/or thuringiensis species), bradyrhizobium spp.
(including one or more of betae, canariense, elkanii, iriomotense,
japonicum, liaonigense, pachyrhizi and/or yuanmingense), captan,
carboxin, chitosan, clothianidin, copper, cyazypyr, difenoconazole,
etidiazole, fipronil, fludioxonil, fluoxastrobin, fluquinconazole,
flurazole, fluxofenim, harpin protein, imazalil, imidacloprid,
ipconazole, isoflavenoids, lipo-chitooligosaccharide, mancozeb,
manganese, maneb, mefenoxam, metalaxyl, metconazole, myclobutanil,
PCNB, penflufen, penicillium, penthiopyrad, permethrine,
picoxystrobin, prothioconazole, pyraclostrobin, rynaxypyr,
S-metolachlor, saponin, sedaxane, TCMTB, tebuconazole,
thiabendazole, thiamethoxam, thiocarb, thiram, tolclofos-methyl,
triadimenol, trichoderma, trifloxystrobin, triticonazole and/or
zinc. PCNB seed coat refers to EPA registration number 00293500419,
containing quintozen and terrazole. TCMTB refers to
2-(thiocyanomethylthio) benzothiazole.
[0478] Seed varieties and seeds with specific transgenic traits may
be tested to determine which seed treatment options and application
rates may complement such varieties and transgenic traits in order
to enhance yield. For example, a variety with good yield potential
but head smut susceptibility may benefit from the use of a seed
treatment that provides protection against head smut, a variety
with good yield potential but cyst nematode susceptibility may
benefit from the use of a seed treatment that provides protection
against cyst nematode, and so on. Likewise, a variety encompassing
a transgenic trait conferring insect resistance may benefit from
the second mode of action conferred by the seed treatment, a
variety encompassing a transgenic trait conferring herbicide
resistance may benefit from a seed treatment with a safener that
enhances the plants resistance to that herbicide, etc. Further, the
good root establishment and early emergence that results from the
proper use of a seed treatment may result in more efficient
nitrogen use, a better ability to withstand drought and an overall
increase in yield potential of a variety or varieties containing a
certain trait when combined with a seed treatment.
Methods for Inhibiting Growth or Killing an Insect Pest and
Controlling an Insect Population
[0479] In some embodiments methods are provided for inhibiting
growth or killing an insect pest, comprising contacting the insect
pest with an insecticidally-effective amount of a recombinant PHI-4
polypeptide. In some embodiments methods are provided for
inhibiting growth or killing an insect pest, comprising contacting
the insect pest with an insecticidally-effective amount of a
recombinant pesticidal protein of SEQ ID NO: 2, SEQ ID NO: 3, SEQ
ID NO: 4, and SEQ ID NOs: 51-819 or a variant thereof.
[0480] In some embodiments methods are provided for controlling an
insect pest population, comprising contacting the insect pest
population with an insecticidally-effective amount of a recombinant
PHI-4 polypeptide. In some embodiments methods are provided for
controlling an insect pest population, comprising contacting the
insect pest population with an insecticidally-effective amount of a
recombinant pesticidal protein of SEQ ID NO: 2, SEQ ID NO: 3, SEQ
ID NO: 4, and SEQ ID NOs: 51-819 or a variant thereof. As used
herein, by "controlling a pest population" or "controls a pest" is
intended any effect on a pest that results in limiting the damage
that the pest causes. Controlling a pest includes, but is not
limited to, killing the pest, inhibiting development of the pest,
altering fertility or growth of the pest in such a manner that the
pest provides less damage to the plant, decreasing the number of
offspring produced, producing less fit pests, producing pests more
susceptible to predator attack or deterring the pests from eating
the plant.
[0481] In some embodiments methods are provided for controlling an
insect pest population resistant to a pesticidal protein,
comprising contacting the insect pest population with an
insecticidally-effective amount of a recombinant PHI-4 polypeptide.
In some embodiments methods are provided for controlling an insect
pest population resistant to a pesticidal protein, comprising
contacting the insect pest population with an
insecticidally-effective amount of a recombinant pesticidal protein
of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NOs: 51-819
or a variant thereof.
[0482] In some embodiments methods are provided for protecting a
plant from an insect pest, comprising expressing in the plant or
cell thereof a recombinant PHI-4 polypeptide. In some embodiments
methods are provided for protecting a plant from an insect pest,
comprising expressing in the plant or cell thereof a recombinant
pesticidal protein of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and
SEQ ID NOs: 51-819 or variants thereof.
Insect Resistance Management (IRM) Strategies
[0483] Expression of B. thuringiensis .delta.-endotoxins in
transgenic corn plants has proven to be an effective means of
controlling agriculturally important insect pests (Perlak, et al.,
1990; 1993). However, insects have evolved that are resistant to B.
thuringiensis .delta.-endotoxins expressed in transgenic plants.
Such resistance, should it become widespread, would clearly limit
the commercial value of germplasm containing genes encoding such B.
thuringiensis .delta.-endotoxins.
[0484] One way to increasing the effectiveness of the transgenic
insecticides against target pests and contemporaneously reducing
the development of insecticide-resistant pests is to use provide
non-transgenic (i.e., non-insecticidal protein) refuges (a section
of non-insecticidal crops/corn) for use with transgenic crops
producing a single insecticidal protein active against target
pests. The United States Environmental Protection Agency
(epa.gov/oppbppdl/biopesticides/pips/bt_corn_refuge_2006.htm, which
can be accessed using the www prefix) publishes the requirements
for use with transgenic crops producing a single Bt protein active
against target pests. In addition, the National Corn Growers
Association, on their website:
(ncga.com/insect-resistance-management-fact-sheet-bt-corn, which
can be accessed using the www prefix) also provides similar
guidance regarding refuge requirements. Due to losses to insects
within the refuge area, larger refuges may reduce overall
yield.
[0485] Another way of increasing the effectiveness of the
transgenic insecticides against target pests and contemporaneously
reducing the development of insecticide-resistant pests would be to
have a repository of insecticidal genes that are effective against
groups of insect pests and which manifest their effects through
different modes of action.
[0486] Expression in a plant of two or more insecticidal
compositions toxic to the same insect species, each insecticide
being expressed at efficacious levels would be another way to
achieve control of the development of resistance. This is based on
the principle that evolution of resistance against two separate
modes of action is far more unlikely than only one. Roush for
example, outlines two-toxin strategies, also called "pyramiding" or
"stacking," for management of insecticidal transgenic crops. (The
Royal Society. Phil. Trans. R. Soc. Lond. B. (1998) 353:777-1786).
Stacking or pyramiding of two different proteins each effective
against the target pests and with little or no cross-resistance can
allow for use of a smaller refuge. The U.S. Environmental
Protection Agency requires significantly less (generally 5%)
structured refuge of non-Bt corn be planted than for single trait
products (generally 20%). There are various ways of providing the
IRM effects of a refuge, including various geometric planting
patterns in the fields and in-bag seed mixtures, as discussed
further by Roush.
[0487] In some embodiments the PHI-4 polypeptides of the disclosure
are useful as an insect resistance management strategy in
combination (i.e., pyramided) with other pesticidal proteins
include but are not limited to Bt toxins, Xenorhabdus sp. or
Photorhabdus sp. insecticidal proteins, and the like.
[0488] Provided are methods of controlling Lepidoptera and/or
Hemiptera insect infestation(s) in a transgenic plant that promote
insect resistance management, comprising expressing in the plant at
least two different insecticidal proteins having different modes of
action.
[0489] In some embodiments the methods of controlling Lepidoptera
and/or Hemiptera insect infestation in a transgenic plant and
promoting insect resistance management the at least one of the
insecticidal proteins comprise a PHI-4 polypeptide insecticidal to
insects in the order Coleoptera.
[0490] In some embodiments the methods of controlling Lepidoptera
and/or Hemiptera insect infestation in a transgenic plant and
promoting insect resistance management the at least one of the
insecticidal proteins comprises a protein of SEQ ID NO: 2, SEQ ID
NO: 3, SEQ ID NO: 4, SEQ ID NO: 51-819 or variants thereof,
insecticidal to insects in the order Coleoptera.
[0491] In some embodiments the methods of controlling Lepidoptera
and/or Hemiptera insect infestation in a transgenic plant and
promoting insect resistance management comprise expressing in the
transgenic plant a PHI-4 polypeptide and a cry protein insecticidal
to insects in the order Coleoptera having different modes of
action.
[0492] In some embodiments the methods of controlling Coleoptera
insect infestation in a transgenic plant and promoting insect
resistance management comprise in the transgenic plant a protein of
SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 51-819 or
variants thereof and a cry protein insecticidal to insects in the
order Lepidoptera and/or Hemiptera having different modes of
action.
[0493] Also provided are methods of reducing likelihood of
emergence of Lepidoptera and/or Hemiptera insect resistance to
transgenic plants expressing in the plants insecticidal proteins to
control the insect species, comprising expression of a PHI-4
polypeptide insecticidal to the insect species in combination with
a second insecticidal protein to the insect species having
different modes of action.
[0494] Also provided are methods of reducing likelihood of
emergence of Coleoptera insect resistance to transgenic plants
expressing in the plants insecticidal proteins to control the
insect species, comprising expression of a protein of SEQ ID NO: 2,
SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 51-819 or variants thereof,
insecticidal to the insect species in combination with a second
insecticidal protein to the insect species having different modes
of action.
[0495] Also provided are means for effective Coleoptera insect
resistance management of transgenic plants, comprising
co-expressing at high levels in the plants two or more insecticidal
proteins toxic to Lepidoptera and/or Hemiptera insects but each
exhibiting a different mode of effectuating its inhibiting growth
or killing activity, wherein the two or more insecticidal proteins
comprise a PHI-4 polypeptide and a cry protein. Also provided are
means for effective Lepidoptera and/or Hemiptera insect resistance
management of transgenic plants, comprising co-expressing at high
levels in the plants two or more insecticidal proteins toxic to
Lepidoptera and/or Hemiptera insects but each exhibiting a
different mode of effectuating its inhibiting growth or activity,
wherein the two or more insecticidal proteins comprise a protein of
SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 51-819 or
variants thereof and a cry protein.
[0496] In addition, methods are provided for obtaining regulatory
approval for planting or commercialization of plants expressing
proteins insecticidal to insects in the order Coleoptera,
comprising the step of referring to, submitting or relying on
insect assay binding data showing that the PHI-4 polypeptide does
not compete with binding sites for cry proteins in such insects. In
addition, methods are provided for obtaining regulatory approval
for planting or commercialization of plants expressing proteins
insecticidal to insects in the order Coleoptera, comprising the
step of referring to, submitting or relying on insect assay binding
data showing that the protein of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID
NO: 4, SEQ ID NO: 51-819 or variant thereof does not compete with
binding sites for cry proteins in such insects.
Methods for Increasing Plant Yield
[0497] Methods for increasing plant yield are provided. The methods
comprise providing a plant or plant cell expressing a
polynucleotide encoding the pesticidal polypeptide sequence
disclosed herein and growing the plant or a seed thereof in a field
infested with a pest against which the polypeptide has pesticidal
activity. In some embodiments, the polypeptide has pesticidal
activity against a lepidopteran, coleopteran, dipteran, hemipteran
or nematode pest, and the field is infested with a lepidopteran,
hemipteran, coleopteran, dipteran or nematode pest.
[0498] As defined herein, the "yield" of the plant refers to the
quality and/or quantity of biomass produced by the plant. By
"biomass" is intended any measured plant product. An increase in
biomass production is any improvement in the yield of the measured
plant product. Increasing plant yield has several commercial
applications. For example, increasing plant leaf biomass may
increase the yield of leafy vegetables for human or animal
consumption. Additionally, increasing leaf biomass can be used to
increase production of plant-derived pharmaceutical or industrial
products. An increase in yield can comprise any statistically
significant increase including, but not limited to, at least a 1%
increase, at least a 3% increase, at least a 5% increase, at least
a 10% increase, at least a 20% increase, at least a 30%, at least a
50%, at least a 70%, at least a 100% or a greater increase in yield
compared to a plant not expressing the pesticidal sequence.
[0499] In specific methods, plant yield is increased as a result of
improved pest resistance of a plant expressing a PHI-4 polypeptide
disclosed herein. Expression of the PHI-4 polypeptide results in a
reduced ability of a pest to infest or feed on the plant, thus
improving plant yield.
[0500] These and other changes may be made to the invention in
light of the above detailed description. In general, in the
following claims, the terms used should not be construed to limit
the invention to the specific embodiments disclosed in the
specification and the claims.
[0501] The entire disclosure of each document cited (including
patents, patent applications, journal articles, abstracts, manuals,
books, or other disclosures) in the Background of the Invention,
Detailed Description, and Examples is herein incorporated by
reference in their entireties.
[0502] The following examples are put forth so as to provide those
of ordinary skill in the art with a complete disclosure and
description of how to make and use the subject invention, and are
not intended to limit the scope of what is regarded as the
invention. Efforts have been made to ensure accuracy with respect
to the numbers used (e.g. amounts, temperature, concentrations,
etc.) but some experimental errors and deviations should be allowed
for. Unless otherwise indicated, parts are parts by weight,
molecular weight is average molecular weight; temperature is in
degrees centigrade; and pressure is at or near atmospheric.
EXPERIMENTALS
Example 1: Generating PHI-4 Genes
[0503] Polynucleotides having single codon substitutions compared
to the PHI-4 polypeptide of SEQ ID NO: 1 were generated. As
described in the examples below, the corresponding PHI-4
polypeptides were expressed, purified and assayed for WCRW
insecticidal activity in order to assess the corresponding activity
diversity. A reverse mutagenesis primer and a complementary forward
mutagenesis primer were designed to create the desired amino acid
substitution(s) at the site(s) of interest. Typically the
mutagenesis primer was between 30 to 45 bases in length with two or
more bases, usually 10 to 15, on both sides of the site of
interest. In the case of saturation mutagenesis, degenerated
primers that cover all possible amino acid residues were used.
Unless otherwise noted, the mutagenic reactions were carried out
using Agilent's QuikChange.TM. Lightening Site-Directed Mutagenesis
kit. Materials provided in the kit are QuikChange.TM. Lightening
Enzyme, 10.times. QuikChange.TM. Lightning Buffer, dNTP mix,
QuikSolution reagent and Dpn1 restriction enzyme according to the
manufactures directions.
[0504] PCR amplifications were typically carried out with
Expand.TM. High Fidelity PCR system (Roche, Switzerland) in 50 ul
containing 50-100 ng templates, 0.4-2 .mu.M primer pair, 200 .mu.M
dNTPs and 2 Units of DNA polymerase. The mutagenesis reaction was
initiated by pre-heating the reaction mixture to 94.degree. C. for
3 min, followed by 16 cycles of the following cycling program:
94.degree. C. for 1 min, 52.degree. C. for 1 min and 68.degree. C.
for 8, 12, 16 or 24 min according to the length of template. The
mutagenesis reaction was completed by incubation at 68.degree. C.
for 1 h. The PCR-amplification products were evaluated by agarose
gel electrophoresis. The PCR products were purified by QIAquick.TM.
PCR purification kit (Qiagen, Germany) and further treated with the
restriction enzyme Dpn1. An aliquot of 1 .mu.l of this PCR product
was typically transformed into BL21(DE3) cells and inoculated on
Luria-Bertani (LB) plate containing 100 pg/ml ampicillin. About 10
colonies in the case of single amino acid mutation or 48 or more
colonies for saturation mutagenesis were selected and plasmid DNA
was isolated for sequencing. Two step sequencing was used, first
for specific mutation site(s) with one sequencing primer followed
by full length sequence confirmation with multiple sequencing
primers.
Example 2: Purification of MBP::PHI-4 Fusion Polypeptides
[0505] Polynucleotides encoding PHI-4 polypeptides were expressed
in a modified pMAL vector (New England Bio Lab) as a fusion (i.e.
MBP::PHI-4; SEQ ID NO: 6) with MBP (maltose binding protein). The
pMAL vector was modified to attach a 6.times.His tag to the
N-terminus of MBP. In order to clone the polynucleotide encoding
the MBP::PHI-4 fusion protein (SEQ ID NO: 6), Sph1 and BamH1 sites
were engineered in the vector at the cloning site. The
polynucleotide (SEQ ID NO: 1) encoding the PHI-4 polypeptide (SEQ
ID NO: 2) was amplified with a forward primer (SEQ ID NO: 32)
overlapping the Sph1 site and a reverse primer (SEQ ID NO: 33)
overlapping the BamH1 site. This PCR product was digested with Sph1
and BamH1 and cloned into pMAL that was precut with the same
enzymes. The forward primer was designed such that polynucleotides
encoding both MBP and PHI-4 polypeptide (SEQ ID NO: 2) within the
MBP::PHI-4 gene (SEQ ID NO:5) were ligated in frame. The plasmid
containing the polynucleotide (SEQ ID NO: 5) encoding the
MBP::PHI-4 polypeptide (SEQ ID NO: 6) was transformed into E. coli
BL21(DE3) cells. The BL21(DE3) cells were grown in MagicMedia.TM.
(Life Technologies) in either 96 deep well plates or flasks in a
shaker running at 250 rpm at 37.degree. C. for 8 hrs. followed by
16.degree. C. for 48-60 hrs. During the 16.degree. C. incubation,
the MBP::PHI-4 polypeptide fusion protein accumulated in the
BL21(DE3) cells as a soluble protein.
[0506] In order to purify the MBP::PHI-4 fusion protein (SEQ ID NO:
6), the E. coli cells were harvested by centrifugation and treated
in a lysozyme solution consisting of 2 mg/ml lysozyme in 50 ml
sodium phosphate buffer at pH 8.0 containing 300 mM NaCl, 2 U/ml
endonuclease (Epicentre) and 5 mM MgCl.sub.2 for 3 hrs. at
37.degree. C. with gentle shaking. The lysozyme treated E. coli
cells were then disrupted with 1% Triton X100 and clear lysate
containing the MBP::PHI-4 proteins were prepared by centrifugation
at 4000 rpm, 30 min (96 well plates) or 9000 rpm (flask produced
samples). His tagged MBP-PHI-4 polypeptide fusion proteins were
purified from the clear lysates by affinity chromatography using
NiNTA agarose (catalog #30450; Qiagen) following the manufacturer's
standard procedure. For high throughput protein purification, Pall
96 deep well filter plates (Pall Corporation; Catalogue #5051) were
used for the affinity chromatography. The purified MPB::PHI-4
polypeptide fusion protein was eluted from NiNTA agarose and passed
through Sephadex G25 to change the phosphate buffer to 25 mM
HEPES-NaOH, pH 8 and used in insect bioassays for determining the
insecticidal activity against Western Corn Rootworm (WCRW). Calipar
GXII capillary electrophoresis with a protein chip (Agilent;
catalogue #P/N760499) was used to determine the MPB::PHI-4
polypeptide concentrations. The protein analysis was repeated at
least 3 times until the final concentration was within the
predetermined deviation (less than 10%). Unless otherwise noted,
the PHI-4 polypeptides disclosed herein were expressed, purified
and assayed for WCRW insecticidal activity as maltose binding
protein fusions (i.e. MBP::PHI-4; SEQ ID NO: 6) as described
above.
Example 3: Determination of WCRW Insecticidal Activity of
MBP::PHI-4 (SEQ ID NO: 6) and MBP::PHI-4-SFR12-004 (SEQ ID NO: 31)
Polypeptides
[0507] The activity of MBP::PHI-4 (SEQ ID NO: 6) and
MBP::PHI-4-SFR12-004 (SEQ ID NO: 31; Example 8) polypeptides
against WCRW (western corn rootworm, Diabrotica virgifera
virgifera) was determined in an artificial diet feeding assay
essentially as described by Cong, R. et al. (Proceedings of the 4th
Pacific Rim Conferences on Biotechnology of Bacillus thuringiensis
and its environmental impact, pp. 118-123, ed. by R. J. Akhurst, C.
E. Beard and P. Hughes, published in 2002, Canberra, Australia).
The assays were conducted on an artificial diet containing
dilutions of these polypeptides. The MBP::PHI-4-SFR12-004
polypeptide fusion (SEQ ID NO:31) and MBP::PHI-4 (SEQ ID NO: 6)
fusions were prepared as above, and 10 .mu.L of protein samples
were mixed with 50 .mu.L of molten (40-50.degree. C.) artificial
insect diet especially prepared for Diabrotica sp. with low
temperature melting agarose, whey protein and wheat germ. The
diet-PHI-4 polypeptide mixture was placed in each well of a 96 well
micro-titer plate. Four or more neonate WCRW larvae were placed in
each well to feed for 4 days at 25.degree. C. and the response of
insects towards the proteins was scored using a 0-3 numerical
scoring system based on the size and mortality of the larvae in
each well. If no response (or normal growth) was seen, a score of 0
was given. When the growth was slightly retarded, a score of 1 was
given. A score of 2 meant that the larvae were severely retarded in
growth (close to neonate size). A score of 3 meant death to all the
larvae in the well. The percent response (% Response) for each
treatment was calculated by dividing the total score, a sum of
scores from replicated wells for each treatment, by the total
highest possible scores and multiplying by 100 to yield "%
Response". For example, if one treatment (one sample, one dose) had
6 replicated wells, the total highest possible score would be
3.times.6=18. An observed set of scores of 3, 2, 2, 3, 2, 2 for six
wells at a given dose for a given variant would result in
(14/18).times.100=78% Response.
[0508] Fast Activity Evaluation (FAE) Analysis:
[0509] The PHI-4 polypeptides at two concentrations were assayed
along with 4 doses (two-fold dilutions bracketing the EC50) of the
reference MBP::PHI-4 fusion protein (SEQ ID NO: 6) within one
96-well assay plate. The concentrations of the PHI-4 polypeptides
were within the 4 doses of the reference protein concentrations,
preferably around the middle point of the 4 dose concentrations.
Each sample plate contained the reference MBP::PHI-4 protein (SEQ
ID NO: 6) in a significant number of wells such as 16 wells in 4
separate doses. In each plate, up to 80 MBP::PHI-4 polypeptide
variants were included and assayed for activity comparison with the
reference PHI-4 polypeptide protein. From a sample plate, 10 ul of
samples from each well were picked by multi-channel pipette and
dispensed in one assay plate containing 50 ul molten diet in each
well and mixed on a shaker. This process of producing the assay
plate was repeated as many as 6 times or more to produce a desired
number of replicate assay plates. After the diet was solidified and
cooled to 4.degree. C., neonate WCRW larvae were placed in each
well, the plate was sealed with perforated Mylar film and incubated
in a constant temperature incubator at 25.degree. C. After 4 days,
the insect responses were scored under a magnifying glass. The
sigmoid dose-response values (Responses) were converted to linear
probit dose-response values using SAS-JMP.RTM., Generalized Linear
Model, Binomial Response, Probit). The response for each protein in
replicates was summed, this sum was compared with the probit
dose--response line of the activity reference protein and the
nominal fold improvement in potency was calculated. This nominal
fold improvement estimated for a given dose in a given experiment
is defined as the Fast Activity Evaluation Guide Number (FAEGN).
For example, if a PHI-4 polypeptide showed a certain % response
value at 40 ppm and comparison to the Probit curve indicated that
the same response is predicted for the reference protein at 100
ppm, then the FAE Guide Number is 2.5 (100/40). According to this
analysis, the PHI-4 polypeptide is nominally 2.5 times more potent
than the reference PHI-4 polypeptide protein. The FAE assay was
typically done with 2 different doses of PHI-4 polypeptides at a
time and performed in three independent experiments, generating 6
FAEGN for each mutant in a typical FAE evaluation. The mean FAEGN
is calculated to yield the Mean FAE Index (MFI). As used herein
"Mean FAE Index" (MFI) refers to the mean of multiple FAEGN
(typically 6 or more); unless otherwise indicated MFI is understood
to be an arithmetic mean of FAEGN. For each protein, a two sided
t-test was done comparing the multiple FAEGN from the clone with
FAEGN values from the reference protein (typically 48-96 FAEGN of
SEQ ID NO: 6). The two-sided t-test was done between these 48-96
FAEGN associated with the reference protein and the 6 or more FAEGN
associated with the variant of interest. The Bonferroni correction
was used to evaluate p-values (number of novel proteins/alpha) for
the hypothesis that a given variant is significantly different in
insecticidal activity compared to the reference protein, MBP::PHI-4
fusion protein (SEQ ID NO: 6) unless otherwise noted. The
Bonferroni correction was used to evaluate p-values (number of
novel proteins/alpha) for the hypothesis that a given variant is
significantly different in insecticidal activity compared to the
reference protein, MBP::PHI-4 fusion protein (SEQ ID NO: 6) unless
otherwise noted.
[0510] Effective Concentration.sub.50 (EC50) evaluation: Variants
of particular interest were assayed at higher power in more
extensive dose response curves to more accurately estimate the
EC50s. The preparation of dose response, infestation, incubation
and scoring were as described for the FAE assay format. EC50
determinations were typically carried out with a no insecticidal
protein control plus seven two-fold dilutions bracketing the
expected EC50 (typically 100 ppm for MBP::PHI-4; SEQ ID NO: 6) and
24 or more replicate wells within a given experiment. As used
herein, the EC50 is defined as the predicted point with 50%
response in the scoring scheme. It is a combination of growth or
feeding Inhibition and lethal responses. In order to determine EC50
values, each treatment (one dose) was repeated 6 or more, usually
24, times.
[0511] Data from exemplary FAE and EC50 determinations are given in
FIGS. 1 and 2 respectively. MBP::PHI-4-SFR12-004 (SEQ ID NO: 31;
Example 8) is a variant with improved insecticidal activity. FIG. 1
shows the primary data for a typical FAE assay. Proteins were
purified and quantified as described above. The % response in a
typical FAE assay is given on the y axis. The protein concentration
(toxin portion of the protein only) is given on the x axis. The
geometric mean FAE Index in this instance is 4.0. FIG. 2 shows the
data for a typical EC50 measurement. Proteins were purified and
quantified as described above. The fractional response (multiply by
100 to get "% Response") is given on the y axis. The inferred EC50s
are 245 ppm (MBP::PHI-1 of SEQ ID NO: 6) and 48 ppm (SFR12-004; SEQ
ID NO: 31). The data indicate that the insecticidal activity of
MBP::PHI-4-SFR12-004 (SEQ ID NO: 31) is increased relative to that
of MBP::PHI-4 (SEQ ID NO: 6).
[0512] The MBP::PHI-4 fusion is rapidly cleaved in the presence of
insect gut fluid to yield MBP and mature PHI-4 protein and it is
believed that the insecticidal activity is due to the cleaved toxin
molecules. The MBP::PHI-4 fusion protein (SEQ ID NO:6) was digested
with 1/100 (w/w) Factor Xa (New England Biolabs) at 25.degree. C.
overnight and the PHI-4 polypeptide was purified by Superdex 200
column chromatography utilizing the size difference and a weak
affinity of MBP to Superdex. The MPB::PHI-4 fusion was also cleaved
with trypsin and the mature PHI-4 polypeptide (derived from SEQ ID
NO: 6) was purified. The mature, purified PHI-4 polypeptide derived
from Factor Xa or trypsin cleavage has a MW of .about.60 kDa as
measured on SDS-PAGE gels and is fully reactive to polyclonal
antisera that also react with the MBP::PHI-4 fusion protein. The
EC50 of this "mature" PHI-4 polypeptide fragment is within
experimental error of the EC50 of the MBP::PHI-4 parental protein
(SEQ ID NO: 6, as calculated on the basis of ppm associated with
the toxin fragment and excluding ppm associated with the MBP domain
of SEQ ID NO: 6.
Example 4: Single Amino Acid PHI-4 Polypeptide Variants (S1-S4)
[0513] A set of 209 PHI-4 polypeptide single amino acid
substitution variants spread across both the N and C terminal
portions of the protein were made and characterized (Megatable 1;
MUT ID: 1-209). The mutagenesis template was the polynucleotide of
SEQ ID NO: 5 encoding PHI-4 (SEQ ID NO: 6) as an MBP fusion. The
mutations were made using the QuickChange kit (Agilent; Catalogue
#200524) essentially as described in Example 1. The particular
amino acid substitutions relative to PHI-4 (SEQ ID NO: 2) are as
indicated in Megatable 1. For example in Megatable 1, the PHI-4
polypeptide identified as MUT ID: 1 has a valine substituted for
the native amino acid alanine at position 202 of PHI-4 (SEQ ID NO:
2) and referred to "A202V". The polypeptide variant for which
activity is reported was prepared as an MBP fusion that is
identical to SEQ ID NO: 6 except for this single amino acid
substitution. In a similar manner, MUT ID: 1-872 (Megatable 1) are
all made in the context of SEQ ID NO: 6; MUT ID: 873-910 (Megatable
1) are made in the context of SEQ ID NO: 8; MUT ID: 911-1135
(Megatable 1) are made in the context of SEQ ID NO: 10. All
polypeptides of Megatable 1 were expressed and purified as MBP
fusions as described in Example 2. The PHI-4 polypeptides were
expressed as MBP fusions and purified as described in Example 2.
The assay protocol for WCRW insecticidal activity of the PHI-4
polypeptides was essentially as described for FAE assays in Example
3 using SEQ ID NO: 6 as the reference protein. For the analysis of
the data a "Mean Deviation Score" was calculated rather than a mean
FAE Index. This is a related metric that is calculated as follows.
Data from four two-fold dilutions of MBP::PHI-4 (typically about
25, 50, 100 and 200 ppm final concentration of PHI-4 fragment in
artificial insect diet) is plotted on a Probit plot. The difference
between response expected for MBP::PHI-4 (SEQ ID NO: 6) at a given
dose, based on the Probit curve, and that observed for the mean
score for a PHI-4 polypeptide variant at that given dose is
calculated and this difference is defined as the Deviation Score. A
negative Deviation Score indicates that the response is lower than
that which is expected for the relevant parental backbone
(typically MBP::PHI-4; SEQ ID NO: 6) at the same concentration and
indicates that the variant is nominally less active than the
parental backbone. A positive Deviation Score indicates that the
variant is nominally more potent than the parental backbone. As
used herein, the Mean Deviation Score refers to the arithmetic mean
of multiple Deviation Scores which are typically derived from
independent experiments. The Mean Deviation Score is used to
estimate rank order of activities associated with a set of variants
within a given experiment. The Mean Deviation Scores for the 209
variants of this example are given in Megatable 1 and is typically
an average of at least three independent Deviation Score
measurements.
Example 5: Single Amino Acid Substitution Mutants #2 (SFR)
[0514] A BLAST search revealed that AXMI-205 is a bacterial
perforin-like protein. Perforin proteins from Clavibactor
michiganensis (GenBank Accession number: YP_001223127; SEQ ID NO:
49), Laccaria bicolor (GenBank Accession number: XP_001885969; SEQ
ID NO: 48), Marinomonas sp. (GenBank Accession number: ZP_01077945;
SEQ ID NO: 38), Nematostella vectensis (GenBank Accession number:
XP_001617993; SEQ ID NO: 50), Photorhabdus luminescens (GenBank
Accession number: NP_928713; SEQ ID NO: 821), and Serratia
proteamaculans (GenBank Accession number: YP_00147861; SEQ ID NO:
820) were found to be homologous to AXMI-205. The N-terminal region
of up to 311 amino acid of AXMI-205 (SEQ ID NO: 35) is highly
homologous to those perforin proteins. Among those perforin
proteins, the 3D X-ray structure of Photorhabdus perforin-like
protein has been published (Science 317, 1548-1551, 2007; PDB ID:
2QP2; SEQ ID NO: 822). According to the leading theory of perforin
mode of action, the protein inserts 5 alpha helices of its
N-terminal region into the target host membrane to form a large
size pore (Proc. Natl. Acad. Sci. USA 102, 600-605, 2005;
Immunology Today, 16, 194-201, 1995). In the Photorhabdus 2QP2
structure, there are two loops between Alpha C and D and Alpha I
and J are considered to be the site for initiating the membrane
insertion of those 5 alpha helices. These loops are called membrane
insertion initiation loops. The primary sequences of those perforin
proteins listed below were aligned using Vector NTI Align X
function in order to identify the membrane insertion loop sequences
of AXMI-205 (SEQ ID NO: 35). Amino acid sequences of V92-A103 and
G211-E220 of SEQ ID NO: 6 were aligned with the membrane insertion
initiation loops identified in the 2QP2 structure. A number of
acidic, basic and other hydrophilic amino acids were found in the
AXMI-205 (SEQ ID NO: 35) membrane insertion loops indicating these
loops are exposed to the solvent.
[0515] Based on this homology model and prior mutation-activity
relationship data, another 664 single amino acid substitution PHI-4
polypeptide variants were made in order to assess the
sequence-insecticidal activity-relationships at the selected
positions. This set of 664 point mutations (Megatable 1; MUT ID:
210-872) were made with MBP::PHI-1 polypeptide of SEQ ID NO 5 as
the DNA template. Mutations were made according to the method of
Example 1. The mutagenesis oligonucleotides used to create an
exemplary mutant (PHI-4-R97D; SEQ ID NO: 7) are SEQ ID NO: 13 and
SEQ ID NO: 14. The other PHI-4 polypeptides (Megatable 1; MUT ID:
210-872) were made in the same manner using mutagenesis
oligonucleotides designed to create the selected substitutions at
the desired residues of the protein. The resulting PHI-4
polypeptides were purified as MBP fusions and the activity measured
in the FAE assay format or EC50 assay format as described in
Examples 2 & 3. The Mean FAE Indices associated with these 664
PHI-4 polypeptides are given in lines 210-872 of Megatable 1.
Example 6: SFR16 Point Mutants
[0516] Another set of 38 single amino acid substitution PHI-4
polypeptide variants (Megatable 1; MUT ID: 873-910) were made with
MBP::PHI-4-R97D (SEQ ID NO 7; Example 5) as the backbone. The
substitutions were selected based on the sequence-activity
relationships inferred from the PHI-4 polypeptide variants of the
preceding Examples. Mutations were made according to the method of
Example 1. Variants were purified as MBP fusions and activity
measured in FAE assay format as described in Examples 2 & 3.
The Mean FAE Indices associated with these mutants are given in
lines 873-910 of Megatable 1. The reference for the Mean FAE Index
in this example is SEQ ID NO: 8.
Example 7: PSR3 Mutants
[0517] The C-terminal domain of AXMI-205 shares significant
homology with proteins that have .beta.-prism 3D structural folding
patterns. In the typical .beta.-prism, the oligosaccharide binding
site is almost always in a cavity formed between the apex and
belt-loops from the same Greek-key motif. The primary amino-acid
sequence motif has been identified as G-X.sub.3-D (SEQ ID NO: 39)
in banana lectin, which has two binding sites (Meagher J L et al
Glycobiology 15:1033-42; 2005). The primary sequence of the PHI-4
polypeptide of SEQ ID NO: 2 contains 3 such motifs. The canonical
structure of these motifs is indicated in FIG. 3. In addition, the
G-X.sub.3-D motif (SEQ ID NO: 39) can be extended toward the
N-terminal direction into the D-X-G-[S/T]-G-X.sub.3-D motif (SEQ ID
NO: 40), which are present 1, 2 or 3 times in 24 proteins that are
orthologous to the C-terminal portion of AXMI-205 (GenBank
accession numbers: gi|136474758; gi|136444345; gi|136141087;
gi|143658948; gi|142085802; gi|135275135; gi|138446054;
gi|294814724; gi|170109524; gi1156316804; gi|156377786;
gi|170109526; gi|77456557; gi|1209377; gi|302823768; gi1302532087;
gi|256764986; gi|302787479; gi|302823738; gi|169762636;
gi|302766657; gi1270056485; gi|302792467; gi|2384884450. Each of
the 3 loops in the PHI-4 polypeptide of SEQ ID NO: 2 has potential
to bind an oligosaccharide, a putative binding receptor present in
WCRW mid-gut cell membrane surface.
[0518] As indicated in Megatable 1, 225 PHI-4 polypeptide variants
(MUT IDs: 911-1135) were made to introduce an additional amino acid
substitution into the PHI-4 polypeptide of PHI-4-D09 (SEQ ID NO:
10) using MBP::PHI-4-D09 (SEQ ID NO: 9) as the DNA template. The
PHI-4-D09 backbone contains the following substitutions relative to
SEQ ID NO: 2: L401, Y98F, L145V, L163V, 1172L, V3551, and P412A
(numbers are relative to the PHI-4 polypeptide backbone of SEQ ID
NO: 2. Mutagenesis was done by a modification of the method of
Dominy et al (Methods in Molecular Biology, Vol. 235:209-223;
2003). Briefly, "NNK" mutagenesis at position 396 was done as
follows. A pMAL vector encoding SEQ ID NO: 9 was amplified by
inverse PCR for 20 cycles using SEQ ID NO: 15 & SEQ ID NO: 16.
The PCR product was diluted 10-fold, subjected to one additional
round of amplification using SEQ ID NO: 16 & SEQ ID NO: 17. The
PCR product was purified on QuiaQuick.TM. column, phosphorylated
with T4 polynucleotide kinase, circularized with T4 DNA ligase and
transformed into E. coli BL21(DE3) cells. Candidate colonies were
amplified by colony PCR and the PCR product was sequenced first
with a single primer to confirm the presence of the desired
mutation and subsequently sequenced fully with multiple primers to
identify clones with no additional mutations. All other PHI-4
polypeptides of this example (Megatable 1, lines 911-1135) were
made by a similar manner using mutagenesis oligonucleotides
designed to create the selected substitutions at the desired
residues of the protein. Positions with multiple desired mutations
were made with degenerate forward primers whereas positions with
only one desired mutation were made with non-degenerate primers.
Clones with the desired sequences were used to express protein
essentially as described in Example 2. Protein purification,
activity measurements and statistical analysis was done essentially
as described in example 3. The Mean FAE Index reflects the fold
difference relative to PHI-4 polypeptide of SEQ ID NO: 6. The Mean
EC50 of PHI-4-D09 (SEQ ID NO: 10) was measured at high statistical
power and is 1.3-fold improved relative to MBP::PHI-4 (SEQ ID NO:
6). PHI-4 polypeptides of this example with Mean FAE
Index>1.3.times. are deemed nominally improved relative to the
parental backbone (MBP::PHI-4-D09; SEQ ID NO: 10) and diversity
meeting this criterion was used for production of subsequent
combinatorial mutants.
Example 8: Identification of Combinatorial Mutants of PHI-4
Polypeptides with Improved Insecticidal Activity as Measured in an
Artificial Insect Diet Feeding Assay
[0519] Activity diversity identified in Examples 4-7 was used to
create 192 combinatorial PHI-4 polypeptide variants (SEQ ID NO:
51-242; Megatable 2). The PHI-4 polypeptide variants were made by
sequential point mutagenesis by the method of Example 1. In all
cases, the indicated PHI-4 polypeptide variants were made as MBP
fusions with the same linker as is indicated in SEQ ID NO 6. The
MBP::PHI-4 polypeptides were expressed and purified as indicated in
Example 2 & 3. Purified MBP::PHI-4 polypeptides were assayed in
FAE assays to derive a Mean FAE Index or in EC50 assays as
indicated in Example 3. Thirty-seven exemplary active PHI-4
polypeptide variants with increased Mean FAE Indices are given in
Table 3, along with the sequence variation relative to SEQ ID NO:
6. The substitutions relative to PHI-4 polypeptide of SEQ ID NO: 2
are given in the right-most column. All proteins were expressed and
purified as MBP fusions proteins. The reference protein for the
Mean FAE Index is MPB::PHI-4 (SEQ ID NO: 6). The functional data on
all of the PHI-4 polypeptides of this example is given in lines
51-242 of Megatable 2.
TABLE-US-00012 TABLE 3 SEQ Ex. ID Mutation List # NO: Alias FAE p
value (vs SEQ ID NO: 2) 8 148 SFR11- 27.4 1.36E-13 R097D, K099L,
E220D, K289L, 001 R293Q 8 225 SFR17- 20.9 0.001577 D042N, E046N,
R097D, K099L, 013 E220D, K289L, R293Q, S333K, G336A, S401H, K402H 8
226 SFR17- 20.1 1.25E-07 D042N, E046N, R097D, K099L, 019 E220D,
K289L, R293Q, S333K, G336A, V355I, S401H, K402H, P412A 8 227 SFR17-
19.5 1.48E-09 D042N, E046N, R097D, K099L, 014 E220D, K289L, S333K,
G336A, S401H, K402H, P412A 8 228 SFR17- 19.0 5.42E-09 D042N, E046N,
R097D, K099L, 011 E220D, K289L, S333K, G336A, S401H, K402H 8 229
SFR17- 17.1 6.82E-10 R097D, K099L, E220D, K289L, 005 R293Q, S401H,
K402H, P412A 8 73 SFR10- 17.1 1.48E-19 R097D, S333K, G336A 032 8
230 SFR17- 16.5 7.08E-09 R097D, K099L, E220D, K289L, 018 R293Q,
S333K, G336A, V355I, S401H, K402H, P412A 8 149 SFR11- 14.8 8.29E-15
R097D, K099L 012 8 231 SFR17- 13.5 7.19E-16 D042N, E046N, R097D,
K099L, 009 E220D, K289L, R293Q, V355I, S401H, K402H, P412A 8 232
SFR17- 13.1 1.63E-10 D042N, E046N, R097D, K099L, 006 E220D, K289L,
R293Q, S401H, K402H, P412A 8 233 SFR17- 12.9 5.18E-12 D042N, E046N,
R097D, K099L, 016 E220D, K289L, R293Q, S333K, G336A, S401H, P412A 8
150 SFR11- 12.8 2.12E-10 R097D, K099L, E220D, K289L 005 8 74 SFR10-
12.0 7.73E-11 R097D, S401H 042 8 234 SFR17- 11.7 1.82E-07 R097D,
K099L, E220D, K289L, 012 R293Q, S333K, G336A, S401H, K402H 8 235
SFR17- 11.3 7.41E-06 D042N, E046N, R097D, K099L, 004 E220D, K289L,
S401H, K402H, P412A 8 236 SFR17- 10.5 2.1E-15 D042N, E046N, R097D,
K099L, 017 E220D, K289L, S333K, G336A, V355I, S401H, K402H, P412A 8
151 SFR11- 9.9 2.08E-09 R097D, K289L 014 8 237 SFR17- 9.7 1E-04
D042N, E046N, R097D, K099L, 003 E220D, K289L, R293Q, S401H, K402H 8
183 SFR13- 9.3 1.5E-11 R097D, K099L, E220D, K289L, 035 V355I,
A396T, P412A, K520E 8 75 SFR10- 8.9 0.003487 R097D, S333V, K520E,
Q527K 72 8 238 SFR17- 8.7 0.010038 D042N, E046N, R097D, K099L, 001
E220D, K289L, S401H, K402H 8 76 SFR10- 8.4 2.98E-05 R097D, G462A,
R464A, K465M 056 8 77 SFR10- 8.2 1.37E-05 R097D, S333K, G336A,
E339N 036 8 239 SFR17- 8.2 4.75E-21 R097D, K099L, E220D, K289L, 015
R293Q, S333K, G336A, S401H, K402H, P412A 8 152 SFR11- 8.2 1.76E-07
R097D, R293Q 015 8 153 SFR11- 8.1 1.7E-06 R097D, E220D, K289L 010 8
240 SFR17- 7.6 5.14E-09 R097D, K099L, E220D, K289L, 002 R293Q,
S401H, K402H 8 78 SFR10- 7.2 9.2E-12 R097D, S333V, G336A, S338V 039
8 79 SFR10- 6.7 8.17E-06 R097D, S401H, K402H, K520E, 82 Q527K 8 80
SFR10- 6.6 2.09E-14 R097D, S401H, K402H 045 8 81 SFR10- 6.4
2.15E-06 R097D, S401G, K402H, K520E, 87 Q527K 8 82 SFR10- 6.3
2.89E-08 R097D, G462A, R464K, K465M 060 8 51 SFR5- 6.2 1.65E-05
R097D, R293Q, R416E, K520E 014 8 184 SFR13- 6.1 1.84E-13 R097D,
K099L, E220D, K289L, 018 V355I, S401G, P412A, K520E 8 154 SFR11-
5.5 1.54E-09 R097D, E220D 013 8 241 SFR17- 5.5 5.11E-22 D042N,
E046N, R097D, K099L, 007 E220D, K289L, V355I, S401H, K402H,
P412A
Example 9: Identification of Combinatorial Mutants of PHI-4
Polypeptides with Improved Insecticidal Activity as Measured in an
Artificial WCRW Insect Diet Feeding Assay
[0520] Activity data from 315 PHI-4 polypeptide combinatorial
variants (SEQ ID NOs 243-558) is provided in Megatable 2. Libraries
were initially prepared by incorporation of diversity into SEQ ID
NO: 5. The diversity was largely derived from that described in
Example 4. Oligonucleotides encoding diversity at forty positions
were incorporated into SEQ ID NO: 5 in a DNA shuffling reaction
essentially as described (Ness et al., Nature Biotechnol. 20, 1251;
2002). Briefly, oligonucleotides typically of 30-45 bases in length
encoding the diversity elements of interest were mixed at 0.02-2
micromolar each in the presence of an appropriate concentration of
fragments of SEQ ID NO: 5. This reaction was assembled, rescued and
cloned essentially as described for synthetic genes in Example 10
and as described (Ness et al., Nature Biotechnol. 20, 1251; 2002).
Improved variants from initial libraries were subjected to family
DNA shuffling essentially as described (A. Crameri, et al Nature
391, 288; 1998). This family shuffled library was screened by
methods similar to those described in Example 3 (FAE) and to those
described in Example 4 (Mean Deviation Score). Selected, improved
PHI-4 polypeptide variants from the second round of DNA shuffling
were further diversified by recombining N terminal and C terminal
domains of elite clones using the method of splicing by overlap
extension (R. Horton, et al., Gene 77:61-68; 1989) to yield novel
variants. All variants were purified by the method of Example 2 and
assayed by the method of Mean Deviations of Example 4. PHI-4
polypeptides variants identified are given in Megatable 2 (SEQ ID
NO: 243-558).
Example 10: Identification of Combinatorial Mutants of PHI-4
Polypeptides with Improved Insecticidal Activity as Measured in an
Artificial WCRW Insect Diet Feeding Assay
[0521] A set of 158 PHI-4 polypeptide combinatorial variants (SEQ
ID NO: 559-716) were prepared by total gene synthesis, essentially
as described by Stemmer et al (Gene 164:49-53; 1995). An additional
treatment was implemented as described (Saaem, I. et al, Nucleic
Acids Research, Published Nov. 29, 2011, 1-8). Briefly, in a
typical gene synthesis reaction a set of oligonucleotides of 120
bases each encoding both top and bottom strands of the target gene
were designed. Complementary oligos typically overlap by 54-65
nucleotides. Oligos to make synthetic genes are combined such that
a final concentration of each oligo is approximately 0.05-1 uM.
Gene assembly is typically done with Herculase II (Agilent) using
the following cycling program: 98.degree. C. 3 min followed by
(96.degree. C..times.30 sec, 40.degree. C..times.30 sec, 72.degree.
C..times.30 sec).times.24 cycles. The initial PCR is then used as
template for a second PCR in which a second pair of primers is used
to amplify the fully synthetic gene product. Typical PCR conditions
for the second synthetic gene reaction were 98.degree. C. 3 min
followed by (96.degree. C. 30 sec, 50.degree. C. 30 sec, 72.degree.
C. 35 sec), .times.24 cycles. Reactions were analyzed by 1% E-gels
(Invitrogen). A subsequent treatment consisting of a re-annealing
step, treatment with Cel1 (Transgenomics; Catalogue #706020) and
subsequent amplification (25 cycles) was done essentially as
described (Saaem, I. et al, Nucleic Acids Research, Published Nov.
29, 2011, 1-8). A third and final amplification of the synthetic
gene was done with similar PCR conditions in a single cycle. The
product of this reaction was purified and ligated by Gibson
ligation method (New England Biolabs; Catalogue ##E2611 L) to an
appropriate vector transformed to chemical competent BL21(DE3)
cells. Sequence verified clones (Lines 559-716 of Megatable 2)
comprising the PHI-4 polypeptide were expressed as MBP fusions,
purified and assayed essentially as described in Examples 2 and 3.
Table 4 shows the SEQ ID NOs and substitutions relative to the
PHI-4 polypeptide of SEQ ID NO: 2 for twenty active variants. The
mean FAE Index is calculated relative to the MBP::PHI-4 backbone
(SEQ ID NO: 6).
TABLE-US-00013 TABLE 4 SEQ Ex. ID MutationList # NO: Alias FAE p
value (vs SEQ ID NO: 2) 10 559 PSR1- 25.6 3.26E-05 D042N, Y098F,
L145V, L153I, 1-076 I172L, Y206F, I283V, V355I, G359A, W389L,
I410V, A417S 10 560 PSR1- 22.7 4.19E-05 D042N, Y098F, I283V, V355I
1-074 10 561 PSR1- 15.9 7.67E-06 E046N, Y098F, L145V, Y171F, 2-145
I172L, D182Q, E278N, V355I, I410V, A417S, Q442E, V455I 10 562 PSR1-
11.6 1.46E-18 F043E, Y098F, L145V, Y171F, 2-082 I172L, Y206F,
E278N, E339Q, V355I, V455I, W457N 10 563 PSR1- 11.0 3.91E-05 F043E,
Y098F, L145V, Y171F, 2-088 I172L, Y206F, E278N, V355I, Q442E,
V455I, W457N 10 564 PSR1- 10.1 1.07E-10 D042N, F043E, Y098F, L145V,
2-094 Y171F, I172L, E278N, M354L, V355I, V455I, W457N 10 565 PSR1-
9.7 2.8E-08 D042N, F043E, Y098F, L145V, 2-110 Y171F, I172L, E278N,
V355I, I410V, Q442E, V455I 10 566 PSR1- 8.5 0.003166 D042N, Y098F,
I283V, V355I, 1-073 A417S 10 567 PSR1- 7.2 1.03E-10 D042N, F043E,
Y098F, L145V, 2-091 Y171F, I172L, V355I, Q442E, V455I, W457N 10 568
PSR1- 7.0 8.39E-08 F043E, Y098F, L145V, Y171F, 2-149 I172L, Y206F,
E278N, V355I, A417S, V455I, W457N 10 569 PSR1- 6.9 3.93E-10 D042N,
F043E, Y098F, L145V, 2-087 Y171F, I172L, E278N, V355I, Q442E,
V455I, W457N 10 570 PSR1- 6.9 1.01E-07 D042N, R097N, Y098F, L145V,
2-158 Y171F, I172L, V355I, I410V, V455I 10 571 PSR1- 6.7 2.02E-05
E046N, Y098F, L145V, Y171F, 2-085 I172L, D182Q, E278N, V355I,
Q442E, V455I, W457N 10 572 PSR1- 6.5 0.010726 D042N, I052V, Y098F,
L145V, 1-053 I172L, Y206F, I283V, V355I, H370R, I410V, P412A,
A417S, T426S, T461S 10 573 PSR1- 6.2 5.28E-07 D042N, F043E, Y098F,
L145V, 2-096 Y171F, I172L, V210I, I283V, M354L, V355I, V455I, W457N
10 574 PSR1- 6.1 2.92E-11 D042N, R097N, Y098F, L145V, 2-135 Y171F,
I172L, V355I, H370R, Q442E, V455I 10 575 PSR1- 5.9 0.018276 D042N,
R097N, Y098F, L145V, 1-014 I172L, I283V, V355I, I410V, Q442E, V455I
10 575 PSR1- 5.8 5.02E-09 E046N, R097N, Y098F, L145V, 2-141 Y171F,
I172L, V355I, Q442E, V455I 10 577 PSR1- 5.6 0.017252 E046N, Y098F,
L145V, L163V, 1-006 I172L, Y206F, V210I, E339Q, V355I, A417S 10 578
PSR1- 5.3 7.35E-05 F043E, Y098F, L145V, Y171F, 2-095 I172L, Y206F,
E278N, M354L, V355I, V455I, W457N
Example 11: Identification of Combinatorial Mutants of PHI-4
Polypeptides with Improved Insecticidal Activity as Measured in an
Artificial Insect Diet Feeding Assay
[0522] Sixty-six PHI-4 polypeptide variants (SEQ ID NO: 717-783),
containing permutations of a number of substitutions, were made by
total gene synthesis, essentially as described in Example 10. The
substitutions were done in the context of a backbone (PSR1-2-105;
SEQ ID NO: 584 from Megatable 2) containing the following
substitutions relative to PHI-4 polypeptide of SEQ ID NO: 2: E46N,
R97N, Y98F, L145V, Y171F, 1172L, V355I, I410V, V455I, and W457N.
The resulting MBP::PHI-4 polypeptide fusion proteins were
expressed, purified, assayed for insecticidal activity on WCRW
larvae and analyzed for insecticidal relative to MBP::PHI-4 (SEQ ID
NO: 6) using the Mean FAE Index metric as described in Examples 2
& 3. Table 5 shows the Mean FAE Indices, SEQ ID NOs and
substitutions relative to PHI-4 polypeptide of SEQ ID NO: 2 for
twenty active PHI-4 polypeptide variants of this example. The Mean
FAE Index was calculated relative to the MBP::PHI-4 backbone (SEQ
ID NO: 6). The insecticidal activities of the PHI-4 polypeptides in
Table 5 (Mean FAE Index) reflect the arithmetic means of three
independent experiments and are expressed as fold WCRW insecticidal
activity improvement of the PHI-4 polypeptide variants relative to
MBP::PHI-4 (SEQ ID NO: 6). As indicated, the mean FAE Indices range
from 0.26.times. to >8.times. (fold improvement relative to
MBP::PHI-4). The majority of the PHI-4 polypeptides have increased
insecticidal activity relative to MBP::PHI-4 (FAE>1). The p
values indicate that the measured differences relative to
MBP::PHI-4 (SEQ ID NO: 6) are highly significant.
TABLE-US-00014 TABLE 5 SEQ Ex. ID Mutation List # NO: Alias FAE (vs
SEQ ID NO: 2) 11 717 PSR7- 10.0 E046N, R097N, Y098F, L145V, 141
Y171F, I172L, V355I, A396K, S401K, D403Y, I410V, V455I, W457N 11
718 PSR7- 8.4 E046N, R097N, Y098F, L145V, 63 Y171F, I172L, V355I,
A396L, S401H, K402G, I410V, V455I, W457N 11 719 PSR7- 8.1 E046N,
R097N, Y098F, L145V, 89 Y171F, I172L, V355I, A396L, S401H, D403Y,
I410V, V455I, W457N 11 720 PSR7- 6.6 E046N, R097N, Y098F, L145V, 94
Y171F, I172L, V355I, A396G, S401K, I410V, V455I, W457N 11 721 PSR7-
6.1 E046N, R097N, Y098F, L145V, 106 Y171F, I172L, V355I, A396K,
D403Y, I410V, V455I, W457N 11 722 PSR7- 6.1 E046N, R097N, Y098F,
L145V, 96 Y171F, I172L, V355I, A396L, S401H, K402W, D403Y, I410V,
V455I, W457N 11 723 PSR7- 5.0 E046N, R097N, Y098F, L145V, 100
Y171F, I172L, V355I, A396K, K402H, I410V, V455I, W457N 11 724 PSR7-
4.7 E046N, R097N, Y098F, L145V, 148 Y171F, I172L, V355I, A396G,
S401K, K402G, D403Y, I410V, V455I, W457N 11 725 PSR7- 4.7 E046N,
R097N, Y098F, L145V, 98 Y171F, I172L, V355I, A396K, S401H, K402W,
D403Y, I410V, V455I, W457N 11 726 PSR7- 4.5 E046N, R097N, Y098F,
L145V, 113 Y171F, I172L, V355I, A396K, S401K, I410V, V455I, W457N
11 727 PSR7- 4.5 E046N, R097N, Y098F, L145V, 121 Y171F, I172L,
V355I, S401H, I410V, V455I, W457N 11 728 PSR7- 4.5 E046N, R097N,
Y098F, L145V, 7 Y171F, I172L, V355I, A396K, S401H, K402H, I410V,
V455I, W457N 11 729 PSR7- 4.2 E046N, R097N, Y098F, L145V, 86 Y171F,
I172L, V355I, A396K, S401G, K402H, I410V, V455I, W457N 11 730 PSR7-
3.7 E046N, R097N, Y098F, L145V, 155 Y171F, I172L, V355I, S401H,
K402G, D403Y, I410V, V455I, W457N 11 731 PSR7- 3.6 E046N, R097N,
Y098F, L145V, 116 Y171F, I172L, V355I, S401K, K402W, D403Y, I410V,
V455I, W457N 11 732 PSR7- 3.4 E046N, R097N, Y098F, L145V, 95 Y171F,
I172L, V355I, S401G, K402H, D403Y, I410V, V455I, W457N 11 733 PSR7-
3.3 E046N, R097N, Y098F, L145V, 90 Y171F, I172L, V355I, A395L,
K402G, I410V, V455I, W457N 11 734 PSR7- 3.3 E046N, R097N, Y098F,
L145V, 97 Y171F, I172L, V355I, A395G, K402H, I410V, V455I, W457N 11
735 PSR7- 2.8 E046N, R097N, Y098F, L145V, 64 Y171F, I172L, V355I,
A396G, S401H, K402W, D403Y, I410V, V455I, W457N 11 736 PSR7- 2.8
E046N, R097N, Y098F, L145V, 93 Y171F, I172L, V355I, S401H, K402W,
D403Y, I410V, V455I, W457N
Example 12: Identification of Combinatorial Mutants of PHI-4
Polypeptides with Improved Insecticidal Activity as Measured in an
Artificial WCRW Insect Diet Feeding Assay
[0523] Thirty six PHI-4 polypeptide variants (Megatable 2; SEQ ID
NO: 784-819), containing permutations of eleven substitutions
(E220D, G336A, K099L, K289L, K402H, K520E, P412A, R097D, S333K,
S401H, V355I; numbering scheme as per SEQ ID NO:2; all variants
made as MBP fusions as indicated in Megatable 2), were made using
site directed mutagenesis as described in Example 1 and PH1-4
polypeptide variants were expressed, purified, assayed for
insecticidal activity on WCRW larvae and analyzed for insecticidal
activity relative to PHI-4 polypeptide of SEQ ID NO: 2 as described
in Examples 2 & 3. Table 6 shows the Mean FAE Indices, SEQ ID
NOs and substitutions relative to the PHI-4 polypeptide of SEQ ID
NO: 2 for twenty active PHI-4 polypeptide variants of this example.
The mean FAE Index is calculated relative to the MBP::PHI-4
backbone (SEQ ID NO: 6). The mean FAE indices reflect the
arithmetic means of three independent experiments. As indicated,
the mean FAE indices range from 4.5 to >8. The p values indicate
that the measured differences relative to MBP::PHI-4 (SEQ ID NO: 6)
are highly significant.
TABLE-US-00015 TABLE 6 SEQ Ex. ID MutationList # NO: Alias FAE (vs
SEQ ID NO: 2) 12 784 SFR15- 18.8 R097D, K099L, E220D, 009 K289L,
S333K, G336A, S401H, K402H, K520E 12 785 SFR15- 8.0 R097D, K099L,
E220D, 019 K289L, S401H, K402H, P412A 12 786 SFR15- 7.9 R097D,
K099L, E220D, 021 K289L, S333K, G336A, S401H, K402H 12 787 SFR15-
7.9 R097D, K099L, E220D, 033 K289L, S333K, V355I, S401H, K402H 12
788 SFR15- 7.3 R097D, K099L, E220D, 020 K289L, V355I, S401H, K402H,
P412A 12 789 SFR15- 7.0 R097D, K099L, E220D, 027 K289L, S333K,
V355I, S401H 12 790 SFR15- 6.6 R097D, K099L, E220D, 036 K289L,
V355I, K520E 12 791 SFR15- 6.6 R097D, K099L, E220D, 007 K289L,
S401H, K402H, P412A, K520E 12 792 SFR15- 5.5 R097D, K099L, E220D,
017 K289L, S401H, K402H 12 793 SFR15- 5.5 R097D, K099L, E220D, 015
K289L, S333K, G336A, P412A 12 794 SFR15- 5.4 R097D, K099L, E220D,
005 K289L, S401H, K402H, K520E 12 795 SFR15- 5.3 R097D, K099L,
E220D, 001 K289L, S333K, G336A, K520E 12 796 SFR15- 5.2 R097D,
K099L, E220D, 030 K289L, V355I 12 797 SFR15- 5.1 R097D, K099L,
S333K, 025 G336A, S401H, K402H, K520E 12 798 SFR15- 5.0 R097D,
K099L, E220D, 011 K289L, S333K, G336A, S401H, K402H, P412A, K520E
12 799 SFR15- 4.9 R097D, K099L, E220D, 012 K289L, S333K, G336A,
V355I, S401H, K402H, P412A, K520E 12 800 SFR15- 4.7 R097D, K099L,
E220D, 029 K289L, S333K, V355I, S401H, P412A 12 801 SFR15- 4.7
R097D, K099L, E220D, 016 K289L, S333K, G336A, V355I, P412A 12 802
SFR15- 4.5 R097D, K099L, E220D, 010 K289L, S333K, G336A, V355I,
S401H, K402H, K520E 12 803 SFR15- 4.5 R097D, K099L, E220D, 003
K289L, S333K, G336A, P412A, K520E
Example 13: Accordance Between FAE and EC50 Assays
[0524] Experimental data on Mean FAE Index and mean EC50 for
twenty-five PHI-4 polypeptide variants is given in FIG. 4. PHI-4
polypeptide variants were first tested in the FAE assay and then
selected ones were retested in a multiple EC50 assays. In general,
the fold improvement in mean FAE Index is modestly larger than the
fold improvement that was subsequently measured in Mean EC50
measurements. This overall trend is as expected from the phenomenon
of regression toward the mean (International Journal of
Epidemiology 2005; 34:215-220). All 25 PHI-4 polypeptides elected
for retesting in EC50 assays repeated as being significantly
improved. FIG. 4 shows the EC50 measurements for representative
variants from Megatable 2 (SEQ ID NO: 610, SEQ ID NO: 595, SEQ ID
NO: 584, SEQ ID NO: 591, SEQ ID NO: 576, SEQ ID NO: 73, SEQ ID NO:
74, SEQ ID NO: 75, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 150,
SEQ ID NO: 150, SEQ ID NO: 149, SEQ ID NO: 167, SEQ ID NO: 167, SEQ
ID NO: 164, SEQ ID NO: 164, SEQ ID NO: 170, SEQ ID NO: 170, SEQ ID
NO: 795, SEQ ID NO: 794, SEQ ID NO: 784, SEQ ID NO: 799, SEQ ID NO:
785, SEQ ID NO: 788, SEQ ID NO: 786, SEQ ID NO: 796, SEQ ID NO:
787).
Example 14: Combinatorial Substitutions
[0525] Example 11 yielded numerous PHI-4 polypeptide variants with
improved insecticidal activity based on combinatorial substitutions
of the three lectin-like motifs described in Example 7. A
combinatorial library was prepared of 120 genes based on this
diversity as follows. SEQ ID NOs 760 & 761 each contains unique
substitutions in loop 1. SEQ ID NOs 717-726; 728-732; 734-737 &
760 contain unique substitutions in loop 2. SEQ ID NOs 761 and 758
contain unique substitutions in loop 3. Gene synthesis was used to
create a combinatorial library of these loop sequences essentially
as described in Example 10. These genes can be expressed and
assayed for activity on WCRW larvae by the methods described
above.
Example 15: Mutagenesis of Putative Protease Sensitive Sites of
PHI-4 Polypeptides
[0526] Trypsin was used to identify the site(s) where proteases
possibly attack (Protease Accessible Sites) the PHI-4 polypeptide
of SEQ ID NO: 2. The PHI-4 polypeptide of SEQ ID NO: 2 in 50 mM
Tris-HCl, pH8 was mixed with 1/50 (weight/weight) trypsin and
incubated for 1 hr at 37.degree. C. It was found that protein was
relatively resistant to trypsin, with no immediate digestion down
to the small fragments, but produced a 55 kDa major band and 24 kDa
minor band by SDS-PAGE analysis after the incubation. These two
bands were excised from the gel and analyzed by mass spectrometry
and N-terminal sequencing. The N-terminal sequencing revealed
SAANAGQLGN (amino acids 3-12 of SEQ ID NO: 2) for the 55 kDa
protein indicating that only two amino acid residues, Methionine
and Alanine were missing from the N-terminal sequence. The
mass-spectrometry, however, showed a loss of C-terminal sequence
from Ser at 521 to Leu at 536 of SEQ ID NO: 2. This indicates that
trypsin digested the PHI-4 polypeptide protein at the C-terminal
side of Lys at 520 of SEQ ID NO: 2. The N-terminal sequence of the
24 kDa band was VDKVLLMD (amino acids 314 to 321 of SEQ ID NO: 2).
The mass-spectrometry analysis on the 24 kDa fragment confirmed the
C-terminal region of PHI-4 polypeptide of SEQ ID NO: 2 starting
with Val at 314 relative to SEQ ID NO: 2 as shown by N-terminal
sequencing and ending at Lys at 520 relative to SEQ ID NO: 2. This
indicated that trypsin digested the PHI-4 polypeptide of SEQ ID NO:
2 at the C-terminal side of Lys at 313 of SEQ ID NO: 2.
[0527] From this experiment, it was found that there are at least
two protease accessible sites, Lys at 313 and Lys at 520 SEQ ID NO:
6. These two sites were mutated to other amino acid residues by
saturation mutagenesis and it was found that mutations at Lys at
313 and Lys at 520 of SEQ ID NO: 2 increase the insecticidal
activity significantly. For example, the activity of the PHI-4
polypeptide variant, K313Q (MUT ID: 889), was enhanced 2.3 fold
over the activity of PHI-4 polypeptide of SEQ ID NO: 2 as measured
in an FAE assay (Megatable 1). The activity of the PHI-4
polypeptide K520Q (MUT ID: 881) was increased 3.1 fold. Activity
increases were also found in combinations with other mutations. For
example, the activity of the PHI-4 polypeptide having the R097D and
K520E substitutions (SEQ ID NO: 52) is 3.5 fold higher than that of
PHI-4-R097D (MUT ID: 8) alone by FAE assay.
Example 16: Saturation Mutagenesis of Amino Acid Residues Selected
by Site Directed Single Amino Acid Mutagenesis
[0528] Certain amino acid residues showed activity changes when
mutated by site directed single amino acid mutagenesis. Those
residues were "Selected" for saturation mutagenesis. For the
purposes of this example, "Selected" can refer to single amino acid
mutations that affect the activity, positively or negatively,
relative to the parental backbone in which they were made. More
specifically substitutions of Megatable 1 with Mean FAE Indices of
<0.7 or of >1.3 are deemed "Selected". For example, Selected
amino acid residues were found by performing site directed
mutagenesis at certain residues such as Arg and Lys. These basic
amino acid residues were mutated to either acidic (Asp, Glu) or
neutral, polar (e.g.: Asn and Gln) residues, and the activity of
those mutants was determined by the FAE insect assay individually.
Acidic amino acid residues such as Asp and Glu were changed to
basic (e.g.: Arg, Lys) or neutral, polar (e.g.: Asn and Gln)
residues and the mutant activity was determined. Neutral, polar
amino acid residues such as Gln and Asn were mutated to either
acidic (Asp, Glu) or basic (e.g.: Arg, Lys) amino acid residues to
see if the activity of those mutants were changed positively (for
example mean FAE Index>1.3 relative to the reference protein) or
negatively (for example mean FAE Index <0.7 relative to the
reference sequence). Another example of finding Selected amino acid
residues is based on the sequence-function relationship. Since
AXMI-205 is a member of the perforin family it is possible to
identify amino acid residues of PHI-4 polypeptide of SEQ ID NO: 2
which are involved in the mode of action elements such as membrane
insertion initiation and receptor binding loops. Amino acid
residues found in those regions were considered Selected for
saturation mutagenesis in this Example. One can use the alanine
scanning to empirically define Selected residues. This technique
was used to find additional Selected amino acid residues in the
putative receptor binding loops.
[0529] After any amino acid residues were determined Selected,
those residues were subjected to saturation or near saturation
mutagenesis to produce a set of up to 19 mutants for each site (20
all possible amino acids minus the amino acid found in the wild
type). The insecticidal activity of all these mutants was
determined by the FAE insect assay. Saturation mutagenesis of the
Selected amino acid residues, was useful for identifying
substitutions with Mean FAE Indices of >1, in many cases
>1.3. When the activity of one single amino acid mutation was
found to be positive by showing increased activity over the PHI-4
polypeptide of SEQ ID NO: 2, the saturation mutagenesis enabled us
to find other mutation(s) that showed further increased activity.
For example, while the FAE Index of E082Q (MUT ID: 370) was
positive (1.37), the saturation mutagenesis at this site revealed
other mutations showing much higher FAE Indices. For example, the
index of E0821 (MUT ID: 219) was 7.80 and that of E082L (MUT ID:
259) was 2.71 indicating that PHI-4 polypeptide of SEQ ID NO: 2
hydrophobic residues are beneficial at this site as far as its
insecticidal activity is concerned.
[0530] Other Selected amino acid substitutions resulted in
decreased activity. When these sites were examined further by
saturation mutagenesis, substitutions with Mean FAE Indices of
>1 were observed. For example, the FAE Indices of K099Q (MUT ID:
677), K099E (MUT ID: 715) were 0.34 and 0.26, respectively. This
shows that Lysine at this site is functionally involved in activity
and that alternative substitutions may result in improved activity.
In this example, the saturation mutagenesis revealed substitutions
with Mean FAE Index >1. For example, the substitution K099L (MUT
ID: 299) has a Mean FAE Index of 5.72 (Megatable 1). Similar
instances were found across the entire PHI-4 polypeptide of SEQ ID
NO: 2, for example those indicated in Table 7. Table 7 shows the
Mean FAE Indices for nine pairs of substitutions. All data is from
Megatable 1.
TABLE-US-00016 TABLE 7 Substitution A Substitution B mean mean MUT
Sub- FAE MUT Sub- FAE ID stitution Index ID stitution Index 570
K074Q 0.7 215 K074E 12.40 596 E203Q 0.59 288 E203T 2.18 800 R235Q
0.06 497 R235K 1.34 906 K313E 0.14 889 K313Q 2.29 838 D395Q 0.03
832 D395R 1.60 784 S398A 0.11 342 S398Q 1.51 629 K402Q 0.47 216
K402F 10.20 842 D403Q 0.03 251 D403Y 3.03 611 D447Q 0.54 211 D447K
31.70
[0531] The serine at position 98 of SEQ ID NO: 2 was Selected by
alanine scanning amino acid residues found in a region of the
protein that is suspected overlap with the receptor binding loops.
Point mutants with improved potency may then be used to prepare and
screen combinatorial libraries based on that diversity.
[0532] Taking mean FAE Index <0.7 as a definition of Selected,
the following positions are deemed Selected: P14, D24, Q38, E53,
R55, R61, Q75, D76, E83, E118, E126, D152, R166, K188, K191, D193,
K242, P243, R248, D254, L266, D268, A270, D274, D298, K313, D315,
K316, D321, V343, S349, Q360, R361, D368, I373, D376, F378, D379,
D394, Y404, Q413, N430, Q449, D497, R500, S504. Saturation or near
saturation mutagenesis at these positions can be performed by the
method of Example 7 or equivalent methods and purified and screened
the variant proteins for activity by the methods of Example 2 &
3 or equivalent methods.
Example 17: Transgenic Expression and Activity Evaluation
[0533] The PHI-4 polypeptides of SEQ ID NOs 22-25 were cloned under
control of the maize ubiquitin promoter (Christensen and Quail,
(1996) Transgenic Research 5:213-218) into a standard vector
suitable for transformation of maize by Agrobacterium. Transgenic
maize plants were produced by the method of Example 20. Selected T0
plants were tested for susceptibility to WCRW feeding by
challenging T0 plants with WCRW larvae. After 19-21 days of
challenge, the roots were visually examined and root nodal injury
scores were recorded as described (Oleson J. et al J. Economic
Entomology 98:1-8; 2005). Root nodal injury scores are indicated in
FIG. 5. The data support the conclusion that the three PHI-4
polypeptide variants provide measurable in planta efficacy for
protection of maize transgenic plants against WCRW. FIG. 5 shows
the TO seedlings in the V3-V4 growth stage were challenged as
described (Oleson J. et al J. Economic Entomology 98:1-8; 2005) and
root nodal injury scores were recorded.
Example 18: In Planta Expression of Fusion Proteins
[0534] Localization of the protein can also play an important role
in in planta accumulation. One can direct proteins such as PHI-4
polypeptides to the chloroplast using a chloroplast targeting
peptide (CTP). Additionally, one can direct expression to the
apoplastic space using fusions to peptides such as the barley alpha
amylase-derived peptide (BAA; SEQ ID NO: 826). One may also direct
transgenically expressed proteins for retention in the endoplasmic
reticulum by fusing to both BAA and the sequence "KDEL" (SEQ ID NO:
828). Proteins can also be directed to the vacuolar space by fusion
with the C terminal peptide from plant defensins such as the maize
defensin 20 C-terminal propeptide (SEQ ID NO: 824). Other
functionally equivalent gene elements may be combined in a similar
manner. One may also direct expression specifically to the roots
with root-specific promoters. Each of these modifications may be
made separately or in combination and any given combination of
elements to improve accumulation of protein in plant tissue or in
functionally improved efficacy of the expressed protein.
Example 19: Transformation of Maize by Particle Bombardment and
Regeneration of Transgenic Plants
[0535] Immature maize embryos from greenhouse donor plants are
bombarded with a DNA molecule containing the PHI-4 polypeptide of
nucleotide sequence (e.g., SEQ ID NO: 1) operably linked to an
ubiquitin promoter and the selectable marker gene PAT (Wohlleben,
et al., (1988) Gene 70: 25-37), which confers resistance to the
herbicide Bialaphos. Alternatively, the selectable marker gene is
provided on a separate DNA molecule. Transformation is performed as
follows. Media recipes follow below.
[0536] Preparation of Target Tissue
[0537] The ears are husked and surface sterilized in 30% CLOROX.TM.
bleach plus 0.5% Micro detergent for 20 minutes, and rinsed two
times with sterile water. The immature embryos are excised and
placed embryo axis side down (scutellum side up), 25 embryos per
plate, on 560Y medium for 4 hours and then aligned within the 2.5
cm target zone in preparation for bombardment.
[0538] Preparation of DNA
[0539] A plasmid vector comprising a nucleotide sequence (e.g., SEQ
ID NO: 1) operably linked to an ubiquitin promoter is made. For
example, a suitable transformation vector comprises a UBI1 promoter
from Zea mays, a 5' UTR from UBI1 and a UBI1 intron, in combination
with a PinlI terminator. The vector additionally contains a PAT
selectable marker gene driven by a CAMV35S promoter and includes a
CAMV35S terminator.
[0540] Optionally, the selectable marker can reside on a separate
plasmid. A DNA molecule comprising a toxin nucleotide sequence as
well as a PAT selectable marker is precipitated onto 1.1 .mu.m
(average diameter) tungsten pellets using a CaCl.sub.2)
precipitation procedure as follows: [0541] 100 .mu.L prepared
tungsten particles in water [0542] 10 .mu.L (1 .mu.g) DNA in Tris
EDTA buffer (1 .mu.g total DNA) [0543] 100 .mu.L 2.5 M CaC1.sub.2
[0544] 10 .mu.L 0.1 M spermidine
[0545] Each reagent is added sequentially to a tungsten particle
suspension, while maintained on the multitube vortexer. The final
mixture is sonicated briefly and allowed to incubate under constant
vortexing for 10 minutes. After the precipitation period, the tubes
are centrifuged briefly, liquid removed, washed with 500 mL 100%
ethanol, and centrifuged for 30 seconds. Again the liquid is
removed, and 105 .mu.L 100% ethanol is added to the final tungsten
particle pellet. For particle gun bombardment, the tungsten/DNA
particles are briefly sonicated and 10 .mu.L spotted onto the
center of each macrocarrier and allowed to dry about 2 minutes
before bombardment.
[0546] Particle Gun Treatment
[0547] The sample plates are bombarded at level #4 in particle gun
#HE34-1 or #HE34-2. All samples receive a single shot at 650 PSI,
with a total of ten aliquots taken from each tube of prepared
particles/DNA.
[0548] Subsequent Treatment
[0549] Following bombardment, the embryos are kept on 560Y medium
for 2 days, then transferred to 560R selection medium containing 3
mg/liter Bialaphos, and subcultured every 2 weeks. After
approximately 10 weeks of selection, selection-resistant callus
clones are transferred to 288J medium to initiate plant
regeneration. Following somatic embryo maturation (2-4 weeks),
well-developed somatic embryos are transferred to medium for
germination and transferred to the lighted culture room.
Approximately 7-10 days later, developing plantlets are transferred
to 272V hormone-free medium in tubes for 7-10 days until plantlets
are well established. Plants are then transferred to inserts in
flats (equivalent to 2.5'' pot) containing potting soil and grown
for 1 week in a growth chamber, subsequently grown an additional
1-2 weeks in the greenhouse, then transferred to classic 600 pots
(1.6 gallon) and grown to maturity. Plants are monitored and scored
for expression of the toxin by assays known in the art or as
described above.
[0550] Bombardment and Culture Media
[0551] Bombardment medium (560Y) comprises 4.0 g/L N6 basal salts
(SIGMA C-1416), 1.0 mL/L Eriksson's Vitamin Mix
(1000.times.SIGMA-1511), 0.5 mg/L thiamine HCl, 120.0 g/L sucrose,
1.0 mg/L 2,4-D and 2.88 g/L L-proline (brought to volume with
deionized H.sub.2O following adjustment to pH 5.8 with KOH); 2.0
g/L Gelrite.TM. (added after bringing to volume with dl H.sub.2O);
and 8.5 mg/L silver nitrate (added after sterilizing the medium and
cooling to room temperature). Selection medium (560R) comprises 4.0
g/L N6 basal salts (SIGMA C-1416), 1.0 mL/L Eriksson's Vitamin Mix
(1000.times. SIGMA-1511), 0.5 mg/L thiamine HCl, 30.0 g/L sucrose,
and 2.0 mg/L 2,4-D (brought to volume with dl H.sub.2O following
adjustment to pH 5.8 with KOH); 3.0 g/L Gelrite.TM. (added after
bringing to volume with dl H.sub.2O); and 0.85 mg/L silver nitrate
and 3.0 mg/L Bialaphos (both added after sterilizing the medium and
cooling to room temperature).
[0552] Plant regeneration medium (288J) comprises 4.3 g/L MS salts
(GIBCO 11117-074), 5.0 mL/L MS vitamins stock solution (0.100 g
nicotinic acid, 0.02 g/L thiamine HCl, 0.10 g/L pyridoxine HCl, and
0.40 g/L Glycine brought to volume with polished D-I H.sub.2O)
(Murashige and Skoog, (1962) Physiol. Plant. 15:473), 100 mg/L
myo-inositol, 0.5 mg/L zeatin, 60 g/L sucrose, and 1.0 mL/L of 0.1
mM abscisic acid (brought to volume with polished dl H.sub.2O after
adjusting to pH 5.6); 3.0 g/L Gelrite.TM. (added after bringing to
volume with dl H.sub.2O); and 1.0 mg/L indoleacetic acid and 3.0
mg/L Bialaphos (added after sterilizing the medium and cooling to
60 C).
[0553] Hormone-free medium (272V) comprises 4.3 g/L MS salts (GIBCO
11117-074), 5.0 mL/L MS vitamins stock solution (0.100 g/L
nicotinic acid, 0.02 g/L thiamine HCl, 0.10 g/L pyridoxine HCl, and
0.40 g/L Glycine brought to volume with polished dl H.sub.2O), 0.1
g/L myo-inositol, and 40.0 g/L sucrose (brought to volume with
polished dl H.sub.2O after adjusting pH to 5.6); and 6 g/L
Bacto-agar (added after bringing to volume with polished dl
H.sub.2O), sterilized and cooled to 60.degree. C.
Example 20: Agrobacterium-Mediated Transformation of Maize and
Regeneration of Transgenic Plants
[0554] For Agrobacterium-mediated transformation of maize with a
toxin nucleotide sequence (e.g., SEQ ID NO: 1), the method of Zhao
can be used (U.S. Pat. No. 5,981,840 and PCT Patent Publication
Number WO 1998/32326; the contents of which are hereby incorporated
by reference). Briefly, immature embryos are isolated from maize
and the embryos contacted with a suspension of Agrobacterium under
conditions whereby the bacteria are capable of transferring the
nucleotide sequence (e.g. SEQ ID NO: 1) to at least one cell of at
least one of the immature embryos (step 1: the infection step). In
this step the immature embryos can be immersed in an Agrobacterium
suspension for the initiation of inoculation. The embryos are
co-cultured for a time with the Agrobacterium (step 2: the
co-cultivation step). The immature embryos can be cultured on solid
medium following the infection step. Following this co-cultivation
period an optional "resting" step is contemplated. In this resting
step, the embryos are incubated in the presence of at least one
antibiotic known to inhibit the growth of Agrobacterium without the
addition of a selective agent for plant transformants (step 3:
resting step). The immature embryos can be cultured on solid medium
with antibiotic, but without a selecting agent, for elimination of
Agrobacterium and for a resting phase for the infected cells. Next,
inoculated embryos are cultured on medium containing a selective
agent and growing transformed callus is recovered (step 4: the
selection step). The immature embryos are cultured on solid medium
with a selective agent resulting in the selective growth of
transformed cells. The callus is then regenerated into plants (step
5: the regeneration step), and calli grown on selective medium can
be cultured on solid medium to regenerate the plants.
Megatable Legends
[0555] Megatable 1. The definitions of the column headings are as
follows: "MUT ID", a unique identifier for each substitutions;
"Backbone", the SEQ ID corresponding to the polypeptide backbone in
which the substitution was made; "Position", amino acid position
according to the numbering convention of SEQ ID NO: 2, "Ref. A.
A.", the standard single letter code for the amino acid present in
the backbone sequence at the indicated position; "Substitution",
the standard single letter code for the amino acid present in the
mutant sequence at the indicated position; "FAE", the arithmetic
Mean FAE Index as further defined in Example 3; "p-value" the
calculated p value associated with the hypothesis that the variant
polypeptide is significantly different than the reference protein
used in that particular FAE assay, as defined further in Example 3;
"EC50 (ppm)", EC50 as defined in example 3 with the EC50 dose given
in ppm for the toxin portion of the sample; "Deviation", Mean
Deviation Score as defined in Example 4; "Example #", the example
number corresponding to the creation of the variant. The reference
protein against which the variant protein is compared is: (MUT IDs:
1-872 and 911-1135) used SEQ ID NO: 6 as the reference protein;
(MUT IDs: 873-910) used SEQ ID NO: 8 as the reference protein.
Megatable 2. The definitions of the column headings are as follows:
"SEQ ID NO:", a unique identifier for each DNA or amino acid
sequence; "Trivial Name", a trivial but unique name for each DNA or
protein sequence; "Reference Protein", the SEQ ID NO corresponding
to the reference protein used in the FAE assays for each variant;
"FAE", the arithmetic Mean FAE Index as further defined in Example
3; "p-value" the calculated p value associated with the hypothesis
that the variant polypeptide is significantly different than the
reference protein used in that particular FAE assay, as defined
further in Example 3; "EC50 Fold", the fold increase in potency as
defined by ratio of reference EC50 to variant EC50 is calculated in
each of multiple experiments and then the mean of these
independently measured numbers is reported as "EC50 Fold";
"Deviation", Mean Deviation Score as defined in Example 4; "Example
#", the example number corresponding to the creation of the
variant. The reference protein against which the variant protein is
compared is: (MUT IDs: 1-872 and 911-1135) used SEQ ID NO: 6 as the
reference protein; (MUT IDs: 873-910) used SEQ ID NO: 8 as the
reference protein.
Sequence CWU 0 SQTB SEQUENCE LISTING The patent application
contains a lengthy "Sequence Listing" section. A copy of the
"Sequence Listing" is available in electronic form from the USPTO
web site
(https://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20210388377A1).
An electronic copy of the "Sequence Listing" will also be available
from the USPTO upon request and payment of the fee set forth in 37
CFR 1.19(b)(3).
0 SQTB SEQUENCE LISTING The patent application contains a lengthy
"Sequence Listing" section. A copy of the "Sequence Listing" is
available in electronic form from the USPTO web site
(https://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20210388377A1).
An electronic copy of the "Sequence Listing" will also be available
from the USPTO upon request and payment of the fee set forth in 37
CFR 1.19(b)(3).
* * * * *
References